



HERBERT
SMITH
FREEHILLS

.....2019

EXPEDEON AG

and

EXPEDEON INC

and

ABCAM PLC

and

ABCAM INC

SALE AND PURCHASE AGREEMENT

Expedeon Holdings Limited

TABLE OF CONTENTS

Clause	Headings	Page
1.	INTERPRETATION.....	1
2.	SALE AND PURCHASE	1
3.	CONSIDERATION	1
4.	ESCROW	3
5.	CONDITIONS.....	3
6.	PRE-COMPLETION OBLIGATIONS	4
7.	COMPLETION	8
8.	SELLER WARRANTIES AND UNDERTAKINGS.....	9
9.	SELLER INDEMNITIES	12
10.	SELLER LIMITATIONS ON LIABILITY	13
11.	PURCHASER WARRANTIES	16
12.	PROTECTION OF PURCHASER INTERESTS	16
13.	INTELLECTUAL PROPERTY	18
14.	EMPLOYEES' INCENTIVE PLAN	19
15.	SHAREHOLDER CLAIMS	19
16.	TERMINATION	20
17.	MISCELLANEOUS	20
18.	NOTICES	25
19.	GOVERNING LAW	27
20.	DISPUTE RESOLUTION	27
	SCHEDULE 1 DETAILS OF SELLER, SHARES AND CONSIDERATION	28
	SCHEDULE 2 DETAILS OF THE COMPANY AND THE SUBSIDIARIES	29
	SCHEDULE 3 ADJUSTMENTS TO CONSIDERATION	34
	SCHEDULE 4 ESCROW.....	39
	SCHEDULE 5 CONDUCT OF BUSINESS.....	41
	SCHEDULE 6 COMPLETION OBLIGATIONS.....	43
	SCHEDULE 7 SELLER WARRANTIES	47
	SCHEDULE 8 PURCHASER WARRANTIES	71
	SCHEDULE 9 PERMITTED LOGO.....	73
	SCHEDULE 10 MATERIAL CONTRACTS	74
	SCHEDULE 11 REAL PROPERTY.....	81
	SCHEDULE 12 INTELLECTUAL PROPERTY.....	83
	SCHEDULE 13 IT TECHNOLOGY SYSTEMS NOT TRANSFERRING.....	99
	SCHEDULE 14 PRODUCTS.....	100
	SCHEDULE 15 US EQUIPMENT	125
	SCHEDULE 16 DEFINITIONS AND INTERPRETATION.....	127

AGREED FORM DOCUMENTS

Consultancy Agreement

CTO Waiver Deed

Deed of Assignment

Directors / Secretaries Resignation Letter

Option Lapse Notice

Management Services Termination Deed

Norman Way Lease Term Sheet

Qualiphi Distribution Agreement

Settlement Agreement

Shareholder Circular

Signing Disclosure Letter

Tax Deed

TruePrime Distribution Agreement

US Inc Transfer Agreement

THIS AGREEMENT is made on

2019

BETWEEN:

- (1) **EXPEDEON AG** a stock incorporation under German law registered with the Commercial Register of the Local Court in Mannheim under no. HRB 335706 and whose registered office is Waldhofer Str. 102, 691203 Heidelberg, Germany (the "**Seller**"); and
- (2) **EXPEDEON INC** a Californian corporation with registered number C2267773 and whose principal offices are located at 10805 Vista Sorrento Parkway, Suite 100, San Diego, CA 92121 (the "**US Seller**") (the US Seller and the Seller being together the "**Sellers**");
- (3) **ABCAM PLC** a company incorporated and registered in England and Wales with company number 03509322 and whose registered office is Discovery Drive, Cambridge Biomedical Campus, Cambridge CB2 0AX (the "**Purchaser**");
- (4) **ABCAM INC** a company incorporated and registered in Massachusetts with company number 837340 and whose registered office is 1 Kendall Square, Suite B2304, Cambridge, MA, 02139-1517, USA (the "**US Purchaser**") (the US Purchaser and the Purchaser being together the "**Purchasers**").

RECITALS:

- (A) The Seller has agreed to sell and transfer to the Purchaser the entire issued share capital of the Company upon the terms and subject to the conditions set out in this Agreement.
- (B) The US Seller has agreed to sell and transfer to the US Purchaser the US Assets (as defined herein) upon the terms and subject to the conditions set out in this Agreement.

IT IS AGREED as follows:

1. INTERPRETATION

- 1.1 The definitions and other interpretative provisions set out in Schedule 16 shall apply throughout this Agreement, unless the contrary intention appears.
- 1.2 In this Agreement, except where the context otherwise requires, any reference to this Agreement includes a reference to the Schedules and the Appendices, each of which forms part of this Agreement for all purposes.

2. SALE AND PURCHASE

Sale and purchase

- 2.1 The Seller is the legal and beneficial owner of and shall, subject to the satisfaction of the Condition, sell and the Purchaser shall purchase the Shares on the basis that they are sold at Completion with Full Title Guarantee and free from any Encumbrance, together with all rights attached to them at the date of this Agreement or subsequently becoming attached to them.
- 2.2 The US Seller is the legal and beneficial owner of and shall sell and the US Purchaser shall purchase the US Assets on the basis that they are sold at the US Effective Time with Full Title Guarantee and free from any Encumbrance.

Waiver of rights

- 2.3 The Seller waives and agrees to procure the waiver of any restrictions on transfer, including pre-emption rights, which may exist in relation to the Shares, under the articles of association of the Company, any shareholders' agreement or otherwise.

3. CONSIDERATION

Consideration

- 3.1 Subject to adjustment in accordance with the terms of this Agreement, the consideration for the sale of the Shares and the sale of the US Assets shall be the payment by the Purchaser of the Purchase Price. The apportionment of the Purchase Price as between the Shares and the US Assets shall be as agreed between the Parties prior to Completion.

Completion Payments

- 3.2 At Completion, the Purchaser shall:
- 3.2.1 pay to the Seller in accordance with Clause 7.3:
- (A) the Completion Consideration Amount; plus
 - (B) the Norman Way Transfer Consideration (such amount to be off-set against the amount payable by the Seller in accordance with Clause 8.18.2); minus
 - (C) a sum equal to the Estimated Net Debt;
- 3.2.2 pay to the Seller (on behalf of the relevant Seller Group Company) the Net Inter-Company Debt as determined with reference to the Estimated Net Debt Statement; and
- 3.2.3 pay the Escrow Amount into the Escrow Account.
- 3.3 If any amount is required to be withheld from any payment of the Purchase Price on account of Tax (whether at Completion or at any later time following adjustment of the Purchase Price in accordance with clauses 3.5 and 3.6 or the operation of the Escrow Account or otherwise) then the Purchaser shall withhold such amount from the relevant payment and shall promptly pay such amount to the relevant Tax Authority due, and provided the Purchaser has done so such amount shall be treated as paid for the purposes of this Agreement.

Notification of Estimated Net Debt at Closing

- 3.4 Not less than two (2) Business Days prior to the Completion Date, the Seller shall prepare and deliver to the Purchaser the Estimated Net Debt Statement setting out the Estimated Net Debt.

Adjustments to consideration

- 3.5 Schedule 3 shall apply.
- 3.6 On the Post Completion Payment Date, if Net Debt as set out in the Statement of Net Debt:
- 3.6.1 exceeds the Estimated Net Debt, the Seller shall pay to the Purchaser, an amount equal to the excess (the "**Net Debt Excess Amount**"); or
- 3.6.2 is less than the Estimated Net Debt, the Purchaser shall pay to the Seller an amount equal to the shortfall (the "**Net Debt Shortfall Amount**").
- 3.7 Where Clause 3.6.1 applies, if the Seller fails to pay the Net Debt Excess Amount to the Purchaser within five (5) Business Days of the Post Completion Payment Date, the Purchaser may elect (in its sole discretion) for an amount equal to the Net Debt Excess Amount to be released from the Escrow Account to the Purchaser. If such election is made, the payment from the Escrow Account shall discharge the Seller's obligation under Clause 3.6.1.

- 3.8 Where Clause 3.6.2 applies, if the Purchaser fails to pay the Net Debt Shortfall Amount to the Seller within five (5) Business Days of the Post Completion Payment Date, the Seller may elect (in its sole discretion) for an amount equal to the Net Debt Shortfall Amount to be released from the Escrow Account to the Seller. If such election is made, the payment from the Escrow Account shall discharge the Purchaser's obligation under Clause 3.6.2.
- 3.9 The Seller shall have no obligation to replenish the Escrow Amount which, if the Seller makes the election referred to in Clause 3.8, shall be reduced by the amount of such payment.
- 3.10 Any amounts paid under this Agreement in respect of breach of this Agreement or any of the Seller Warranties, or pursuant to the Tax Deed, shall so far as permitted by law, be made by way of an adjustment of the Purchase Price.

4. **ESCROW**

Schedule 4 shall apply in relation to the Escrow Amount.

5. **CONDITIONS**

- 5.1 Completion is conditional on the passing at a duly convened shareholders' meeting of the Seller of a Shareholder Resolution (the "**Condition**") on or before 1 January 2020 (or such later date as the Seller and the Purchaser may agree in writing) (the "**Longstop Date**").

Waiver

- 5.2 The Purchaser may, by written notice to the Sellers, waive the Condition in whole or in part at any time on or before the Longstop Date.

Satisfaction of the Condition

- 5.3 The Seller shall be responsible for, and shall use all reasonable endeavours to satisfy or procure the satisfaction of, the Condition as soon as possible and in any event on or before the Longstop Date.
- 5.4 In addition to its obligations under Clause 5.3, with respect to the satisfaction of the Condition, the Seller shall, at its own expense:
- 5.4.1 keep the Purchaser regularly informed as to the progress of the Shareholder Approval process and shall promptly inform the Purchaser of any communications in connection with the Transaction, the Shareholder Meeting or the Shareholder Approval prior to the Shareholder Meeting, including reasonable details in relation to the same;
 - 5.4.2 procure that on 11 November 2019, the Shareholder Approval Documentation is published, dispatched or made available in accordance with Applicable Law, including sections 121 et seqq. and section 179a para 2 of the German Stock Corporation Act (*Aktiengesetz*), as well as section 49 of the German Securities Trading Act (*Wertpapierhandelsgesetz*);
 - 5.4.3 procure that the Shareholder Meeting, and all processes relating to the same, are conducted in accordance with all Applicable Laws; and
 - 5.4.4 procure that the Shareholder Meeting is duly notarized.
- 5.5 The Seller warrants that:
- 5.5.1 it has prepared the Shareholder Approval Documentation, with the assistance of Heuking, with due care and skill;

- 5.5.2 the Shareholder Approval Documentation is compliant with all Applicable Laws (including the German Stock Corporation Act (*Aktiengesetz*) and the German Securities Act (*Wertpapierhandelsgesetz*)); and
 - 5.5.3 it has appointed separate legal counsel (the identity of which was co-ordinated with the Purchaser and the costs of which are to be discharged by the Seller) to support the Chairman of the Seller's supervisory board in relation to the Shareholder Approval process and the Shareholder Meeting.
- 5.6 The Seller further:
- 5.6.1 represents to the Purchaser that the management board and the supervisory board of the Seller have approved the Transaction and have resolved that they will unanimously and unqualifiedly recommend to the shareholders of the Seller to vote in favour of the Shareholder Resolution (as the management board members themselves will undertake to do in respect of their own respective shareholdings in the Seller);
 - 5.6.2 undertakes to procure that the recommendation referred to in 5.6.1 is not withdrawn prior to receipt of Shareholder Approval; and
 - 5.6.3 undertakes that it will not at any time amend or waive any provision of any Irrevocable Undertaking and that it will diligently exercise all rights or recourses it may have in the event of a breach of any Irrevocable Undertaking by the signatory thereof.
- 5.7 The Seller shall not, and shall procure that none of its Affiliates shall, take any action that could be expected to adversely affect, prevent or delay the satisfaction of the Condition.
- 5.8 The Seller represents and undertakes on its own behalf and on behalf of its Employees and representatives that in obtaining, procuring or satisfying the Condition, it will not breach any Applicable Laws.

Notification of satisfaction of the Condition

- 5.9 The Seller shall notify the Purchasers of the satisfaction of the Condition as soon as possible after the Condition has been satisfied and in any event within one (1) Business Day of satisfaction.

Failure to satisfy the Condition

- 5.10 If the Condition:
- 5.10.1 remains unsatisfied on the Longstop Date and has not been waived on or before that date; or
 - 5.10.2 becomes impossible to satisfy on or before the Longstop Date and has not been waived by the Purchaser within five Business Days of such Condition becoming impossible to satisfy,
- the Purchaser may give notice to the Sellers that it wishes to terminate this Agreement.

6. PRE-COMPLETION OBLIGATIONS

Normal course

Pending Completion, the Seller shall procure that each Group Company and the US Seller, to the extent relevant to the US Assets, continues to carry on business in the normal course in compliance with all laws and regulations applicable to it and in substantially the same manner as its businesses have been carried in the 12 month period prior to the date of this Agreement, so as to maintain each such business as a going concern

Protection of business and assets

- 6.1 Pending Completion, the Sellers shall procure that each Group Company takes all reasonable steps to preserve and protect its business and assets and the Sellers shall notify the Purchaser in writing promptly of any adverse change in such business or assets.

Access

- 6.2 Subject to Applicable Law, pending Completion the Sellers shall procure that the Purchaser and any person authorised by it:
- 6.2.1 is given full access to all the books and records, documents, information, data and financial affairs, including the statutory books, minute books, contracts, customer lists, supplier lists and leases of the Group (or of the US Seller, to the extent relevant to the US Assets) save for unredacted versions of such documentation presently redacted or retained in the clean room of the Data Room and any such documentation which contains details of confidential know-how or trade secrets including in respect of manufacturing, capabilities or on-going research and development projects; and
- 6.2.2 may visit and inspect any premises of the Group and discuss the affairs, finances and accounts of the Group with its officers and Employees.

Conduct of Business

- 6.3 Schedule 5 shall apply and, pending Completion, the Sellers shall notify the Purchaser immediately of any matter, circumstance, act or omission which is or may be a breach of Schedule 5.
- 6.4 The Seller shall notify the Purchaser in writing as soon as reasonably practicable of becoming aware of any fact, matter or circumstance:
- 6.4.1 that causes, or may reasonably be expected to cause, any of the Seller Warranties given at the date of this Agreement to be untrue, misleading or breached; or
- 6.4.2 which will be or may be a breach of any of the Seller Warranties when such Seller Warranties are repeated at Completion, or which may render such Seller Warranty to be untrue, misleading or breached.

Transfer of the US Seller

- 6.5 By no later than 31 December 2019, the Seller shall, at its own expense, procure the transfer of the entire issued share capital (free from Encumbrance) of the US Seller from the Company to the Seller or any Affiliate of the Seller (excluding a Group Company) by:
- 6.5.1 executing, and procuring the execution by the Company, of the US Inc Transfer Agreement; and
- 6.5.2 completing all filings, registrations or other similar corporate processes in relation to the same.

Financing

- 6.6 The Seller shall:
- 6.6.1 no later than five (5) Business Days prior to the Completion Date, obtain the appropriate consents, waivers and/or confirmations from the relevant counterparties in respect of:

- (A) the waiver of prepayment notice periods and required payment dates such that prepayment and cancellation of the Prepayment Facilities can be made on the Completion Date;
 - (B) the confirmation of the estimated amounts (inclusive of all fees, break costs and other outstanding amounts) required to effect prepayment and cancellation in full of the Prepayment Facilities; and
 - 6.6.2 not less than five (5) Business Days prior to the Completion Date, deliver to Boost and Santander the applicable Prepayment Notice;
 - 6.6.3 not less than five (5) Business Days prior to the Completion Date, procure the production of draft prepayment, cancellation and release documentation required in respect of each Prepayment Facility ("**Draft Release Documentation**"); and
 - 6.6.4 provide copies of any Draft Release Documents to the Purchaser within two (2) Business Days of receipt,
- in each case, in such form as is agreed between the Parties, acting reasonably, and provide copies of the same to the Purchaser.

Employees

- 6.7 Prior to Completion, the Seller shall procure that Expedeon Asia Pte Ltd lawfully terminates the employment of all of its current employees (such that Expedeon Limited has no residual liability in relation to such employees).

Agreements

- 6.8 Pending Completion, the Seller and the Purchaser shall, and shall procure (so far as it is within their power to do so) that the relevant contracting parties shall:
 - 6.8.1 enter into an Escrow Agreement in relation to the Escrow Account; and
 - 6.8.2 use all reasonable endeavours to negotiate and agree the form of the Norman Way Lease on the basis of the Norman Way Lease Term Sheet.
- 6.9 The Purchaser and the Seller shall each use their best endeavours to negotiate and agree the final form of the US Transitional Services Agreement and to ensure the same is executed and delivered at Completion.
- 6.10 The Purchaser and the Seller shall co-operate and use their respective reasonable endeavours to procure that the Option Lapse Notices are executed by the Optionholders and delivered at Completion.

Patent Revival

- 6.11 The Seller shall procure that each Group Company pay all renewal fees promptly and take all steps necessary to maintain or renew the registrations of Seller Group IP and respond to any correspondence from patent or trade mark offices in a prompt and diligent manner. The Seller shall consult the Purchaser prior to making any filing or substantive response to patent or trade mark offices giving the Purchaser no less than five (5) Business Days to review such filings or response and shall incorporate any comments provided by the Purchaser in relation to such filings or response.
- 6.12 The Sellers shall file to the United States Patent and Trademark Office a petition for revival of abandoned US patent application (US15/691271 (US2018113125) as soon as reasonably practicable after the date of the Agreement (and no later than 29 November 2019) and further a substantive response to the outstanding office action dated 3 April 2019 should be filed by the Sellers in parallel and no later than 29 November 2019.

Accounts

- 6.13 The Seller undertakes to file the Overdue Accounts with Companies House no later than 13 December 2019.

Sanctions

- 6.14 By no later than 30 November 2019, the Sellers shall provide the Purchaser with a list of all counterparties of each Group Company to enable the Purchaser to check against the Sanctions Lists ("**Sanctions Search**").
- 6.15 If the Sanctions Search results indicate any potential issues with any counterparty, the Parties shall cooperate and use reasonable endeavours to remedy such issue prior to Completion.

Transitional Services

- 6.16 Without prejudice to Clause 17.23, if any services or assets are identified prior to, or after, Completion which are provided by, or owned by, the Seller or any of its Affiliates (excluding any member of the Group) and which are required by the Group in order to conduct its business as is currently conducted or as has been conducted within the 12 month period immediately prior to this Agreement, the Parties shall (subject to the Seller or its Affiliate still owning or otherwise having the benefit of such service or asset) agree the terms of, and enter into, a transitional services agreement in relation to the same.

Contracts

- 6.17 The Seller and the Purchaser shall cooperate and use reasonable endeavours to procure that the US Contract be amended (or a new contract entered into) in the manner agreed by the Parties prior to Completion to ensure that Group receives the benefit of the part of the US Contract required in relation to the US Assets.
- 6.18 The Seller undertakes to procure that, if the Draft 10X agreement is executed, the only Seller Group Company that will enter into the final agreement shall be a Group Company nominated by the Purchaser.

Properties

- 6.19 Prior to Completion, the Seller undertakes to (at its own cost) procure an up to date asbestos survey and management register for Norman Way and to provide a copy of the report and register to the Purchaser as soon as reasonably practicable.

Filing

- 6.20 In the event that the proposed sale of the US Assets pursuant to the terms of this Agreement are determined to come within the Pilot Program regulations (the "**Regulations**") issued on behalf of the Committee on Foreign Investment in the United States (CFIUS) (31 C.F.R Part 801), the Parties agree either:
- 6.20.1 to cooperate to take such steps as are reasonably required to comply with the Regulations before Completion, including preparing and submitting, as soon as possible, a mandatory declaration or a joint voluntary notice to CFIUS; or
- 6.20.2 to take such steps as a reasonably necessary to ensure that the Regulations do not apply to the Transaction.

7. COMPLETION

Completion Date

- 7.1 Completion shall, subject to the satisfaction of the Condition, take place on the Completion Date at the offices of Herbert Smith Freehills LLP or at such other place as the Seller and Purchaser shall agree.

Sellers' obligations

- 7.2 At Completion the Sellers shall:

7.2.1 observe and perform all of the provisions of Part 1 of Schedule 6 (as applicable); and

7.2.2 deliver to the Purchaser all securely stored Intellectual Property held at Norman Way.

Purchaser's obligations

- 7.3 At Completion, the Purchaser shall observe and perform all of the provisions of Part 2 of Schedule 6.

All Shares

- 7.4 The Purchaser shall not be obliged to complete the purchase of any of the Shares unless the Seller completes the sale of all the Shares simultaneously, but completion of the purchase of some of the Shares will not affect the rights of the Purchaser with respect to the purchase of the others.

Sellers' default at Completion

- 7.5 The Purchaser shall not be obliged to complete this Agreement unless the Sellers comply fully with Clause 7.2 and the provisions of Part 1 of Schedule 6.

- 7.6 If, in any respect, the Sellers have not complied with the requirements of Clause 7.2 and the provisions of Part 1 of Schedule 6 at the time and on the date set for Completion, the Purchaser may:

7.6.1 defer Completion to a date selected by the Purchaser being not more than 28 days after that date (in which case this Clause shall apply to Completion as so deferred); or

7.6.2 proceed to Completion as far as practicable and in any case without prejudice to its rights under this Agreement; or

7.6.3 give notice to the Sellers that it wishes to terminate this Agreement.

Purchaser's default at Completion

- 7.7 The Sellers may but shall not be obliged to complete this Agreement unless the Purchaser complies fully with Clause 7.3 and the provisions of Part 2 of Schedule 6.

- 7.8 If, in any respect, the Purchaser has not complied with the requirements of Clause 7.3 and the provisions of Part 2 of Schedule 6 at the time and on the date set for Completion, the Sellers may:

7.8.1 defer Completion to a date selected by the Sellers being not more than 28 days after that date (in which case this Clause shall apply to Completion as so deferred); or

7.8.2 proceed to Completion as far as practicable and in any case without prejudice to its rights under this Agreement; or

7.8.3 give notice to the Purchaser that it wishes to terminate this Agreement.

US Assets

- 7.9 The Parties agree that title to the US Assets shall transfer at the US Effective Time.
- 7.10 Subject to Clause 7.13, at the US Effective Time, the US Employees will cease to be employed by the US Seller and will become employed as at-will employees of the US Purchaser. The US Purchaser shall have sole discretion to determine all terms and conditions of the US Employees' employment. The US Purchaser shall have no obligation to offer employment to any other current or former employee, officer, director, independent contractor or consultant of the US Seller.
- 7.11 The Sellers shall be solely responsible, and the Purchasers shall have no obligations for, any compensation or other amounts payable to the US Employees, or to any other current or former employee, officer, director, independent contractor or consultant of the US Seller, including, without limitation, hourly pay, commission, bonus, salary, accrued vacation, other incentive, fringe, pension or profit sharing benefits or severance pay for any period relating to service with the US Seller at any time prior to the US Effective Time. The Sellers shall pay all such amounts to all entitled persons prior to the US Effective Time.
- 7.12 The Sellers shall remain solely responsible for the satisfaction of all Employment Claims to the extent that such claims relate to events occurring prior to the US Effective Time. The Sellers also shall remain solely responsible for all worker's compensation claims of the US Employees, or any other current or former employees, officers, directors, independent contractors or consultants of the US Seller which relate to events occurring prior to the US Effective Time. The Sellers shall pay, or cause to be paid, all such amounts to the appropriate persons as and when due.
- 7.13 Subject to applicable law, in the event that the Parties consider it reasonably likely that any claim or liability may arise as a result of the termination of the employment of any US Employee, the Parties shall co-operate with a view to finding a resolution to enable the relevant US Employee to become employed by the US Purchaser in accordance with Clause 7.10. If no suitable resolution can be agreed by the Parties prior to Completion, either the Purchaser or the US Seller may elect that such employee shall remain with the Seller Group and shall not transfer in accordance with Clause 7.10

8. SELLER WARRANTIES AND UNDERTAKINGS

Seller Warranties

- 8.1 Subject to the limitations in Clause 10, the Seller warrants and represents to the Purchaser in the terms of the Seller Warranties.
- 8.2 Subject to the limitations in Clause 10, the Seller shall procure that the Seller Warranties are, and warrants to the Purchaser that the Seller Warranties will be, true and accurate at Completion by reference to the facts and circumstances then subsisting and, for this purpose, the Seller Warranties shall be deemed to be repeated at Completion (and, in respect of the US Assets, at the US Effective Time) as if any express or implied reference in the Seller Warranties to the date of this Agreement was replaced by a reference to the Completion Date.
- 8.3 Each of the Seller Warranties shall be construed as a separate and independent warranty and except where this Agreement expressly provides otherwise, each Seller Warranty is not limited by the other provisions of this Agreement, including the other Seller Warranties.

Seller's knowledge

- 8.4 Where any of the Seller Warranties is qualified by the expression "to the best of the knowledge, information and belief of the Seller" or "so far as the Seller is aware" or any similar expression, that Seller Warranty shall be deemed to include an additional statement that it has been made after due, diligent and careful enquiry by the Seller of Heikki Lanckriet, David Roth, Nick Gee, Anne Hinton, Angela Howe and Dan Jones.
- 8.5 The Seller shall immediately disclose to the Purchaser any matter or thing which arises or of which it becomes aware after entering into this Agreement which is inconsistent with or a breach of any of the Seller Warranties or which might render any of the Seller Warranties misleading.

Purchaser's reliance

- 8.6 The Seller acknowledges that, in entering into this Agreement, the Purchaser has relied upon the representations by the Seller solely in the terms of the Seller Warranties and the Purchaser has not relied upon any other statements or representations made at any time by the Seller or its advisors.

Covenant not to sue

- 8.7 The Seller shall not (if a claim is made against it in connection with the sale of the Shares or the US Assets to the Purchaser) make any claim against any Group Company or against any director, Employee, agent or officer of any Group Company on whom the Seller may have relied before agreeing to any term of this Agreement or the Tax Deed or authorising any statement in the Disclosure Letters. The Seller acknowledges that it has no rights to make any such claim. The rights of each Group Company and any director, Employee, agent or officer of any Group Company under this Clause are subject to the provisions of Clause 17.11.

Accounts

- 8.8 In calculating the liability of the Seller in respect of any Claim no credit shall be given to the Seller for any understatement of the value of any asset nor overstatement of the amount of any liability in the Accounts, nor shall credit be given to the Seller for any provision or reserve in the Accounts which proves to be unnecessary or greater than the amount of the item in respect of which it is provided or reserved.

Repayment of costs

- 8.9 The Seller covenants to pay to the Purchaser an amount equal to all liabilities in respect of any Actions and all Costs which the Purchaser may (acting reasonably) suffer or incur or which may be brought against the Purchaser in any jurisdiction arising, directly or indirectly, out of, or in respect of, or in connection with:
- 8.9.1 the settlement of any claim that any of the Seller Warranties is untrue or inaccurate;
 - 8.9.2 any legal proceedings brought by the Purchaser claiming that any of the Seller Warranties is untrue or inaccurate and in which judgment is given in favour of the Purchaser; and
 - 8.9.3 the enforcement of any such settlement or judgment relating to this Agreement or its subject matter.

No double recovery

- 8.10 The Purchaser agrees that it shall not be entitled to recover damages or obtain payment, reimbursement, restitution or indemnity more than once in respect of any one shortfall, damage, deficiency, breach or other set of circumstances which give rise to one or more General Claims. For this purpose, recovery by the relevant Group Company shall be deemed to be recovery by the Purchaser.

Notifications in relation to Contingent Consideration

- 8.11 The Seller shall deliver to the Purchaser evidence (in a form satisfactory to the Purchaser) that it has paid (or otherwise fulfilled its obligations in relation to) the Contingent Consideration within five (5) Business Days of the relevant payment (or other act by which the Seller fulfils its obligations in respect of the Contingent Consideration) being made.

Contracts

- 8.12 Prior to Completion, the Seller shall:
- 8.12.1 use its reasonable endeavours to obtain the written consent to the assignment of each of the Identified Contracts to Expedeon Limited from the relevant counterparties;
 - 8.12.2 following receipt of such written consent, enter into, and procure the entry into by Expedeon Limited of a Deed of Assignment in respect of the relevant Identified Contract; and
 - 8.12.3 provide the required written notice of assignment to the relevant counterparty pursuant to the terms of the Deed of Assignment.
- 8.13 If the Seller fails to satisfy the requirements of Clause 8.12 by Completion, the Seller shall use its reasonable endeavours to satisfy the requirements of Clause 8.12 as soon as possible after Completion.
- 8.14 Prior to Completion the Seller shall use its reasonable endeavours to obtain the Change of Control Consents.
- 8.15 If the Seller fails to satisfy the requirements of Clause 8.14 by Completion, the Seller shall use its reasonable endeavours to satisfy the requirements of Clause 8.14 as soon as possible after Completion.
- 8.16 Following Completion and until entry into a Deed of Assignment, the Seller shall hold the benefit of the relevant Identified Contract and any assets relating thereto on trust for the Purchaser and shall account to the Purchaser in respect of any monies or other benefits received by the Seller in relation thereto and the Purchaser shall be entitled to the use and enjoyment of such contracts and any assets relating thereto to the extent the Seller is not constrained by operation of law or any third party from providing such use and enjoyment.
- 8.17 The Buyer shall be responsible for all costs and expenses incurred by the Seller in satisfying the requirements of Clauses 8.12 to 8.16, including any fees which may be charged by the relevant counterparties to the Identified Contracts in giving their consent to the assignment, or which may be charged by the relevant counterparties to obtain the Change of Control Consents.

Norman Way

- 8.18 The Seller shall:
- 8.18.1 transfer the Norman Way Freehold from Expedeon Limited to the Seller or an Affiliate of the Seller (the "**Freehold Transfer**") at Completion; and

- 8.18.2 pay the Norman Way Transfer Consideration to the Purchaser at Completion; and
 - 8.18.3 ensure the full, irrevocable and unconditional release of the Security on Completion; and
 - 8.18.4 provide the Purchaser with a copy of the proposed Freehold Transfer and obtain the Purchaser's approval (not to be unreasonably delayed or withheld) to the form of the Freehold Transfer prior to Completion (such Freehold Transfer shall include an indemnity in favour of the Purchaser in relation to any title matters).
- 8.19 The Seller shall notify the Purchaser of the amount of the Norman Way Transfer Consideration on or prior to 15 December 2019.
- 8.20 Following completion of the Freehold Transfer, the Seller undertakes to complete (or procure the completion of) all filings and other registrations and pay all fees, expenses and taxes in respect of the Freehold Transfer as soon as reasonably practicable and, in any event, prior to any deadlines for the same.
- 8.21 For the avoidance of doubt, neither Expedeon Limited nor the Purchaser shall have any liability to the Seller in respect of any taxes paid by the Seller in respect of the Freehold Transfer under Clause 8.18 to 8.20 or in respect of any other liability to make a payment of Taxation in respect of the Freehold Transfer.

9. SELLER INDEMNITIES

Seller indemnities

- 9.1 Subject to Clause 9.2, the Seller covenants to pay to the Purchaser in respect of all Actions and all Costs relating to or in connection with the indemnities in this Clause 9.1 which the Purchaser or any of the Indemnified Persons may suffer or incur or which may be brought against any of them in any jurisdiction arising, directly or indirectly, out of, in respect of, or in connection with:
- 9.1.1 any liability of any Group Company relating to:
 - (A) the Company's ownership of the US Seller prior to the US Inc Transfer Date; and
 - (B) the business conducted by the US Seller prior to the US Inc Transfer Date;
 - 9.1.2 the Contingent Consideration;
 - 9.1.3 any Shareholder Claim; and
 - 9.1.4 any claim in relation to the Company's ownership of Norman Way.

Third party rights

- 9.2 The rights of the Indemnified Persons (other than any Indemnified Person that is a Party) under Clause 9.1 are subject to the provisions of Clause 17.11.

Actions by third parties

- 9.3 If the Purchaser becomes aware of any Action brought by a third party against an Indemnified Person in respect of which indemnification may be sought under Clause 9.1 ("**Third Party Action**") the Purchaser shall, as soon as practicable, notify the Seller giving reasonable details, so far as they are known to the Purchaser, of the relevant facts and circumstances relating to the Third Party Action, provided that failure by the Purchaser to notify the Seller shall not relieve the Seller from the obligation to indemnify the Indemnified Persons except only to the extent that the Seller suffers actual prejudice as a result of such failure and will not, in any case, relieve the Seller from any liability which it may have otherwise than on account of any indemnity given under Clause 9.1.
- 9.4 The Purchaser (or such other person as the Purchaser may in its sole discretion decide) shall have conduct of all Third Party Actions.
- 9.5 The Purchaser must take reasonable measures to procure that:
- 9.5.1 reports are given to the Seller at reasonable intervals regarding the progress of any Third Party Action;
- 9.5.2 there is reasonable advance consultation with the Seller in relation to any Third Party Action,
- provided that the Purchaser shall (subject to its general duty to mitigate its losses) not be under any obligation to take into account any requirements of the Seller in connection with the conduct of the Third Party Action, nor to provide the Seller with a copy of any document which, in the sole opinion of the Purchaser, (i) is or may be privileged in the context of the Third Party Action; (ii) breaches or may breach any obligation of confidentiality or any legal or regulatory requirements; (iii) adversely affects or may adversely affect any insurance policy of the Purchaser or any Group Company or the ability of any such person to pursue a claim thereunder; or (iv) is or may be inappropriate taking into account any actual or potential conflicting interests between the Purchaser and the Seller having regard to the Purchaser's own commercial interests and reputation.
- 9.6 The Seller shall, and shall procure that each Group Company from time to time and its respective officers, Employees, advisers and agents shall, provide the Purchaser with all information, reasonable assistance, reasonable access and facilities, including the availability of personnel, in relation to any Third Party Action as the Purchaser may reasonably request.
- 9.7 The Seller agrees that:
- 9.7.1 if it becomes aware of any matter or circumstance relevant for the purpose of Clause 9.1, or any matter or circumstance which may give rise to a Third Party Action, it shall promptly notify the Purchaser thereof and shall promptly provide the Purchaser with such information and copies of such documents relating to the matter or circumstance as the Purchaser may reasonably request; and
- 9.7.2 it will not, without the prior written consent of the Purchaser, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened Action in respect of which indemnification may be sought under Clause 9.1 (whether or not an Indemnified Person is an actual or potential party to such claim).

10. SELLER LIMITATIONS ON LIABILITY

Disclosure

- 10.1 Without prejudice to the Purchaser's right to terminate this Agreement pursuant to Clause 16.1.3, the Seller shall not be liable in respect of:

- 10.1.1 a General Claim (in relation to the Business Warranties given as at the date of this Agreement) or a claim for breach of the Tax Warranties given as at the date of this Agreement to the extent that the facts and circumstances giving rise to such General Claim or claim for breach of the Tax Warranties are fairly disclosed (with sufficient details to identify the value, nature and scope of the matter disclosed) in the Signing Disclosure Letter; or
 - 10.1.2 any claim for breach of any of the Repeated Warranties (excluding the Fundamental Warranties) to the extent that the facts and circumstances giving rise to the claim for breach of the Repeated Warranties are fairly disclosed (with sufficient details to identify the value, nature and scope of the matter disclosed) in the Supplemental Disclosure Letter.
- 10.2 The Supplemental Disclosure Letter shall:
- 10.2.1 not include any general disclosures nor shall it include any general disclosure documents;
 - 10.2.2 make no disclosure of any matters or things which arose (or which the Seller first became aware of) before, and including, the date of this Agreement.

Time limits

- 10.3 The Seller shall not be liable for any General Claim unless the Purchaser gives to the Seller written notice containing a summary of the nature of the General Claim as far as is known to the Purchaser, on or before the date being 24 months from Completion.
- 10.4 The Seller shall not be liable for any Tax Claim unless the Purchaser gives written notice containing a summary of the nature of the Tax Claim as far as it is known to the Purchaser to the Seller on or before the date being 7 years from Completion.
- 10.5 The Seller shall not be liable for:
- 10.5.1 any General Indemnity Claim (excluding the Contingent Consideration Indemnity) unless the Purchaser gives to the Seller written notice containing a summary of the nature of the General Indemnity Claim as far as is known to the Purchaser on or before the date being 24 months from the date of Completion; and
 - 10.5.2 any Contingent Consideration Indemnity Claim unless the Purchaser gives to the Seller written notice containing a summary of the nature of the Contingent Consideration Indemnity Claim as far as is known to the Purchaser on or before the date being 6 months from the TGR Consideration Payment Date.

Monetary Limits

- 10.6 Subject to the additional limitations set out in Clauses 10.7, 10.8 and 10.9 and 10.10, the aggregate amount of the liability of the Sellers in respect of all all Title and Capacity Claims, claims under the Tax Deed, General Claims, Tax Warranty Claims and General Indemnity Claims howevers arising (save in the case of fraud) under this Agreement shall not exceed an amount equal to 100% of the Purchase Price (prior to any adjustment).
- 10.7 The aggregate amount of the liability of the Seller in respect of the aggregate of Title and Capacity Claims shall not exceed an amount equal to 100% of the Purchase Price (prior to any adjustment).
- 10.8 The aggregate amount of the liability of the Seller in respect of the aggregate of all claims under the Tax Deed shall not exceed an amount equal to 30% of the Purchase Price (prior to any adjustment).

- 10.9 The aggregate amount of the liability of the Seller in respect of the aggregate of all General Claims and Tax Warranty Claims shall not exceed 12% of the Purchase Price (prior to any adjustment).
- 10.10 The aggregate amount of the liability of the Seller in respect of:
- 10.10.1 the US Inc Indemnity shall not exceed €3,000,000;
 - 10.10.2 the Contingent Consideration Indemnity shall not exceed €1,500,000;
 - 10.10.3 the Shareholder Claim Indemnity shall not exceed €3,000,000; and
 - 10.10.4 the Norman Way Indemnity shall not exceed £600,000.
- 10.11 The Seller shall have no liability in respect of any Claim (other than a Title and Capacity Claim, Indemnity Claim and claims under the Tax Deed) unless the aggregate amount of the liability of the Seller in respect of all that Claim (together with any Claims which arise from the same event or set of circumstances or relate to the same subject matter exceeds €100,000 in which case the Seller shall be liable for the full amount of such Claims not just the excess.
- 10.12 The Seller shall have no liability in respect of any Claim (other than a Title and Capacity Claim, Indemnity Claim or claims under the Tax Deed) unless the relevant Claim (or the aggregate of a series of connected Claims or Claims arising out of similar facts or circumstances) for which it would be liable in the absence of clause 10.11 exceeds €1,200,000 in which case the Seller shall be liable for the full amount of such Claim not just the excess.

Changes in law, regulation and practice

- 10.13 The Seller shall not be liable in respect of a Claim to the extent that the Claim arises or is increased as a result of:
- 10.13.1 any change in generally accepted accounting practice after the Completion Date;
 - 10.13.2 any change in the accounting policies or practice of the Purchaser, its group undertakings or any Group Company after the Completion Date; or
 - 10.13.3 the passing of any legislation, or making of any subordinate legislation after the Completion Date.

Sums recoverable from third parties

- 10.14 Where the Purchaser is entitled to recover from any person any sum in respect of any matter or event which gives rise to a Claim, the Purchaser shall use its reasonable endeavours to recover that sum and shall keep the Seller informed of the conduct of such recovery. The Purchaser shall not be restricted from pursuing that or any other Claim in relation to the same subject matter against the Seller. Any sum recovered by the Purchaser before settlement or final determination of the Claim (less any costs and expenses properly incurred by the Purchaser and each Group Company in recovering the sum and any Tax attributable to or suffered in respect of the sum recovered) will reduce the amount of the Claim by an equivalent amount. If recovery is delayed until after the Claim has been satisfied by the Seller, the Purchaser shall (subject to the remaining provisions of this Clause) repay to the Seller the amount so recovered (less any costs and expenses properly incurred by the Purchaser and each Group Company in recovering the sum and any Tax attributable to or suffered in respect of the sum recovered). If the amount so recovered exceeds the amount of the Claim satisfied by the Seller the Purchaser shall be entitled to retain the excess.

Actions by third parties

10.15 If the Purchaser becomes aware of any claim, action or demand made against it, or any Group Company by a third party (a **"Third Party Claim"**) which may give rise to a Claim (other than an Indemnity Claim, in respect of which the provisions of Clause 9.3 to 9.7 shall apply):

10.15.1 the Purchaser shall, as soon as practicable, notify the Seller giving reasonable details, so far as they are known to the Purchaser, of the relevant facts and circumstances relating to the Third Party Claim; and

10.15.2 the Purchaser shall keep the Seller reasonably informed of all material developments in relation to the Third Party Claim within its knowledge.

Mitigation

10.16 Nothing in this Clause 10 restricts or limits any general obligation at law of the Purchaser, or any Group Company to mitigate any loss or damage which it may suffer or incur as a consequence of any breach of any Seller Warranties.

11. PURCHASER WARRANTIES

The Purchaser warrants to the Seller in the terms of the warranties set out in Schedule 8.

12. PROTECTION OF PURCHASER INTERESTS

Definitions

12.1 In this Clause 12:

12.1.1 each of the following words and expressions shall have the following meanings:

- (A) **"Competing Business"** means any business which competes or proposes to compete with any business carried on at Completion by any Group Company (or which is undertaken in connection with the US Assets) or with any business which at Completion any Group Company proposes to carry on in the immediate or foreseeable future;
- (B) **"Excluded Business"** means the business of Expedeon Biotech SLU as conducted immediately prior to Completion and the electrophoresis business of the US Seller, excluding, for the avoidance of doubt, any business of the type associated with the US Assets;
- (C) **"Recognised Stock Exchange"** has the meaning given to it in section 1137 of the CTA 2010;
- (D) **"Restricted Products or Services"** means the Products and any other products or services of the same type as or similar to or competitive with the Products or services supplied by any Group Company at Completion save for those Products supplied as part of the Excluded Business and those Products supplied under the Distribution Agreements; and
- (E) **"Seller Related Person"** means any Affiliate of the Seller; and

12.1.2 references to acting directly or indirectly include acting alone or on behalf of any other person or jointly with or through or by means of any other person including any Affiliate.

Competition

- 12.2 The Seller covenants with the Purchaser that, at any time during the period of 24 months from Completion, it shall not (and shall procure that no Seller Related Persons shall), directly or indirectly, carry on or be engaged or interested in a Competing Business, save that the Seller may carry out the Excluded Business.

Customers

- 12.3 The Seller covenants with the Purchaser that, at any time during the period of 24 months from Completion, it shall not (and shall procure that no Seller Related Persons shall), directly or indirectly:

12.3.1 accept orders for or supply or cause orders to be accepted for or cause to be supplied Restricted Products or Services to any person; or

12.3.2 solicit, canvass or approach or endeavour to solicit, canvass or approach or cause to be solicited, canvassed or approached any person for the purpose of offering to that person Restricted Products or Services.

Employees

- 12.4 The Seller covenants with the Purchaser that, at any time during the period of eighteen months from Completion, it shall not (and shall procure that no Seller Related Persons shall), directly or indirectly solicit or entice away or endeavour to solicit or entice away or cause to be solicited or enticed away from any Group Company any person who is, and was at Completion, employed or directly or indirectly engaged by any Group Company, with a view to inducing that person to leave such employment or engagement (whether or not such person would commit a breach of his contract of employment or engagement by reason of leaving).

Confidentiality

- 12.5 The Seller covenants with the Purchaser that, until the expiration of five years from Completion, it shall not (and shall procure that none of its Seller Related Persons shall) disclose or use, for its own benefit or that of any other person any Know How, confidential information or trade secrets which it possesses concerning the business or affairs of any Group Company, the US Contracts, the US IP or of any person having dealings with any Group Company, except any such Know How or information which is in the public domain other than by reason of any breach by the Seller of any of its obligations under this Agreement or any breach by any person of any duty of confidentiality in relation to the business or affairs of any Group Company.

Permitted interests

- 12.6 Nothing in Clause 12 shall prevent the Seller or any Seller Related Person from holding for investment:

12.6.1 up to 5% of any class of shares or securities of any company traded on a recognised stock exchange; and

12.6.2 up to 10% of any class of securities not so quoted or dealt.

Use of Expedeon name

- 12.7 Subject to Clause 13.3 and to shareholder approval, the Seller shall, and shall procure that any Seller Related Persons shall, cease all use in any manner (including in any signage, stationery, websites, domain names, company names, publications or other materials) of "Expedeon" and any similar name or composite name including any such names and any related logo or device including any such name save for the Permitted Logo.

Severability

- 12.8 Each of the restrictions set out in Clauses 12.2, 12.3, 12.4, 12.5 and 12.7 of this Agreement is separate and severable and, in the event of any such restriction (including the defined expressions in Clauses 12.1.1(A), 12.1.1(B), 12.1.1(C), 12.1.1(D), 12.1.1(E) and 12.1.2) being determined as unenforceable in whole or in part for any reason, such unenforceability shall not affect the enforceability of the remaining restrictions or, in the case of part of a restriction being unenforceable, the remainder of that restriction.

Benefit of restrictions

- 12.9 The restrictions entered into by the Seller in Clauses 12.2, 12.3, 12.4, 12.5 and 12.7 are given to the Purchaser for itself and for each other member of the Purchaser Group. The rights of each member of the Purchaser Group (other than the Purchaser) under this Clause are subject to the provisions of Clause 17.11.

13. INTELLECTUAL PROPERTY

Seller IP

- 13.1 The Sellers hereby grant (or shall procure that any relevant Seller Group Company shall grant) to the Purchaser, each of its Affiliates and all Group Companies a non-exclusive royalty-free perpetual worldwide licence under the Seller US IP, in each case, provided that such licence shall only permit use of the Seller US IP in ways which do not exceed the purposes for which, the manner in which and the extent to which that Seller US IP was used for, or in connection with, the operation of the US Assets before the date of this Agreement. The Purchaser, its Affiliates and the Group Companies shall have the right to grant a sub-licence of the Seller US IP to any third party for the purpose of operating the US Assets in accordance with the terms of such licence. The Sellers agree to use all reasonably efforts to notify any proposed future purchaser, transferee or licensee of the Seller US IP of the terms of such licence and shall ensure that the terms of the licence shall be binding upon its successors in title and any subsequent purchaser, assignee or licensee of the Seller US IP.
- 13.2 The Sellers agree, on behalf of themselves and on behalf of any Seller Group Company, not to sue, commence, prosecute or cause to be commenced or prosecuted against the Purchaser, each of its Affiliates and any Group Companies any action, suit or other proceeding based upon any Seller Group IP in relation to and to the extent that any Seller Group IP that has been used by or for the business of any Group Company in the three (3) years prior to Completion.

Run-off licence to Seller

- 13.3 The Purchaser hereby grants (or shall procure that any relevant Group Company shall grant) to the Seller, each of its Affiliates and all Seller Group Companies a limited run-off licence to continue to use the EXPEDEON trade mark and any Intellectual Property relating thereto, for a maximum period (to run from the Completion Date) of: (i) equal to the relevant shelf life for selling off of any existing stock held by any Seller Group Company at the Completion Date; or (ii) six months for all other uses of the EXPEDEON trade mark. Following expiration of such run-off licence, the Seller, each of its Affiliates and all Seller Group Companies shall cease all use of the EXPEDEON trade mark and any Intellectual Property relating thereto, and all remaining inventory and products bearing the EXPEDEON trade mark owned by, and in the possession or control of, the Seller, any of its Affiliates or any Seller Group Company must be destroyed or rebranded.

14. **EMPLOYEES' INCENTIVE PLAN**

- 14.1 The Seller will make, or shall procure that the relevant member of the Seller's Group shall make, timely returns of information relating to the participation in any share incentive, share option, profit sharing or other incentive arrangement or scheme (together, the "**Schemes**") by any Employee of any Group Company or any US Employee to HM Revenue and Customs in the United Kingdom or to the revenue authorities in any other jurisdiction, to the extent that it is required to do so by such authorities.
- 14.2 Where the Purchaser, or such other appropriate member of the Purchaser's Group, is required to make returns of information relating to the participation in the Schemes by an Employee of any Group Company or a US Employee, the Seller will supply all information which the Purchaser, or such other appropriate member of the Purchaser's Group, may require, and which is requested in writing by the Purchaser, or such other appropriate member of the Purchaser's Group, in connection with the completion of such returns in relation to the Schemes. The Seller shall action the request for information not later than one month from receipt.

15. **SHAREHOLDER CLAIMS**

- 15.1 The Seller shall be solely responsible for the costs and conduct of any Shareholder Claims and undertakes to:
- 15.1.1 conduct the relevant Shareholder Claim with due care, including by adhering to all process and timing requirements in relation to the same;
 - 15.1.2 obtain legal advice in relation to the relevant Shareholder Claim (including in relation to the merits of the Shareholder Claim and the likelihood of its success);
 - 15.1.3 keep the Purchaser informed at reasonable intervals and upon request by the Purchaser regarding the progress of the Shareholder Claim (the information to be provided includes legal advice obtained by the Seller subject to legal privilege provisions);
 - 15.1.4 avoid taking any action which may adversely impact upon this Agreement, any other agreements contemplated herein or the Transaction.
- 15.2 Upon request of the Purchaser the Seller shall in accordance with any Applicable Law convene a shareholders' meeting (the "**Additional Shareholder Meeting**") at which resolutions will be proposed to:
- 15.2.1 resolve upon ratification (*Bestätigung*) of the Shareholder Approval (in the event that at any shareholder of the Seller has filed a contestation claim (*Anfechtungsklage*) against the Shareholder Approval); and/or
 - 15.2.2 approve the Transaction (in the event that any shareholder of the Seller has filed a claim for annulment (*Nichtigkeitsklage*) against the Shareholder Approval).
- 15.3 The Seller shall hold the Additional Shareholder Meeting within 9 weeks of a request from the Purchaser pursuant to Clause 15.2. For the avoidance of doubt, the Seller shall bear all costs associated with the preparation for the Additional Shareholder Meeting. The obligations of the Seller (and the representations and warranties given by the Seller) pursuant to Clauses 5.4, 5.5, 5.6, 5.7, 5.8 and 5.9 shall apply (*mutatis mutandis*) to the Additional Shareholder Meeting.
- 15.4 The Purchaser shall reimburse the Seller for the costs of the Additional Shareholder Meeting unless the Purchaser presents a legal evaluation to the Seller stating that the Additional Shareholder Meeting will have significant legal advantages.

16. **TERMINATION**

Termination events

16.1 Subject to Clause 16.2, this Agreement shall automatically terminate with immediate effect and each Party's rights and obligations shall cease to have force and effect if:

16.1.1 the Purchaser gives notice to the Seller pursuant to Clause 7.6.3 that it wishes to terminate this Agreement; or

16.1.2 the Sellers give notice to the Purchaser pursuant to Clause 7.8.3 that they wish to terminate this Agreement; or

16.1.3 if:

(A) before Completion, the Purchaser becomes aware that any of the Fundamental Warranties, was at the date of this Agreement, or has since become, untrue or misleading or has been breached; or

(B) the Seller is unable to repeat any of the Fundamental Warranties at Completion,

and, in either case, the Purchaser gives notice to the Seller that it wishes to terminate.

Effect of termination

16.2 The termination of this Agreement shall not affect:

16.2.1 any rights or obligations which have accrued or become due prior to the date of termination; and

16.2.2 the continued existence and validity of the rights and obligations of the Parties under any provision which is expressly or by implication intended to continue in force after termination (together with those Clauses necessary for their interpretation) including this Clause and Clauses 1, 8, 9, 10, 11, 17.1, 17.2, 17.3, 17.4, 17.5, 17.6, 17.7, 17.8, 17.9, 17.10, 17.11, 17.12, 17.13, 17.15, 17.16, 17.17, 17.18, 17.19, 17.20, 17.24, 18, 19 and 20.

17. **MISCELLANEOUS**

Announcements

17.1 Subject to the remaining provisions of this Clause 17.1, no Party shall release any announcement or despatch any announcement or circular, relating to this Agreement unless the form and content of such announcement or circular have been submitted to, and agreed by, the other Parties. Nothing in this Clause 17.1 shall prohibit any Party from making any announcement or despatching any circular as required by law or regulation or any regulatory body in which case, the announcement shall only be released or the circular despatched after consultation with the other Parties and after taking into account the reasonable requirements of the other Parties as to the content of such announcement or circular.

17.2 The Seller shall at the Purchaser's request supply such information and reports concerning each Group Company as may be required by the Purchaser to comply with any Applicable Law or regulation or the rules of the Financial Conduct Authority or the London Stock Exchange as to any prospectus, continuing obligations or circular to be published by the Purchaser or any announcement required to be made in relation to this Agreement or any matters contemplated by it.

Confidentiality

- 17.3 Each Party undertakes to the other Party that, before and after the expiry or termination of this Agreement, it:
- 17.3.1 shall (and shall procure that its officers, Employees and agents) preserve the confidentiality of the Confidential Information belonging to the other Party; and
 - 17.3.2 shall not, by failure to exercise due care or otherwise by any act or omission disclose to any person, or use or exploit commercially for its own purposes, any Confidential Information belonging to the other Party (and it shall not permit or allow its officers, Employees, agents or contractors to do any such thing),
subject to the provisions of Clauses 17.5 and 17.6.
- 17.4 For the purposes of Clauses 17.3, 17.5 and 17.6, "**Confidential Information**" means any information which a Party may have or acquire as a result of negotiating, entering into or performing its obligations pursuant to this Agreement, relating to:
- 17.4.1 the existence and contents of this Agreement and any other agreement or arrangement contemplated by this Agreement;
 - 17.4.2 the business, finances, assets, liabilities, customers, suppliers, personnel, plans or intentions, market opportunities, operations, processes, product information, dealings, transactions, Know How, or affairs of any Group Company from time to time; and
 - 17.4.3 the business, finances, assets, liabilities, customers, suppliers, personnel, plans or intentions, market opportunities, operations, processes, product information, dealings, transactions, Know How, or affairs of the other Party or any of their group undertakings (other than any Group Company) from time to time,
- provided that such information concerning the Group in relation to the period before Completion shall not be treated as Confidential Information belonging to the Seller following Completion and such information concerning the Group in relation to the period before or after Completion shall be treated as Confidential Information belonging to the Purchaser.
- 17.5 The restrictions contained in Clause 17.3 shall not apply to the disclosure by a Party of any Confidential Information:
- 17.5.1 pursuant to the terms of this Agreement;
 - 17.5.2 subject to Clause 17.6,
 - (A) to the extent required by Applicable Law;
 - (B) to a court, arbitrator or administrative tribunal in the course of proceedings before it to which the disclosing Party is a party in a case where such disclosure is required by such proceedings; or
 - (C) which is required to be disclosed by the regulations of any recognised exchange upon which the share capital of the disclosing Party is or is proposed to be from time to time listed or dealt in, or the regulations of any regulatory or supervisory authority to which such Party is or may become subject;
 - 17.5.3 to any Tax Authority to the extent reasonably required for the purposes of the Tax affairs of the Party concerned or a member of its group;
 - 17.5.4 where it has reasonable grounds to believe that another Party is involved in activity which may constitute a breach of Corruption Laws or an offence under the Modern Slavery Act 2015;

- 17.5.5 to any professional advisers who are bound by a duty of confidence to such Party which applies to any information disclosed;
- 17.5.6 to the extent that the relevant Confidential Information is in the public domain otherwise than by breach of this Agreement by any Party;
- 17.5.7 which is disclosed to such Party by a third party who is not in breach of any undertaking or duty as to confidentiality whether express or implied;
- 17.5.8 which that Party lawfully possessed prior to obtaining it from another Party; or
- 17.5.9 which is information that a prudent prospective purchaser of shares in (i) the Company or (ii) any Group Company or (iii) any parent company from time to time of the Seller or the Purchaser, or a prospective provider of debt finance to any such prudent prospective purchaser, might reasonably require to know and which is disclosed to any such person pursuant to bona fide negotiations for a sale of such shares and for this purpose "bona fide negotiations" shall mean negotiations for an arm's length sale to such a prudent prospective purchaser which, in the reasonable opinion of the disclosing Party, is willing and able to complete the purchase of such shares, provided that:
 - (A) if the Purchaser is the disclosing Party, the information disclosed shall relate only to the matters contained in Clauses 17.4.1 and 17.4.2;
 - (B) if the Seller is the disclosing Party, the information disclosed shall relate only to the matters contained in Clause 17.4.1;
 - (C) before any information is disclosed, the intended recipient of such information shall have given a confidentiality undertaking (in terms which are no less strict than these Clauses 17.3 to 17.6 to the disclosing Party and the other Parties; and
 - (D) before any information is disclosed, the Disclosing Party shall have given notice to the other Parties specifying the information which is to be disclosed.

- 17.6 If a Party becomes required, in circumstances contemplated by Clause 17.5.2, to disclose any Confidential Information such Party shall (to the extent permitted by Applicable Law) give to the other Party such notice as is practical in the circumstances of such disclosure and shall co-operate with the other Party, having due regard to the other Party's views, and take such steps as the other Party may reasonably require in order to enable it to mitigate the effects of, or avoid the requirements for, any such disclosure.

Joint and several liability

- 17.7 Where in this Agreement any liability is undertaken by two or more persons (including in respect of any Claim) the liability of each of them shall be joint and several.

No partnership

- 17.8 Nothing in this Agreement or in any document referred to in it shall constitute any of the Parties a partner of any other, nor shall the execution, completion and implementation of this Agreement confer on any Party any power to bind or impose any obligations to any third parties on any other Party or to pledge the credit of any other Party.

Assignment

- 17.9 None of the Parties to this Agreement may assign (whether absolutely or by way of security and whether in whole or in part), transfer, mortgage, charge or otherwise dispose in any manner whatsoever of the benefit of this Agreement and no Party may sub-contract or delegate in any manner whatsoever its performance under this Agreement without the prior written consent of the other Parties, provided that, following any such assignment, the Seller's liability under this Agreement shall be no greater than if the assignment had not occurred.
- 17.10 In the event of an assignment pursuant to Clause 17.9, the original contracting Party remains liable to procure the performance of its obligations under the Agreement by the assignee.

Third party rights

- 17.11 With the exception of:
- 17.11.1 the rights of each Group Company and of any director, Employee, officer or agent of each Group Company to enforce the terms contained in Clause 8.7;
 - 17.11.2 the rights of an Indemnified Person (other than an Indemnified Person who is a Party) to enforce the terms contained in Clause 9.1; and
 - 17.11.3 the rights of each member of the Purchaser Group (other than the Purchaser and the US Purchaser) to enforce the terms contained in Clause 12,
- (each such party being, for the purposes of this Clause 17.11, a "**Third Party**"),
- no term of this Agreement is enforceable under the Contracts (Rights of Third Parties) Act 1999 by a person who is not a Party to this Agreement. The rights of the relevant Third Parties to enforce the terms of Clause 8.7, Clause 9.1 and Clause 12 are subject to the condition that the Purchaser has the right (which it may waive in whole or in part in its absolute discretion and without the consent of or consultation with any Third Party) to have the sole conduct of any proceedings in relation to the enforcement of such rights (including any decision as to commencement or compromise of such proceedings) but will not owe any duty or have any liability to any of the Third Parties in relation to such conduct. The rights of the relevant Third Parties under Clause 8.7, Clause 9.1 and Clause 12 are also subject to the terms of Clauses 17.9, 17.10, 19 and Clause 20. The Parties to this Agreement may by agreement rescind or vary any term of this Agreement without the consent of any of the Third Parties.

Entire agreement

- 17.12 Each of the Parties to this Agreement confirms on behalf of itself and its Affiliates that this Agreement together with the agreed form documents, represents the entire understanding, and constitutes the whole agreement, in relation to its subject matter and supersedes any previous agreement between the Parties with respect thereto and, without prejudice to the generality of the foregoing, excludes any warranty, condition or other undertaking implied at law or by custom, usage or course of dealing.

Unenforceable provisions

- 17.13 Without prejudice to Clause 12.8, if any provision or part of this Agreement is void or unenforceable due to any Applicable Law, it shall be deemed to be deleted and the remaining provisions of this Agreement shall continue in full force and effect.

Effect of Completion

- 17.14 So far as it remains to be performed, this Agreement shall continue in full force and effect after Completion. The rights and remedies of the Parties shall not be affected by Completion.

Waiver

- 17.15 The rights and remedies of the Parties shall not be affected by any failure to exercise or delay in exercising any right or remedy or by the giving of any indulgence by any other Party or by anything whatsoever except a specific waiver or release in writing and any such waiver or release shall not prejudice or affect any other rights or remedies of the Parties. No single or partial exercise of any right or remedy shall prevent any further or other exercise thereof or the exercise of any other right or remedy.

Variation

- 17.16 No variation of this Agreement (or any of the documents referred to in it) shall be valid unless it is in writing (which, for this purpose, does not include email) and signed by or on behalf of each of the Parties. The expression "variation" includes any variation, supplement, deletion or replacement however effected.

Counterparts

- 17.17 This Agreement may be executed in any number of counterparts and by the Parties to it on separate counterparts, each of which when executed and delivered shall be an original, but all the counterparts together constitute one instrument.

Taxation of payments

- 17.18 Any payment made by or due from the Seller under, or pursuant to the terms of, this Agreement or the Tax Deed shall be free and clear of all Taxation whatsoever save only for any deductions or withholdings required by law.

Payments net of Tax

- 17.19 If any deductions or withholdings are required, or any payments made by or due from the Seller to the Purchaser under this Agreement or pursuant to the Tax Deed are liable for Taxation in the hands of the Purchaser, or would have been liable for Taxation but for the utilisation of any Tax relief in respect of such liability, the Seller shall be liable to pay to the Purchaser such further sums as shall be required to ensure that the net amount received and retained by the Purchaser will equal the full amount which would have been received under the relevant provisions of this Agreement and the Tax Deed in the absence of any such deductions, withholdings or Taxation liabilities and after giving credit for any relief from or credit in respect of the Tax or in respect of the deduction or withholding or the matter giving rise to it, provided that such relief or credit has been both obtained and utilised by the Purchaser.

Costs

- 17.20 The Parties shall pay their own costs in connection with the preparation and negotiation of this Agreement and any matter contemplated by it, but if the Purchaser exercises any right to terminate or rescind the Agreement (including rescission in the case of misrepresentation) the Seller shall indemnify the Purchaser against all expenses and costs incurred by it in investigating the affairs of the Group and in relation to the preparation and negotiation of the Agreement and the agreed form documents.

Further assurance

- 17.21 The Seller shall after Completion execute all such deeds and documents and do all such things as the Purchaser may require for perfecting the transactions intended to be effected under, or pursuant to, this Agreement and for giving the Purchaser the full benefit of the provisions of this Agreement, including vesting in the Purchaser the legal and beneficial title to the Shares and to the US Assets.

- 17.22 The Seller shall, and shall use all reasonable endeavours to ensure that any necessary third party shall, both before and after Completion and at the expense of the Seller execute, sign and do all such instruments, applications, documents, acts and things as may be required by the Purchaser to enable the Purchaser or its nominee to enjoy the full benefit of the Intellectual Property owned or used by any Group Company or owned by the Seller or group undertaking of the Seller relating to the business of the Group, including, without limitation, the progressing of any and all applications in relation to such Intellectual Property.

Wrong pockets

- 17.23 If, after Completion, any of the parties reasonably believe that any assets, including any Intellectual Property, should have been transferred pursuant to this Agreement, the parties shall consult with one another in good faith and reasonably cooperate to determine if such asset is held by the wrong party and, if so determined, the parties shall (or shall procure that any necessary third party shall) as soon as reasonably practicable sign, execute and deliver all deeds, documents and instruments and do all acts and things that shall be necessary, expedient or desirable (but within the scope of what is commercially reasonable) to effect the transfer of such asset to the appropriate party as soon as practicable and for no consideration.

Language

- 17.24 This Agreement was negotiated in English and, to be valid, all certificates, notices, communications and other documents made in connection with it shall be in English. If all or any part of this Agreement or any such certificate, notice, communication or other document is for any reason translated into any language other than English the English text shall prevail. Each of the Parties understands English and is content for all communications relating to this Agreement to be served on it in English.

18. NOTICES

- 18.1 A notice (including any approval, consent or other communication) given in connection with this Agreement and the documents referred to in it must be in writing and must be given by one of the following methods:

- 18.1.1 by hand (including by courier or process server) to the address of the addressee;
- 18.1.2 by pre-paid recorded delivery or airmail if posted to or from a place outside the United Kingdom to the address of the addressee; or
- 18.1.3 by email (including by attachment to an email) to the email address(es) specified for that addressee,

being the address or email address(es) which is specified in Clause 18.2 in relation to the Party to whom the notice is addressed, and marked for the attention of the person so specified, or to such other address, or marked for the attention of such other person, as the relevant Party may from time to time specify by notice given to the other Party in accordance with this Clause.

- 18.2 The relevant addresses and specified details for each of the Parties at the date of this Agreement is as follows:

Purchaser

Address: Discovery Drive, Cambridge Biomedical Campus,
Cambridge CB2 0AX

Email: marc.perkins@abcam.com

with a copy to: legal@abcam.com

For the
attention of:

The Company Secretary

US Purchaser

Address: 1 Kendall Square, Suite B2304, Cambridge, MA, 02139-1517, USA

Email: marc.perkins@abcam.com

with a copy to: legal@abcam.com

For the
attention of:

The Company Secretary

Seller

Address: Waldhofer Str. 102, 691203 Heidelberg, Germany

Email: heikki.lanckriet@expedeon.com

For the
attention of:

Heikki Lanckriet

US Seller

Address: 10805 Vista Sorrento Parkway, Suite 100, San Diego, CA 9212

Email: heikki.lanckriet@expedeon.com

For the
attention of:

Heikki Lanckriet

18.3 Subject to Clause 18.4, a notice is deemed to be received:

18.3.1 in the case of a notice given by hand (including by courier or process server), at the time when the notice is left at the relevant address;

18.3.2 in the case of a notice given by posted letter, on the third day after posting or, if posted to or from a place outside the United Kingdom, the seventh day after posting; and

18.3.3 in the case of a notice given by email, 4 hours after the time at which the email is sent (in the time zone of the recipient's postal address in Clause 18.2) to the email address(es) specified for that Party in Clause 18.2, provided that the sender does not within that 4 hour period receive a delivery failure or delay notification in respect of the email address (or, if more than one email address is specified for that Party, in respect of all of the email addresses).

18.4 A notice received or deemed to be received on a day which is not a business day in the place of receipt, or after 5pm on any business day in the place of receipt, shall be deemed to have been received on the next following business day in the place of receipt (and for the purposes of this Clause a business day in the place of receipt shall mean a day (other than a Saturday or Sunday) on which banks are open for general business in that place).

19. **GOVERNING LAW**

This Agreement and any dispute or claim arising out of or in connection with it or its subject matter, existence, negotiation, validity, termination or enforceability (including non-contractual disputes or claims) shall be governed by and construed in accordance with English law.

20. **DISPUTE RESOLUTION**

20.1 Each Party irrevocably agrees that the Courts of England shall have exclusive jurisdiction in relation to any dispute or claim arising out of or in connection with this Agreement or its subject matter, existence, negotiation, validity, termination or enforceability (including non-contractual disputes or claims).

20.2 Each Party irrevocably waives any right that it may have to object to an action being brought in those Courts, to claim that the action has been brought in an inconvenient forum, or to claim that those Courts do not have jurisdiction.

20.3 Regardless of whether the courts of any country other than England have jurisdiction to consider a dispute falling within Clause 20.1 of this Agreement, each Party irrevocably undertakes that it will neither issue or cause to be issued originating or other process in respect to such a dispute in any jurisdiction other than England.

20.4 In the event that any Party commences an action in the courts of any country other than England (a **"foreign action"**), the Party which commenced the foreign action shall indemnify the other Party(ies) in respect of any and all costs and liabilities which they have incurred in connection with the foreign action, whether or not those costs and liabilities would be recoverable apart from the provisions of this Clause.

This Agreement has been duly executed by the Parties (or their duly authorised representatives) on the date specified at the beginning of this Agreement.

SCHEDULE 1

DETAILS OF SELLER AND SHARES

Seller's names and addresses	Number and class of Shares held at date of Agreement
(1)	(2)
Expedeon AG	18,328,724 ordinary shares of £0.01 each
Waldhofer Str. 102, 691203 Heidelberg, Germany	2,500,000 B ordinary shares of \$0.50 each

SCHEDULE 2

DETAILS OF THE COMPANY AND THE SUBSIDIARIES

PART 1

DETAILS OF THE COMPANY

Registered number: 06785444

Company status: Private limited company

Country of incorporation: England and Wales

Registered office: 25 Norman Way Industrial Estate
Norman Way
Over
Cambridge
CB24 5QE

Issued share capital: £183,287.24 and \$1,250,000 made up of
18,328,724 ordinary shares of £0.01 each and
2,500,000 B ordinary shares of \$0.50 each

Directors: Dr Heikki Lanckriet
David John Roth

Secretary (if any): None

Auditors: Ernst & Young LLP

Outstanding charges:

Charge Code	Date of Creation	Persons entitled	Brief description
0678 5444 0003	28/08/2018	IL2 (2018) S.A.R.L	Contains fixed charge(s) Contains negative pledge
0678 5444 0004	28/08/2018	IL2 (2018) S.A.R.L	Contains fixed charge(s) Contains negative pledge
0678 5444 0005	28/08/2018	IL2 (2018) S.A.R.L	Contains fixed charge(s) Contains negative pledge Contains floating charge Floating charge covers all the property or undertaking of the property

PART 2

DETAILS OF THE SUBSIDIARIES

Name: **Expedeon Limited**

Registered number: 04681599

Company status: Private limited company

Country of incorporation: England and Wales

Registered office: 25 Norman Way Industrial Estate, Norman Way, Over
Cambridge, CB24 5QE

Issued share capital: £579.2224 made up of 5,792,224 ordinary shares of
£0.0001 each

Registered shareholders: The Company

Directors: Dr Heikki Lanckriet
David John Roth

Secretary (if any): None

Auditors: Ernst & Young LLP

Outstanding charges:

Charge Code	Date of Creation	Persons entitled	Brief description
0468 1599 0006	10/04/2017	Santander UK PLC	Freehold property known as land on the south side of Norman Way, Over, Title number: CB101090 Contains fixed charge(s) Contains negative pledge
0468 1599 0008	28/08/2018	IL2 (2018) S.A.R.L	Registered Property at 25 Norman Way Industrial Estate, Over, Cambridge, Title number: CB427355; and Unregistered Property at 1 st Floor, Ashwell Point, Sawston Contains fixed charge(s) Contains negative pledge Contains floating charge Floating charge covers all the property or undertaking of the company.

Name: **Innova Biosciences Ltd.**
 Registered number: 04415674
 Company status: Private limited company
 Country of incorporation: England and Wales
 Registered office: 25 Norman Way Industrial Estate, Norman Way, Over
 Cambridge, CB24 5QE
 Issued share capital: £148,830 made up of 148,830 ordinary shares of £1 each
 Registered shareholders: The Company
 Directors: Dr Heikki Lanckriet
 David John Roth
 Secretary (if any): None
 Auditors: Ernst & Young LLP
 Outstanding charges:

Charge Code	Date of Creation	Persons entitled	Brief description
0441 5674 0001	28/08/2018	IL2 (2018) S.A.R.L.	Contains fixed charge(s) Contains floating charge Floating charge covers all the property or undertaking of the company Contains negative pledge

Name: **TGR BioSciences Pty. Ltd.**
 Registered number: 097 258 789
 Company status: Proprietary limited company
 Country of incorporation: South Australia, Australia
 Registered office: 31 Dalgleish Street, Thebarton, South Australia, 5031
 Australia
 Issued share capital: AUD\$13,078,679.65 made up of 864,764 ordinary shares
 of AUD\$15.12399 each
 Registered shareholders: The Company
 Directors: Anne Therese Hinton

Michael Francis Crouch
Dr Heikki Lanckriet

Secretary (if any):

Anne Therese Hinton

Auditors:

Ernst & Young

Outstanding charges:

PPSR Registration Number	Charge number	Date of Creation	Persons Entitled	Brief description
201808240078460	50840823	24/08/2018	IL2 (2018) SARL	All present and after-acquired property no exceptions
201808240078473	50840822	24/08/2018	IL2 (2018) SARL	Intangible property - Intellectual property - Trade mark
201808240078487	50840821	24/08/2018	IL2 (2018) SARL	Intangible property - Intellectual property - Patent
201808240078494	50840819	24/08/2018	IL2 (2018) SARL	Intangible property - Intellectual property - Patent
201808240078516	50840818	24/08/2018	IL2 (2018) SARL	Intangible property - Intellectual property - Patent
201808240078500	50840817	24/08/2018	IL2 (2018) SARL	Intangible property - Intellectual property - Patent
201808240078528	50840816	24/08/2018	IL2 (2018) SARL	Intangible property - Intellectual property - Patent
201808240078544	50840814	24/08/2018	IL2 (2018) SARL	Intangible property - Intellectual property - Patent
201808240078537	50840815	24/08/2018	IL2 (2018) SARL	Intangible property - Intellectual property - Patent

Expedeon Asia Pte. Ltd.

Name:

Registered number: 201325785K

Company status: Private limited company

Country of incorporation: Singapore

Registered office: 531A Upper Cross Street, #04-98 Hong Lim Complex, Singapore (051531)

Issued share capital: S\$1 made up of 1 ordinary share of S\$1

Registered shareholders: Expedeon Limited

Directors: Tan Diliang (Chen Diliang)
Dr Heikki Lanckriet

Secretaries (if any): Tee Wey Lih
Darren Ku Zhi You

Auditors: *Unaudited*

Outstanding charges: None

Astranet Systems Ltd.

Name:

Registered number: 04215505

Company status: Private limited company (Dormant and active proposal to strike off)

Country of incorporation: England and Wales

Registered office: 25 Norman Way Industrial Estate, Norman Way, Over, Cambridge, CB24 5QE

Issued share capital: £100 made up of 100 ordinary shares of £1 each

Registered shareholders: Expedeon Limited

Directors: Dr Heikki Lanckriet

Secretary (if any): None

Auditors: None

Outstanding charges: None

SCHEDULE 3

ADJUSTMENTS TO CONSIDERATION

PART 1

COMPLETION BALANCE SHEET

1. INTERPRETATION

For the purposes of this Schedule 3 the following additional terms are defined:

"Accounting Policies" means the accounting principles, bases, conventions, rules and estimation techniques set out or referred to in Part 2 of this Schedule 3;

"Auditors" means Ernst & Young LLP;

"Cash" means cash (whether in hand or credited to any account with any bank, financial institution or similar institution or entity) and cash equivalents of the Group Companies (including all interest accrued thereon) at the Effective Time determined in accordance with paragraph 2 of this Schedule 3, including:

(a) marketable securities and short term investments; and

(b) cheques received by, honoured and made payable to any Group Company prior to Completion;

but excluding:

(c) any cash and cash equivalents held on trust on behalf of any customer; and

(d) any cash overdraft amounts and the amounts of any cheques issued on the accounts of any Group Company;

"Completion Balance Sheet" means the unaudited consolidated balance sheet of the Group in the form set out in Part 3 of this Schedule 3;

"Debt" means the amount at the Effective Time of all outstanding principal amounts (including any accrued but unpaid interest therein) under or in respect of:

(a) any borrowings of any Group Company (including overdrafts) owed to any bank, financial institution or other entity (exclusive of any credit card borrowings);

(b) any inter-company balances owed by any Group Company to any Seller Group Company (including shareholder loans, trading balances, recharges and other indebtedness) net of any such inter-company balances owed by any Seller Group Company to any Group Company (**"Net Inter-Company Debt"**),

(c) indebtedness arising under any bond, note, loan or similar instrument;

(d) debt break or early termination fees including, for the avoidance of doubt, early termination fees and/or prepayment fees payable to IL2 (2018) S.A.R.L or Santander UK Plc;

(e) accrued interest payable up to the Completion Date including that in relation to loans, notes, finance leases, hire purchase agreements and similar instruments;

(f) corporation tax payable, as adjusted for any tax relief claims recognised in accordance with the applicable tax laws;

(g) principal amounts payable under finance leases (excluding additional amounts which would be required to be reflected as a result of implementation of IFRS 16) or hire purchase agreements, excluding operating leases;

(h) any fees or expenses incurred, or to be paid, by any Group Company in relation to the Transaction (including any fees or expenses of any legal counsel, accountants, auditors, consultants or other professionals or any bonuses payable as a result of the Transaction) excluding any retention bonuses agreed between the parties to be payable by the Purchaser;

"Draft Statements" means a draft Completion Balance Sheet and a draft Statement of Net Debt prepared in accordance with paragraph 2 of this Schedule 3;

"Effective Time" has the meaning given to it in Schedule 16;

"Estimated Net Debt" means the Seller's good faith estimate of Net Debt of the Group at the Effective Time based on the information available at the time such calculation is made;

"Net Debt" means Debt less Cash at the Effective Time as set out in the Completion Balance Sheet;

"Purchaser's Accountants" means such accountants as the Purchaser nominates, other than Ernst & Young LLP;

"Seller's Accountants" means Ernst & Young LLP;

"Statement of Net Debt" means the statement of Net Debt to be prepared in accordance with this Schedule 3 and in the form set out in Part 3 of this Schedule 3;

2. **PREPARATION OF COMPLETION BALANCE SHEET AND STATEMENT OF NET DEBT**

2.1 The Purchaser shall prepare and instruct the Purchaser's Accountants to review the draft Completion Balance Sheet and to prepare a draft Statement of Net Debt on the basis of that draft Completion Balance Sheet.

2.2 The Seller shall procure that the Seller's Accountants, the Auditors and any former auditors of the Company and the Subsidiaries provide to the Company, the Purchaser and the Purchaser's Accountants all reasonable assistance to prepare and review the draft Completion Balance Sheet and the draft Statement of Net Debt, including access to all working papers. The Seller and the Purchaser acknowledge that hold harmless letters may be required in connection with the provision of such reasonable assistance by the Auditors, the Seller's Accountants and any former auditors.

2.3 The Purchaser shall deliver within 45 Business Days of the Completion Date to the Seller and the Seller's Accountants the Draft Statements.

2.4 The Seller shall notify the Purchaser in writing within 30 days of receipt of the Draft Statements stating whether the Seller agrees with the Draft Statements and, if it does not so agree, such notification shall give reasonable details of any disagreement and the adjustments which, in the opinion of the Seller should be made (the **"Disputed Details"**). Within 30 days of receipt of the Disputed Details, the Purchaser shall be obliged to submit to the Seller written notification giving reasonable details of its response to the Disputed Details (the **"Purchaser Dispute Response"**). In the case of disagreement, the Parties shall (in conjunction with their respective accountants) meet and discuss the Disputed Details and the Purchaser Dispute Response (if any) in order to seek to reach agreement upon such adjustments (if any) to the Draft Statements as are acceptable to the Seller and the Purchaser in order to put such draft documents in final form.

2.5 If the Seller is satisfied with the Draft Statements, either as originally submitted or after adjustments agreed between the Seller and the Purchaser (or if the Seller does not notify the Purchaser of any Disputed Details within the said 30 day period) the Draft Statements shall comprise the Completion Balance Sheet and Statement of Net Debt for the purposes of this Agreement.

2.6 If the Purchaser and the Seller fail for any reason to resolve all matters in dispute either:

2.6.1 if the Purchaser chooses not to submit a Purchaser Dispute Response, within 20 days of receipt by the Purchaser of the Disputed Details; or

2.6.2 if the Purchaser chooses to submit a Purchaser Dispute Response, within 20 days of receipt by the Seller of the Purchaser Dispute Response,

the matters in dispute shall be referred for resolution on the application of either the Seller or the Purchaser to an independent accountant being a partner in an independent firm of internationally recognised chartered accountants (the **"Expert Accountant"**) to be appointed (in default of nomination by agreement between the Seller and the Purchaser without undue delay) by the President for the time being of the Institute of Chartered Accountants (England and Wales). In giving his decision, the Expert Accountant shall state what adjustments (if any) are necessary to the Draft Statements in order for them to have been prepared in accordance with this Agreement. Such Draft Statements shall, subject to and following any such adjustments, comprise the Completion Balance Sheet and the Statement of Net Debt for the purposes of this Agreement.

- 2.7 If there is a referral to an Expert Accountant, the following provisions shall apply:
- 2.7.1 the Purchaser (or the Purchaser's Accountants) and the Seller (or the Seller's Accountants) shall each prepare a written statement on the matters in dispute which, together with any relevant documents, shall be submitted to the Expert Accountant and to the other Party;
 - 2.7.2 each of the Purchaser and the Seller may submit one set of written comments on the other Party's written statement to the Expert Accountant;
 - 2.7.3 the Expert Accountant shall be entitled:
 - (A) to stipulate the time periods within which the Parties shall prepare and submit the written statement and written comments referred to in this paragraph 2 (such time periods to be at least 14 days) and to disregard any written statement or comments not delivered to the Expert Accountant within the time periods so stipulated;
 - (B) to require the Parties and their respective accountants to attend one or more meetings and to raise enquiries of them about any matters which the Expert Accountant considers relevant;
 - (C) in the absence of agreement between the Parties, to determine the procedure to be followed in undertaking the expert determination, insofar as the procedure is not set out herein; and
 - (D) to appoint advisers (including legal advisers) if required;
 - 2.7.4 the Purchaser and the Seller shall use all reasonable endeavours to procure that the Expert Accountant is given all such assistance and access to documents and other information as he may reasonably require in order to make his decision;
 - 2.7.5 the Expert Accountant shall be requested to give his decision on matters in dispute arising out of the Disputed Details (and the Purchaser Dispute Response, if any), with written reasons for his decision, within 60 days of the date of his appointment; and
 - 2.7.6 save in the case of fraud or manifest error, the decision by the Expert Accountant shall be final and binding on all concerned and shall be given by the Expert Accountant acting as an expert and not as an arbitrator.
- 2.8 The costs of the Purchaser's Accountants, the Auditors, and any former statutory auditors of the Company and the Subsidiaries pursuant to the provisions of this Clause shall be borne by the Purchaser. The costs of the Seller's Accountants shall be borne by the Seller. Each of the Purchaser and Seller shall bear its own legal costs.
- 2.9 The costs of the Expert Accountant (including the cost for his appointment, his expenses and the costs of any advisers to the Expert Accountant) shall be borne by the Seller and the Purchaser in such proportions as the Expert Accountant shall determine in his absolute discretion (or, in the absence of any such determination, by the Seller and the Purchaser in equal amounts).

PART 2

ACCOUNTING POLICIES

The following accounting principles, bases, conventions, rules and estimation techniques shall be applied in the preparation of the Completion Balance Sheet as required by Part 1 of this Schedule 3.

1. GENERAL

The Completion Balance Sheet shall be prepared on the following basis:

- 1.1.1 first, on a basis consistent with the Accounts; and
- 1.1.2 secondly, and subject to paragraph 1.1.1 above, according to IFRS at the date of the Completion Balance Sheet.

PART 3

FORM OF COMPLETION BALANCE SHEET AND STATEMENT OF NET DEBT

	Balance Sheet at [Completion date] £'000	Net Debt £'000
ASSETS		
NON-CURRENT ASSETS		
Property, plant & equipment	X	
Other non-current assets	X	
Deferred tax assets	X	
Goodwill	X	
Intangible assets, net	X	
	X	
CURRENT ASSETS		
Financial assets	X	
Interco-receivables	X	X
Other current assets	X	
Trade accounts receivable	X	
Financial assets held for sale	X	
Cash and cash equivalents	X	X
Cash and cash equivalents - pledged	X	X
Inventories	X	
Accrued expenses	X	
TOTAL ASSETS	X	
CURRENT LIABILITIES		
Bank overdrafts	(X)	(X)
Interco-payables	(X)	(X)
Borrowings	(X)	(X)
Trade accounts payable	(X)	
Other current liabilities	(X)	
Financial liabilities - current	(X)	(X)
Provisions	(X)	
Deferred income	(X)	
	(X)	
NON-CURRENT LIABILITIES		
Deferred tax liabilities	(X)	
Borrowings	(X)	(X)
Financial liabilities - non-current	(X)	(X)
	(X)	
NET ASSETS / (LIABILITIES)	X / (X)	
NET CASH / (DEBT)		X / (X)

SCHEDULE 4

ESCROW

1. ESTABLISHMENT OF THE ESCROW ACCOUNT AND INSTRUCTIONS

- 1.1 The Seller and the Purchaser shall execute and deliver the Escrow Agreement to the Escrow Agent prior to Completion.
- 1.2 On the Completion Date, the Purchaser shall pay the Escrow Amount into the Escrow Account in accordance with Clause 3 and Part 2 of Schedule 6.
- 1.3 The Seller and the Purchaser shall give such instructions to the Escrow Agent as may be required to give full effect to the provisions of this Agreement.
- 1.4 No releases or withdrawals from the Escrow Account shall be made otherwise than in accordance with the provisions of the Escrow Agreement or this Agreement save with the prior written consent of the Seller and the Purchaser.
- 1.5 The Seller and the Purchaser agree that the Escrow Agent shall only have those duties, obligations and responsibilities expressly specified in the Escrow Agreement and shall have no implied (whether by law or otherwise) duties, obligations or responsibilities.
- 1.6 The cost of the Escrow Account and the Escrow Agent shall be paid by the Purchaser and the Sellers in equal amounts.

2. RELEASE OF ESCROW AMOUNTS

- 2.1 If, at any time before the Escrow Release Date, any claims under this Agreement are admitted by, or settled with the Sellers, or determined or the subject of a judgment of a court of England and Wales and in favour of the Purchaser, then within 5 Business Days after any and each such agreement, determination or judgment, the Seller and the Purchaser shall instruct the Escrow Agent to cause the release to the Purchaser's Nominated Account, a sum which is equal to the amount (if any) which shall have been agreed or determined or adjudged to be payable together with the interest (less any Tax required to be deducted or withheld from such interest by Applicable Law) earned on that sum in the Escrow Account from Completion to the date of release.
- 2.2 On the Business Day immediately following the Escrow Release Date, the Purchaser and the Seller shall instruct the Escrow Agent to pay to the Seller an amount equal to the amount which is standing to the credit of in the Escrow Account on the Escrow Release Date less an amount equal to the aggregate of any:
 - 2.2.1 claims that have been notified by the Purchaser to the Seller in accordance with Clause 10.3 to 10.5 of this Agreement on or prior to the Escrow Release Date and are outstanding as at the Escrow Release Date; and
 - 2.2.2 Contingent Consideration which remains to be paid by the Seller as at the Escrow Release Date.

3. ESCROW CLAIMS THE SUBJECT OF A RETENTION

- 3.1 On a Claim Retention Release Date, the Seller and the Purchaser shall instruct the Escrow Agent to release from the Escrow Account:
 - 3.1.1 to the Purchaser's Nominated Account, a sum equal to the amount (if any) which shall have been admitted by, or settled with, the applicable Seller or determined or finally adjudged by a court in accordance with this Agreement in favour of the Purchaser to be payable in respect of such Claims together with the interest (less any Tax required to be deducted or withheld from such interest by Applicable Law) earned on that sum in the Escrow Account from Completion to the date of release; and

3.1.2 to the Seller's Nominated Account, an amount (if any) equal to the amount which is retained in the Escrow Account following the application of paragraph 3.1.1 above, less:

(A) any sums which remain subject to a retention under Paragraph 2.2.1 of this Schedule 4; and

(B) any Contingent Consideration which remains to be paid by the Seller as at the Claim Retention Release Date,

together with the interest (less any Tax required to be deducted or withheld from such interest by Applicable Law) earned on that sum in the Escrow Account from Completion to the date of release.

3.2 On a Contingent Consideration Retention Release Date, the Seller and the Purchaser shall instruct the Escrow Agent to release from the Escrow Account to the Seller's Nominated Account, an amount equal to the the amount which is then retained in the Escrow Account, less:

3.2.1 any sums which remain subject to a retention under Paragraph 2.2.1 of this Schedule 4; and

3.2.2 any Contingent Consideration which remains to be paid by the Seller as at the Contingent Consideration Retention Release Date,

together with the interest (less any Tax required to be deducted or withheld from such interest by Applicable Law) earned on that sum in the Escrow Account from Completion to the date of release.

4. **RECEIPTS**

If any sum is remitted to the Seller's Nominated Account (or, as the case may be, to the Purchaser's Nominated Account) in accordance with this Agreement, receipt of the same shall be a good discharge of the obligations of the Party remitting such sum.

SCHEDULE 5

CONDUCT OF BUSINESS

Without prejudice to Clauses 6.1, 6.2 and 6.3, pending Completion the Sellers shall procure that, without the prior written consent of the Purchaser (which, in the cases of paragraphs 7, 14, 19, 24 and 27) such consent shall not to be unreasonably withheld or delayed, no Group Company shall (save to the extent explicitly required by Clauses 6.5 to 6.13):

1. create, allot or issue any shares or agree, arrange or undertake to do any of those things;
2. give or agree to give any option, right to acquire or call (whether by conversion, subscription or otherwise) in respect of any of its share or loan capital;
3. acquire or agree to acquire an interest in a corporate body or merge or consolidate with a corporate body or any other person, enter into any demerger transaction or participate in any other type of corporate reconstruction;
4. acquire or dispose of, or agree to acquire or dispose of, any material assets, businesses or undertakings or any material revenues or assume or incur, or agree to assume or incur, any material liability, obligation or expense (actual or contingent);
5. pass any resolution by its members in general meeting or make any alteration to its articles of association;
6. declare, make or pay any dividend or other distribution;
7. enter into any contract, liability or commitment which is incapable of being terminated within 3 months or could involve expenditure or liability which is of a material nature;
8. create, grant or allow to subsist any Encumbrance or other agreement or arrangement which has the same or similar effect to the granting of security in respect of all or any part of the undertaking, property or assets of any Group Company;
9. repay (other than in the ordinary course of business or in respect of amounts owed between Group Companies), acquire, redeem or create any borrowings or other indebtedness or obligation in the nature of borrowings (including obligations pursuant to any debenture, bond, note, loan stock or other security and obligations pursuant to finance leases);
10. make any advance, loan or deposit of money other than in the ordinary course of business or cancel, release or assign any indebtedness owed to it;
11. move or change the ownership of inventory other than in the normal course of business;
12. alter the invoicing or collection cycle of trade receivables or other financial assets compared with that in the normal course of business reflected in Financial Information contained in the Data Room;
13. alter the payment cycle of trade and other payables or other financial liabilities compared with that in the normal course of business reflected in Financial Information contained in the Data Room;
14. make, or agree to make, capital commitments or expenditure exceeding £25,000;
15. (i) lease, licence or part with or share possession or occupation of; or
(ii) surrender or otherwise dispose of any property held or occupied or which may be acquired by any Group Company (other than the Norman Way Freehold) or enter into any agreement or arrangement to do so;
16. breach any covenants on its part that are contained in any lease or licence of any property held or occupied by it;
17. enter into, amend the terms of, or terminate any partnership, joint venture or other profit sharing agreement, provided that a counterparty's termination of such an agreement shall not be a breach of this paragraph;
18. make any material change to the management and organisation of the Group or Group Companies or the manner in which they carry on the business;

19. modify or terminate any rights under any of its contracts which are material to the businesses of the Group or any Group Company;
20. remove or allow to be removed from any premises of the Group any plant and machinery;
21. disclose or agree to disclose to any person any technical or confidential information of any Group Company;
22. fail to renew or fail to take any action to defend or preserve any Intellectual Property or Know How;
23. enter into any agreement or arrangement to license, part with or share any Intellectual Property (other than in the ordinary course of business);
24. initiate, settle or abandon any claim, litigation, arbitration or other proceedings or make any admission of liability by or on behalf of any Group Company except, in any case, in relation to debt collection in the ordinary course of the business of sums not exceeding £25,000 for any single claim or as otherwise instructed by the Purchaser in writing;
25. make any material change (from the point of view of the relevant Employee or category of Employees) in the terms and conditions of employment (contractual or non-contractual), working practices or collective agreements relating to such practices of any Employee or category of Employees;
26. make any change in the remuneration of or (without limitation) other terms of employment of or vary the duties of or dismiss or terminate the employment of any director of any Group Company or any Employee with annual remuneration in excess of £50,000 (or the pro rata equivalent for part-time Employees);
27. appoint any attorneys, agents or sub-contractors;
28. vary any terms of any of its policies of insurance, knowingly take any action which may invalidate any of its policies of insurance or take out any additional or replacement policies of insurance (other than renewals of the policies of insurance on substantially the same terms as those in force at the date of this Agreement);
29. enter into any transaction with any person otherwise than at arms' length and for full value;
30. make any proposal for the winding up or liquidation of any Group Company;
31. propose any scheme or plan of arrangement, reconstruction, amalgamation or demerger;
32. change its accounting reference date;
33. change its auditors or make any change to its accounting practices or policies, except where such change is recommended by its auditors as a consequence of a change in generally accepted accounting practices or policies applicable to companies carrying on businesses of a similar nature, or as a consequence of a change in law;
34. make, revoke or change any Tax election, adopt or change any Tax accounting method, practice or period, grant or request a waiver or extension of any limitation on the period for audit and examination or assessment and collection of Tax, file any amended tax return or settle or compromise any contested Tax liability;
35. redeem or purchase any shares or reduce its issued share capital, or any uncalled or unpaid liability in respect thereof, or any capital redemption reserve, share premium account or other reserve that is not freely distributable;
36. create or amend any Employee share scheme, or grant or issue any options under any such scheme;
37. adopt or participate in any pension scheme (other than its existing pension schemes) or amend any of its existing pension schemes or review any such scheme or vary or cease contributions made to any such scheme; or

agree, undertake or otherwise give any binding undertaking to do any of the above.

SCHEDULE 6 COMPLETION OBLIGATIONS

PART 1

SELLER'S OBLIGATIONS

At Completion, the Seller shall:

2. deliver or cause to be delivered to the Purchaser:

Authority

- 2.1.1 a copy of or extracts from the minutes of meeting of the directors of the Seller authorising the Seller to enter into and perform its obligations under the Transaction Documents, certified to be a true and complete copy or extracts by a director or the secretary of the Seller;
- 2.1.2 a copy of the notarial certified minutes of the Shareholder Meeting;
- 2.1.3 a copy of or extracts from the minutes of meeting of the directors of the US Seller authorising the US Seller to enter into and perform its obligations under this Agreement, certified to be a true and complete copy or extracts by a director or the secretary of the US Seller;
- 2.1.4 if relevant, any power of attorney or other authority under which this Agreement or any document referred to in it is executed on behalf of the Seller or US Seller;

Transfer of shares

- 2.1.5 transfers of all the Shares each duly executed by the Seller in favour of the Purchaser or its nominee together with definitive share certificates for them each showing the name of the Seller as the registered holder;
- 2.1.6 share certificates showing the name of the Company or another Group Company as registered holder in respect of all the shares in each of the Subsidiaries;
- 2.1.7 an indemnity in respect of the missing share certificates in Innova Biosciences Ltd;
- 2.1.8 an irrevocable power of attorney from the Seller in the agreed form relating to the exercise of rights in respect of the Shares pending their registration in the name of the Purchaser or its nominee;

Releases

- 2.1.9 evidence, in a form satisfactory to the Purchaser, that, subject only to Completion, each of the Prepayment Facilities will be prepaid and cancelled in full and that any Encumbrance (including the Security) granted in connection with the Prepayment Facilities has been fully, irrevocably and unconditionally discharged (including, but not limited to, pay-off letters, a termination letter (in the case of the Santander Overdraft), forms DS1 and deeds of release executed by Santander and Boost (as applicable));

Business Matters

- 2.1.10 the Management Services Termination Deed duly executed by the parties thereto;
- 2.1.11 any Deeds of Assignments or Change of Control Consents;
- 2.1.12 (to the extent not already provided prior to Completion), the up to date asbestos survey and management register for Norman Way required pursuant to Clause 6;
- 2.1.13 evidence, in a form satisfactory to the Purchaser that:
 - (A) the Overdue Accounts have been duly filed; and
 - (B) that the Australian Securities and Investments Commission's public records for TGR BioSciences Pty. Ltd. are correct and up-to-date;

Agreed Form Documents

- 2.1.14 the Tax Deed duly executed by or on behalf of the Seller;
- 2.1.15 the CTO Waiver duly executed by or on behalf of the parties thereto;

- 2.1.16 the Consultancy Agreement duly executed by or on behalf of the Seller;
- 2.1.17 the Settlement Agreements duly executed by or on behalf of the parties thereto;
- 2.1.18 the Escrow Agreement duly executed by or on behalf of the Seller;
- 2.1.19 the Settlement Agreements duly executed by or on behalf of the Parties thereto;
- 2.1.20 the Norman Way Lease duly executed by or on behalf of the Seller and the Company;
- 2.1.21 the Distribution Agreements duly executed by or on behalf of Expedeon Biotech S.L.U;
- 2.1.22 the written resignations of all directors and any secretaries of the Company and each of the Subsidiaries (other than any director or secretary whom the Purchaser may wish to remain in office) executed as a deed and waiving all claims against the Company and the Subsidiaries in the agreed form;

Supplemental Disclosure Letter

- 2.1.23 the Supplemental Disclosure Letter (if any) executed by or on behalf of the Seller;

Company Administrative matters

- 2.1.24 in respect of each Group Company which is incorporated in England and Wales, any authentication code issued by Companies House or email confirmation from the Seller that no such code has been issued; and
 - 2.1.25 email confirmation from the Seller as to whether or not each Group Company which is incorporated in England and Wales has signed up to Companies House Protected Online Filing Scheme.
3. use its reasonable endeavours to deliver, or cause to be delivered to the Purchaser or put in possession of a Group Company:
- 3.1.1 to the extent not in the possession of a Group Company or the advisors, agents or attorneys of a Group Company, all:
 - (A) material books of account or references of customers and suppliers and other material records;
 - (B) books and records of each Group Company relating to the Employees (and of the US employees) and directors of each Group Company;
 - (C) cheque books (if any), certificates of incorporation, common seals, and all statutory and minute books (which shall be written up to, but not including, the date of Completion) of each Group Company;
 - (D) files relating to the prosecution or maintenance of the Group's patent portfolio and regulatory documents relating to the Group's products;
 - (E) any due diligence materials (including any memory sticks, cd roms or hard copy documents) relating to the Acquisitions (including any "Due Diligence Materials" as defined under the TGR SPA);
 - (F) leases and licences relating to each of the Real Properties;
4. procure that the following business is transacted at meetings of the directors of each Group Company:
- 4.1.1 the directors of the Company shall approve registration of the transfers of the Shares to the Purchaser or its nominee and the entry of the Purchaser in the register of members of the Company as the Company's sole shareholder, in each case subject only to the transfers being presented duly stamped and shall approve its entry into any relevant Transaction Document;
 - 4.1.2 the situation of the registered office of each Group Company which is incorporated in England and Wales shall be changed to Discovery Drive, Cambridge Biomedical Campus, Cambridge CB2 0AX;

- 4.1.3 the situation of the registered office of TGR BioSciences Pty. Ltd and Expedeon Asia Pte shall be changed to the address notified to the Seller by the Purchaser no later than 10 Business Days prior to Completion;
 - 4.1.4 the accounting reference date be changed to 30 June;
 - 4.1.5 all existing mandates for the operation of the bank accounts of each Group Company shall be revoked and new mandates issued giving authority to persons nominated by the Purchaser, provided that the Purchaser has provided all necessary information to the Seller by 30 November 2019;
 - 4.1.6 any person nominated by the Purchaser for appointment as a director or the secretary of the Company or any Group Company shall be so appointed; and
5. take such steps as are required to transfer the Shares, including registering the transfer of the Shares pursuant to this Agreement in the share register of the Company, reflecting the transfer of the Shares to the Purchaser and the cancellation of the documents of title in relation to the Shares, if any, issued to the Seller.

PART 2

PURCHASER OBLIGATIONS

At Completion, the Purchaser shall:

1. deliver or cause to be delivered to the Seller:
 - 1.1.1 a copy of or extracts from the minutes of a meeting of the directors of the Purchaser authorising the Purchaser to enter into and perform its obligations under the Transaction Documents, certified to be a true and complete copy or extract by a director or the secretary of the Purchaser; and
 - 1.1.2 the Consultancy Agreement duly executed by or on behalf of the Purchaser;
 - 1.1.3 the Escrow Agreement duly executed on behalf of the Purchaser;
 - 1.1.4 the Tax Deed duly executed on behalf of the Purchaser;
 - 1.1.5 the Distribution Agreements duly executed on behalf of the Purchaser;
 - 1.1.6 the US Transitional Services Agreement duly executed by or on behalf of the Purchaser;
2. pay by electronic transfer to the account of the Seller (details of which account shall be provided in writing to the Purchaser no later than 15 December 2019) the amounts set out in Clause 3.2.1 and receipt of the total of such amounts in cleared funds in the nominated account on the date of Completion or such later time as the Seller may agree shall constitute a valid discharge of the Purchaser's obligations under Clause 3.2.1.

SCHEDULE 7

SELLER WARRANTIES

PART 1 – SELLER TITLE AND CAPACITY WARRANTIES

1. TITLE

1.1 Entire issued share capital

The Shares constitute the entire issued share capital of the Company.

1.2 Title to Shares

The Seller is the legal and beneficial owner of, and is or will at Completion be entitled to transfer the legal and beneficial title to, those Shares set out opposite the Seller's name in column (2) of Schedule 1, free from any Encumbrances.

1.3 Title to the US Assets

The US Seller is the legal and beneficial owner of, and is or will at Completion be entitled to transfer the legal and beneficial title to the US Assets, free from any Encumbrances.

1.4 Share capital of Subsidiaries

The entire issued share capital of each Subsidiary is as shown in Part 2 of Schedule 2 and such share capital of each of the Subsidiaries is beneficially owned as shown in Part 2 of Schedule 2, free from any Encumbrances.

1.5 Issued shares

All the issued shares of each Group Company are fully paid up and no Group Company has exercised or purported to exercise or claimed any lien over any of their shares. There are no obligations of the Seller whatsoever to pay in any additional capital or to provide any other contribution such as a contribution in kind.

1.6 Rights of third parties

No person has the right to call for the issue of any share or loan capital of any Group Company by reason of any conversion rights or under any option or other agreement.

1.7 Company and the Subsidiaries

1.7.1 The details of the Company and the Subsidiaries set out in Schedule 2 are accurate and complete.

1.7.2 The Subsidiaries are the only subsidiary undertakings of the Company and the Company has no interest in the share capital or other securities of any other body corporate.

Conduct in relation to capital

1.7.3 No Group Company has:

- (A) at any time repaid or redeemed or agreed to repay or redeem any shares of any class of its share capital or otherwise reduced or agreed to reduce any class of its issued share capital or purchased any of its own shares or carried out any transaction having the effect of a reduction of capital;
- (B) at any time made or resolved or agreed to make any issue of shares or other securities by way of capitalisation of profits or reserves; or
- (C) given any financial assistance in contravention of the Companies Acts.

2. CAPACITY

2.1 Incorporation

The Sellers are duly incorporated, duly organised and validly existing under the laws of their respective jurisdictions and have full power to conduct their business as conducted at the date of this Agreement.

2.2 Corporate power and authority

Subject to the satisfaction of the Condition, the Sellers have corporate power and authority to enter into and perform this Agreement and any agreement entered into pursuant to the terms of this Agreement and the provisions of this Agreement and any agreement entered into pursuant to the terms of this Agreement, constitute valid and binding obligations on the Sellers and are enforceable against the Sellers, in accordance with their respective terms.

2.3 Due authorisation, execution and delivery

The Sellers have duly authorised, executed and delivered this Agreement and will, subject to the satisfaction of the Condition, at Completion have authorised, executed and delivered any agreements to be entered into pursuant to the terms of this Agreement.

2.4 No breach

The execution and delivery by the Sellers of, and the performance by the Sellers of their respective obligations under, this Agreement entered into pursuant to the terms of this Agreement will neither:

2.4.1 result in a breach of or conflict with any provision of its memorandum or articles of association certificate of incorporation, by-laws or equivalent constitutional documents;

2.4.2 result in a material breach of, or constitute a material default under, any instrument to which it is a party or by which it is bound; or

2.4.3 result in a breach of any Applicable Laws;

2.5 Consents

All consents, permissions, authorisations approvals and agreements of third parties and all authorisations, registrations, declarations, filings with any governmental department, commission, agency or other organisation having jurisdiction over the Sellers which are necessary or desirable for the Sellers to obtain in order to enter into and perform this Agreement and any agreement entered into pursuant to the terms of this Agreement in accordance with its terms, have been unconditionally obtained in writing and have been disclosed in writing to the Purchaser.

2.6 Proceedings

There are no:

2.6.1 outstanding judgments, orders, injunctions or decrees of any governmental or regulatory body or arbitration tribunal against or affecting the Sellers or any of their group undertakings;

2.6.2 lawsuits, actions or proceedings pending or, to the knowledge of the Seller, threatened against or affecting the Sellers or any of their group undertakings; or

2.6.3 investigations by any governmental or regulatory body which are pending or, to the knowledge of the Seller, threatened against the Sellers or any of their group undertakings,

and which, in each case, has or could have a material adverse effect on the ability of the Sellers to perform its obligations under this Agreement or any agreement entered into pursuant to the terms of this Agreement.

2.7 **Solvency**

No order has been made, petition presented or meeting convened for the winding up of either of the Sellers or any of their group undertakings, nor any other action taken in relation to the appointment of an administrator, liquidator, receiver, administrative receiver, compulsory manager or any provisional liquidator (or equivalent in any other jurisdiction) (or other process whereby the business is terminated and the assets of the company concerned are distributed amongst the creditors or shareholders or any other contributors), and there are no proceedings under any applicable insolvency, reorganisation or similar laws in any relevant jurisdiction, and no events have occurred which, under Applicable Laws, would justify any such proceedings.

PART 2 – SELLER BUSINESS WARRANTIES

1. ACCOUNTS

1.1 General

The Accounts:

- 1.1.1 have been prepared in accordance with FRS 101 and suitable accounting policies and estimates;
- 1.1.2 show a true and fair view of the state of affairs of each Group Company as at the Accounts Date and of its profit or loss and cash flows for the accounting reference period ended on that date;
- 1.1.3 comply with the requirements of all Applicable Laws; and
- 1.1.4 (save as the Accounts expressly disclose) are prepared using the same estimation techniques and accounting policies as those adopted in preparing the Previous Accounts.

1.2 Position since Accounts Date

Since the Accounts Date:

- 1.2.1 apart from the dividends provided for or disclosed in the Accounts no dividend or other distribution has been declared, paid or made by any Group Company to any other party than a Group Company;
- 1.2.2 the business of all Group Companies has been carried on in the ordinary course and so as to maintain it as a going concern;
- 1.2.3 there has been no event, change or occurrence which, individually or together with any other event, change or occurrence, has, or would, or could reasonably be expected to have, a material adverse effect on or cause a material adverse change to the financial or trading position or prospects of any Group Company;
- 1.2.4 there has been no material reduction in the value of the assets of any Group Company on the basis of the valuations adopted in the Accounts;
- 1.2.5 no Group Company has lost any important customer or source of supply or been affected by any abnormal trading factor and the Seller is not aware of any facts likely to give rise to any such effect whether before or after Completion;
- 1.2.6 no Group Company has acquired or disposed of or agreed to acquire or dispose of any business or any material asset other than trading stock in the ordinary course of business (other than pursuant to this Agreement or otherwise in connection with the Pre-Completion Reorganisation);;
- 1.2.7 no debtor has been released by any Group Company on terms that they pay less than the book value of any debt (subject to settlement discounts on the usual terms which have been disclosed to the Purchaser) and no debt has been written off or has proved to be irrecoverable to any extent; and
- 1.2.8 the same estimation techniques and accounting policies as those used to prepare the Accounts have continued to be used by the Group and the Company without alteration.

1.3 Reporting Packs

The Reporting Packs:

1.3.1 (save as expressly disclosed in the Reporting Packs) have been prepared using the same estimation techniques and accounting policies as those adopted in preparing the Accounts; and

1.3.2 have been properly and carefully prepared and are not misleading.

AcquisitionCo Accounts

The AcquisitionCo Accounts:

1.3.3 (save as expressly disclosed in the AcquisitionCo Accounts) have been prepared using the same estimation techniques and accounting policies as those adopted in preparing the Accounts; and

1.3.4 have been properly and carefully prepared and are not misleading.

Financial Information

The Financial Information has been carefully prepared and, so far as the Seller is aware, the Financial Information is not inaccurate or misleading.

2. ASSETS

2.1 Title to Assets

2.1.1 The assets (excluding assets leased or the subject of operating or finance leases which have been disclosed) included in the Accounts or acquired by any Group Company since the Accounts Date (other than trading stock disposed of since that date in the ordinary course of business) and all other assets used or employed by any Group Company:

(A) are the absolute property of such Group Company free from any Encumbrance and are not the subject of any leasing, hiring or hire purchase agreement or agreement for payment on deferred terms or assignment or factoring or other similar agreement (unless specifically disclosed in the Accounts);

(B) are in the possession or under the control of the relevant Group Company; and

(C) constitute all of the assets required by each Group Company to conduct the business of the Group as it is currently conducted.

2.2 Condition of plant, machinery and equipment

The plant, machinery, office equipment, computer systems and vehicles used by each Group Company are in good repair, regularly maintained and fully serviceable and comply with any applicable legal requirement or restriction and the vehicles are duly licensed and suitable for the purposes for which they are used.

2.3 Acquisition at arm's length

No Group Company has, within the period of twenty four months ending on the date of this Agreement, acquired any asset on terms which were not arm's length.

2.4 Realisation of inventory

The present inventory of each Group Company will, if disposed of within twelve months from the date of this Agreement, realise in total at least the amount at which it is included in its books.

2.5 Sufficiency

The Group owns, or is otherwise legally entitled to use and dispose of, all of the assets, including the US Assets, currently used by the Group in the course of its businesses, and those assets, taken together with the services the Group will receive pursuant to the US Transitional Services Agreement, are sufficient to enable the Group to carry on its businesses following Completion in the manner conducted as at the date of this Agreement.

2.6 **Nature of debts**

No Group Company is owed any money other than trade debts incurred in the ordinary course of business and cash at bank.

3. **FINANCIAL OBLIGATIONS**

3.1 **General**

3.1.1 No Group Company has outstanding any obligation for the payment or repayment of money, whether present or future, actual or contingent (a "**Financial Obligation**"), nor have any of them entered into or agreed to enter into any agreement or arrangement the purpose of which is to raise money or provide finance or credit or to guarantee or indemnify any Financial Obligation or to prevent or limit loss in respect of any Financial Obligation.

3.1.2 No Group Company assumed any obligation, direct or indirect, actual or contingent, to purchase or assume any indebtedness of any person or to make an investment in or loan to any person or to purchase assets of any person where, in each case, such obligation is assumed in order to maintain or assist the ability of such person to meet its indebtedness or to protect it from loss.

3.1.3 No Group Company has subsisting over the whole or any part of its present or future revenues or assets any Encumbrance.

3.1.4 No Financial Obligation of any Group Company has become or is now due and payable, or capable of being declared due and payable, before its normal or originally stated maturity and no demand or other notice requiring the payment or repayment of money before its normal or originally stated maturity has been received by any Group Company.

3.1.5 Save for matters arising from the Transaction, no event or circumstance has occurred, or may occur with the giving of notice or lapse of time, determination of materiality or satisfaction of any other condition, which does or may result in any Financial Obligation becoming due and payable before its normal or originally stated maturity or which otherwise alters the right of any Group Company to draw money or exercise its rights under an agreement relating to a Financial Obligation.

3.2 **Grants and subsidies**

No Group Company has done or agreed to do anything as a result of which:

3.2.1 any investment grant or other grant or any subsidy received by any Group Company is or may be liable to be refunded wholly or partly; or

3.2.2 any application made by any Group Company for such a grant or subsidy shall or may be refused wholly or partly,

and neither the signature nor the performance of the Agreement shall have any such result.

3.3 **Loans to directors and connected persons**

There is not outstanding:

3.3.1 any loan made by any Group Company to, or debt owing to any Group Company by, the Seller or any director of any Group Company or any person connected with any of them; or

- 3.3.2 any agreement or arrangement to which any Group Company is a party and in which the Seller or any director of any Group Company or any person connected with any of them is interested.

4. REAL ESTATE

4.1 Interests

The Real Properties comprise all the land and buildings owned by the Group or used or occupied by the Group or in which any Group Company has any other interest, right or liability.

4.2 Title

4.3 In the case of each of the Real Properties:

- 4.3.1 the Group Company named as the registered proprietor (or owner/tenant if unregistered) of the relevant Real Property in Schedule 11 is the sole legal and beneficial owner of it and has a good and marketable title to it and has in its possession or under its control, free of any lien, all relevant original title deeds and documents necessary to prove the title of the relevant Group Company;
- 4.3.2 the information contained in Schedule 11 is true and accurate in all respects;
- 4.3.3 where the title requires registration under local law it has been properly registered with title absolute and a Group Company is the registered proprietor;
- 4.3.4 there are no Encumbrances or trusts affecting it;
- 4.3.5 it benefits from all rights, easements, covenants and entitlements as are necessary for its beneficial use and enjoyment and no such rights, easements, covenants or entitlements are subject to any restrictions as to their exercise or terms entitling any person to terminate or curtail them;
- 4.3.6 a Group Company is in possession of, owns, uses and occupies it free from any lease, covenant, restriction, stipulation, easement, licence, underlease, tenancy, right, limitation, option, right of pre-emption, customary or public right, local land charge, mining or mineral right, franchise, exception or reservation or other right or interest in or over land;
- 4.3.7 there are, so far as the Seller is aware, no circumstances existing which would entitle any third party to exercise a right of entry or to take possession or which would in any other way affect or restrict the continued possession, enjoyment or use of it by the Group; and
- 4.3.8 there are no outstanding unobserved or unperformed obligations.

4.4 Statutory obligations, notices and orders

- 4.5 No notice, order, proposal, application, request or schedule of dilapidations affecting or relating to any of the Real Properties has been served or made by any authority or other person or by any Group Company and, so far as the Seller is aware, there are no circumstances which are likely to result in any being served or made.
- 4.6 There has been no breach of any requirement of any current or previous statutes, laws, regulations, orders or notices which affect the Real Properties and there are no circumstances which may result in any such order or notice being made or served.

4.7 Planning and development matters

- 4.7.1 The existing use of each of the Real Properties as stated in Schedule 11 is the actual use to which each of the Real Properties is put and is permitted under applicable planning law and regulation.

- 4.7.2 No development at any of the Real Properties has been carried out in breach of applicable planning law and regulation.
- 4.7.3 Any planning consents and permissions affecting the Real Properties are unconditional or subject only to conditions which have been satisfied.
- 4.7.4 There are no proposals for the compulsory acquisition of the whole or any part of any of the Real Properties or affecting any access to or egress from any of them.

4.8 Condition of Real Properties

The Real Properties are in good and substantial repair and fit for the purposes for which they are presently used. There is no material defect in the construction or condition of any of the Real Properties and no Group Company is expecting to have to expend any material sum of money in respect of the Real Properties in the next 12 months.

4.9 Leasehold and Licensed Real Properties

4.10 In relation to each of the Real Properties which is leasehold or Licensed:

- 4.10.1 it is held under the terms of the lease or licence which is summarised in Part 2 of Schedule 11 and no licences or collateral assurances, undertakings or concessions have been made by any party to the lease or licence respectively;
- 4.10.2 the relevant Group Company has paid the rent and all other sums payable under the lease or licence on the due dates for payment and the last demand for rent was unqualified and each lease is valid and in full force;
- 4.10.3 the relevant Group Company has observed and performed the covenants and the conditions contained in the lease and the licence in all material respects, and has received no complaint regarding any alleged breach of any of such covenants and conditions and nor is the Group in dispute with the landlord or licensee (as the case may be) in relation to any matters relating to the lease or licence;
- 4.10.4 the landlord or licensee (as the case may be) has observed and performed the covenants and conditions contained in the lease in all material respects; and
- 4.10.5 there are no rent reviews currently outstanding or under negotiation or the subject of a reference to an expert or arbitrator or the courts.

4.11 Other involvement in relation to property

No Group Company has at any time given any covenant or entered into any agreement, deed or other document in any capacity whatsoever in respect of any freehold or leasehold property in respect of which any actual contingent or potential liability remains with any Group Company.

5. ENVIRONMENT AND HEALTH AND SAFETY

5.1 Environmental Law compliance

Each Group Company complies and has at all times prior to the date of this Agreement complied with Environmental Law.

5.2 Complaints and proceedings

- 5.2.1 No Group Company has received a complaint (whether or not in writing) or a notice alleging a breach of, or a liability under, Environmental Law.

- 5.2.2 No Group Company is, or has in the previous two (2) years been, engaged in any prosecution, regulatory, litigation, arbitration, action or other proceedings or settlement under any Environmental Law, or concerning any Environmental Permit or any Hazardous Substance, and, so far as the Seller is aware, there are no facts or circumstances which are likely to give rise to any such prosecution, investigation, litigation, arbitration, action, proceedings or settlement by or against any Group Company.

5.3 Environmental Permits

- 5.3.1 Each Group Company has obtained and complies, and at all times prior to the date of this Agreement has obtained and complied, with each Environmental Permit required to carry on their respective business and no action has been taken to vary, revoke or suspend the same.
- 5.3.2 No Group Company holds or, so far as the Seller is aware, is required to hold, any registration or authorisation for any substance, article or mixture manufactured, imported or used by it under Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) and the related implementing legislation.

5.4 Contamination and pollution at the Real Properties

- 5.4.1 So far as the Seller is aware, no Hazardous Substance has been disposed of or released in, on or under the Real Properties nor has any Hazardous Substance migrated to or from the Real Properties, in each case to an extent that could result in liability for any investigation, assessment, monitoring, clean up or any other remedial action pursuant to Environmental Law.
- 5.4.2 The Real Properties are not being nor have they been used for the treatment, deposit or disposal of waste.

5.5 Environmental and Health and Safety Reports

- 5.5.1 Attached to the Signing Disclosure Letter are copies of each environmental, and each health and safety, audit, assessment, survey, report or investigation (each an "**Environmental and Health and Safety Report**") in the control of, or otherwise carried out by or on behalf of the Seller or any Group Company in relation to the Real Properties or otherwise relevant to the business of each Group Company.
- 5.5.2 Each recommendation made in each Environmental and Health and Safety Report has been implemented.

5.6 Previously used land/third party land

- 5.6.1 No Group Company has caused or permitted the release or disposal of any Hazardous Substance in on or under land that it previously owned, occupied or used or on any third party land (and no Group Company is liable to remediate the same).
- 5.6.2 The Seller is not aware of any pending or threatened action against a Group Company with respect to any contamination or pollution at, or other adverse Environmental Condition relating to, the land referred to in paragraph 5.6.1.
- 5.6.3 The Real Properties are the only properties which the Group has owned, occupied or used during the period from 1 January 2017 to the date of this Agreement.

5.7 Environmental agreements

No Group Company has given any environmental covenant, warranty, undertaking, representation, indemnity or similar provision concerning liability (actual or potential) for an identified adverse condition relating to the Environment.

5.8 Environmental problems near the properties

So far as the Seller is aware, there are no adverse conditions relating to the Environment near the Real Properties (including any waste disposal site) which is likely to interfere with activities at, or involve liability in respect of, the Real Properties.

6. INTELLECTUAL PROPERTY

6.1 Ownership and Title

- 6.1.1 Complete and accurate details of all registered Intellectual Property (including applications for any such right) owned by or registered to any Group Company or owned by or registered to the Sellers or group undertaking of the Seller and relating to the business of the Group are set out in Part 1 and Part 3 of Schedule 12 and all such rights and all other Intellectual Property material to the business of the Group (including relating to the underlying technology, invention and the proposed patent application for antibody based assays using oligo-conjugated antibodies against biological targets in conjunction with rolling circle amplification to establish detection and quantification of such biological target(s), other than in the Qualiphi enzyme itself) are owned solely, legally and beneficially by the company identified as the proprietor of the relevant rights free from any Encumbrance or any arrangement that restricts their disclosure, use or transfer.
- 6.1.2 All renewal and application fees and other steps required for the maintenance or protection or enforcement of any Intellectual Property owned by any Group Company or by the Sellers or group undertaking of the Seller in connection with the business have been paid and taken and no steps need to be taken to meet any administrative or procedural deadline in order to maintain or obtain any rights or registrations in respect of such Intellectual Property.
- 6.1.3 Neither the validity or subsistence of the registered Intellectual Property required to be listed in Part 1 of Schedule 12 and the rights, title or interest of any Group Company or the Sellers or any group undertaking of the Seller and relating to the business of the Group in such registered Intellectual Property is the subject of any current, pending or threatened challenge, claim or proceedings (including opposition, cancellation, modification, revocation or rectification) nor has it been in the last three years. There are no facts or matters which might give rise to any such challenge, claim or proceedings.
- 6.1.4 No steps need to be taken in the next six months to meet any administrative or procedural deadline in order to maintain or obtain any rights or registrations in respect of such Intellectual Property.
- 6.1.5 So far as the Seller is aware, it has provided complete and accurate information sufficient to allow the Purchaser to evaluate the extent and adequacy of the patent filings and patent coverage of the inventions relating to the Products.
- 6.1.6 The document contained in the Data Room at 21.01 is true and accurate.
- 6.1.7 All Employees, Employees, directors, contractors and agents who have developed any Intellectual Property for the Group (or any of the US IP), or who are otherwise engaged in relation to the business of the Group, have
 - (A) entered into a valid written agreement with a Group Company which requires them to fully and effectively disclose such Intellectual Property, and to assign such Intellectual Property, to the relevant Group Company; and
 - (B) effected all such Intellectual Property assignments referred to in (A) above.

6.2 Licences

- 6.2.1 Complete and accurate copies (or in the case of unwritten licences, agreements or arrangements details) of all licences, agreements and arrangements relating to Intellectual Property granted to or by any Group Company or to or by the Sellers or a group undertaking of the Seller and relating to the business of the Group are set out in Part 2 of Schedule 12.
- 6.2.2 No person has breached or is in breach of and no Group Company nor the Sellers nor any group undertaking of the Seller has within the last 24 months received or issued a written notice in respect of any breach or termination, in relation to any of the licences, agreements or arrangements disclosed pursuant to paragraph 6.2.1 and no such licences, agreements or arrangements are capable of termination as a result of the transfer of or change in the underlying ownership or control of the Group.

6.3 **Sufficiency**

- 6.3.1 So far as the Seller is aware:

- (A) the list of all Intellectual Property set out in Part 1 of Schedule 12;
- (B) the US IP;
- (C) the other Intellectual Property owned by or registered to any Group Company; and
- (D) any Intellectual Property licensed by the Sellers in connection with the Transaction, including under the Distribution Agreements or pursuant to Clause 13.1 of this Agreement),

constitute all material Intellectual Property necessary to carry on the business of the Group in the manner currently carried on and to fulfil any existing plans and proposals for the business of the Group.

- 6.3.2 No Seller Group Company owns or is licensed to use any Intellectual Property or information which is also used in the business of the Group.

6.4 **Infringement of third party rights**

- 6.4.1 None of the activities of the Group, the Seller or the group undertakings of the Seller which relate to the business of the Group have infringed or infringe the Intellectual Property of any third party.
- 6.4.2 None of the Intellectual Property owned by any Group Company or owned by the Seller or group undertaking of the Seller and relating to the business of the Group are the subject of any litigation, arbitration, mediation, administrative or criminal proceedings and so far as the Seller is aware no such proceedings are pending, threatened or expected.
- 6.4.3 No Group Company, nor the US Seller, has in the past 3 years received pursuant to Applicable Law written notice by any Employee or former Employee of such Group Company (or the US Seller in respect of the US Employees only) claiming compensation in relation to any registered Intellectual Property owned by the Group, the US Seller or any other Intellectual Property material to the businesses of the Group.
- 6.4.4 None of the activities of the Group, the Seller or the group undertakings of the Seller which relate to the business of the Group have amounted or amount to an unjustified threat of proceedings in relation to Intellectual Property.

6.5 **Infringement by third parties**

- 6.5.1 So far as the Seller is aware no third party is infringing any Intellectual Property owned or used by any Group Company or owned by the Seller or group undertaking of the Seller relating to the business of the Group.
- 6.5.2 Neither the Seller nor any Group Company has knowingly permitted any infringement of any Intellectual Property owned or used by any Group Company or owned by the Seller or group undertaking of the Seller relating to the business of the Group without taking action in relation to that infringement.

6.6 Confidential information

- 6.6.1 No confidential information or Know How relating to the business of the Group, or the US Assets, has been disclosed, or permitted, undertaken or arranged to be disclosed to any person (except in the ordinary course of business and under an obligation of confidence) and so far as the Seller is aware there is and there has been no unauthorised use of such confidential information of Know How by any third party.
- 6.6.2 Nothing done or omitted to be done by any Group Company has breached, or is breaching, any right of any third party to confidence.

7. DATA PROTECTION

- 7.1 Each Group Company has complied in the last three years in all material respects with all applicable requirements of the Data Protection Legislation including maintaining all necessary notifications and registrations, and paying all applicable data protection fees.
- 7.2 There are, and in the past three years there have been, no instances of accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to, Personal Data stored or otherwise processed by a Group Company, and the Seller is not aware of any fact or matter which may give rise to such an occurrence.
- 7.3 No Group Company has received any notice alleging non-compliance with any Data Protection Legislation and no order has been made against any Group Company for the rectification, blocking, erasure or destruction of any data under any Data Protection Legislation.

8. CYBER SECURITY

8.1 Cyber security technical and organisational measures

- 8.1.1 Each Group Company has in place appropriate technical and organisational measures to manage the ability of its network and information systems to resist, at a given level of confidence, a "**Cyber Incident**", being any incident that compromises (or attempts to compromise) the availability, authenticity, integrity or confidentiality of stored or transmitted or processed data of whatever nature, or the systems, networks or other infrastructure on which such data resides, or the related services offered by, or accessible via, those network and information systems.
- 8.1.2 Each Group Company has complied with any applicable standards relating to the technical and organisational measures in paragraph 8.1.1, such as ISO/IEC 27001.

8.2 Policies

- 8.2.1 Each Group Company has in place reasonable and proportionate policies and procedures for Employees of the Group Companies describing acceptable and secure use of Information Technology and all such policies have been disclosed.
- 8.2.2 Each Group Company has in place reasonable and proportionate plans, policies and procedures, including appropriate training, in relation to responding to, and mitigating the effects of, Cyber Incidents.

8.3 **Cyber incidents**

No Group Company has been the subject of any Cyber Incident (each a "**Company Cyber Incident**"), whether it has been notified to a governmental or other regulatory body or not.

8.4 **Audits and investigations**

8.4.1 There is not pending, or in existence, any material audit, investigation or enquiry by, or on behalf of, any governmental or other regulatory body in respect of any Company Cyber Incident; and no Group Company has received written notice that it is the subject of any such ongoing material audit, official investigation or inquiry or proceedings brought by any governmental or other regulatory body.

8.4.2 No Group Company has been fined, censured or otherwise sanctioned or the subject of any enforcement action by any governmental or other regulatory body in relation to any Company Cyber Incident and there has been no suggestion or threat of the same.

8.4.3 No Group Company has any actual, threatened or anticipated liability associated with or arising from any Company Cyber Incident.

9. **INFORMATION TECHNOLOGY**

9.1 Each element of the Information Technology is legally and beneficially owned by a Group Company, or validly licensed to a Group Company pursuant to a written agreement, in each case free from Encumbrances.

9.2 There are, and in the past three years there have been:

9.2.1 no performance degradations or breakdowns of, or logical or physical intrusions into, any Information Technology or public communications network; and

9.2.2 no instances of accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to, data stored or otherwise processed by any Group Company,

which have had (or are having) an adverse effect on any Group Company, and the Seller is not aware of any fact or matter which may give rise to such an occurrence.

9.3 The Information Technology is in good working order in all material respects and has sufficient scalability, capacity, functionality and performance to meet the current business requirements of the Group and those reasonably projected for the next 12 months.

9.4 All material licences of, and material services relating to, the Information Technology are provided under written Information Technology Agreements which are in full force and effect in accordance with their terms and have been complied with in all material respects by the relevant Group Companies and, so far as the Seller is aware, by the respective counterparties to them.

9.5 True and complete copies of all the Information Technology Agreements material to the business of the Group as carried on prior to Completion have been disclosed.

9.6 The Group has the right to gain access to the source code, other than the Group Source Code, to all software included in the Information Technology under the terms of a binding agreement with a reputable escrow agent on the agent's standard terms.

9.7 There are no rights or provisions under any third party agreements or arrangements to which the Seller or the Group are a party that could be triggered by this Agreement (or Completion) which would in any way impede, breach or otherwise hinder the Purchaser's ability to use the Information Technology.

9.8 So far as the Seller is aware, there has been no use of open source software that would require any Intellectual Property of the Group to be:

- 9.8.1 disclosed or distributed in source code form;
- 9.8.2 licensed for the purpose of making derivative works;
- 9.8.3 attributed to a third party; or
- 9.8.4 redistributable at no or minimal charge.

10. **COMMERCIAL ARRANGEMENTS AND CONDUCT**

Material Contracts

- 10.1.1 All contracts relating to the business of the Group which constitute a Material Contract are listed in Schedule 10.
- 10.1.2 Complete copies of each Material Contract and the US Contract have been provided in the Data Room.
- 10.1.3 All Material Contracts and the US Contract are in full force and effect in accordance with their terms, and the material terms thereof have been complied with by the relevant Group Company that is a party to such agreements, and so far as the Seller is aware, by each other party thereto in all material respects.
- 10.1.4 No Group Company is currently renegotiating any material term of any Material Contract, which upon conclusion, would have an adverse or detrimental effect on the business of the Group.
- 10.1.5 No counterparty to a Material Contract or US Contract has ceased trading or dealing with any Group Company (or in the case of the US Contract, the US Seller), and no Group Company, nor the US Seller, has received valid written notice of termination of a Material Contract or US Contract or written notice from any counterparty to the same that it is otherwise ceasing trading or dealing with such Group Company and the Seller is not aware of any fact or circumstance which may result in a Material Contract or US Contract being terminated or renegotiated.
- 10.1.6 The 10X Contract has not been entered into by any Group Company, the Seller or any of its Affiliates.

10.2 **Other contracts**

The Seller has disclosed in the Data Room or the Disclosure Letters:

- 10.2.1 any contract to which any Group Company is a party of guarantee, indemnity or suretyship or any contract to secure any obligation of any person;
- 10.2.2 any agreement or arrangement between any Group Company or the US Seller and a major distributor, supplier or customer of the Group;
- 10.2.3 any joint venture, consortium or partnership agreement or arrangement to which any Group Company is a party;
- 10.2.4 any sale or purchase option or similar agreement or arrangement affecting any assets owned or used by any Group Company (including any rights in any Products or Intellectual Property) or by which it is bound;
- 10.2.5 any liability, obligation or commitment of any kind (other than those listed in paragraphs 10.2.1 to 10.2.4) above on the part of any Group Company (including a capital commitment) which:
 - (A) is incapable of complete performance within twelve months from the date of this Agreement; or
 - (B) has not been incurred in the ordinary course of business; or

(C) is, or is likely to be, of major significance to the Group,
entered into within the period commencing 24 months prior to the date of this Agreement and which are material to the business of the Group as carried on prior to Completion.

10.3 Previous Acquisitions

10.3.1 Neither the Seller nor any Group Company has made any claim under any Acquisition Agreement, nor been in receipt of any claim from any counterparty of any Acquisition Agreement, and the Seller is not aware of any fact, matter or circumstance which may result in any such claim being made or received.

10.3.2 No Group Company has any outstanding material obligations, including any obligation to pay any outstanding consideration, under any Acquisition Agreement.

10.4 Effect of Agreement on other agreements

There is no agreement or arrangement between a Group Company and any other person which will or may be terminated as a result of this Agreement (or Completion) or which will be materially affected by it or which includes any provision with respect to a change in the control, management or shareholders of any Group Company.

10.5 Commercial position

So far as the Seller is aware:

10.5.1 there is no substantial customer or supplier of the Group who has (i) ceased purchasing from or supplying to it or (ii) who is likely after the date of this Agreement (or Completion) to reduce substantially or terminate purchases from or supplies to it or otherwise seek to amend the terms of its agreement or arrangements with the Group; and

10.5.2 there are no special circumstances which might lead to the manufacture by the Group of any products, or the supply by or to it of any products or services, being restricted or hindered.

10.6 Products

10.6.1 The information contained in Schedule 14 is true and accurate in all material respects as at the date of this Agreement.

10.6.2 The manufacturing and development of the Products has been carried out in material compliance with Applicable Law.

10.6.3 During the last two (2) years, no Group Company has sold or supplied any Product that, at the time of manufacturing was unsafe or had a material defect.

10.6.4 No product liability claim has been brought by any consumer against any Group Company in relation to any Product in the twelve (12) months prior to the date of this Agreement.

11. LITIGATION

11.1 Legal proceedings

Apart from normal debt collection, no Group Company is engaged or proposing to engage in any litigation, arbitration, prosecution or other legal proceedings, and there are no claims or actions (whether criminal or civil) in progress, outstanding or, so far as the Seller is aware, pending or threatened against any Group Company any of their assets or any of their directors or in respect of which any Group Company is liable to indemnify any party.

11.2 Unlawful acts

Each Group Company complies with, and has at all times prior to the date of this Agreement, complied with Applicable Laws and no Group Company and none of their officers or Employees has by any act or default committed any criminal or unlawful act, any breach of trust, any material breach of contract or statutory duty or any tortious act in connection with the businesses or affairs of the Group.

11.3 Official investigations

No governmental or official investigation or inquiry concerning any Group Company is in progress or threatened and, so far as the Seller is aware, there are no circumstances which are likely to give rise to any such investigation or inquiry.

12. ETHICS AND SANCTIONS

12.1 Ethics

12.1.1 No Group Company nor any of their respective directors, officers, or employees, and so far as the Seller is aware, no agents, representatives or any person who performs services for or on behalf of any Group Company or any of their agents or representatives is engaged, nor has at any time been engaged, in any activity, practice or conduct which would constitute an actionable offence or violation under any Corruption Laws.

12.1.2 No Group Company has conducted or initiated any internal investigation or made a voluntary, directed or involuntary disclosure to any governmental authority or similar agency with respect to any alleged or suspected violation of any Corruption Laws.

12.1.3 No Group Company nor any of their directors, officers, or employees (within their official capacity), nor so far as the Seller is aware, their respective agents, representatives, nor any person who performs services for or on behalf of any Group Company or any of their agents or representatives, has received any notice, request, or citation, has been subject to investigation, audit, prosecution or any action or proceeding by any governmental authority for any alleged, suspected, actual or potential non-compliance with or offence under any Corruption Laws.

12.2 Sanctions

12.2.1 No Group Company nor any Group Company's directors and Employees is a Sanctioned Person, and no Group Company nor Group Company's directors and Employees acts directly or indirectly on behalf of a Sanctioned Person.

12.2.2 No Group Company is incorporated, located, resident or carrying on a trade or business in a country which is subject to Sanctions.

12.2.3 Each Group Company is in compliance with all applicable Sanctions and is not engaged in any activities that would reasonably be expected to result in any Group Company being designated as a Sanctioned Person.

12.2.4 No Group Company and, so far as the Sellers are aware, none of their respective directors, officers, Employees, agents, representatives, or persons who perform services for or on behalf of any Group Company, has routine or material interactions with any Public Official, in connection with the business (or any part of it) of any Group Company.

13. INSURANCE

13.1 Policies

All policies of insurance taken out in connection with the business or assets of the Group have been disclosed to the Purchaser, are written in the name of the relevant Group Company and are in full force and effect; and no Group Company has done or omitted to do or allowed anyone to do or not to do anything which might render any of those policies void or voidable and has complied with all conditions attached to them.

13.2 Claims

No claim under any policy of insurance taken out in connection with the business or assets of the Group is outstanding and, so far as the Seller is aware, there are no circumstances likely to give rise to such a claim.

14. CORPORATE ORGANISATION AND BUSINESS

14.1 Constitution

The copies of the constitutional documents of the Group Companies delivered to the Purchaser are true and complete copies and each of the Group Companies has complied with all the provisions of its constitutional documents.

14.2 Register of members

The register of members of each Group Company contains complete and accurate records of the members of that Group Company and no Group Company has received any notice of any application or intended application for rectification.

14.3 Books and registers

14.3.1 The books, registers and records (including all accounting records) of each Group Company are complete and accurate and up to date and maintained and retained in accordance with Applicable Laws.

14.3.2 All such documents and records and other necessary documents and records relating to its affairs are in the possession or under the direct control, and subject to the unrestricted access, of the Group and have been retained for such a period as required by Applicable Laws.

14.4 Compliance with company law

All legal requirements have been complied with in connection with the formation of each Group Company, the strike off of Astranet Systems Ltd and with issues of their shares and other securities, and each Group Company and its officers have complied with all legal requirements as to filings, registrations, reporting and other formalities.

14.5 Powers of attorney

No powers of attorney have been given by any Group Company except any given incidental to and only for the purposes of enforcement of any security.

14.6 Licences, permissions and consents

All licences, permissions and consents required for the carrying on of the businesses of the Group have been obtained by the relevant Group Company and are in full force and effect and the Seller is not aware of any circumstances indicating that any of those licences, permissions or consents is likely to be revoked or not renewed in the ordinary course.

14.7 Other aspects of carrying on business

14.7.1 No Group Company uses on its stationery or vehicles or otherwise carries on business under any name other than its corporate name.

14.7.2 No Group Company has any branch outside England or any permanent establishment outside the United Kingdom.

14.7.3 Each Group Company has complied in all material respects with all legal requirements applicable to its businesses, whether in the United Kingdom or in any other country.

15. EMPLOYEES

15.1 Disclosure of Material Facts

- 15.1.1 The following facts and matters relating to the employment or engagement of all Employees of any Group Company (and, in relation to paragraphs 15.1.1(B) and (C), former Employees of any Group Company) and the US Employees, have been disclosed to the Purchaser:
- (A) their respective salaries, ages, length of continuous employment, notice periods, standard hours of work, work locations, bonus, commission and/or other incentive arrangements, pensions, superannuation and/or other retirement benefits and any other employment, benefits or insurance policies relating to such Employees;
 - (B) any other agreement, arrangement or practice relating to their employment, including those for the making of any payment or the provision of any benefit on the redundancy, retirement or other termination of employment or services of any such Employee or former Employee beyond any obligation to make any minimum payment due under relevant legislation; and
 - (C) any arrangement under which any such Employee or former Employee is or may become entitled to any consideration or payment relating to the transaction contemplated by this Agreement.
- 15.1.2 All material facts and matters relating to all industrial instruments covering all or any of the Employees of any Group Company and collective agreements, arrangements and practices with any trade union, staff association, European or national or local works council or other body representing all or any of the Employees of any Group Company or the US Employees (an "**Employee Body**"), and all material particulars of any requests to negotiate or agree, or any claims to rights to, or any cessation of rights to, information, consultation or collective bargaining arrangements in respect of all or any of such Employees made or occurring within the last 2 years, have been disclosed in writing to the Purchaser.
- 15.1.3 Copies of all contracts of employment or for services with (a) directors of any Group Company and (b) Senior Employees of any Group Company, together with all amendments, variations or supplements, have been provided to the Purchaser together with current rates of remuneration and entitlement to benefits of all such individuals.
- 15.1.4 Copies of all standard form contracts of employment or for services and any staff handbooks, policies and procedures applicable to any category of Employee of any Group Company and the US Employees have been provided to the Purchaser together with a copy of all contracts of employment or for services with any such Employee that are not in the standard form.
- 15.1.5 No current Employee of any Group Company, nor any US Employee, with a notice period in excess of 3 months has given notice of termination of his/her contract of employment or for services or is under notice of termination and no former Employee of any Group Company has ceased to be such an Employee within the last 6 months.
- 15.1.6 No person whose contract of employment with any Group Company or the US Seller terminated within the last 12 months is, to the knowledge of the Seller, engaged in any activity or conduct prohibited by restrictive covenants (including express confidentiality clauses) applicable to that person or is, to the knowledge of the Seller, acting otherwise in breach of any continuing obligations to the relevant Group Company or the US Seller.
- 15.1.7 There has been no increase in excess of 3% in the remuneration of (a) any director or Senior Employee of any Group Company or (b) a material number of Employees of any Group Company or (c) the US Employees, which has taken effect within the last 12 months.

- 15.1.8 Within the last 3 years there have not been any disposals or acquisitions of a business or undertaking or part thereof by any Group Company covered or alleged to have been covered by legislation providing for the transfer, on such disposal or acquisition, of the contracts of individuals engaged in the business, undertaking or part thereof or of any duties or liabilities under or in connection with any such contracts.
- 15.1.9 No Employee or US Employee holds any share options other than under the Seller's Share Plan (and details of all options held under the Seller's Share Plan by any Employee or US Employee have been disclosed).

15.2 **Compliance with Requirements**

Each Group Company has, in relation to each of its Employees and to each of its former Employees and to each individual who has formerly provided services directly or indirectly to such Group Company, and the US Seller has in relation to each of the US Employees:

- 15.2.1 complied with its obligations under all relevant domestic and international legislation and all other relevant regulations, industrial instruments and codes of practice;
- 15.2.2 complied with its obligations under all domestic and international legislation and other regulations and codes of practice relevant to its relations with any Employee Body and with all collective agreements and other industrial instruments from time to time in force relating to such relations or the conditions of employment or services of any such Employee;
- 15.2.3 ensured that all employees working in a particular jurisdiction have the legal right to work, conducted adequate immigration checks and maintained adequate and suitable records regarding the employment or services of such Employee; and
- 15.2.4 discharged fully its obligations (to the extent that they have become due) to pay all salaries, wages, commissions, bonuses, overtime pay, holiday pay, sick pay, insurance premiums, superannuation, accrued entitlement under incentive schemes, Tax and national insurance or social security contributions and other benefits of or connected with employment or services up to the date of this Agreement.

15.3 **Agreements**

No Group Company has entered into and there is not in effect:

- 15.3.1 any contract of employment or for services with any Employee of any Group Company which contains a notice period of more than 3 months or which entitles such Employee to compensation exceeding the value of 3 months' gross remuneration if terminated without notice;
- 15.3.2 any agreement, arrangement or practice relating to, or any negotiation for, any variation of the emoluments or other terms or conditions of employment or services of any of its directors or Senior Employees or of a material number of Employees of any Group Company;
- 15.3.3 any contract, agreement or arrangement with any director or Employee pursuant to which such director or Employee is entitled to any bonus or remuneration linked to revenue or sales of any Company or the Group has been disclosed; or
- 15.3.4 any agreement, arrangement or practice for the provision to any Group Company directly or indirectly, in return for remuneration, of the services of any consultant, contractor, or other individual(s) other than an Employee.

15.4 **Disputes**

- 15.4.1 No dispute has arisen within the last 2 years and no dispute is currently threatened between any Group Company and any Employee (or the US Seller and any US Employee) or former Employee or individual formerly providing services directly or indirectly to such Group Company or any trade union, staff association, European or national or local works council or other body representing or seeking to represent any such Employee or former Employee.
- 15.4.2 No industrial action has taken place within the last 2 years and no industrial action is currently threatened between any Group Company and a material number or category of its Employees or former Employees or individuals formerly providing services directly or indirectly to such Group Company.
- 15.4.3 There are no existing or threatened legal proceedings against any Group Company of whatsoever nature in relation to any of its Employees or former Employees.
- 15.4.4 No enquiries or investigations have been undertaken or threatened affecting any Group Company by any recognised body seeking to promote equal opportunities within the last 2 years.

16. **PENSIONS**

- 16.1 Other than pursuant to the Disclosed Schemes, no Group Company is under any legal liability or other obligation to pay pensions, superannuation or gratuities or any similar payment to or in respect of any Employee or officer or former Employee or officer, nor is any Group Company a party to any arrangement to which it contributes, is bound to contribute or could be required to contribute or make any payment, either now or in the future, under which benefits of any kind are payable to or in respect of any Employee or officer or former Employee or officer on retirement, death or disability or on the attainment of a specified age or on the completion of a specified number of years of service. To the extent that any such arrangement existed in the past, no Group Company has any subsisting liability in respect of it.
- 16.2 True and complete copies of all documents containing the provisions governing the Disclosed Schemes and full particulars of the benefits and entitlements under the Disclosed Schemes (including any discretionary practices) and the contributions payable to the Disclosed Schemes have been provided to the Purchaser. There is no obligation to make contributions to or provide benefits under the Disclosed Schemes other than as provided for in such documents and particulars.
- 16.3 Each Group Company has duly complied with its obligations under the Disclosed Schemes and all amounts due to be paid to the Disclosed Schemes have been paid in full when due.
- 16.4 The Disclosed Schemes have at all times been administered in accordance with all applicable legal, regulatory and administrative requirements and in compliance with the provisions of their governing documents.
- 16.5 The membership data relating to the Disclosed Schemes that has been disclosed to the Purchaser is complete, accurate and up-to-date.
- 16.6 No claims, actions or complaints have been made or are pending, threatened or anticipated in relation to the Disclosed Schemes (other than routine claims for benefits) and there are no facts or circumstances likely to give rise to any such claims, actions or complaints.
- 16.7 No material fees, charges, taxes or expenses in respect of the Disclosed Schemes have been incurred and remain unpaid.
- 16.8 No Group Company has been a party to any act or deliberate failure to act, and nor have any circumstances existed involving any Group Company, which might result in any regulatory sanctions being threatened against or imposed upon that Group Company in relation to the Disclosed Schemes.
- 16.9 Each Group Company has complied with the employer obligations under any applicable automatic enrolment requirements and full details of the arrangements made by each Group Company for this purpose have been disclosed to the Purchaser.

- 16.10 No Group Company has accepted a transfer of employees to which the Transfer of Undertakings (Protection of Employment) Regulations 2006 (SI 2006/246), or analogous regime, applied and where the transferred Employees had rights in a defined benefit pension scheme that would or might fall outside of the exemption for occupational pension schemes under regulation 10 of those regulations.

17. ANTITRUST

- 17.1 No Group Company is or has been and no Seller Group Company in relation to the businesses of the Group is or has been party to any agreement, arrangement or concerted practice, or involved in any conduct, course of conduct, action or omission which infringes or would otherwise be void and unenforceable pursuant to any applicable legislation, law, regulation or administrative provision in any jurisdiction relating to antitrust, competition, mergers, unfair competition, consumer protection, anti-competitive agreements or practices or behaviour or any similar matter.
- 17.2 No Group Company is and no Seller Group Company in relation to the businesses of the Group is bound by or otherwise party to any order, direction or decision of, or undertakings or commitments given to, any Competition Authority under any applicable legislation, law, regulation or administrative provision in any jurisdiction relating to antitrust, competition, mergers, unfair competition, consumer protection, anti-competitive agreements or practices or behaviour or any similar matter or for any other reason.
- 17.3 No Competition Authority has imposed or threatened to impose any fine or penalty, or order, direction, or remedy, upon any Group Company or on any Seller Group Company in relation to the businesses of the Group for infringement of any applicable legislation, law, regulation or administrative provision in any jurisdiction relating to antitrust, competition, mergers, unfair competition, consumer protection, anti-competitive agreements or practices or behaviour or any similar matter or for any other reason.
- 17.4 The Seller not is aware of any actual or threatened, formal or informal, investigation by any Competition Authority or any action or threatened complaint, litigation or other action by any private party in relation to the businesses of the Group relating to antitrust, competition, mergers, unfair competition, consumer protection, anti-competitive agreements or practices or behaviour or any similar matter, and so far as the Seller is aware no such investigation, complaint or action is likely.

18. INSOLVENCY

- 18.1 No steps have been taken or proposed in relation to the winding up, bankruptcy, administration, insolvency, dissolution or re organisation of any Group Company, nor has any analogous procedure or step been taken or proposed in any jurisdiction in relation to any Group Company, nor has any analogous procedure or step been taken or proposed in any jurisdiction in relation to any Group Company.
- 18.2 No administrator, receiver, administrative receiver, liquidator, compulsory manager or similar officer has been appointed in respect of any Group Company or any of their respective assets, and no steps intended to result in such an appointment have been taken.
- 18.3 No compromise or arrangement with any creditor has been proposed in respect of any Group Company
- 18.4 No step has been taken towards enforcement of any security over any asset of any Group Company.

19. OTHER MATERIAL LIABILITIES

So far as the Seller is aware, there are no outstanding liabilities (actual or contingent) or any other indebtedness between any Group Company and any third party which are in excess of €100,000 and which are not included or otherwise fully provided for in the Accounts.

PART 3 – SELLER TAX WARRANTIES

1. Compliance

- 1.1 Each Group Company has properly complied in all material respects with all statutory provisions, rules, regulations, orders and directions (including in relation to Tax Records) required of it under any legislation or otherwise required by law, all submitted filings and other Tax Records are and remain at the date of this Agreement complete, correct and accurate in all material respects and all Tax Records assumed to have been submitted for the purposes of drawing up the Accounts have been properly submitted.
- 1.2 Each Group Company has duly and punctually paid all Tax (including where required by way of deduction or withholding and including any requirement to account for such deducted or withheld tax) for which it is liable to have paid and no Group Company is liable nor has it been within the seven years prior to the date of this Deed been liable, to pay any interest, fine or other penalty in connection with Tax.

2. Accounts

- 2.1 Full provision or reserve as appropriate has been made in the Accounts in respect of any period ended on or before the Accounts Date for any liability to Tax (whether actual, contingent or disputed) assessed, liable to be assessed or deemed to be assessed on any Group Company or for which any Group Company is accountable at the Accounts Date whether or not that Group Company has or may have any right to reimbursement against any other person including (without prejudice to the generality of the foregoing) Tax in respect of income, profits or gains held, earned, accrued, arising, received or deemed for Tax purposes to have been earned, accrued, arisen, received by or to any person on or before the Accounts Date or by reference to any event occurring, act done, transaction effected or circumstances existing on or before the Accounts Date.

3. Events since the Accounts Date

- 3.1 Since the Accounts Date:
 - 3.1.1 no Group Company has been involved in any transaction (other than pursuant to this Agreement or otherwise in connection with the Pre-Completion Reorganisation) outside the ordinary course of business which has given or may give rise to a liability to Taxation on that Group Company;
 - 3.1.2 no accounting period of any Group Company has ended; and
 - 3.1.3 no disposal has taken place or other event occurred which will or may have the effect of crystallising a liability to Tax which should have been included in the provision for deferred Tax contained in the Accounts if such a disposal or other event had been planned or predicted at the date on which the Accounts were drawn.

4. Tax disputes

- 4.1 No Group Company has been or is involved in any dispute with any Tax Authority, and no Group Company is the subject of any enquiry with any Tax Authority concerning any matter other than routine enquiries of a minor nature. None of the Warrantors is aware of any circumstances which would or would be likely to give rise to such as a dispute or enquiry.
- 4.2 The German tax dispute described in page 38 of the Seller's Group Management Report for the 2018 fiscal year relating to the Seller's entitlement to deduct input tax does not currently have, and will not have any effect and/or impact on any Group Company. No provision has been made or has been required to have been made in the Accounts in connection with the dispute.

5. Tax residence and permanent establishments

- 5.1 Each Group Company has at all times since its incorporation been resident for Tax purposes only in the country in which it was incorporated and will also be so resident at Completion.
- 5.2 No Group Company has any permanent establishments in any jurisdiction outside its jurisdiction of incorporation.

6. Transfer taxes and duties

All documents to which any Group Company is a party and which relate to any assets of the Group Company and in the enforcement of which the Purchaser or any Group Company is or may be interested or which is or may be necessary or desirable to prove title to such assets, have been duly and properly stamped or, if appropriate, otherwise annotated as any Tax due being fully and properly paid.

7. **Tax Records and information**

Each Group Company possesses all Tax Records and other records, agreements, filings, clearances, computations, evidence and related documents and information required to support all tax returns and any other tax filings made, or which will need to be made, in respect of all periods commencing on or before Completion.

8. **Clearances**

Where any clearance of consent for a transaction, scheme or arrangement has been sought from a Tax Authority, that transaction, scheme or arrangement has been implemented strictly in accordance with the terms of such clearance or consent and any conditions attaching to such clearance or consent.

9. **Groups, fiscal consolidations and fiscal unities**

9.1 There has been disclosed full details of:

9.1.1 every group which each Group Company is and has been in the seven years prior to Completion a member for any Tax purpose.

9.1.2 copies of every agreement relating to the use, transfer or surrender of Group Relief, any claims or elections governing the use of or allocation of Tax Reliefs between Group Companies, in each case to which any Group Company has been or is party to or was or is otherwise involved in.

9.1.3 any arrangements for the payment or proposed or future payment of any Tax liabilities to which any other Group Company was or is a party.

9.2 No Group Company will become liable to any Tax or lose any Tax Relief otherwise available to it in consequence of entering into this Agreement, or anything done pursuant to its terms including Completion.

10. **Employees**

Each Group Company has properly, in full and on a timely basis, paid or accounted to the relevant Tax Authority for any Tax and social security contributions due on, deducted or withheld from any payment or on the provision of any benefit or other reward or emolument to any Employee or officer or former or future Employee or officer of that Group Company or any person required to be treated as an Employee or officer or in any case, a third party connected with any of them or that Group Company by any Tax Authority.

11. **Transfer pricing**

All transactions entered into by each Group Company have been entered into on an arm's length basis and the consideration (if any) which has been charged, received or paid by the relevant Group Company on all transactions entered into by it has been equal to the consideration which would have been expected to be charged, received or paid between independent persons dealing at arm's length.

12. **Disposal of material assets**

No Group Company has disposed of or acquired any material asset in circumstances such that the consideration given or deemed to be given on such disposal or acquisition may be adjusted by a Tax Authority for any reason.

13. **VAT**

13.1 Each Group Company is and always has been a fully taxable person for VAT purposes and each is registered as such with the relevant Tax Authority in the jurisdictions where such registration is required under Tax Statute.

13.2 All supplies made by each Group Company including those made in respect of all Real Properties in which the Group Company has or has had an interest are subject to VAT in full.

Each Group Company is able to and does fully recover or obtains credit or allowance for any VAT paid by that Group Company.

14. **Anti-avoidance**

No Group Company is or has been party to or otherwise directly or indirectly involved in any scheme, arrangement, transaction or series of transactions the main purpose, or one of the main purposes of which was the obtaining of a tax advantage, the deferral of Tax, reduction, the avoidance of tax, or which resulted in any Tax related gain or loss arising with no corresponding commercial or economic gain or loss.

15. **Secondary Liabilities**

15.1 No transaction, act, omission or event has occurred (including the execution or implementation of this Agreement) in consequence of which any Group Company is or may be held liable for any Tax, an amount in respect of Tax, or is or will be denied or deprived of any Tax Relief otherwise available to it or is or may otherwise be held liable for or to indemnify any person in respect of any Tax or amount in respect of Tax which is primarily or directly chargeable against or attributable to any person other than another Group Company (whether by reason of any such company being or having been a member of the same group of companies or otherwise).

15.2 No transaction, act, omission, or event has occurred which has resulted in or may result in any charge, lien, security interest, encumbrance or other third party right including any Tax Authority arising over any Group Company's assets in respect of unpaid Tax or an amount in respect of Tax which remains unpaid.

16. **Criminal Finances Act**

Each Group Company has implemented and maintains reasonable "prevention procedures" designed to prevent persons associated with the relevant Group Company from committing tax evasion facilitation for the purposes of the defence in section 45(2) and section 46(3) of the Criminal Finances Act 2017.

SCHEDULE 8

PURCHASER WARRANTIES

1. INCORPORATION

The Purchaser is duly incorporated and validly existing under the laws of its jurisdiction and has full power to conduct its business as conducted at the date of this Agreement.

2. CORPORATE POWER AND AUTHORITY

The Purchaser has corporate power and authority to enter into and perform this Agreement and any agreement entered into pursuant to the terms of this Agreement and the provisions of this Agreement and any agreement entered into pursuant to the terms of this Agreement, constitute valid and binding obligations on the Purchaser and are enforceable against the Purchaser, in accordance with their respective terms.

3. DUE AUTHORISATION, EXECUTION AND DELIVERY

The Purchaser has duly authorised, executed and delivered this Agreement and will, at Completion, have authorised, executed and delivered any agreements to be entered into pursuant to the terms of this Agreement.

4. NO BREACH

The execution and delivery by the Purchaser of, and the performance by the Purchaser of its obligations under, this Agreement and any agreement entered into pursuant to the terms of this Agreement will not:

- 4.1.1 result in a breach of or conflict with any provision of its memorandum or articles of association or equivalent constitutional documents;
- 4.1.2 result in a material breach of, or constitute a material default under, any instrument to which it is a party or by which it is bound; or
- 4.1.3 result in a breach of any Applicable Laws or regulations or of any order, decree or judgment of any court or any governmental or regulatory authority in any jurisdiction.

5. CONSENTS

All consents, permissions, authorisations approvals and agreements of third parties and all authorisations, registrations, declarations, filings with any governmental department, commission, agency or other organisation having jurisdiction over the Purchaser which are necessary for the Purchaser to obtain in order to enter into and perform this Agreement and any agreement entered into pursuant to the terms of this Agreement in accordance with its terms, have been unconditionally obtained in writing and have been disclosed in writing to the Seller.

6. PROCEEDINGS

There are no:

- 6.1.1 outstanding judgments, orders, injunctions or decrees of any governmental or regulatory body or arbitration tribunal against or affecting the Purchaser or any of its group undertakings;
- 6.1.2 lawsuits, actions or proceedings pending or, to the knowledge of the Purchaser, threatened against or affecting the Purchaser or any of its group undertakings; or
- 6.1.3 investigations by any governmental or regulatory body which are pending or threatened against the Purchaser or any of its group undertakings, so far as the Purchaser is aware,

and which, in each case, has or could have a material adverse effect on the ability of the Purchaser to perform its obligations under this Agreement or any agreement entered into pursuant to the terms of this Agreement.

7. **SOLVENCY**

No order has been made, petition presented or meeting convened for the winding up of the Purchaser or any of its group undertakings, nor any other action taken in relation to the appointment of an administrator, liquidator, receiver, administrative receiver, compulsory manager or any provisional liquidator (or equivalent in any other jurisdiction) (or other process whereby the business is terminated and the assets of the company concerned are distributed amongst the creditors or shareholders or any other contributors), and there are no proceedings under any applicable insolvency, reorganisation or similar laws in any relevant jurisdiction, and no events have occurred which, under Applicable Laws, would justify any such proceedings.

SCHEDULE 9
PERMITTED LOGO



SCHEDULE 10

MATERIAL CONTRACTS

Data Room reference	Data Room filename
20.01	[Redacted counterparty]
44	[Redacted counterparty]-TGR SDA Agmt Executed Effective 1 June 10
45	1st Amendment [Redacted counterparty] -TGR_Supply Agreement 28Feb2011
46	2nd Amendment TGR-[Redacted counterparty] Supply Agreement 22 March 2012
47	3rd Amendment TGR-[Redacted counterparty] Supply Agreement 3 June 2013
48	4th Amendment [Redacted counterparty]-TGR SDA Agmt - 16 Sep 2014
49	[Redacted] transfer amendment 9-1-2014
50	[Redacted counterparty]_correction [redacted] amendment
51	5th Amendment [Redacted counterparty]-TGR SDA Agmt - 04Jan2016
52	6th Amendment_[Redacted counterparty]-TGR SDA Agmt 15June2019
20.02	[Redacted counterparty]
20.02.01	[Redacted]
17	[Redacted counterparty] Innova Distribution and License (License superseded) 2014
20	Exp Ltd_[Redacted counterparty] Apr 18 - [redacted] Supply & License
20.02.02	[Redacted]
12	[Redacted counterparty] Distribution Agmt 4 Nov 2011
13	E1 License fully executed 26Nov2012
14	E1_[redacted]_RestrictionRemoval_1May2013
15	E1_DuplexNotification_16May2013
16	[Redacted counterparty]_Completion_TechTransfer 10May2013
18	[Redacted counterparty] Sales price change 2016
19	[Redacted counterparty] Pricing Structure 2018
20.03	[Redacted counterparty]
20.03.01	0413 [Redacted counterparty] Supply Agreement
20.03.02	0413a [Redacted counterparty] Supply Agreement Amendment 1
20.03.03	[Redacted counterparty] Distribution Agreement Oct 2007
20.03.04	[Redacted counterparty] Distribution Agreement May 2013
20.03.05	[Redacted counterparty] Distribution Agreement Feb 2017
20.04	[Redacted counterparty]
29	[Redacted counterparty] -TGR Supply Agmt [redacted]- 10 Feb 2010
31	[Redacted counterparty] -TGR Supply Agmt [redacted] Feb 2010
38	Expedeon [Redacted counterparty] Quality Agreement - Supplier final
39	1310 [Redacted counterparty] distribution agreement July 2013
40	1312 [Redacted counterparty] Agreement addendum add [redacted] Dec 2013
41	[Redacted counterparty] Innova Supply AgreeemntJ an 2017_Redacted sequence only
42	[Redacted counterparty] innova_Expedeon Supply Amendment 20181211_Redacted sequence only
75	S - 0395 [Redacted counterparty] _email chain dated 17 Feb 2017 relating to document 41_Redacted
20.05	[Redacted counterparty]
43	[Redacted counterparty] _Expedeon_Non_Exclusive_Agreement_fully_executed

20.06	[Redacted counterparty]
01	0291 [Redacted counterparty] _Innova Supply agreement_Redacted sequence only
02	0162 [Redacted counterparty] _Innova Supply Amendment Jan 2013_Redacted sequence only
03	0294 [Redacted counterparty] to Innova note License Assignment Sept 2015
04	0295 [Redacted counterparty] to Innova note License Assignment March 2016
425	[Redacted counterparty] July 19_Sequence _Redacted
20.07	[Redacted counterparty]
20.07.01	Expedeon
25	Innova Biosciences LTC License and Supply Agreement 9-Mar-2017
26	Innova Sygnis AG First Amendment to License and Supply Agreement 2-May-2...
27	[Redacted counterparty] original agreement
28	[Redacted counterparty] 2nd Amendment [redacted]10-31-18 5065
20.07.02	[Redacted counterparty]
05	[Redacted counterparty] -TGR Executed Supply Agmt 3 Mar 2011
06	[Redacted counterparty] -TGR Executed Supply Agmt amendment1 23 Feb 2012
07	[Redacted counterparty] LetterExclusivity_21March2013
08	[Redacted counterparty] _[redacted] assignment_1 June2015
09	[Redacted counterparty] _TGR_Pricing letter_19February2016
20.09	[Redacted counterparty]
10	[Redacted counterparty] Innova Custom Labelling Agreement 2008
11	[Redacted counterparty] Innova Distribution and Supply 2011
30	[Redacted counterparty] -TGR Supply Agmt [redacted] 15 Feb 2010
65	[Redacted counterparty] Supply Agreement - 20181001
20.10	[Redacted counterparty]
32	[Redacted counterparty] Supply Agreement
33	[Redacted counterparty] Supply and License Agreement 20190524
34	TGR_[Redacted counterparty] License Executed_27July2017
20.11	[Redacted counterparty]
21	[Redacted counterparty] _TGR_Plate Manufacture_20Feb2015_TGR executed
22	[Redacted counterparty] _TGR_Plate Manufacture Amendment_20Feb2016
23	[Redacted counterparty] _TGR_Plate Manufacture Amendment_3June2017
24	[Redacted counterparty] _TGR_Plate Manufacture Amendment_1August2018
20.12	[Redacted counterparty]
	Disclosed at 17.03_ 10x 20180820-Expedeon [Redacted counterparty] Compatible Product Agreement 30 aug 19 _DRAFT
20.13	Other
20.13.002	001_0001 [Redacted counterparty]
20.13.003	002_0002 [Redacted counterparty]
20.13.004	003_0003 [Redacted counterparty]
20.13.005	004_0004 [Redacted counterparty]
20.13.006	005_0005 [Redacted counterparty]
20.13.007	006_0006 [Redacted counterparty]
20.13.008	007_0007 [Redacted counterparty]
20.13.009	008_0008 [Redacted counterparty]
20.13.010	009_0009 [Redacted counterparty]

20.13.011	010_0011 [Redacted counterparty]
20.13.012	011_0012 [Redacted counterparty]
20.13.013	012_0013 [Redacted counterparty]
20.13.014	013_0018 [Redacted counterparty]
20.13.015	014_0019 [Redacted counterparty]
20.13.016	015_0020 [Redacted counterparty]
20.13.017	016_0021 [Redacted counterparty]
20.13.018	017_0022 [Redacted counterparty]
20.13.019	018_0023 [Redacted counterparty]
20.13.020	019_0024 [Redacted counterparty]
20.13.021	020_0025 [Redacted counterparty]
20.13.022	021_0026 [Redacted counterparty]
20.13.023	022_0028 [Redacted counterparty]
20.13.024	023_0028a [Redacted counterparty]
20.13.025	024_0029 [Redacted counterparty]
20.13.026	025_0030 [Redacted counterparty]
20.13.027	026_0031 [Redacted counterparty]
20.13.028	027_0033 [Redacted counterparty]
20.13.029	028_0034 [Redacted counterparty]
20.13.030	029_0043 [Redacted counterparty]
20.13.031	030_0049 [Redacted counterparty]
20.13.032	031_0050 [Redacted counterparty]
20.13.033	032_0051 [Redacted counterparty]
20.13.034	033_0052 [Redacted counterparty]
20.13.035	034_0053 [Redacted counterparty]
20.13.036	035_0054 [Redacted counterparty]
20.13.037	036_0055 [Redacted counterparty]
20.13.038	037_0057 [Redacted counterparty]
20.13.039	038_0070 [Redacted counterparty]
20.13.040	039_0073 [Redacted counterparty]
20.13.041	040_0074 [Redacted counterparty]
20.13.042	041_0075 [Redacted counterparty]
20.13.043	042_0087 [Redacted counterparty]
20.13.044	043_0088 [Redacted counterparty]
20.13.045	044_0089 [Redacted counterparty]
20.13.046	045_0090 [Redacted counterparty]
20.13.047	046_0092 [Redacted counterparty]
20.13.048	047_0093 [Redacted counterparty]
20.13.049	048_0095 [Redacted counterparty]
20.13.050	049_0098 [Redacted counterparty]
20.13.051	050_0099 [Redacted counterparty]
20.13.052	051_0100 [Redacted counterparty]
20.13.053	052_0101 [Redacted counterparty]
20.13.054	053_0102 [Redacted counterparty]
20.13.055	054_0103 [Redacted counterparty]

20.13.056	055_0104 [Redacted counterparty]
20.13.057	056_0105 [Redacted counterparty]
20.13.058	057_0106 [Redacted counterparty]
20.13.059	058_0107 [Redacted counterparty]
20.13.060	059_0108 [Redacted counterparty]
20.13.061	060_0109 [Redacted counterparty]
20.13.062	061_0110 [Redacted counterparty]
20.13.063	062_0111 [Redacted counterparty]
20.13.064	063_0112 [Redacted counterparty]
20.13.065	064_0113 [Redacted counterparty]
20.13.066	065_0114 [Redacted counterparty]
20.13.067	066_0115 [Redacted counterparty]
20.13.068	067_0117 [Redacted counterparty]
20.13.069	068_0118 [Redacted counterparty]
20.13.070	069_0119 [Redacted counterparty]
20.13.071	070_0122 [Redacted counterparty]
20.13.072	071_0124 [Redacted counterparty]
20.13.073	072_0133 [Redacted counterparty]
20.13.074	073_0135 [Redacted counterparty]
20.13.075	074_0137 [Redacted counterparty]
20.13.076	075_0138 [Redacted counterparty]
20.13.077	076_0139 [Redacted counterparty]
20.13.078	077_0140 [Redacted counterparty]
20.13.079	078_0141 [Redacted counterparty]
20.13.080	079_0142 [Redacted counterparty]
20.13.081	080_0145 [Redacted counterparty]
20.13.082	081_0158 [Redacted counterparty]
20.13.083	082_0160 [Redacted counterparty]
20.13.084	083_0161 [Redacted counterparty]
20.13.085	084_0162 [Redacted counterparty]
20.13.086	085_0167 [Redacted counterparty]
20.13.087	086_0167a [Redacted counterparty]
20.13.088	087_0168 [Redacted counterparty]
20.13.089	088_0168a [Redacted counterparty] Cancellation
20.13.090	089_0170 [Redacted counterparty]
20.13.091	090_0171 [Redacted counterparty]
20.13.092	091_0172 [Redacted counterparty]
20.13.093	092_0178 [Redacted counterparty]
20.13.094	093_0181 [Redacted counterparty]
20.13.095	094_0184 [Redacted counterparty]
20.13.096	095_0202 [Redacted counterparty]
20.13.097	096_0207 [Redacted counterparty]
20.13.098	097_0210 [Redacted counterparty]
20.13.099	098_0211 [Redacted counterparty]
20.13.100	099_0213 [Redacted counterparty]

20.13.101	100_0217 [Redacted counterparty]
20.13.102	101_0218 [Redacted counterparty]
20.13.103	102_0221 [Redacted counterparty]
20.13.104	103_0227 [Redacted counterparty]
20.13.105	104_0236 [Redacted counterparty]
20.13.106	105_0237 [Redacted counterparty]
20.13.107	106_0243 [Redacted counterparty]
20.13.108	107_0246 [Redacted counterparty]
20.13.109	108_0248 [Redacted counterparty]
20.13.110	109_0249 [Redacted counterparty]
20.13.111	110_0251 [Redacted counterparty]
20.13.112	111_0256 [Redacted counterparty]
20.13.113	112_0256b [Redacted counterparty]
20.13.114	113_0260 [Redacted counterparty]
20.13.115	114_0262 [Redacted counterparty]
20.13.116	115_0266 [Redacted counterparty]
20.13.117	116_0270 [Redacted counterparty]
20.13.118	117_0279 [Redacted counterparty]
20.13.119	118_0280 [Redacted counterparty]
20.13.120	119_0281 [Redacted counterparty]
20.13.121	120_0281a [Redacted counterparty]
20.13.122	121_0282 [Redacted counterparty]
20.13.123	122_0285 [Redacted counterparty]
20.13.124	123_0286 [Redacted counterparty]
20.13.125	124_0288 [Redacted counterparty]
20.13.126	125_0292 [Redacted counterparty]
20.13.127	126_0293 [Redacted counterparty]
20.13.128	127_0296 [Redacted counterparty]
20.13.129	128_0297 [Redacted counterparty]
20.13.130	129_0301 [Redacted counterparty]
20.13.131	130_0302 [Redacted counterparty]
20.13.132	131_0307 [Redacted counterparty]
20.13.133	132_0310 [Redacted counterparty]
20.13.134	133_0313 [Redacted counterparty]
20.13.135	134_0315 [Redacted counterparty]
20.13.136	135_0316 [Redacted counterparty]
20.13.137	136_0327 [Redacted counterparty]
20.13.138	137_0328 [Redacted counterparty]
20.13.139	138_0345 [Redacted counterparty]
20.13.140	139_0346 [Redacted counterparty]
20.13.141	140_0346a [Redacted counterparty] Extension
20.13.142	141_0349 [Redacted counterparty]
20.13.143	142_0360 [Redacted counterparty]
20.13.144	143_0364 [Redacted counterparty]
20.13.145	144_0364a [Redacted counterparty]

20.13.146	145_0371 [Redacted counterparty]
20.13.147	146_0374 [Redacted counterparty]
20.13.148	147_0378 [Redacted counterparty]
20.13.149	148_0380 [Redacted counterparty]
20.13.150	149_0385 [Redacted counterparty]
20.13.151	150_0387 [Redacted counterparty] Supply Agreement Fully Signed
20.13.152	151_0388 [Redacted counterparty] Supply Agreement
20.13.153	152_0393 [Redacted counterparty]
20.13.154	153_0393 [Redacted counterparty] Supply and License
20.13.155	154_0396 [Redacted counterparty] Supply Agreement
20.13.156	155_0398 [Redacted counterparty] Subscription [Redacted counterparty] - NAV V2 HL
20.13.157	156_0399 [Redacted counterparty]
20.13.158	157_0400 [Redacted counterparty]
20.13.159	158_0400 [Redacted counterparty]
20.13.160	159_0402 [Redacted counterparty]
20.13.161	160_0403 [Redacted counterparty]
20.13.162	161_0404 [Redacted counterparty] Commercial Marketing Agreement
20.13.163	162_0405 [Redacted counterparty]
20.13.164	163_0411 [Redacted counterparty]
20.13.165	164_0412 [Redacted counterparty] Supply and License Full Signed
20.13.166	165_0415 [Redacted counterparty] Supply Agreement 20181201
20.13.167	166_0417 [Redacted counterparty] - Supply & Distribution
20.13.168	167_0421 [Redacted counterparty] Supply & License
20.13.169	168_0452 [Redacted counterparty] Full Contract
20.13.170	169_283 [Redacted counterparty]
20.13.171	170_[Redacted counterparty] Distributorship Agreement 11.04.17
20.13.172	171_388 [Redacted counterparty] Supply Agreement
20.13.173	172_391 [Redacted counterparty] Signed
20.13.174	173_396 [Redacted counterparty] Full Version Signed
20.13.175	174_399 [Redacted counterparty] Supply and Licence Signed
20.13.176	175_422 [Redacted counterparty] Supply & Distribution
20.13.177	176_426 [Redacted counterparty]
20.13.178	177_444 [Redacted counterparty]
20.13.179	178_4A [Redacted counterparty] Agreement 10.05.2017
20.13.180	179_AH [Redacted counterparty] Agreement 15.02.2017
20.13.181	180_[Redacted counterparty] Agreement 10.01.2017
20.13.182	181_[Redacted counterparty] Distributorship Agreement partially executed 31.03.17
20.13.183	182_[Redacted counterparty] Termination Letter - 9th July 2019
20.13.184	183_[Redacted counterparty] termination letter Scan_29072019131839
20.13.185	184_[Redacted counterparty] Agreement 10.05.2017
20.13.186	185_[Redacted counterparty] Agreement 21.12.2016
20.13.187	186_[Redacted counterparty] Agreement 21.12.2016
20.13.188	187_[Redacted counterparty] Supply & Distribution Agreement
20.13.189	188_[Redacted counterparty] Agreement 23.02.2017

20.13.190	189_[Redacted counterparty] Agreement 15.02.2017
20.13.191	190_[Redacted counterparty] Agreement 27.01.2017
20.13.192	191_[Redacted counterparty] Agreement 21.12.2016
20.13.193	192_[Redacted counterparty] Amendment May 2017
20.13.194	193_[Redacted counterparty] Agreement 25.01.2017
20.13.195	194_[Redacted counterparty] Distributorship Agreement partially executed 18.04.17
20.13.196	195_[Redacted counterparty] Agreement 02.03.2017
20.13.197	196_[Redacted counterparty] Agreement 09.03.2017
20.13.198	197_[Redacted counterparty] Agreement 12.04.2017
20.13.199	198_[Redacted counterparty] Agreement 21.12.2016
20.13.200	199_licensing agreement signed by [Redacted counterparty]
20.13.201	200_[Redacted counterparty] Agreement 15.02.2017
20.13.202	201_[Redacted counterparty] -2015n239860_02
20.13.203	202_[Redacted counterparty] Agreement 21.12.2016
20.13.204	203_[Redacted counterparty] Agreement 15.02.2017
20.13.205	204_[Redacted counterparty] Agreement 10.01.2017
20.13.206	205_[Redacted counterparty] Agreement 21.12.2016
20.13.207	206_[Redacted counterparty] Agreement 21.12.2016
20.13.208	207_[Redacted counterparty] Distributorship Agreement 05.
20.13.209	208_Supply & Distribution Agreement June 2015
20.13.210	209_[Redacted counterparty] Agreement 15.02.2017
20.13.211	210_Termination Letter - 9th July 2019
20.13.212	211_[Redacted counterparty] 20190723 [Redacted counterparty]
20.13.213	212_[Redacted counterparty] agreement
20.13.214	213_[Redacted counterparty] Agreement 27.03.2017
20.13.215	214_[Redacted counterparty] Agreement 20.01.2017
20.13.216	215_0010 [Redacted counterparty]
20.13.217	216_0253 [Redacted counterparty]
20.13.218	217_0318 [Redacted counterparty]
20.13.219	218_136_[Redacted counterparty]
20.13.220	219_294_[Redacted counterparty]

SCHEDULE 11

REAL PROPERTY

PART 1

FREEHOLD REAL PROPERTIES

Description of Real Property (including title number if registered)	Registered Proprietor (or owner if unregistered)	Existing Use	Real Property the subject of an option to tax real estate election under Schedule 10 to the VATA 1994
25 Norman Way, Over, Cambridgeshire, CB24 5QE, United Kingdom	Expedeon Ltd	Overflow car park	Yes
Land adjacent to 25 Norman Way	Expedeon Ltd	Business use	Yes

PART 2

LEASEHOLD REAL PROPERTIES

Description of property (including title number if registered)	Registered proprietor or tenant if unregistered (including guarantor if any)	Date and term of lease	Current Rent	Existing Use	Original parties to lease	Property subject to option to tax or real estate election (so VAT charged on Rent)
1st Floor, Ashwell Point, Babraham Road, Sawston, CB22 3LJ	Innova Biosciences Limited	Undated – 5 year term	£41,134.50	Offices within class B1 of the Town and Country Planning (Use Classes) Order 1987.	(1) Innova Biosciences Limited (2) Pigeon (Sawston) LLP	Yes, VAT charged on rent
31 Dalglish Street, Thebarton, SA 5031, Adelaide Australia	TGR Biosciences Pty Ltd ABN 39 097 258789	16 January 2018 (2 years)	\$102,606 for the Laboratory Area of the Premises; and \$53,616 for the Office Area of the Premises.	Scientific laboratory and office accommodation	(1) Bionomics Limited ACN 075 582 740; (2) TGR Biosciences Pty Ltd ABN 39 097 258789	Australian GST charged on rent

SCHEDULE 12

INTELLECTUAL PROPERTY

PART 1

INTELLECTUAL PROPERTY

PATENTS

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date
TGR FAMILY 1					
US	ANALYTE DETECTION	13/436764 (US2012270207)	US9086407	In force	Filed 30.3.2012, but earlier filing date of 12.11.2010
US	ANALYTE DETECTION	14/641942 (US2015241421)	US9261500	In force	Filed 30.3.2012, but earlier filing date of 12.11.2010
US	ANALYTE DETECTION	15/073326 (US2016195521)	US9476874	In force	Filed 30.3.2012, but earlier filing date of 12.11.2010
US	ANALYTE DETECTION	14/940983 (US2016061827)	US9778252	In force	Filed 30.3.2012, but earlier filing date of 12.11.2010
US	ANALYTE DETECTION	US15/691271 (US2018113125)		Recently Abandoned	Filed 30.3.2012, but earlier filing date of 12.11.2010
EP	DETECTION OF MULTIPLE ANALYTES	12764101.7	EP2786150	In force at least in DE, FR, GB	30.3.2012
EP	DETECTION OF MULTIPLE ANALYTES	18182576.1	EP3435082	Pending	30.3.2012
TGR FAMILY 2					
US	IMMUNOLOGICAL TESTING	15/849,075 (US2018136202)		Pending	Filed 20.12.2017, but earlier filing date of 30.9.2016
US	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	15/764,210 (US2018275121)		Pending	30.9.2016
EP	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	16856992.9 (EP3356822)		Pending	30.9.2016
AU	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	AU2016341539		Pending	30.9.2016
CA	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	CA3000584		Pending	30.9.2016

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date
CN	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	CN108603877		Pending	30.9.2016
HK	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	HK1254374		Pending	30.9.2016
JP	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	JP2018533017		Pending	30.9.2016
MX	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	MX2018004029		Pending	30.9.2016
IN	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	IN201847012443		Pending	30.9.2016
	TGR FAMILY 3				
US	LATERAL FLOW ANALYTE DETECTION	US16/017815 (US2019145971)		Pending	28.7.2016 (continuation of US2017370925)
US	LATERAL FLOW ANALYTE DETECTION	US16/310774 (US20190331670)		Pending	
EP	LATERAL FLOW ANALYTE DETECTION	17818731.6 (EP3475703)		Pending	26.6.2017
AU	LATERAL FLOW ANALYTE DETECTION	AU2017287704		Pending	26.6.2017
CA	LATERAL FLOW ANALYTE DETECTION	CA3028017		Pending	26.6.2017
CN	LATERAL FLOW ANALYTE DETECTION	CN109642902		Pending	26.6.2017
JP	LATERAL FLOW ANALYTE DETECTION	JP2019521367		Pending	26.6.2017
MX	LATERAL FLOW ANALYTE DETECTION	MX2018016216		Pending	26.6.2017
IN	LATERAL FLOW ANALYTE DETECTION	IN201847049349		Pending	26.6.2017

TGR NON-LIVE PATENTS / PATENT APPLICATIONS

Country	Title	Official No	Filing Date
---------	-------	-------------	-------------

Country	Title	Official No	Filing Date
	TGR Family 1		
WO	ANALYTE DETECTION	WO2011057347 (PCT/AU2010/001517)	12.11.2010
WO	ONE-STEP IMMUNOASSAY DETECTION OF ANALYTES	WO2012129610 (PCT/AU2012/000329)	30.3.2012
WO	DETECTION OF MULTIPLE ANALYTES	WO2012129611 (PCT/AU2012/000330)	30.3.2012
US	DETECTION OF ANALYTES	US14/008430 (US2014127719)	30.3.2012
US	DETECTION OF ANALYTES	US15/188594 (US2017138937)	21.6.2012
EP		EP2786148	30.3.2012
AU		AU2009905550	12.11.2009
US		US61/470359	31.3.2011
US		US61/470395	31.3.2011
US		US61/523687	15.8.2011
	TGR family 2		
US	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	US15/282,634 (US2017097339)	30.9.2016
WO	ANALYTE DETECTION WITH MULTIPLE SUBSTRATES	WO2017068431 (PCT/IB2016/001981)	30.9.2016
US		US62/236676	2.10.2015
US		US62/237522	5.10.2015
	TGR family 3		
US	LATERAL FLOW ANALYTE DETECTION	US15/222376 (US2017370925)	28.7.2016
WO	LATERAL FLOW ANALYTE DETECTION	WO2018000025	26.6.2017
US		US62/355133	27.6.2016
US	LATERAL FLOW ANALYTE DETECTION	US15/222376	28.7.2016

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date
	Family 3				
EP	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	14730479.4 (EP3003385)		In force at least in DE, FR	30.05.2014

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date
US	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	US14/894828 (US2016122416)		Pending Office action due on 20.11.19. One month further extension possible.	30.05.2014
CN	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	CN105592860		Pending	30.05.2014
AU	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	AU2014273034		Pending Notice of Acceptance will publish on 21 Nov 2019. Any amendments must be filed by 21 February 2020. An issue fee will also be payable around that time (exact deadline not apparent)	30.05.2014
GB	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	GB1309759.7 (GB2516808)		Pending Office Action due on 14.12.19. Initial deadline was 14.10.19. Retrospective extension will need to be requested.	31.5.2013
GB	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	GB1522774.7 (GB2530217)		Pending Office action due on 8.12.19. Initial deadline was 8.10.19. Retrospective extension will need to be requested.	30.5.2014
	Family 4				
AU	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	AU2008263586	AU2008263586	In force	12.06.2008
CN	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	CN200880103454 (CN101790684)	CN101790684	Granted	12.06.2008
CA	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	CA2688646	CA 2688646	In force	12.06.2008
EP	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	08762548.9 (EP2171457)	EP2171457	In force at least in DE, FR	12.06.2008
GB	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF	GB1000496.8 (GB2467041)	GB2467041	In force	12.06.2008

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date
CONJUGATES					
JP	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	JP20100511730 (JP2010529186)	JP5444554	In force	12.06.2008
NZ	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	NZ20080581699	NZ581699	In force	12.06.2008
US	Production of conjugates	US12/664147 (US2010184184)	US9,176,125	In force	12.06.2008
Family 13+14					
AU	Conjugation reactions	AU2011222742	AU2011222742	In force	15.3.2011
CA	Conjugation reactions	CA2791726	CA2791726	In force	15.3.2011
CN	Conjugation reactions	CN201190022576 (CN102933547)	CN102933547	In force	15.3.2011
EP	Conjugation reactions	11711383.7	EP2566845	In force at least in DE, FR and GB Annuity for the UK validation of the EP patent due on 5.03.20	15.3.2011
GB	Conjugation reactions	GB1003697.8	GB2478359	In force	5.3.2010
JP	Conjugation reactions	JP20120555498 (JP2013527137)	JP6118560	In force	15.3.2011
US	Conjugation reactions	US13/048477 (US20120237998)	US8,877,892	In force	15.3.2011
Family 15					
AU	Production of Conjugates	AU2006324488	AU2006324488	In force Renewal fees due on 12.12.19	12.12.2006
CA	Production of Conjugates	CA2630399	CA2630399	In force Renewal fees due on 12.12.19	12.12.2006
CN	Production of Conjugates	CN200680046760 (CN101330931)	CN101330931	In force	12.12.2006
EP	Production of Conjugates	06820492.4 (EP1968641)	EP1968641	In force at least in DE and FR Renewal fees due on 12.12.19	12.12.2006
GB	Production of Conjugates	GB0808916.1 (GB2446088)	GB2446088	In force Renewal fees due on 12.12.19	12.12.2006
JP	Production of Conjugates	JP20080545077 (JP5380074)	JP5380074	In force	12.12.2006

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date
NZ	Production of Conjugates	<u>NZ20060568386</u> <u>(NZ568386)</u>	NZ568386	In force Renewal fees due on 12.12.1941	12.12.2006
US	Production of Conjugates	US12/096000 (US20080299637)	US8,492,129	In force	12.12.2006

INNOVA NON-LIVE PATENTS / PATENT APPLICATIONS

Country	Title	Official No	Filing Date
	Family 1		
GB	Improved enzyme assay	GB20050006074	24.3.2005
	Family 3		
WO	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	<u>WO2014191560</u>	30.05.2014
JP	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	<u>JP2016530216</u>	30.05.2014
GB		GB20130009759	31.05.2013
	Family 4		
GB		GB 0711560.3	14.06.2007
	Family 5		
GB	AN ASSAY FOR ADP USING AN ADP BINDING PROTEIN	<u>GB2394286</u>	17.9.2002
WO	ADP Assay	<u>WO2004027421</u>	17.9.2003
AU	ADP Assay	<u>AU2003264887</u>	17.9.2003
	Family 6		
GB	Coated nanoparticle	GB201211773	3.07.2012
	Family 7		
GB	ADP assay	GB200417588	6.08.2004
	Family 8		
GB	ADP assay	GB200318551	7.8.2003
	Family 9		
GB	Coated nanoparticle	GB201311942	3.07.2013
	Family 12		
GB	Improved enzyme assay	GB200606627	1.04.2006
	Family 13		
JP	Conjugation reactions	JP2017083461	15.3.2011
WO	Conjugation reactions	WO2011107810	15.3.2011
	Family 15		
US		US20130295641	

Country	Title	Official No	Filing Date
WO	Production of Conjugates	WO2007068906	12.12.2006
GB		GB0525223	12.12.2005
GB		GB0614533	21.07.2006
	Family 16		
GB		GB0506971.1	6.04.2005
WO	Formation of aggregates in enzyme assays	WO2006106340	6.04.2006
	Family 17		
GB	Coated nanoparticles	GB201411827	2.07.2014
	Family 18		
GB	Coated nanoparticle	GB20110011878	11.07.2011

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date	Applicant/Assignee according to public register
	Family 1					
AU	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	AU2007245443	AU2007245443	In force	30.4.2007	Expedeon Limited
CA	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	CA2649835	CA2649835	In force	30.4.2007	Expedeon Limited
CN	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	CN200780021434 (CN101473228)	CN101473228	Granted	30.4.2007	Expedeon Ltd
EP	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	07733647.7 (EP2016421)	EP2016421	In force in DE, GB, FR	30.4.2007	Expedeon Limited or Ltd - inconsistency in national registers
EP	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	10187154.9 (EP2295979)	EP2295979	In force in DE, GB, FR	30.4.2007	Expedeon Limited or Ltd - inconsistency in national registers
GB	Dextrin-containing reagents for detecting and quantifying proteins	GB0608377.8 (GB2437545)	GB2437545	In force	28.4.2006	Expedeon Limited

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date	Applicant/Assignee according to public register
HK	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	09112060.1 (HK1132796)	HK1132796	In force	30.4.2007	Expedeon Limited
JP	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	JP20090507182 (JP2009535614)	JP5698904	In force	30.4.2007	Expedeon Limited
SG	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	SG20110030103	SG171630	In force	30.4.2007	Expedeon Limited
US	Protein detection reagents and methods with dyes and dextrans	US12/226,797 (US20090298185)	US8,778,277	In force	30.4.2007	Expedeon Limited
US	Protein detection reagents and methods with dyes and dextrans	US13/278699 (US 20120190120)	US8,785,203	In force	30.4.2007	Expedeon Limited
Family 3						
WO	UNIVERSAL LATERAL FLOW IMMUNOASSAY	WO2019081361		Pending	19.10.2018	Expedeon Ltd
Family 4						
EP	PROGRAMMABLE ELECTROPHORETIC NOTCH FILTER SYSTEMS AND METHODS	10770207.8 (EP2425216)	EP2425216	In force in DE, GB, FR	27.4.2010	Expedeon Holdings Ltd.
US	PROGRAMMABLE ELECTROPHORETIC NOTCH FILTER SYSTEMS AND METHODS	US12/967,890 (US20110220501)	US8,926,817	In Force	14.12.2010	Expedeon Holdings Ltd.
Family 5						
	Electrophoresis gel and method of making same	US11/612,073 (US 20070187252)	US7,731,829	In force	18.12.2006	Expedeon, Inc.
	Electrophoresis gel and method of making same	US12/794,889 (US 2010-0236932)	US8,034,224	In force	18.12.2006	Expedeon, Inc.
Family 8						
AU	Methods and kits for stabilising, protecting and solubilising	AU2005235800	AU2005235800	In force	25.4.2005	Expedeon Limited

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 November 2019	Filing Date	Applicant/Assignee according to public register
	proteins					
EP	METHODS AND KITS FOR FOLDING PROTEINS IN THE PRESENCE OF LINEAR OR BRANCHED SUGAR POLYMERS	05738550.2 (EP1742962)	EP1742962	In force in GB	25.4.2005	Expedeon Limited
EP	METHODS AND KITS FOR STABILISING, PROTECTING AND SOLUBILISING PROTEINS	05739183.1 EP1749018	EP1749018	In force in GB	25.4.2005	Expedeon Limited
HK	METHODS AND KITS FOR STABILISING, PROTECTING AND SOLUBILISING PROTEINS	HK1100669		In force	25.4.2005	Novexin Limited
IN	A METHODS FOR STABILIZING PROTEINS AND A COMPOSITION COMPRISING PROTEIN	IN259558 (3896/CHENP/2006)		In force	25.4.2005	Expedeon Limited
US	METHODS AND KITS FOR FOLDING PROTEINS	US11/587,267 (US 20080281085)	US8,119,615	In force	25.4.2005	Expedeon Limited
	Family 9					
US	Electrophoresis gel assembly	US10/306,754 (US 20030141190)	US7,033,477	In Force	27.11.2002	Expedeon, Inc.
	Family 10					
WO	WO2019197365	WO2019197365		Pending	09.04.2019	Expedeon Ltd

EXPEDEON NON-LIVE PATENT / PATENT APPLICATIONS

Country	Title	Official No	Filing Date	Applicant/Assignee according to public register
	Family 1			
IN	Reagents and methods	5722/CHENP/2008	30.4.2007	Expedeon Limited
WO	PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS	WO2007125372	30.4.2007	Expedeon Limited
	Family 4			
US	PROGRAMMABLE ELECTROPHORETIC NOTCH FILTER SYSTEMS AND METHODS	US 8/926,817	27.4.2010	Expedeon Ltd
	Family 5			
WO	ELECTROPHORESIS GEL AND METHOD OF MAKING	WO2007095485	12.02.2007	Pagegel, Inc

Country	Title	Official No	Filing Date	Applicant/Assignee according to public register
	SAME			
	Family 7			
US	Protein market pellets and method of making and using the same	US7,153,403 (US 2003-0196897)	15.4.2003	Pagegel, Inc
	Family 8			
CA	METHODS AND KITS FOR STABILISING, PROTECTING AND SOLUBILISING PROTEINS	CA2563877	25.4.2005	Novexin Limited
GB	Methods for folding and stabilisation of proteins	GB 0409088 (GB2405872)	23.04.2004	Novexin Ltd
GB	Methods for Stabilising, Protecting, Solubilising and Folding Proteins	GB 0505229	15.03.2005	Novexin Limited
	METHODS AND KITS FOR STABILISING, PROTECTING AND SOLUBILISING PROTEINS	GB0421613	29.09.2004	Novexin Limited
GB	Method for controlling protein aggregation and refolding	GB0321449 (GB2405871)	12.09.2003	Novexin Ltd
JP	METHODS AND KITS FOR FOLDING PROTEINS	JP2008501314	25.04.2005	Novexin Limited
JP		JP2008501639	25.04.2005	Novexin Limited
SG		SG126629		Novexin Ltd
SG	METHODS AND KITS FOR STABILISING, PROTECTING AND SOLUBILISING PROTEINS	SG152238	25.04.2005	Novexin Ltd
	Methods and Kits for Stabilising, Protecting and Solubilising Proteins	US 20080161230	25.04.2005	Novexin Limited
WO	METHODS FOR FOLDING PROTEINS AND REDUCING PROTEIN AGGREGATION	WO2005026196	13.09.2004	Novexin Limited
WO	METHODS AND KITS FOR STABILISING, PROTECTING AND SOLUBILISING PROTEINS	WO2005103067	25.04.2005	Novexin Limited
WO	METHODS AND KITS FOR FOLDING PROTEINS IN THE PRESENCE OF LINEAR OR BRANCHED SUGAR POLYMERS	WO2005103068	25.04.2005	Novexin Limited
	Family 9			
WO	ELECTROPHORESIS GEL ASSEMBLY AND METHOD OF ASSEMBLING THE	WO03048754	27.11.2002	Alpenfels and others

Country	Title	Official No	Filing Date	Applicant/Assignee according to public register
---------	-------	-------------	-------------	---

SAME

TRADEMARKS

Trademark	Number	Status	Proprietor
European Trademarks			
Amintra	6610869	Registered	Expedeon Limited
Expedeon	6610943	Registered	Expedeon Limited
GELFREE	8571184	Registered	Expedeon Limited
Run Blue	6611008	Registered	Expedeon Limited
Lightning Link	9283078	Registered	Innova Biosciences Limited
Lightning-Link	17289612	Registered	Innova Biosciences Limited
Thunder-Link	10659407	Registered	Innova Biosciences Limited
InnovaCoat	10659449	Registered	Innova Biosciences Limited
Tornado-Link	12259727	Registered	Innova Biosciences Limited
FLEXLISA/FlexLISA	16688137	Registered	Innova Biosciences Limited
SUREFIRE	861105	Registered (International TM)	TGR BioSciences Pty Ltd
SUREFIRE HV	9535436	Registered	TGR BioSciences Pty Ltd
SUREFIRE ULTRA	9535386	Registered	TGR BioSciences Pty Ltd
InstantBlue	18065775	Application under examination	Expedeon Limited
CAPTSURE	18065777	Application published	TGR BioSciences Pty Ltd
ELISA-ONE	10135556	Registered	TGR BioSciences Pty Ltd
FLEXLISA/FlexLISA	3210943	Registered (British TM)	Innova Biosciences Limited
US Trademarks			
Amintra	3846945	Registered	Expedeon Limited
Expedeon	3846944	Registered	Expedeon Limited
GELFREE	5100089	Registered	Expedeon Holdings Ltd.
Run Blue	5156061	Registered	Expedeon, Ltd.
Lightning Link	4044212	Registered	Innova Biosciences Limited
Lightning-Link	5788570	Registered	Innova Biosciences Limited
Thunder-Link	4345434	Registered	Innova Biosciences Limited
InnovaCoat	4390466	Registered	Innova Biosciences Limited
SUREFIRE	3228037	Registered	TGR BioSciences Pty Ltd
InstantBlue		Application filed, published for opposition	Expedeon, Ltd
CAPTSURE	-	Application filed	Expedeon, Ltd
ELISAONE		Application filed	TGR BioSciences Pty Ltd

Other Trademarks

Jurisdiction	Trademark	Number	Status	Proprietor
AU	SUREFIRE	952664	Registered	TGR BioSciences Pty Ltd
AU	SUREFIRE HV	1395044	Registered	TGR BioSciences Pty Ltd
AU	SUREFIRE PLUS	1367587	Registered	TGR BioSciences Pty Ltd
AU	SUREFIRE ULTRA	1367588	Registered	TGR BioSciences Pty Ltd
JP	SUREFIRE HV	5444352	Registered	TGR BioSciences Pty Ltd
JP	SUREFIRE ULTRA	5444357	Registered	TGR BioSciences Pty Ltd
JP	ELISA-ONE	5417899	Registered	TGR BioSciences Pty Ltd

PART 2

LICENCES AND AGREEMENTS

The licenses and agreements which are disclosed in folders 18 and 20 of the Data Room.

PART 3
EXCLUDED INTELLECTUAL PROPERTY

Country	Title	Application No. (Publication No.)	Patent Number	Status as of 7 August 2019	Filing Date	Applicant/Assignee according to public register
Family 1 Expedeon SLU patents						
CN	Methods for amplification and sequencing using thermostable TthPrimPol	CN201480026962 (CN105283558)	CN105283558	In force	14.3.2014	KOMATSU MFG CO LTD
EP	METHODS FOR AMPLIFICATION AND SEQUENCING USING THERMOSTABLE TTHPRIMPOL	14710552.2 (EP2971080)	EP2971080	In force in DE	14.3.2014	Expedeon, S.L.
HK	METHODS FOR AMPLIFICATION AND SEQUENCING USING THERMOSTABLE TTHPRIMPOL	16106736.8 (HK1218768)	HK1218768	In force	14.3.2014	SYGNIS BIOTECH S.L.U.
JP	METHODS FOR AMPLIFICATION AND SEQUENCING USING THERMOSTABLE TTHPRIMPOL	JP20150562213 (JP2016509853)		Pending	14.3.2014	SYGNIS BIOTECH S.L.U.
US	METHODS FOR AMPLIFICATION AND SEQUENCING USING THERMOSTABLE TTHPRIMPOL	US14/776901 (US20160040143)		Pending	14.3.2014	SYGNIS BIOTECH S.L.U.
Family 2 Expedeon SLU patents						
WO	METHODS AND KITS FOR AMPLIFICATION OF DOUBLE STRANDED DNA	WO2019101596		Pending	14.11.2018	Expedeon SLU (Assigned to SLU from Expedeon Ltd)

Country	Title	Official No	Filing Date	Applicant/Assignee		
---------	-------	-------------	-------------	--------------------	--	--

Family 1

EP	METHODS FOR AMPLIFICATION AND SEQUENCING USING THERMOSTABLE TTHPRIMPOL	EP13159629.8	15.03.2013	X-Pol Biotech, S.L.U
WO	METHODS FOR AMPLIFICATION AND SEQUENCING USING THERMOSTABLE TTHPRIMPOL	WO2014140309	14.03.2014	SYGNIS BIOTECH S.L.U.

Trademark	Number	Status	Proprietor
European Trademark			
TruePrime	13431341	Registered	Expedeon Limited assigned to Expedeon S.L.U
SunScript	13793021	Registered	Expedeon Limited assigned to Expedeon S.L.U
TrueScript	13728043	Registered	Expedeon Limited assigned to Expedeon S.L.U
QualiPhi	8277444	Registered	Expedeon Limited assigned to Expedeon S.L.U
MagniPhi	8277436	Registered	Expedeon Limited assigned to Expedeon S.L.U

SCHEDULE 13

IT TECHNOLOGY SYSTEMS NOT TRANSFERRING

(a) Hardware

Expedeon Inc

IT assets based at Expedeon Inc are not transferring across

Expedeon Ltd

Mobile Phones:

Mobile phone Heikki Lanckriet

Mobile phone David Roth

Laptops

Laptop Heikki Lanckriet

Laptop David Roth

Laptop Charlotte

Laptop Francesca Fallon

Desktops

Desktop serving the building access control system

Other Hardware in 25 Norman Way which is part of the Fixtures and Fittings of the building including

CAT5 cabling

Fibre Modem

Fixed WIFI access points

Wall data points

Server cabinet

Server Rack

Patch Panels

(b) Software

Navision

Navision for Expedeon Inc which is running on physical server at 25 Norman Way. This is being migrated to a cloud server as we speak.

(c) Data

Files

All Expedeon AG Files

All Expedeon Inc Files

All Expedeon SLU Files

Heikki Lanckriet files

David Roth files

Charlotte Neville files

Francesca Fallon files

Seller Group (excluding any Group Company) Finance Folder

DD Room Folder

Email boxes of the following employees

UK Employees - Heikki Lanckriet, David Rot, Francesca Fallon, Charlotte Neville

All Spanish employees

All US employees (save for the US Employees as defined in this Agreement)

Data in salesforce related to

Expedeon Inc customers (to the extent it relates solely to the Excluded US Business)

CBS products]

SCHEDULE 14

PRODUCTS

21010	PPS Silent Surfactant - 10mg
21011	PPS Silent Surfactant - 5 x 1mg
42102	Gelfree 8100 Cartridge kit 12% Tris Acetate
42103	Gelfree 8100 Cartridge kit 8% Tris Acetate
42104	Gelfree 8100 Cartridge kit 5% Tris Acetate
42105	Gelfree 8100 Cartridge kit 10% Tris Acetate
42202	Gelfree 8100 HEPES Running Buffer - 500ML
42203	Gelfree 8100 HEPES Running Buffer 700ml
42205	Gelfree 8100 HEPES Running Buffer - 50ml
42302	Gelfree 8100 Tris Acetate Sample Buffer
42402	Gelfree 8100 Cartridge 12% Tris Acetate
42403	Gelfree 8100 Cartridge 8% Tris Acetate
42404	Gelfree 8100 Cartridge 5% Tris Acetate
42405	Gelfree 8100 Cartridge 10% Tris Acetate
42506	Proteoloc Protease Inhibitor Cocktail - 3ml
42507	Proteoloc Protease Inhibitor Cocktail - 3 x 10ml
42516	Proteoloc Protease Inhibitor Cocktail EDTA-FREE - 3ml
42517	Proteoloc Protease Inhibitor Cocktail EDTA-FREE - 3 x 10ml
44101	UPX Universal Protein Extraction Kit
44102	YPX Yeast Protein Extraction Kit
44120	Proteoquant BCA Assay - 1960 reactions
44130	Proteoquant BCA Assay - 3920 reactions
44132	Proteoquant BCA Assay Reagent A 500ML
44133	Proteoquant BCA Assay Reagent B 25ml
44200	Proteoloc EDTA Solution 1ml
44204	Proteoloc Protease Inhibitor Cocktail - 10x 1ml
44212	Proteoloc Protease Inhibitor NO-EDTA 1ml
44214	Proteoloc Protease Inhibitor Cocktail EDTA-FREE - 10x 1ml
44250	FASP Protein Digestion Kit
44255	FFPE-FASP Protein Digestion Kit
48100	Gelfree 8100 Fractionation Station
3CE0005	3C - Express - 500 Units in 250 ul
3CE0050	3C - Express - 5000 Units in 2500 ul
44202X	Proteoloc Protease Inhibitor Cocktail - - 1ml
800-10	pIMAGO HRP Phosphoprotein Detection on Western Blot (complete kit) - 10 mini-blots
800-40	pIMAGO HRP Phosphoprotein Detection on Western Blot (complete kit) - 40 mini-blots
801-10	pIMAGO Fluor 550 Phosphoprotein Detection on Western Blot (complete kit) - 10 mini-blots
801-40	pIMAGO Fluor 550 Phosphoprotein Detection on Western Blot (complete kit) - 40 mini-blots
802-10	pIMAGO Fluor 680 Phosphoprotein Detection on Western Blot (complete kit) - 10 mini-blots
802-40	pIMAGO Fluor 680 Phosphoprotein Detection on Western Blot (complete kit) - 40 mini-blots
803-10	pIMAGO Fluor 800 Phosphoprotein Detection on Western Blot (complete kit) - 10 mini-blots
803-40	pIMAGO Fluor 800 Phosphoprotein Detection on Western Blot (complete kit) - 40 mini-blots
900-100	pIMAGO HRP Colorimetric Phosphoprotein Detection on Microplate (complete kit) - 100 wells
900-400	pIMAGO HRP Colorimetric Phosphoprotein Detection on Microplate (complete kit) - 100 wells
901-100	pIMAGO Fluor 550 Phosphoprotein Detection on Microplate (complete kit) - 100 wells
901-400	pIMAGO Fluor 550 Phosphoprotein Detection on Microplate (complete kit) - 400 wells
902-100	pIMAGO Fluor 680 Phosphoprotein Detection on Microplate (complete kit) - 100 wells
902-400	pIMAGO Fluor 680 Phosphoprotein Detection on Microplate (complete kit) - 400 wells
903-100	pIMAGO Fluor 800 Phosphoprotein Detection on Microplate (complete kit) - 100 wells
903-400	pIMAGO Fluor 800 Phosphoprotein Detection on Microplate (complete kit) - 400 wells
A301901	Acrylamide/Bis-acrylamide 30% solution
A302905	Acrylamide/Bis-acrylamide 30% solution
A401901	Acrylamide/Bis-acrylamide 40% solution
ABH0100	HRP Labelled Anti-Blue Antibody 100ul -
ACO0010	Amintra CoHis - 10 ml medium
ACO0025	Amintra CoHis - 25 ml medium
ACO0100	Amintra CoHis - 100 ml medium

ADS0050

Amintra Desalting Spin Column pack of 50

ADS0100	Amintra Desalting Spin Column - pack of 100
AGC150	Empty Gravity Columns (0.5-2ml) - pack of 50 medium
AGC250	Empty Gravity Columns (2-6ml) - pack of 50
AGM0001	Protein G Magnetic Resin 1ml of 20% slurry (0.2 ml medium)
AGM0005	Protein G Magnetic Resin 5ml of 20% slurry (1 ml medium)
AGM0025	Protein G Magnetic Resin 25ml of 20% slurry (5 ml medium)
AGS0005	Amintra Glutathione Resin - 5 ml medium
AGS0010	Amintra Glutathione Resin - 10 ml medium
AGS0025	Amintra Glutathione Resin - 25 ml medium
AGS0100	Amintra Glutathione Resin - 100 ml medium
AGS1000	Amintra Glutathione Resin - 1L medium
AHP0005	Amintra Heparin - 10 ml of 50% slurry (5ml medium) AHP0025Amintra Heparin - 50 ml of 50% slurry (25ml medium) AMA0001
AMB0100	Amintra MBP Resin - 100ml of medium
AMB1000	MBP Resin - 1000 ml medium
AMCO100	Empty Mini Columns (100-250 $\frac{1}{4}$ l) - pack of 100
AMCO25	Empty Mini Columns (100-250 $\frac{1}{4}$ l) - pack of 25
AMG0002	Glutathione Magnetic Resin - 2ml of 50% slurry (1 ml medium) AMG0005Glutathione Magnetic Resin - 5ml of 50% slurry (2.5 ml medium)
AMN0005	Ni-Magnetic Resin - 5ml of 50% slurry (2.5 ml medium)
AMN000T	Ni-Magnetic Resin for His Tagged proteins -
AMN0025	Ni-Magnetic Resin - 25ml of 50% slurry (12.5 ml medium) AMS0025Amintra NHS-Activated Resin - 50 ml of 50% slurry (25ml medium)
ANN0010	Amintra Ni-NTA - 10 ml medium ANN0025 Amintra Ni-NTA - 25 ml medium ANN0100 Amintra Ni-NTA - 100 ml medium
Protein G - 100 ml medium APL0002	Amintra Protein L resin -
2ml medium APL0005	Amintra Protein L resin - 5ml medium
APL0010	Amintra Protein L resin - 10ml medium
ASA0002	Amintra Streptavidin resin - 2ml medium
ASA0005	Amintra Streptavidin resin - 5ml medium
ASA0010	Amintra Streptavidin resin - 10ml medium
ASCO25	Empty Spin Columns (50-100 $\frac{1}{4}$ l) - pack of 25
BCG00812	RunBlue SDS Gel 8% 12 well - 8x10
BCG00827	RunBlue SDS Gel 8% 17 well - 8x10
BCG01012	RunBlue SDS Gel 10% 12 well - 8x10
BCG01027	RunBlue SDS Gel 10% 17 well - 8x10
BCG01212	RunBlue SDS Gel 12% 12 well - 8x10
BCG01227	RunBlue SDS Gel 12% 17 well - 8x10
BCG01612	RunBlue SDS Gel 16% 12 well - 8x10
BCG01627	RunBlue SDS Gel 16% 17 well - 8x10
BCG20812	RunBlue SDS Gel 2-8% 12 well - 8x10
BCG40812	RunBlue SDS Gel 4-8% 12 well - 8x10
BCG40827	RunBlue SDS Gel 4-8% 17 well - 8x10

BCG41212	RunBlue SDS Gel 4-12% 12 well - 8x10			
BCG41212B	Biofuraw SDS Precast Cassette Gel 4-12% 12 well - 8x10			
BCG41227	RunBlue SDS Gel 4-12% 17 well - 8x10			
BCG41227B	Biofuraw SDS Precast Cassette Gel 4-12% 17 well - 8x10			
BCG42012	RunBlue SDS Gel 4-20% 12 well - 8x10			
BCG42012B	RunBlue SDS Gel 4-20% 12 well - 8x10			
BCG42027	RunBlue SDS Gel 4-20% 17 well - 8x10			
BCG42027B	RunBlue SDS Gel 4-20% 17 well - 8x10			
BCG82012	RunBlue SDS Gel 10-20% 12 well - 8x10			
BCN01012	RunBlue Native Gel 10% 12 well - 8x10			
BCN01027	RunBlue Native Gel 10% 17 well - 8x10			
BCN02012	RunBlue Native Gel 20% 12 well - 8x10			
BCN02027	RunBlue Native Gel 20% 17 well - 8x10			
BCN20812	RunBlue Native Gel 2-8% 12 well - 8x10			
BCN20827	RunBlue Native Gel 2-8% 17 well - 8x10			
BCN32012	RunBlue Native Gel 3-20% 12 well - 8x10			
BCN32027	RunBlue Native Gel 3-20% 17 well - 8x10			
BFMX05L	Bradford MX - 500ml			
BFMX1L	Bradford MX - 1 L BFR05L	Bradford Red - 500 ml BFR1L	Bradford Red - 1L BFR05L	Bradford Ultra - 500ml
BFUT	Bradford Ultra Trial Pack - 15ml			
BPE301-100	Bis-Tris buffer			
BS001	BSA Standards for quantification reagents 10x1ml (2mg/ml)	CCG01226	RunBlue MIDI SDS Gel 12% 26 well - 10x15	
CCG41220	RunBlue MIDI SDS Gel 4-12% 20 well - 10x15			
CCG41226	RunBlue MIDI SDS Gel 4-12% 26 well - 10x15			
CCG42026	RunBlue MIDI SDS Gel 4-20% 26 well - 10x15			
ECLA0020	ECL Extra 20ml (Sample)			
ECLA0250	ECL Extra - 250ml ECLA0500	ECL Extra - 500ml		
ECLB0050	Western Blot Stripping Buffer - 50ml			
ECLB0500	Western Blot Stripping Buffer - 500ml			
ECLB5000	Western Blot Stripping Buffer - 5L			
ECLD0020	ECL Extended 20ml (Sample) ECLD0100			
	ECL Extended - 100ml			
ECLD0200	ECL Extended - 200ml ECLM0020	ECL Extreme 20ml (Sample) ECLM0100	ECL Extreme - 100ml ECLM0200	ECL Extreme - 200ml
ECLP0250	ECL Pico - 250ml			
ECLP0500	ECL Pico - 500ml			

ECLS0020	ECL Express 20ml (Sample)
ECLS0100	ECL Express - 100ml
ECLS0250	ECL Express - 250ml
ECLS0500	ECL Express - 500ml
ISB1L	InstantBlue Protein Stain
ISBST	Stain Tray - InstantBlue
ISBT	Instant Blue trial pack - 30ml
NBS41212	RunBlue BIS-TRIS Gel 4-12% 12 well - 10x10
NBT00812	RunBlue Bis-Tris Gel 8% 12 well
NBT00827	RunBlue Bis-Tris Gel 8% 17 well
NBT01012	RunBlue Bis-Tris Gel 10% 12 well
NBT01027	RunBlue Bis-Tris Gel 10% 17 well
NBT01212	RunBlue Bis-Tris Gel 12% 12 well
NBT01227	RunBlue Bis-Tris Gel 12% 17 well
NBT41212	RunBlue Bis-Tris Gel 4-12% 12 well
NBT41227	RunBlue Bis-Tris Gel 4-12% 17 well NPP
	Nvoy Polymer Pack - 5g
NPPS	Nvoy Polymer Pack - 1.25g
NXA04510	RunBlue Gel Drying Solution 1L (1X Concentrate)
NXA05103	RunBlue prestain dual colour markers - 30ul
NXA05160	RunBlue prestained dual colour Markers - 600µl
NXA19001	Blot Sandwich NC 90x85mm 2/pk
NXA19020	RunBlue Blot Sandwich NC 90x85mm - pack of 20
NXA29320	RunBlue Blot Sandwich PVDF90X85 mm - pack of 20
NXA30001	RunBlue Antioxidant 800x - 1ml
NXA30010	RunBlue Antioxidant - 10ml
NXA32001	RunBlue DTT Reducer - 1ml (10X Concentrate)
NXA32020	RunBlue DTT Reducer - 0.2ml (10X Concentrate)
NXA6050	RunBlue prestained tri-colour Marker - 500µl
NXB14050	RunBlue Rapid SDS Run Buffer 50ml
NXB14500	RunBlue Rapid SDS Run Buffer - 500ml
NXB31002	RunBlue LDS Sample Buffer 2 ml (4x Concentrate)
NXB31005	RunBlue LDS Sample Buffer - 0.5ml (4X Concentrate)
NXB31010	RunBlue LDS Sample Buffer - 10ml (4X Concentrate)
NXB32002	4x LDS Sample Buffer – BisTris - 2ml
NXB32010	RunBlue 4x LDS Sample Buffer - Bis-Tris - 10ml
NXB33002	RunBlue Native Sample Buffer - 2ml
NXB33010	RunBlue Native Sample Buffer - 10ml (4X Concentrate)
NXB33050	RunBlue Native Sample Buffer - 0.5ml
NXB3B100	RunBlue LDS Sample Buffer - 100ml
NXB50051	RunBlue SDS Run Buffer TEO-Tricine -
NXB50425	RunBlue SDS Run Buffer TEO-Tricine - 4L (20X Conc)
NXB50500	RunBlue SDS Run Buffer TEO-Tricine - 500ml (20X Conc)
NXB61050	RunBlue Native Run Buffer - 50ml (20x concentrate)
NXB61500	RunBlue Native Run Buffer 500ml (20X Concentrate)
NXB70051	MES Run Buffer - 20x - 50ml
NXB70425	MES Buffer - 4L (8 X 500ml)
NXB70500	RunBlue MES Run Buffer - 500 ml (20x Concentrate)
NXB75000	MOPS Run Buffer - 20x - 1ml
NXB75051	MOPS Run Buffer - 20x - 50ml
NXB75425	MOPS Buffer - 4L (8 X 500ml)
NXB75500	RunBlue MOPS Run Buffer - 500 ml (20x Concentrate) NXB82425RunBlue Tris-Glycine-SDS Blot Buffer - 4L (10x Concentrate) NXB825
NXB86425	RunBlue Tris-Glycine Blot Buffer - 4L (10x Concentrate)
NXB86500	RunBlue Tris-Glycine Blot Buffer - 500 ml (10x Concentrate)
NXB87500	InstantBlot Transfer Buffer 500ml 10X

NXG00801	RunBlue SDS Gel 8% 1 well - 10x10
NXG00802	RunBlue SDS Gel 8% 2 well - 10x10
NXG00812	RunBlue SDS Gel 8% 12 well - 10x10
NXG00827	RunBlue SDS Gel 8% 17 well - 10x10
NXG01001	RunBlue SDS Gel 10% 1 well - 10x10
NXG01002	RunBlue SDS Gel 10% 2 well - 10x10
NXG01012	RunBlue SDS Gel 10% 12 well - 10x10
NXG01027	RunBlue SDS Gel 10% 17 well - 10x10
NXG01201	RunBlue SDS Gel 12% 1 well - 10x10
NXG01202	RunBlue SDS Gel 12% 2 well - 10x10
NXG01212	RunBlue SDS Gel 12% 12 well - 10x10
NXG01227	RunBlue SDS Gel 12% 17 well - 10x10
NXG01601	RunBlue SDS Gel 16% 1 well - 10x10
NXG01602	RunBlue SDS Gel 16% 2 well - 10x10
NXG01612	RunBlue SDS Gel 16% 12 well - 10x10
NXG01627	RunBlue SDS Gel 16% 17 well - 10x10
NXG02012	RunBlue SDS Gel 20% 12 well - 10x10
NXG40801	RunBlue SDS Gel 4-8% 1 well - 10x10
NXG40802	RunBlue SDS Gel 4-8% 2 well - 10x10
NXG40812	RunBlue SDS Gel 4-8% 12 well - 10x10
NXG40827	RunBlue SDS Gel 4-8% 17 well - 10x10
NXG41201	RunBlue SDS Gel 4-12% 1 well - 10x10
NXG41202	RunBlue SDS Gel 4-12% 2 well - 10x10
NXG41212	RunBlue SDS Gel 4-12% 12 well - 10x10
NXG41227	RunBlue SDS Gel 4-12% 17 well - 10x10
NXG42001	RunBlue SDS Gel 4-20% 1 well - 10x10
NXG42002	RunBlue SDS Gel 4-20% 2 well - 10x10
NXG42012	RunBlue SDS Gel 4-20% 12 well - 10x10
NXG42027	RunBlue SDS Gel 4-20% 17 well - 10x10
NXG42027B	Biofuraw SDS Gel 4-20% 17-well - 10x10
NXN01012	RunBlue Native Gel 10% 12 well - 10x10
NXN01027	RunBlue Native Gel 10% 17 well - 10x10
NXN01202	RunBlue Native Gel 12% 2D well - 10x10
NXN02012	RunBlue Native Gel 20% 12 well - 10x10
NXN02027	RunBlue Native Gel 20% 17 well - 10x10
NXN20812	RunBlue Native Gel 2-8% 12 well - 10x10
NXN20827	RunBlue Native Gel 2-8% 17 well - 10x10
NXN32012	RunBlue Native Gel 3-20% 12 well - 10x10
NXN32027	RunBlue Native Gel 3-20% 17 well - 10x10
PCG2001-10EA	Sigma SDS Gel 10% 12w - 10x10 -10pk
PCG2001-2EA	Sigma SDS Gel 10% 12w - 10x10 -2pk
PCG2002-10EA	Sigma SDS Gel 12% 12w - 10x10 -10pk
PCG2002-2EA	Sigma SDS Gel 12% 12w - 10x10 -2pk
PCG2003-10EA	Sigma SDS Gel 4-12% 12w - 10x10 -10pk
PCG2003-2EA	Sigma SDS Gel 4-12% 12w - 10x10 -2pk
PCG2004-10EA	Sigma SDS Gel 4-20% 12w - 10x10 -10pk
PCG2004-2EA	Sigma SDS Gel 4-20% 12w - 10x10 -2pk
PCG2005-10EA	Sigma SDS Gel 10% 17w - 10x10 -10pk
PCG2005-2EA	Sigma SDS Gel 10% 17w - 10x10 -2pk
PCG2006-10EA	Sigma SDS Gel 12% 17w - 10x10 -10pk
PCG2006-2EA	Sigma SDS Gel 12% 17w - 10x10 -2pk
PCG2007-10EA	Sigma SDS Gel 4-12% 17w - 10x10 -10pk
PCG2007-2EA	Sigma SDS Gel 4-12% 17w - 10x10 -2pk
PCG2008-10EA	Sigma SDS Gel 4-20% 17w - 10x10 -10pk
PCG2008-2EA	Sigma SDS Gel 4-20% 17w - 10x10 -2pk
PCG2009-10EA	Sigma SDS Gel 10% 12w - 8x10 -10pk
PCG2009-2EA	Sigma SDS Gel 10% 12w - 8x10 -2pk
10EA	Sigma SDS Gel 12% 12w - 8x10 -10pk

PCG2010-2EA	Sigma SDS Gel 12% 12w - 8x10 -2pk		
PCG2011-10EA	Sigma SDS Gel 4-12% 12w - 8x10 -10pk PCG2011-2EA		
2EA	Sigma SDS Gel 4-12% 12w - 8x10 -2pk PCG2012-10EA	Sigma SDS Gel 4-20% 12w - 8x10 -10pk PCG2012-2EA	Sigma SDS Gel 4-20%
	Sigma SDS Gel 4-12% 17w - 8x10 -2pk PCG2016-10EA	Sigma SDS Gel 4-20% 17w - 8x10 -10pk PCG2016-2EA	Sigma SDS Gel 4-20%
SDS Gel 4-8% 12 well - 8x10 - 10pk PCG2019-2EA	Sigma SDS Gel 4-8% 12 well - 8x10 - 2pk PCG2020-10EA	Sigma SDS Gel 4-8% 17 well - 8x10 - 10pk PCG2020-2EA	
	Sigma SDS Gel 4-8% 17 well - 8x10 - 2pk PCG2101-10EA	Sigma BisTris 8 % 12well - 10x10 - 10pk	
PCG3001-4L	TRUPAGE SDS RUNNING BUFFER, 20X PCG3001-500ML	TRUPAGE SDS RUNNING BUFFER, 20X	
PCG3001-50ML	TRUPAGE SDS RUNNING BUFFER, 20X 50ml TRIAL		
PCG3003-4L	TRUPAGE SDS EXPRESS RUNNING BUFFER, 20X		
PCG3003-500ML	TRUPAGE SDS EXPRESS RUNNING BUFFER, 20X		
PCG3005-1ML	TRUPAGE DTT SAMPLE REDUCER, 10X		
PCG3007-10ML	TRUPAGE RUNNING ANTIOXIDANT, 800X		
PCG3009-10ML	TRUPAGE LDS SAMPLE BUFFER, 4X		
PCG3009-1ML	TRUPAGE LDS SAMPLE BUFFER, 4X 1ML TRIAL		
PCG3011-4L	TRUPAGE TRANSFER BUFFER, 20X(10X) PCG3011-500ML	TRUPAGE TRANSFER BUFFER, 20X(10X) PMACTM02	PolyMAC-Ti M (25 re
PMACTM05	PolyMAC-Ti M (50 reactions)		
PMACTM10	PolyMAC-Ti M (100 reactions)		
STP	Stabil-PAC (Contains 6x 10mg NVoy Polymer + Release Agents)		
STP-MX	Stabil-PAC Maxi (Contains 6x 40mg NVoy Polymer + Release Agents)	STPT	Stabil-PAC Trial
TEV0010	TEV Express - 1000 units in 50 ul TEV0100	TEV - Express - 10,000 Units in 500ul TGS00001	GST Prepacked - 1m
TNN00001	AminTrap HIS Prepacked columns - 1ml Sample		
TNN00005	AminTRAP HIS Prepacked columns - 5ml Sample		
TNN50001	AminTRAP HIS Prepacked Columns 1ml - Pack of 5		
TNN50005	AminTRAP HIS Prepacked Columns 5ml - Pack of 5		
TRI-COLOUR-MARKERS	RunBlue Prestained Tri-Colour Markers		
5000-0000	2view Goat anti-Rabbit [Gold/HRP] - 10ml		
5000-CUS	2view TM Goat anti-Rabbit [Gold/HRP] - 1ml		
5001-0000	2view Goat anti-Mouse [Gold/HRP] - 10ml		
5001-CUS	2view TM Goat anti-Mouse [Gold/HRP] - 1ML		
5002-0000	2view Donkey anti-Goat [Gold/HRP] - 10ml		
5002-CUS	2view TM Donkey anti-Goat [Gold/HRP] - 1ML		
5999-1L	Ponceau S Solution - 1L		
1000-0040	400nm Blue Latex Conjugation Kit - 4 Reaction Mini Kit		
1000-0100	400nm Blue Latex Conjugation Kit - 10 Reaction Mini Kit		
1000-0120	400nm Blue Latex Conjugation Kit - 1 Reaction Midi Kit		

1002-0040	400nm Red Latex Conjugation Kit - 4 Reaction Mini Kit
1002-0100	400nm Red Latex Conjugation Kit - 10 Reaction Mini Kit
1002-0120	400nm Red Latex Conjugation Kit - 1 Reaction Midi Kit
1004-0040	400nm Black Latex Conjugation Kit - 4 Reaction Mini Kit
1004-0100	400nm Black Latex Conjugation Kit - 10 Reaction Mini Kit
1004-0120	400nm Black Latex Conjugation Kit - 1 Reaction Midi Kit
1020-0040	Antibody Concentration & Clean Up Kit - for Latex & Europium
1200-0040	200nm Europium Conjugation Kit - 4 Reaction Mini Kit
1200-0100	200nm Europium Conjugation Kit - 10 Reaction Mini Kit
1200-0120	200nm Europium Conjugation Kit - 1 Reaction Midi Kit
1220-0001	200nm Europium - Streptavidin Conjugate - 1 Reaction Mini Vial
1220-0120	200nm Europium - Streptavidin Conjugate - 1 Reaction Midi Vial
1300-0005	Magnetic Conjugation Kit - 3 Reaction Mini Kit
1300-0010	Magnetic Conjugation Kit - 10 Reaction Mini Kit
1300-0015	Magnetic Conjugation Kit - 1 Reaction Midi Kit
1901-0025	LifeXtend HRP Conjugate Stabilizer. 250ml
2000-0100	Protein A - HRP - 100µg
2000-1000	Protein A - HRP - 1mg
2001-0100	Protein A - Alkaline Phosphatase - 100µg
2001-1000	Protein A - Alkaline Phosphatase - 1mg
2002-0100	Protein A - R-Phycoerythrin - 100µg
2002-1000	Protein A - R-Phycoerythrin - 1mg
201-0010	40nm Gold Nanoparticles (1 OD) - 10ml
2010-0100	Streptavidin - HRP - 100µg
201-0100	40nm Gold Nanoparticles (1 OD) - 100ml
2010-1000	Streptavidin - HRP - 1mg
2011-0100	Streptavidin - Alkaline Phosphatase - 100µg
2011-1000	Streptavidin - Alkaline Phosphatase - 1mg
2012-0100	Streptavidin - R-Phycoerythrin - 100µg
2012-1000	Streptavidin - R-Phycoerythrin - 1mg
2014-0100	Streptavidin - Fluorescein - 100µg
2014-1000	Streptavidin - Fluorescein - 1mg
2050-0020	Biotinylated BSA - 20mg
210-0005	40nm Colloidal Gold 10OD 5ml
210-0010	40nm Gold Nanoparticles (10 OD) - 10ml
210-0100	40nm Gold Nanoparticles (10 OD) - 100ml
212-0010	40nm Gold Nanoparticles (15 OD) - 10ml
212-0100	40nm Gold Nanoparticles (15 OD) - 100ml
212-CUS 600ML	40nm Gold Nanoparticles 150D 600ml
213-0200	40nm InnovaCoat® GOLD (10 OD) Goat Anti Rabbit IgG Conjugate - 200µl
213-1000	40nm InnovaCoat® GOLD (10 OD) Goat Anti Rabbit IgG Conjugate - 1ml
214-0200	10nm InnovaCoat® GOLD (10 OD) Goat Anti Mouse IgG Conjugate - 200µl
214-1000	10nm InnovaCoat® GOLD (10 OD) Goat Anti Mouse IgG Conjugate - 1ml
215-0200	20nm InnovaCoat® GOLD (10 OD) Goat Anti Mouse IgG Conjugate - 200µl
215-1000	20nm InnovaCoat® GOLD (10 OD) Goat Anti Mouse IgG Conjugate - 1ml
216-0200	40nm InnovaCoat® GOLD (10 OD) Goat Anti Mouse IgG Conjugate - 200µl
216-1000	40nm InnovaCoat® GOLD (10 OD) Goat Anti Mouse IgG Conjugate - 1ml
217-0200	80nm InnovaCoat® GOLD (10 OD) Goat Anti Mouse IgG Conjugate - 200µl
217-1000	80nm InnovaCoat® GOLD (10 OD) Goat Anti Mouse IgG Conjugate - 1ml
218-0200	10nm InnovaCoat® GOLD (10 OD) Goat Anti Rabbit IgG Conjugate - 200µl
218-1000	10nm InnovaCoat® GOLD (10 OD) Goat Anti Rabbit IgG Conjugate - 1ml
219-0200	20nm InnovaCoat® GOLD (10 OD) Goat Anti Rabbit IgG Conjugate - 200µl
219-1000	20nm InnovaCoat® GOLD (10 OD) Goat Anti Rabbit IgG Conjugate - 1ml
220-0010	40nm Gold Nanoparticles (20 OD) - 10ml
220-0100	40nm Gold Nanoparticles (20 OD) - 100ml
221-0200	80nm InnovaCoat® GOLD (10 OD) Goat Anti Rabbit IgG Conjugate - 200µl
221-1000	80nm InnovaCoat® GOLD (10 OD) Goat Anti Rabbit IgG Conjugate - 1ml
222-0200	40nm InnovaCoat® GOLD (10 OD) Protein A Conjugate - 200µl

222-1000	40nm InnovaCoat® GOLD (10 OD) Protein A Conjugate - 1ml
223-0200	40nm InnovaCoat® GOLD (10 OD) Protein G Conjugate - 200µl
223-1000	40nm InnovaCoat® GOLD (10 OD) Protein G Conjugate - 1ml
224-0200	20nm InnovaCoat® GOLD (10 OD) Protein A Conjugate - 200µl
224-1000	20nm InnovaCoat® GOLD (10 OD) Protein A Conjugate - 1ml
225-0200	20nm InnovaCoat® GOLD (10 OD) Protein G Conjugate - 200µl
225-1000	20nm InnovaCoat® GOLD (10 OD) Protein G Conjugate - 1ml
228-0005	10nm InnovaCoat® GOLD - 3 Reaction Mini Kit
228-0010	10nm InnovaCoat® GOLD - 10 Reaction Mini Kit
228-0015	10nm InnovaCoat® GOLD - 1 Reaction Midi Kit
228-9993	InnovaCoat GOLD 10nm midi vial
228-9994	InnovaCoat GOLD 10nm maxi vial
228-9995	InnovaCoat GOLD 10nm mini vial
229-0005	20nm InnovaCoat® GOLD - 3 Reaction Mini Kit
229-0010	20nm InnovaCoat® GOLD - 10 Reaction Mini Kit
229-0015	20nm InnovaCoat® GOLD - 1 Reaction Midi Kit
229-0050	InnovaCoat® GOLD 1 Reaction 20nm Maxi Kit
229-9993	InnovaCoat GOLD 20nm midi vial
229-9994	InnovaCoat GOLD 20nm maxi vial
229-9995	InnovaCoat GOLD 20nm mini vial
230-0005	40nm InnovaCoat® GOLD - 3 Reaction Mini Kit
230-0010	40nm InnovaCoat® GOLD - 10 Reaction Mini Kit
230-0015	40nm InnovaCoat® GOLD - 1 Reaction Midi Kit
230-0050	InnovaCoat® GOLD 1 Reaction 40nm Maxi Assembly
230-9993	InnovaCoat GOLD 40nm midi vial
230-9994	InnovaCoat GOLD 40nm maxi vial
230-9995	InnovaCoat GOLD 40nm mini vial
231-0005	80nm InnovaCoat® GOLD - 3 Reaction Mini Kit
231-0010	80nm InnovaCoat® GOLD - 10 Reaction Mini Kit
231-0015	80nm InnovaCoat® GOLD - 1 Reaction Midi Kit
231-0050	INNOVACOAT® GOLD 1 REACTION 80NM MAXI ASSEMBLY
231-9993	InnovaCoat GOLD 80nm midi vial
231-9994	InnovaCoat GOLD 80nm maxi vial
231-9995	InnovaCoat GOLD 80nm mini vial
232-0005	60nm InnovaCoat® GOLD - 3 Reaction Mini Kit
232-0010	60nm InnovaCoat® GOLD - 10 Reaction Mini Kit
232-0015	60nm InnovaCoat® GOLD - 1 Reaction Midi Kit
232-9993	InnovaCoat GOLD 60nm midi vial
232-9994	InnovaCoat GOLD 60nm maxi vial
232-9995	InnovaCoat GOLD 60nm mini vial
240-0200	40nm InnovaCoat® GOLD (10 OD) Biotin Conjugate - 200µl
240-1000	40nm InnovaCoat® GOLD (10 OD) Biotin Conjugate - 1ml
250-0200	40nm InnovaCoat® GOLD (10OD) Streptavidin Conjugate - 200µl
250-1000	40nm InnovaCoat® GOLD (10OD) Streptavidin Conjugate - 1ml
251-0200	20nm InnovaCoat® GOLD (10OD) Streptavidin Conjugate - 200µl
251-1000	20nm InnovaCoat® GOLD (10OD) Streptavidin Conjugate - 1ml
252-0200	10nm InnovaCoat® GOLD (10OD) Streptavidin Conjugate - 200µl
252-1000	10nm InnovaCoat® GOLD (10OD) Streptavidin Conjugate - 1ml
260-0005	AbPure™ Protein A Purification System - 1 mini purification
260-0010	AbPure™ Protein A Purification System - 3 mini purifications
261-0005	AbPure™ Mouse Specific Purification System - 1 mini purification
261-0010	AbPure™ Mouse Specific Purification System - 3 mini purifications
262-0010	AbPure™ Antibody Concentration and Clean-Up Kit - 3 columns
263-0100	AbPure™ BSA Removal Kit - 1ml
264-0030	AbPure™ TCS Antibody Purification System - 1 midi purification
264-0500	AbPure™ Antibody Purification System - 3 midi purifications
265-0200	AbPure™ Universal Magnetic Purification System - 20µg to 200µg Ab purification
265-1006	8-Tube Magnetic Stand

270-0005	40nm InnovaCoat® GOLD - Maleimide - 3 Reaction Mini Kit
270-0015	40nm InnovaCoat® GOLD - Maleimide - 1 Reaction Midi Kit
270-9993	InnovaCoat GOLD Maleimide 40nm midi vial
270-9995	InnovaCoat GOLD Maleimide 40nm mini vial
270-9998	InnovaCoat GOLD Maleimide Quencher vial
271-0005	20nm InnovaCoat® GOLD - Maleimide - 3 Reaction Mini Kit
271-0015	20nm InnovaCoat® GOLD - Maleimide - 1 Reaction Midi Kit
271-9993	InnovaCoat GOLD Maleimide 20nm midi vial
271-9995	InnovaCoat GOLD Maleimide 20nm mini vial
272-0005	10nm InnovaCoat® GOLD - Maleimide - 3 Reaction Mini Kit
272-0015	10nm InnovaCoat® GOLD - Maleimide - 1 Reaction Midi Kit
280-0000	40nm InnovaCoat® GOLD - Hydrazide - 3 vials (to label 10-30ug Ab each)
280-0100	40nm InnovaCoat® GOLD - Hydrazide - 1 vial (to label 10-30ug Ab)
280-0300	40nm InnovaCoat® GOLD - Hydrazide - 1 vial (to label 30-90ug Ab)
3001-0020	10nm Gold Nanoparticles (1 OD) - 20ml
3001-0100	10nm Gold Nanoparticles (1 OD) - 100ml
3010-0020	10nm Gold Nanoparticles (10 OD) - 20ml
3010-0100	10nm Gold Nanoparticles (10 OD) - 100ml
302-0125	PiColorlock ALS - 625/1560 assays DISC
303-0030	PiColorLock - 30ml
303-0125	PiColorLock - 125ml
303-0500	PiColorlock Gold 500ml
303-1000	PiColorlock Gold - 1L
310-0005	Lightning-Link® Rapid Fluorescein Labeling Kit - 1 x up to 200µg Ab
310-0010	Lightning-Link® Rapid Fluorescein Labeling Kit - 3 x up to 200µg Ab
310-0015	Lightning-Link® Rapid Fluorescein Labeling Kit - 1 x up to 2mg Ab
310-0030	Lightning-Link® Rapid Fluorescein Labeling Kit - 3 x up to 20µg Ab
310-1000	LL® Rapid Fluorescein Labeling Kit (10 x up to 200
310-9901	LL-Rapid Fluorescein - 20ug vial
310-9902	LL-Rapid Fluorescein - 200ug vial
310-9903	LL-Rapid Fluorescein - 2mg vial
310-9904	LL-Rapid Fluorescein - 4mg vial
310-9905	LL-Rapid Fluorescein - 10mg vial
310-9906	LL-Rapid Fluorescein - 20mg vial
310-9907	LL-Rapid Fluorescein - 40mg vial
311-0005	Lightning-Link® Rapid Rhodamine Labeling Kit - 1 x up to 200µg Ab
311-0010	Lightning-Link® Rapid Rhodamine Labeling Kit - 3 x up to 200µg Ab
311-0015	Lightning-Link® Rapid Rhodamine Labeling Kit - 1 x up to 2mg Ab
311-0030	Lightning-Link® Rapid Rhodamine Labeling Kit - 3 x up to 20µg Ab
311-9901	LL-Rapid Rhodamine - 20ug vial
311-9902	LL-Rapid Rhodamine - 200ug vial
311-9903	LL-Rapid Rhodamine - 2mg vial
311-9904	LL-Rapid Rhodamine - 4mg vial
311-9905	LL-Rapid Rhodamine - 10mg vial
311-9906	LL-Rapid Rhodamine - 20mg vial
311-9907	LL-Rapid Rhodamine - 40mg vial
313-0005	Lightning-Link® Rapid AMCA Labeling Kit - 1 x up to 200µg Ab
313-0010	Lightning-Link® Rapid AMCA Labeling Kit - 3 x up to 200µg Ab
313-0015	Lightning-Link® Rapid AMCA Labeling Kit - 1 x up to 2mg Ab
313-0030	Lightning-Link® Rapid AMCA Labeling Kit - 3 x up to 20µg Ab
313-9901	LL-Rapid AMCA - 20ug vial
313-9902	LL-Rapid AMCA - 200ug vial
313-9903	LL-Rapid AMCA - 2mg vial
313-9904	LL-Rapid AMCA - 4mg vial
313-9905	LL-Rapid AMCA - 10mg vial
313-9906	LL-Rapid AMCA - 20mg vial
313-9907	LL-Rapid AMCA - 40mg vial
315-0005	Lightning-Link® Rapid Texas Red® Labeling Kit - 1 x up to 200µg Ab

315-0010	Lightning-Link® Rapid Texas Red® Labeling Kit - 3 x up to 200µg Ab
315-0015	Lightning-Link® Rapid Texas Red® Labeling Kit - 1 x up to 2mg Ab
315-0030	Lightning-Link® Rapid Texas Red® Labeling Kit - 3 x up to 20µg Ab
315-9901	LL-Rapid Texas Red - 20ug vial
315-9902	LL-Rapid Texas Red - 200ug vial
315-9903	LL-Rapid Texas Red - 2mg vial
315-9904	LL-Rapid Texas Red - 4mg vial
315-9905	LL-Rapid Texas Red - 5mg vial
315-9906	LL-Rapid Texas Red - 20mg vial
315-9907	LL-Rapid Texas Red - 40mg vial
320-0005	Lightning-Link® Rapid DyLight® 350 Labeling Kit - 1 x up to 200µg Ab
320-0010	Lightning-Link® Rapid DyLight® 350 Labeling Kit - 3 x up to 200µg Ab
320-0015	Lightning-Link® Rapid DyLight® 350 Labeling Kit - 1 x up to 2mg Ab
320-0030	Lightning-Link® Rapid DyLight® 350 Labeling Kit - 3 x up to 20µg Ab
3201-0010	20nm Gold Nanoparticles (1 OD) - 10ml
3201-0100	20nm Gold Nanoparticles (1 OD) - 100ml
320-9901	LL-Rapid DyLight 350 - 20ug vial
320-9902	LL-Rapid DyLight 350 - 200ug vial
320-9903	LL-Rapid DyLight 350 - 2mg vial
320-9904	LL-Rapid DyLight 350 - 4mg vial
320-9905	LL-Rapid DyLight 350 - 10mg vial
320-9906	LL-Rapid DyLight 350 - 20mg vial
320-9907	LL-Rapid DyLight 350 - 40mg vial
3210-0010	20nm Gold Nanoparticles (10 OD) - 10ml
321-0005	Lightning-Link® Rapid DyLight® 405 Labeling Kit - 1 x up to 200µg Ab
321-0010	Lightning-Link® Rapid DyLight® 405 Labeling Kit - 3 x up to 200µg Ab
3210-0100	20nm Gold Nanoparticles (10 OD) - 100ml
321-0015	Lightning-Link® Rapid DyLight® 405 Labeling Kit - 1 x up to 2mg Ab
321-0030	Lightning-Link® Rapid DyLight® 405 Labeling Kit - 3 x up to 20µg Ab
3210-CUSTOM500ML	20nm Colloidal Gold 100D
3215-0010	20nm Gold Nanoparticles (15 OD) - 10ml
3215-0100	20nm Gold Nanoparticles (15 OD) - 100ml
321-9901	LL-Rapid DyLight 405 - 20ug vial
321-9902	LL-Rapid DyLight 405 - 200ug vial
321-9903	LL-Rapid DyLight 405 - 2mg vial
321-9904	LL-Rapid DyLight 405 - 4mg vial
321-9905	LL-Rapid DyLight 405 - 10mg vial
321-9906	LL-Rapid DyLight 405 - 20mg vial
321-9907	LL-Rapid DyLight 405 - 40mg vial
322-0005	Lightning-Link® Rapid DyLight® 488 Labeling Kit - 1 x up to 200µg Ab
322-0010	Lightning-Link® Rapid DyLight® 488 Labeling Kit - 3 x up to 200µg Ab
322-0015	Lightning-Link® Rapid DyLight® 488 Labeling Kit - 1 x up to 2mg Ab
322-0030	Lightning-Link® Rapid DyLight® 488 Labeling Kit - 3 x up to 20µg Ab
322-9901	LL-Rapid DyLight 488 - 20ug vial
322-9902	LL-Rapid DyLight 488 - 200ug vial
322-9903	LL-Rapid DyLight 488 - 2mg vial
322-9904	LL-Rapid DyLight 488 - 4mg vial
322-9905	LL-Rapid DyLight 488 - 10mg vial
322-9906	LL-Rapid DyLight 488 - 20mg vial
322-9907	LL-Rapid DyLight 488 - 40mg vial
323-0005	Lightning-Link® Rapid DyLight® 550 Labeling Kit - 1 x up to 200µg Ab
323-0010	Lightning-Link® Rapid DyLight® 550 Labeling Kit - 3 x up to 200µg Ab
323-0015	Lightning-Link® Rapid DyLight® 550 Labeling Kit - 1 x up to 2mg Ab
323-0030	Lightning-Link® Rapid DyLight® 550 Labeling Kit - 3 x up to 20µg Ab
323-9901	LL-Rapid DyLight 550 - 20ug vial
323-9902	LL-Rapid DyLight 550 - 200ug vial
323-9903	LL-Rapid DyLight 550 - 2mg vial
323-9904	LL-Rapid DyLight 550 - 4mg vial

323-9905	LL-Rapid DyLight 550 - 10mg vial
323-9906	LL-Rapid DyLight 550 - 20mg vial
323-9907	LL-Rapid DyLight 550 - 40mg vial
324-0005	Lightning-Link® Rapid DyLight® 594 Labeling Kit - 1 x up to 200µg Ab
324-0010	Lightning-Link® Rapid DyLight® 594 Labeling Kit - 3 x up to 200µg Ab
324-0015	Lightning-Link® Rapid DyLight® 594 Labeling Kit - 1 x up to 2mg Ab
324-0030	Lightning-Link® Rapid DyLight® 594 Labeling Kit - 3 x up to 20µg Ab
324-9901	LL-Rapid DyLight 594 - 20ug vial
324-9902	LL-Rapid DyLight 594 - 200ug vial
324-9903	LL-Rapid DyLight 594 - 2mg vial
324-9904	LL-Rapid DyLight 594 - 4mg vial
324-9905	LL-Rapid DyLight 594 - 10mg vial
324-9906	LL-Rapid DyLight 594 - 20mg vial
324-9907	LL-Rapid DyLight 594 - 40mg vial
325-0005	Lightning-Link® Rapid DyLight® 633 Labeling Kit - 1 x up to 200µg Ab
325-0010	Lightning-Link® Rapid DyLight® 633 Labeling Kit - 3 x up to 200µg Ab
325-0015	Lightning-Link® Rapid DyLight® 633 Labeling Kit - 1 x up to 2mg Ab
325-0030	Lightning-Link® Rapid DyLight® 633 Labeling Kit - 3 x up to 20µg Ab
325-9901	LL-Rapid DyLight 633 - 20ug vial
325-9902	LL-Rapid DyLight 633 - 200ug vial
325-9903	LL-Rapid DyLight 633 - 2mg vial
325-9904	LL-Rapid DyLight 633 - 4mg vial
325-9905	LL-Rapid DyLight 633 - 10mg vial
325-9906	LL-Rapid DyLight 633 - 20mg vial
325-9907	LL-Rapid DyLight 633 - 40mg vial
326-0005	Lightning-Link® Rapid DyLight® 650 Labeling Kit - 1 x up to 200µg Ab
326-0010	Lightning-Link® Rapid DyLight® 650 Labeling Kit - 3 x up to 200µg Ab
326-0015	Lightning-Link® Rapid DyLight® 650 Labeling Kit - 1 x up to 2mg Ab
326-0030	Lightning-Link® Rapid DyLight® 650 Labeling Kit - 3 x up to 20µg Ab
326-9901	LL-Rapid DyLight 650 - 20ug vial
326-9902	LL-Rapid DyLight 650 - 200ug vial
326-9903	LL-Rapid DyLight 650 - 2mg vial
326-9904	LL-Rapid DyLight 650 - 4mg vial
326-9905	LL-Rapid DyLight 650 - 10mg vial
326-9906	LL-Rapid DyLight 650 - 20mg vial
326-9907	LL-Rapid DyLight 650 - 40mg vial
327-0005	Lightning-Link® Rapid DyLight® 680 Labeling Kit - 1 x up to 200µg Ab
327-0010	Lightning-Link® Rapid DyLight® 680 Labeling Kit - 3 x up to 200µg Ab
327-0015	Lightning-Link® Rapid DyLight® 680 Labeling Kit - 1 x up to 2mg Ab
327-0030	Lightning-Link® Rapid DyLight® 680 Labeling Kit - 3 x up to 20µg Ab
327-9901	LL-Rapid DyLight 680 - 20ug vial
327-9902	LL-Rapid DyLight 680 - 200ug vial
327-9903	LL-Rapid DyLight 680 - 2mg vial
327-9904	LL-Rapid DyLight 680 - 4mg vial
327-9905	LL-Rapid DyLight 680 - 10mg vial
327-9906	LL-Rapid DyLight 680 - 20mg vial
327-9907	LL-Rapid DyLight 680 - 40mg vial
328-0005	Lightning-Link® Rapid DyLight® 755 Labeling Kit - 1 x up to 200µg Ab
328-0010	Lightning-Link® Rapid DyLight® 755 Labeling Kit - 3 x up to 200µg Ab
328-0015	Lightning-Link® Rapid DyLight® 755 Labeling Kit - 1 x up to 2mg Ab
328-0030	Lightning-Link® Rapid DyLight® 755 Labeling Kit - 3 x up to 20µg Ab
328-9901	LL-Rapid DyLight 755 - 20ug vial
328-9902	LL-Rapid DyLight 755 - 200ug vial
328-9903	LL-Rapid DyLight 755 - 2mg vial
328-9904	LL-Rapid DyLight 755 - 4mg vial
328-9905	LL-Rapid DyLight 755 - 10mg vial
328-9906	LL-Rapid DyLight 755 - 20mg vial
328-9907	LL-Rapid DyLight 755 - 40mg vial

329-0005	Lightning-Link® Rapid DyLight® 800 Labeling Kit - 1 x up to 200µg Ab
329-0010	Lightning-Link® Rapid DyLight® 800 Labeling Kit - 3 x up to 200µg Ab
329-0015	Lightning-Link® Rapid DyLight® 800 Labeling Kit - 1 x up to 2mg Ab
329-0030	Lightning-Link® Rapid DyLight® 800 Labeling Kit - 3 x up to 20µg Ab
329-9901	LL-Rapid DyLight 800 - 20ug vial
329-9902	LL-Rapid DyLight 800 - 200ug vial
329-9903	LL-Rapid DyLight 800 - 2mg vial
329-9904	LL-Rapid DyLight 800 - 4mg vial
329-9905	LL-Rapid DyLight 800 - 10mg vial
329-9906	LL-Rapid DyLight 800 - 20mg vial
329-9907	LL-Rapid DyLight 800 - 40mg vial
332/820-SAMPLE	Lightning-Link Rapid Alexa 488 Sample
332-0005	Lightning-Link® Rapid Alexa Fluor® 488 Labeling Kit - 1 x up to 200µg Ab
332-0010	Lightning-Link® Rapid Alexa Fluor® 488 Labeling Kit - 3 x up to 200µg Ab
332-0015	Lightning-Link® Rapid Alexa Fluor® 488 Labeling Kit - 1 x up to 2mg Ab
332-0030	Lightning-Link® Rapid Alexa Fluor® 488 Labeling Kit - 3 x up to 20µg Ab
333-0005	Lightning-Link® Rapid Alexa Fluor® 555 - 1 reaction up to 200ug
333-0010	Lightning-Link® Rapid Alexa Fluor® 555 - 3 reactions each upto 200ug
333-0015	Lightning-Link® Rapid Alexa Fluor® 555 - 1 reaction upto 1mg
333-0030	Lightning-Link® Rapid Alexa Fluor® 555 - 3 reactions each upto 20ug
333-9901	LL Alexa 555 10mg
333-9902	LL Alexa 555 100mg
333-9903	LL Alexa 555 1mg
334-0005	Lightning-Link® Rapid Alexa Fluor® 568 - 1 reaction up to 200ug
334-0010	Lightning-Link® Rapid Alexa Fluor® 568 - 3 reactions each upto 200ug
334-0015	Lightning-Link® Rapid Alexa Fluor® 568 - 1 reaction upto 1mg
334-0030	Lightning-Link® Rapid Alexa Fluor® 568 - 3 reactions each upto 20ug
334-9901	LL Rapid Alexa 568 10mg
334-9902	LL Rapid Alexa 568 100mg
334-9903	LL Rapid Alexa 568 1mg
335-0005	Lightning-Link® Rapid Alexa Fluor® 594 - 1 reaction up to 200ug
335-0010	Lightning-Link® Rapid Alexa Fluor® 594 - 3 reactions each upto 200ug
335-0015	Lightning-Link® Rapid Alexa Fluor® 594 - 1 reaction upto 2mg
335-0030	Lightning-Link® Rapid Alexa Fluor® 594 - 3 reactions each upto 20ug
335-9901	LL Rapid Alexa 594 10mg
335-9902	LL Rapid Alexa 594 100mg
335-9903	LL Rapid Alexa 594 1mg
336-0005	Lightning-Link® Rapid Alexa Fluor® 647 - 1 reaction up to 200ug
336-0010	Lightning-Link® Rapid Alexa Fluor® 647 - 3 reactions each upto 200ug
336-0015	Lightning-Link® Rapid Alexa Fluor® 647 - 1 reaction upto 2mg
336-0030	Lightning-Link® Rapid Alexa Fluor® 647 - 3 reactions each upto 20ug
336-9901	LL Rapid Alexa 647 10mg
336-9902	LL Rapid Alexa 647 100ug
336-9903	LL Rapid Alexa 647 1mg
337-0005	Lightning-Link® Rapid Alexa Fluor® 700 - 1 reaction up to 200ug
337-0010	Lightning-Link® Rapid Alexa Fluor® 700 - 3 reactions each upto 200ug
337-0015	Lightning-Link® Rapid Alexa Fluor® 700 - 1 reaction upto 2mg
337-0030	Lightning-Link® Rapid Alexa Fluor® 700 - 3 reactions each upto 20ug
337-9901	LL Rapid Alexa 700 10ug
337-9902	LL Rapid Alexa 700 100ug
3400-0001	40nm InnovaCoat® GOLD - Carboxyl (40 OD) - 1ml
3400-0005	40nm InnovaCoat® GOLD - Carboxyl (40 OD) - 5ml
340-0005	Lightning-Link® Rapid Cy3 Labeling Kit - 1 x up to 200µg Ab
340-0010	Lightning-Link® Rapid Cy3 Labeling Kit - 3 x up to 200µg Ab
340-0015	Lightning-Link® Rapid Cy3 Labeling Kit - 1 x up to 2mg Ab
340-0030	Lightning-Link® Rapid Cy3 Labeling Kit - 3 x up to 20µg Ab
340-9901	LL-Rapid Cy3 - 20ug vial
340-9902	LL-Rapid Cy3 - 200ug vial

340-9903	LL-Rapid Cy3 - 2mg vial
340-9904	LL-Rapid Cy3 - 4mg vial
340-9905	LL-Rapid Cy3 - 10mg vial
340-9906	LL-Rapid Cy3 - 20mg vial
340-9907	LL-Rapid Cy3 - 40mg vial
342-0005	Lightning-Link® Rapid Cy5 Labeling Kit - 1 x up to 200µg Ab
342-0010	Lightning-Link® Rapid Cy5 Labeling Kit - 3 x up to 200µg Ab
342-0015	Lightning-Link® Rapid Cy5 Labeling Kit - 1 x up to 2mg Ab
342-0030	Lightning-Link® Rapid Cy5 Labeling Kit - 3 x up to 20µg Ab
342-9901	LL-Rapid Cy5 - 20ug vial
342-9902	LL-Rapid Cy5 - 200ug vial
342-9903	LL-Rapid Cy5 - 2mg vial
342-9904	LL-Rapid Cy5 - 4mg vial
342-9905	LL-Rapid Cy5 - 10mg vial
342-9906	LL-Rapid Cy5 - 20mg vial
342-9907	LL-Rapid Cy5 - 40mg vial
343-0005	Lightning-Link® Rapid Cy5.5 Labeling Kit - 1 x up to 200µg Ab
343-0010	Lightning-Link® Rapid Cy5.5 Labeling Kit - 3 x up to 200µg Ab
343-0030	Lightning-Link® Rapid Cy5.5 Labeling Kit - 3 x up to 20µg Ab
343-9901	LL-Rapid Cy5.5 - 20ug vial
343-9902	LL-Rapid Cy5.5 - 200ug vial
343-9903	LL-Rapid Cy5.5 - 2mg vial
343-9904	LL-Rapid Cy5.5 - 4mg vial
343-9905	LL-Rapid Cy5.5 - 10mg vial
343-9906	LL-Rapid Cy5.5 - 20mg vial
343-9907	LL-Rapid Cy5.5 - 40mg vial
349-0005	Lightning-Link® Rapid Atto 390 Labeling Kit - 1 x up to 200µg Ab
349-0010	Lightning-Link® Rapid Atto 390 Labeling Kit - 3 x up to 200µg Ab
349-0030	Lightning-Link® Rapid Atto 390 Labeling Kit - 3 x up to 20µg Ab
349-9901	LL-Rapid Atto 390 - 20ug vial
349-9902	LL-Rapid Atto 390 - 200ug vial
349-9903	LL-Rapid Atto 390 - 2mg vial
349-9904	LL-Rapid Atto 390 - 4mg vial
349-9905	LL-Rapid Atto 390 - 10mg vial
349-9906	LL-Rapid Atto 390 - 20mg vial
349-9907	LL-Rapid Atto 390 - 40mg vial
350-0005	Lightning-Link® Rapid Atto 488 Labeling Kit - 1 x up to 200µg Ab
350-0010	Lightning-Link® Rapid Atto 488 Labeling Kit - 3 x up to 200µg Ab
350-0015	Lightning-Link® Rapid Atto 488 Labeling Kit - 1 x up to 2mg Ab
350-0030	Lightning-Link® Rapid Atto 488 Labeling Kit - 3 x up to 20µg Ab
350-1000	LL® Rapid Atto 488 Labeling Kit 10 x up to 200µg A
350-9901	LL-Rapid Atto 488 - 20ug vial
350-9902	LL-Rapid Atto 488 - 200ug vial
350-9903	LL-Rapid Atto 488 - 2mg vial
350-9904	LL-Rapid Atto 488 - 4mg vial
350-9905	LL-Rapid Atto 488 - 10mg vial
350-9906	LL-Rapid Atto 488 - 20mg vial
350-9907	LL-Rapid Atto 488 - 40mg vial
351-0005	Lightning-Link® Rapid Atto 565 Labeling Kit - 1 x up to 200µg Ab
351-0010	Lightning-Link® Rapid Atto 565 Labeling Kit - 3 x up to 200µg Ab
351-0030	Lightning-Link® Rapid Atto 565 Labeling Kit - 3 x up to 20µg Ab
351-9901	LL-Rapid Atto 565 - 20ug vial
351-9902	LL-Rapid Atto 565 - 200ug vial
351-9903	LL-Rapid Atto 565 - 2mg vial
351-9904	LL-Rapid Atto 565 - 4mg vial
351-9905	LL-Rapid Atto 565 - 10mg vial
351-9906	LL-Rapid Atto 565 - 20mg vial
351-9907	LL-Rapid Atto 565 - 40mg vial

352-0030	LL Rapid Atto594 (3 reactions each up to 20ug) DISC
353-0005	Lightning-Link® Rapid Atto 633 Labeling Kit - 1 x up to 200µg Ab
353-0010	Lightning-Link® Rapid Atto 633 Labeling Kit - 3 x up to 200µg Ab
353-0015	Lightning-Link® Rapid Atto 633 Labeling Kit - 1 x up to 2mg Ab
353-0030	Lightning-Link® Rapid Atto 633 Labeling Kit - 3 x up to 20µg Ab
353-9901	LL-Rapid Atto 633 - 20ug vial
353-9902	LL-Rapid Atto 633 - 200ug vial
353-9903	LL-Rapid Atto 633 - 2mg vial
353-9904	LL-Rapid Atto 633 - 4mg vial
353-9905	LL-Rapid Atto 633 - 10mg vial
353-9906	LL-Rapid Atto 633 - 20mg vial
353-9907	LL-Rapid Atto 633 - 40mg vial
354-0005	Lightning-Link® Rapid Atto 700 Labeling Kit - 1 x up to 200µg Ab
354-0010	Lightning-Link® Rapid Atto 700 Labeling Kit - 3 x up to 200µg Ab
354-9901	LL-Rapid Atto 700 - 20ug vial
354-9902	LL-Rapid Atto 700 - 200ug vial
354-9903	LL-Rapid Atto 700 - 2mg vial
354-9904	LL-Rapid Atto 700 - 4mg vial
354-9905	LL-Rapid Atto 700 - 10mg vial
354-9906	LL-Rapid Atto 700 - 20mg vial
354-9907	LL-Rapid Atto 700 - 40mg vial
362-0005	Lightning-Link® Rapid FluoProbes 647H Labeling Kit - 1 x up to 200µg Ab
362-0010	Lightning-Link® Rapid FluoProbes 647H Labeling Kit - 3 x up to 200µg Ab
362-0015	Lightning-Link® Rapid FluoProbes 647H Labeling Kit - 1 x up to 2mg Ab
362-0030	Lightning-Link® Rapid FluoProbes 647H Labeling Kit - 3 x up to 20µg Ab
362-9901	LL-Rapid FluoProbes647H - 20ug vial
362-9902	LL-Rapid FluoProbes647H - 200ug vial
362-9903	LL-Rapid FluoProbes647H - 2mg vial
362-9904	LL-Rapid FluoProbes647H - 4mg vial
362-9905	LL-Rapid FluoProbes647H - 10mg vial
362-9906	LL-Rapid FluoProbes647H - 20mg vial
362-9907	LL-Rapid FluoProbes647H - 40mg vial
370/820-SAMPLE	LightningLink Rapid Biotin A Conjugation and Clean-Up Kit
370-0005	Lightning-Link® Rapid Biotin Type A Labeling Kit - 1 x up to 200µg Ab
370-0010	Lightning-Link® Rapid Biotin Type A Labeling Kit - 3 x up to 200µg Ab
370-0015	Lightning-Link® Rapid Biotin Type A Labeling Kit - 1 x up to 2mg Ab
370-0030	Lightning-Link® Rapid Biotin Type A Labeling Kit - 3 x up to 20µg Ab
370-9901	LL-Rapid Biotin Type A - 20ug vial
370-9902	LL-Rapid Biotin Type A - 200ug vial
370-9903	LL-Rapid Biotin Type A - 2mg vial
370-9904	LL-Rapid Biotin Type A - 4mg vial
370-9905	LL-Rapid Biotin Type A - 10mg vial
370-9906	LL-Rapid Biotin Type A - 20mg vial
370-9907	LL-Rapid Biotin Type A - 40mg vial
371-0005	Lightning-Link® Rapid Biotin Type B Labeling Kit - 1 x up to 200µg Ab
371-0010	Lightning-Link® Rapid Biotin Type B Labeling Kit - 3 x up to 200µg Ab
371-0015	Lightning-Link® Rapid Biotin Type B Labeling Kit - 1 x up to 2mg Ab
371-0030	Lightning-Link® Rapid Biotin Type B Labeling Kit - 3 x up to 20µg Ab
371-1000	LL® Rapid Biotin B Labeling Kit 10 x up to 200µg A
371-9901	LL-Rapid Biotin Type B - 20ug vial
371-9902	LL-Rapid Biotin Type B - 200ug vial
371-9903	LL-Rapid Biotin Type B - 2mg vial
371-9904	LL-Rapid Biotin Type B - 4mg vial
371-9905	LL-Rapid Biotin Type B - 10mg vial
371-9906	LL-Rapid Biotin Type B - 20mg vial
371-9907	LL-Rapid Biotin Type B - 40mg vial
3801-0010	80nm Gold Nanoparticles (1 OD) - 10ml
3801-0100	80nm Gold Nanoparticles (1 OD) - 100ml

3810-0010	80nm Gold Nanoparticles (10 OD) - 10ml
3810-0100	80nm Gold Nanoparticles (10 OD) - 100ml
3815-0010	80nm Gold Nanoparticles (15 OD) - 10ml
3815-0100	80nm Gold Nanoparticles (15 OD) - 100ml
4000-0030	Conjugate Check&Go! Antibody Labeling Confirmation Kit - 30 Strips
4001-0030	Biotin Check&Go! Antibody Labeling Confirmation Kit - 30 Strips
4002-0030	HRP Check&Go! Antibody Labeling Confirmation Kit - 30 Strips
401-0002	Maleimide-HRP - 2mg
401-0005	Maleimide-HRP - 5mg
402-0002	Maleimide-Alkaline Phosphatase - 2mg
402-0005	Maleimide-Alkaline Phosphatase - 5mg
403-0002	Maleimide-R Phycoerythrin - 2mg
403-0005	Maleimide-R Phycoerythrin - 5mg
404-0002	Maleimide-Allophycocyanin-XL - 2mg
405-0002	Maleimide-Streptavidin - 2mg
405-0005	Maleimide-Streptavidin - 5mg
407-0002	Maleimide-Ovalbumin - 2mg
407-0005	Maleimide-Ovalbumin - 5mg
408-0002	Maleimide-BSA - 2mg
408-0005	Maleimide-BSA - 5mg
409-0002	Maleimide-KLH - 2mg
409-0005	Maleimide-KLH - 5mg
418-0002	Thiol Quantification Kit - 2 plates
419-0002	Protein Thiolation Kit - 1 reaction up to 2mg protein
419-0005	Protein Thiolation Kit - 1 reaction up to 5mg protein
4200-0010	FlexLISA® HRP - 1 x 96 well clear stripwell plate
4200-0020	FlexLISA® AP - 1 x 96 well clear stripwell plate
4200-0030	FlexLISA® HRP - 1 x 96 well black stripwell plate
4200-0040	FlexLISA® AP - 1 x 96 well black stripwell plate
425-0000	Thunder-Link® Plus Oligo Conjugation Kit - 1 reaction + control
425-0002	Antibody Activation Reagent PLUS vial
425-0005	Thunder-Link® Plus Conjugate Clean Up Reagent
425-0030	Thunder-Link® PLUS Oligo Conjugation System
425-0300	Thunder-Link® Plus Oligo Conjugation Kit - 3 reactions + control
4300-0100	Universal LFA Kit - 100 Strips
450-0001	KLH Immunogen Kit Antigens with Amine Groups - 1 x2mg reaction
450-0500	KLH Immunogen Kit Antigens with Amine Groups - 3 x 2mg reactions
451-0001	Ovalbumin Immunogen Kit Antigens with Amine Groups - 1 x2mg reaction
451-0500	Ovalbumin Immunogen Kit Antigens with Amine Groups - 3 x 2mg reactions
452-0001	BSA Immunogen Kit Antigens with Amine Groups - 1 x2mg reaction
452-0500	BSA Immunogen Kit Antigens with Amine Groups - 3 x 2mg reactions
460-0001	KLH Immunogen Kit Antigens with Sulfhydryl Groups - 1 x2mg reaction
460-0500	KLH Immunogen Kit Antigens with Sulfhydryl Groups - 3 x 2mg reactions
461-0001	Ovalbumin Immunogen Kit Antigens with Sulfhydryl Groups - 1 x2mg reaction
461-0500	Ovalbumin Immunogen Kit Antigens with Sulfhydryl Groups - 3 x 2mg reactions
462-0001	BSA Immunogen Kit Antigens with Sulfhydryl Groups - 1 x2mg reaction
462-0500	BSA Immunogen Kit Antigens with Sulfhydryl Groups - 3 x 2mg reactions
470-0001	KLH Immunogen Kit Antigens with Carboxyl Groups - 1 x2mg reaction
470-0500	KLH Immunogen Kit Antigens with Carboxyl Groups - 3 x 2mg reactions
471-0001	Ovalbumin Immunogen Kit Antigens with Carboxyl Groups - 1 x2mg reaction
471-0500	Ovalbumin Immunogen Kit Antigens with Carboxyl Groups - 3 x 2mg reactions
472-0001	BSA Immunogen Kit Antigens with Carboxyl Groups - 1 x2mg reaction
472-0010	BSA Immunogen Kit Antigens with Carboxyl Groups - 3 x 1mg reactions
472-0015	BSA Immunogen Kit Antigens with Carboxyl Groups - 1 x1mg reaction
472-0500	BSA Immunogen Kit Antigens with Carboxyl Groups - 3 x 2mg reactions
501-0015	Pi Bind Phosphate Binding Resin - 5g
505-0001	High Capacity GTP Agarose - 2ml
505-0002	High Capacity GTP Agarose - 5ml

510-0002	High Capacity ATP Agarose - 2ml
510-0005	High Capacity ATP Agarose - 5ml
520-0002	Control Resin-2ml
520-0002	GTP Agarose - Control Resin - 2ml - Control Resin - 2ml
520-0002A	ATP Agarose - Control Resin - 2ml - Control Resin - 2ml
601-0120	ATPase Enzyme Assay Kit - 2 plates
601-0121	ATPase Enzyme Assay Kit - 5 plates
601-9999	10mM Lyophilized ATP - 0.5ml per vial
602-0120	GTPase Enzyme Assay Kit - 2 plates
602-0121	GTPase Enzyme Assay Kit - 5 plates
602-9999	10mM Lyophilized GTP - 0.5ml per vial
701/820-SAMPLE	Lightning-Link HRP Conjugation and Clean-Up Kit
701-0000	Lightning-Link® HRP Labeling Kit - 3 x up to 400µg Ab
701-0002	Lightning-Link® HRP Labeling Kit - 1 x up to 4mg Ab
701-0003	Lightning-Link® HRP Labeling Kit - 5 x up to 4mg Ab
701-0004	Lightning-Link® HRP Labeling Kit - 1 x up to 20mg Ab
701-0010	Lightning-Link® HRP Labeling Kit - 1 x up to 400µg Ab
701-0030	Lightning-Link® HRP Labeling Kit - 3 x up to 40µg Ab
701-1000	Lightning-Link® HRP Labeling Kit 10 x up 400µg Ab
701-9902	LL-HRP - 400ug vial
701-9903	LL-HRP - 4mg vial
701-9904	LL-HRP - 8mg vial
701-9905	LL-HRP - 20mg vial
701-9906	LL-HRP - 40mg vial
701-9907	LL-HRP - 80mg vial
702-0005	Lightning-Link® Alkaline Phosphatase Labeling Kit - 1 x 100µg Ab
702-0010	Lightning-Link® Alkaline Phosphatase Labeling Kit - 3 x 100µg Ab
702-0015	Lightning-Link® Alkaline Phosphatase Labeling Kit - 1 x 1mg Ab
702-0030	Lightning-Link® Alkaline Phosphatase Labeling Kit - 3 x 10µg Ab
702-1000	Lightning-Link® AP Labeling Kit (10 x 100µg Ab)
702-1X10MG CUS	U AP 1x10mg
702-1X5MG CUS	U AP 1x5mg
702-9901	LL-Alk Phos - 10ug vial
702-9902	LL-Alk Phos - 100ug vial
702-9903	LL-Alk Phos - 1mg vial
702-9904	LL-Alk Phos - 2mg vial
702-9905	LL-Alk Phos - 5mg vial
702-9906	LL-Alk Phos - 10mg vial
702-9907	LL-Alk Phos - 20mg vial
703/820-SAMPLE	Lightning-Link R-PE Conjugation and Clean-Up Kit
703-0003	Lightning-Link® R-PE Labeling Kit - 5 x 600µg Ab
703-0004	Lightning-Link® R-PE Labeling Kit - 1 x 3mg Ab
703-0005	Lightning-Link® R-PE Labeling Kit - 1 x 60µg Ab
703-0010	Lightning-Link® R-PE Labeling Kit - 3 x 60µg Ab
703-0015	Lightning-Link® R-PE Labeling Kit - 1 x 600µg Ab
703-0030	Lightning-Link® R-PE Labeling Kit - 3 x 10µg Ab
703-1000	Lightning-Link® R-PE Labeling Kit (10 x 60µg Ab)
703-9901	LL-R-PE - 10ug vial
703-9902	LL-R-PE - 60ug vial
703-9903	LL-R-PE - 600ug vial
703-9904	LL-R-PE - 1.2mg vial
703-9905	LL-R-PE - 3mg vial
703-9906	LL-R-PE - 6mg vial
703-9907	LL-R-PE - 12mg vial
704-0010	LightningLink Biotin Type A 3 reaction 200ug DIS
704-0015	LightningLink Biotin Type A 1 REACTI up 2mg DISC
704-0030	LightningLink Biotin Type A 3 reaction 20ug DISC
704-9901	LL Biotin A 10ug

704-9902	LL Biotin A 100ug
705-0005	Lightning-Link® APC Labeling Kit - 1 x 100µg Ab
705-0010	Lightning-Link® APC Labeling Kit - 3 x 100µg Ab
705-0015	Lightning-Link® APC Labeling Kit - 1 x 1mg Ab
705-0030	Lightning-Link® APC Labeling Kit - 3 x 10µg Ab
705-1000	Lightning-Link® APC Labeling Kit (10 x 100µg Ab)
705-9901	LL-APC - 10ug vial
705-9902	LL-APC - 100ug vial
705-9903	LL-APC - 1mg vial
705-9904	LL-APC - 2mg vial
705-9905	LL-APC - 5mg vial
705-9906	LL-APC - 10mg vial
705-9907	LL-APC - 20mg vial
705-CUS	LL APC 0.5mg
705-CUS1	LL APC 0.3mg
706-0010	Lightning-Link® GOx Labeling Kit - 3 x 100µg Ab
706-0015	Lightning-Link® GOx Labeling Kit - 1 x 1mg Ab
706-0030	Lightning-Link® GOx Labeling Kit - 3 x 10µg Ab
706-9901	LL-GOx - 10ug vial
706-9902	LL-GOx - 100ug vial
706-9903	LL-GOx - 1mg vial
706-9904	LL-GOx - 2mg vial
706-9905	LL-GOx - 5mg vial
706-9906	LL-GOx - 10mg vial
706-9907	LL-GOx - 20mg vial
707-0005	Lightning-Link® Fluorescein Labeling Kit - 1 x up to 200µg Ab
707-0010	Lightning-Link® Fluorescein Labeling Kit - 3 x up to 200µg Ab
707-0015	Lightning-Link® Fluorescein Labeling Kit - 1 x up to 2mg Ab
707-0030	Lightning-Link® Fluorescein Labeling Kit - 3 x up to 20µg Ab
707-1000	LightningLink® Fluorescein Labeling Kit 10 200µg Ab
707-9901	LL-Fluorescein - 20ug vial
707-9902	LL-Fluorescein - 200ug vial
707-9903	LL-Fluorescein - 2mg vial
707-9904	LL-Fluorescein - 4mg vial
707-9905	LL-Fluorescein - 10mg vial
707-9906	LL-Fluorescein - 20mg vial
707-9907	LL-Fluorescein - 40mg vial
708-0005	Lightning-Link® Streptavidin Labeling Kit - 1 x 100µg Ab
708-0010	Lightning-Link® Streptavidin Labeling Kit - 3 x 100µg Ab
708-0015	Lightning-Link® Streptavidin Labeling Kit - 1 x 1mg Ab
708-0030	Lightning-Link® Streptavidin Labeling Kit - 3 x 10µg Ab
708-9901	LL-Streptavidin - 20ug vial
708-9902	LL-Streptavidin - 200ug vial
708-9903	LL-Streptavidin - 2mg vial
708-9904	LL-Streptavidin - 4mg vial
708-9905	LL-Streptavidin - 10mg vial
708-9906	LL-Streptavidin - 20mg vial
708-9907	LL-Streptavidin - 40mg vial
715-0010	LightningLink Biotin Type B 3 reaction 200ug DIS
715-0015	LightningLink Biotin Type B 1 REACTI up 2mg DISC
715-0030	LightningLink Biotin Type B 3 reaction 20ug DISC
715-9901	LL Biotin B 10ug
715-9902	LL Biotin B 100ug
716-0005	Lightning-Link® B-PE Labeling Kit - 1 x 60µg Ab
716-0010	Lightning-Link® B-PE Labeling Kit - 3 x 60µg Ab
716-0015	Lightning-Link® B-PE Labeling Kit - 1 x 600µg Ab
716-9901	LL-B-PE - 10ug vial
716-9902	LL-B-PE - 60ug vial

716-9903	LL-B-PE - 600ug vial
716-9904	LL-B-PE - 1.2mg vial
716-9905	LL-B-PE - 3mg vial
716-9906	LL-B-PE - 6mg vial
716-9907	LL-B-PE - 12mg vial
717-0010	Lightning-Link Avidin (3x100ug) DISC
717-0030	Lightning-Link Avidin (3x10ug) DISC
717-9901	LL Avidin 10mg
717-9902	LL Avidin 100mg
718-0005	Lightning-Link® PerCP Labeling Kit - 1 x 100µg Ab
718-0010	Lightning-Link® PerCP Labeling Kit - 3 x 100µg Ab
718-0015	Lightning-Link® PerCP Labeling Kit - 1 x 1mg Ab
718-0030	Lightning-Link® PerCP Labeling Kit - 3 x 10µg Ab
718-9901	LL-PerCP - 20ug vial
718-9902	LL-PerCP - 200ug vial
718-9903	LL-PerCP - 2mg vial
718-9904	LL-PerCP - 4mg vial
718-9905	LL-PerCP - 10mg vial
718-9906	LL-PerCP - 20mg vial
718-9907	LL-PerCP - 40mg vial
718-CUS	LL per CP 0.5mg
718-CUS1	LL per CP 0.3mg
760-0005	Lightning-Link® R-PE/Cy5 Labeling Kit - 1 x 60µg Ab
760-0010	Lightning-Link® R-PE/Cy5 Labeling Kit - 3 x 60µg Ab
760-0015	Lightning-Link® R-PE/Cy5 Labeling Kit - 1 x 600µg Ab
760-0030	Lightning-Link® R-PE/Cy5 Labeling Kit - 3 x 10µg Ab
760-9901	LL-R-PE/Cy5 - 10ug vial
760-9902	LL-R-PE/Cy5 - 60ug vial
760-9903	LL-R-PE/Cy5 - 600ug vial
760-9904	LL-R-PE/Cy5 - 1.2mg vial
760-9905	LL-R-PE/Cy5 - 3mg vial
760-9906	LL-R-PE/Cy5 - 6mg vial
760-9907	LL-R-PE/Cy5 - 12mg vial
761-0005	Lightning-Link® R-PE/Cy5.5 Labeling Kit - 1 x 60µg Ab
761-0010	Lightning-Link® R-PE/Cy5.5 Labeling Kit - 3 x 60µg Ab
761-0015	Lightning-Link® R-PE/Cy5.5 Labeling Kit - 1 x 600µg Ab
761-0030	Lightning-Link® R-PE/Cy5.5 Labeling Kit - 3 x 10µg Ab
761-9901	LL-R-PE/Cy5.5 - 10ug vial
761-9902	LL-R-PE/Cy5.5 - 60ug vial
761-9903	LL-R-PE/Cy5.5 - 600ug vial
761-9904	LL-R-PE/Cy5.5 - 1.2mg vial
761-9905	LL-R-PE/Cy5.5 - 3mg vial
761-9906	LL-R-PE/Cy5.5 - 6mg vial
761-9907	LL-R-PE/Cy5.5 - 12mg vial
762-0005	Lightning-Link® R-PE/Cy7 Labeling Kit - 1 x 60µg Ab
762-0010	Lightning-Link® R-PE/Cy7 Labeling Kit - 3 x 60µg Ab
762-0015	Lightning-Link® R-PE/Cy7 Labeling Kit - 1 x 600µg Ab
762-0030	Lightning-Link® R-PE/Cy7 Labeling Kit - 3 x 10µg Ab
762-9901	LL-R-PE/Cy7 - 10ug vial
762-9902	LL-R-PE/Cy7 - 60ug vial
762-9903	LL-R-PE/Cy7 - 600ug vial
762-9904	LL-R-PE/Cy7 - 1.2mg vial
762-9905	LL-R-PE/Cy7 - 3mg vial
762-9906	LL-R-PE/Cy7 - 6mg vial
762-9907	LL-R-PE/Cy7 - 12mg vial
763-0005	Lightning-Link® PerCP/Cy5.5 Labeling Kit - 1 x 100µg Ab
763-0010	Lightning-Link® PerCP/Cy5.5 Labeling Kit - 3 x 100µg Ab
763-0015	Lightning-Link® PerCP/Cy5.5 Labeling Kit - 1 x 1mg Ab

763-0030	Lightning-Link® PerCP/Cy5.5 Labeling Kit - 3 x 10µg Ab
763-9901	LL-PerCP/Cy5.5 - 10ug vial
763-9902	LL-PerCP/Cy5.5 - 100ug vial
763-9903	LL-PerCP/Cy5.5 - 1mg vial
763-9904	LL-PerCP/Cy5.5 - 2mg vial
763-9905	LL-PerCP/Cy5.5 - 5mg vial
763-9906	LL-PerCP/Cy5.5 - 10mg vial
763-9907	LL-PerCP/Cy5.5 - 20mg vial
764-0005	Lightning-Link® APC/Cy5.5 Labeling Kit - 1 x 100µg Ab
764-0010	Lightning-Link® APC/Cy5.5 Labeling Kit - 3 x 100µg Ab
764-0015	Lightning-Link® APC/Cy5.5 Labeling Kit - 1 x 1mg Ab
764-0030	Lightning-Link® APC/Cy5.5 Labeling Kit - 3 x 10µg Ab
764-9901	LL-APC/Cy5.5 - 10ug vial
764-9902	LL-APC/Cy5.5 - 100ug vial
764-9903	LL-APC/Cy5.5 - 1mg vial
764-9904	LL-APC/Cy5.5 - 2mg vial
764-9905	LL-APC/Cy5.5 - 5mg vial
764-9906	LL-APC/Cy5.5 - 10mg vial
764-9907	LL-APC/Cy5.5 - 20mg vial
765-0005	Lightning-Link® APC/Cy7 Labeling Kit - 1 x 100µg Ab
765-0010	Lightning-Link® APC/Cy7 Labeling Kit - 3 x 100µg Ab
765-0015	Lightning-Link® APC/Cy7 Labeling Kit - 1 x 1mg Ab
765-0030	Lightning-Link® APC/Cy7 Labeling Kit - 3 x 10µg Ab
765-1000	Lightning-Link® APC/Cy7 Labeling Kit 10 x 100µg Ab
765-9901	LL-APC/Cy7 - 10ug vial
765-9902	LL-APC/Cy7 - 100ug vial
765-9903	LL-APC/Cy7 - 1mg vial
765-9904	LL-APC/Cy7 - 2mg vial
765-9905	LL-APC/Cy7 - 5mg vial
765-9906	LL-APC/Cy7 - 10mg vial
765-9907	LL-APC/Cy7 - 20mg vial
767-0005	Lightning-Link® R-PE/Texas Red® Labeling Kit - 1 x 60µg Ab
767-0010	Lightning-Link® R-PE/Texas Red® Labeling Kit - 3 x 60µg Ab
767-0015	Lightning-Link® R-PE/Texas Red® Labeling Kit - 1 x 600µg Ab
767-0030	Lightning-Link® R-PE/Texas Red® Labeling Kit - 3 x 10µg Ab
767-9901	LL-R-PE/Texas Red - 10ug vial
767-9902	LL-R-PE/Texas Red - 60ug vial
767-9903	LL-R-PE/Texas Red - 600ug vial
767-9904	LL-R-PE/Texas Red - 1.2mg vial
767-9905	LL-R-PE/Texas Red - 3mg vial
767-9906	LL-R-PE/Texas Red - 6mg vial
767-9907	LL-R-PE/Texas Red - 12mg vial
768-0005	Lightning-Link® R-PE/Atto 594 Labeling Kit - 1 x 60µg Ab
768-0010	Lightning-Link® R-PE/Atto 594 Labeling Kit - 3 x 60µg Ab
768-0015	Lightning-Link® R-PE/Atto 594 Labeling Kit - 1 x 600µg Ab
768-0030	Lightning-Link® R-PE/Atto 594 Labeling Kit - 3 x 10µg Ab
768-9901	LL-R-PE/Atto 594 - 10ug vial
768-9902	LL-R-PE/Atto 594 - 60ug vial
768-9903	LL-R-PE/Atto 594 - 600ug vial
768-9904	LL-R-PE/Atto 594 - 1.2mg vial
768-9905	LL-R-PE/Atto 594 - 3mg vial
768-9906	LL-R-PE/Atto 594 - 6mg vial
768-9907	LL-R-PE/Atto 594 - 12mg vial
790-CUS1	LL Modifier 1.5ml
798-0005	Lightning-Link® Alkaline Phosphatase AF (Animal Free)
798-0010	Lightning-Link® Alkaline Phosphatase AF (Animal Free)
798-0015	Lightning-Link® Alkaline Phosphatase AF (Animal Free)
798-0030	Lightning-Link® Alkaline Phosphatase AF (Animal Free)

820-0100	AbSelect BSA Removal Kit - 1ml
830-0005	AbSelect™ Mouse Specific Purification System - 1 purification
830-0010	AbSelect™ Mouse Specific Purification System - 3 purifications
832-0005	AbSelect™ Mouse Specific Purification System - 1 purification
832-0500	AbSelect™ Mouse Specific Purification System - 3 purifications
842-0500	AbSelect™ Rat Specific Purification System - 3 purifications
851-0024	Protein A Resin - 2ml
860-0005	AbSelect™ Protein A Purification System - 1 purification
860-0010	AbSelect™ Protein A Purification System - 3 purifications
861-0010	AbSelect™ Antibody Concentration and Clean-Up Kit - 3 columns
862-0030	AbSelect™ Protein A Purification System - 1 purification
862-0500	AbSelect™ Protein A Purification System - 3 purifications
863-0030	AbSelect™ Protein A Purification System - 1 purification
863-0500	AbSelect™ Protein A Purification System - 3 purifications
890-0005	AbSelect™ Protein G Purification System - 1 purification
890-0010	AbSelect™ Protein G Purification System - 3 purifications
893-0030	AbSelect™ Protein G Purification System - 1 purification
893-0500	AbSelect™ Protein G Purification System - 3 purifications
895-0024	Protein G Resin - 2ml
901-0005	LifeXtend HRP Conjugate Stabilizer - 50ml
901-1000	LifeXtend HRP Stabilizer (1 Litre)
CUL-701-0002	Lightning-Link® HRP Labeling Kit - 1 x up to 4mg Ab CUL-
701-0004	Lightning-Link® HRP Labeling Kit - 1 x up to 20mg Ab CUL-
701-0010	Lightning-Link® HRP Labeling Kit - 1 x up to 400µg Ab CUL-
701-0030	Lightning-Link® HRP Labeling Kit - 3 x up to 40µg Ab CUL-
702-25000	Lightning-Link AP (1x25mg)
CUL-702-5000	Lightning-Link AP (1x5mg)
CUL-705-0005	Lightning-Link® APC Labeling Kit - 1 x 100µg Ab CUL-
761-0100	Lightning-Link PE/Cy5.5 (1x100ug Antibody) CUL-
762-0100	Lightning-Link PE/Cy7 (1x100ug antibody)
CUL-765-0005	Lightning Link APC/Cy7 (1x100ug)
CUL-768-0100	LightningLink® RPE/Atto 594 Labeling Kit 100ug Ab
DDDD1220-0001	200nm Europium - Streptavidin -
DNU-333-0005	Lightning Link Rapid Alexa Fluor 555 (1*200ug)
DNU-333-0010	Lightning Link Rapid Alexa Fluor 555 (3*200ug)
DNU-333-0015	Lightning-Link Rapid Alexa Fluor 555 (1*1mg) DNU-
333-0030	Lightning Link Rapid Alexa Fluor (3*20ug)
DNU-334-0005	Lightning-Link Rapid Alexa Fluor (1*200ug)
DNU-334-0010	Lightning-Link Rapid Alexa Fluor 568
DNU-334-0015	Lightning-Link Rapid Alexa Fluor 568 (1*1mg)
DNU-335-0005	Lightning-Link® Rapid Alexa Fluor® 594 - 1 reaction up to 200ug
DNU-335-0010	Lightning-Link® Rapid Alexa Fluor® 594 - 3 reactions each upto 200ug
DNU-335-0015	Lightning-Link® Rapid Alexa Fluor® 594 - 1 reaction upto 2mg
DNU-335-0030	Lightning-Link® Rapid Alexa Fluor® 594 - 3 reactions each upto 20ug
DNU-336-0005	Lightning-Link® Rapid Alexa Fluor® 647 - 1 reaction up to 200ug
DNU-336-0010	Lightning-Link® Rapid Alexa Fluor® 647 - 3 reactions each upto 200ug
DNU-336-0015	Lightning-Link® Rapid Alexa Fluor® 647 - 1 reaction upto 2mg
DNU-336-0030	Lightning-Link® Rapid Alexa Fluor® 647 - 3 reactions each upto 20ug
DNU-337-0005	Lightning-Link® Rapid Alexa Fluor® 700 - 1 reaction up to 200ug
DNU-337-0010	Lightning-Link® Rapid Alexa Fluor® 700 - 3 reactions each upto 200ug
DNU-337-0015	Lightning-Link® Rapid Alexa Fluor® 700 - 1 reaction upto 2mg
DNU-337-0030	Lightning-Link® Rapid Alexa Fluor® 700 - 3 reactions each upto 20ug
M139-0010	Lightning-Link® 139La, 1x 10ug M139-
0100	Lightning-Link® 139La, 1x 100ug M139-0100
	Lightning-Link 139 La kit - 1x 100ug M141-0010
	Lightning-Link® 141Pr, 1x 10ug M141-0100
	Lightning-Link® 141Pr, 1x 100ug M142-0010
	Lightning-Link 142 Nd - 1 x 10 µg

M142-0100 Lightning-Link 142Nd - 1 x 100 µg
 M143-0010 Lightning-Link 143 Nd - 1 x 10 µg M143-
 0100 Lightning-Link 143Nd - 1 x 100 µg M144-0010
 Lightning-Link® 144Nd, 1x 100ug M144-0100
 Lightning-Link® 144Nd, 1x 100ug M146-0010
 Lightning-Link 146 Nd - 1 x 10 µg M146-0100
 Lightning-Link 146Nd - 1 x 100 µg M147-0010
 Lightning-Link 147Sm - 1 x 10 µg M147-0100
 Lightning-Link 147Sm - 1 x 100 µg M148-0010
 Lightning-Link 148Nd - 1 x 10 µg M148-0100
 Lightning-Link 148Nd - 1 x 100 µg M149-0010
 Lightning-Link 149Sm - 1 x 10 µg M149-0100
 Lightning-Link 149Sm - 1 x 100 µg M151-0010
 Lightning-Link 151 Eu kit - 1 x 100ug M151-0010
 Lightning-Link® 151Eu, 1x 100ug M151-0100
 Lightning-Link 151 Eu kit - 1x 100ug M151-0100
 Lightning-Link® 151Eu, 1x 100ug M152-0010
 Lightning-Link 152Sm - 1 x 10 µg M152-0100
 Lightning-Link 152Sm - 1 x 100 µg M153-0010
 Lightning-Link 153 Eu kit - 1x 100ug M153-0010
 Lightning-Link® 153Eu, 1x 100ug M153-0100
 Lightning-Link 153 Eu kit - 1x 100ug M153-0100
 Lightning-Link® 153Eu, 1x 100ug M154-0010
 Lightning-Link 154 Sm kit - 1x 100ug M154-0010
 Lightning-Link® 154Sm, 1x 100ug M154-0100
 Lightning-Link 154 Sm kit - 1x 100ug M154-0100
 Lightning-Link® 154Sm, 1x 100ug M156-0010
 Lightning-Link 156Gd - 1 x 10 µg M156-0100
 Lightning-Link 156Gd - 1 x 100 µg M158-0010
 Lightning-Link 158Gd - 1 x 10 µg M158-0100
 Lightning-Link 158Gd - 1 x 100 µg M159-0010
 Lightning-Link 159 Tb kit - 1x 100ug M159-0010
 Lightning-Link® 159Tb, 1x 100ug M159-0100
 Lightning-Link® 159Tb, 1x 100ug M159-0100
 Lightning-Link 159 Tb kit - 1 x 100ug M160-0010
 Lightning-Link 160Gd - 1 x 10 µg M160-0100
 Lightning-Link 160Gd - 1 x 100 µg M162-0010
 Lightning-Link 162Dy - 1 x 10 µg M162-0100
 Lightning-Link 162Dy - 1 x 100 µg M164-0010
 Lightning-Link 164Dy - 1 x 10 µg M164-0100
 Lightning-Link 164Dy - 1 x 100 µg M165-0010
 Lightning-Link 165 Ho kit - 1x 100ug M165-0010
 Lightning-Link® 165Ho, 1x 100ug M165-0100
 Lightning-Link® 165Ho, 1x 100ug M165-0100
 Lightning-Link 165 Ho - 1x 100ug M166-0010
 Lightning-Link 166Er - 1 x 10 µg M166-0100
 Lightning-Link 166Er - 1 x 100 µg M167-0010
 Lightning-Link 167Er - 1 x 10 µg M167-0100
 Lightning-Link 167Er - 1 x 100 µg M168-0010
 Lightning-Link 168Er - 1 x 10 µg M168-0100
 Lightning-Link 168Er - 1 x 100 µg M169-0010
 Lightning-Link® 169Tm, 1x 100ug M169-0010
 Lightning-Link 169 Tm- 1 x 100ug M169-0100
 Lightning-Link 169 Tm - 1x 100ug M169-0100
 Lightning-Link® 169Tm, 1x 100ug M170-0010
 Lightning-Link 170Er - 1 x 10 µg M170-0100
 Lightning-Link 170Er - 1 x 100 µg M171-0010
 Lightning-Link 171Yb - 1 x 10 µg

M171-0100	Lightning-Link 171Yb - 1 x 100 µg		
M172-0010	Lightning-Link 172Yb - 1 x 10 µg M172-		
0100	Lightning-Link 172Yb - 1 x 100 µg M174-0010		
	Lightning-Link 174Yb - 1 x 10 µg M174-0100		
	Lightning-Link 174Yb - 1 x 100 µg M175-0010		
	Lightning-Link 175 Lu kit - 1 x 10ug M175-0010		
	Lightning-Link® 175Lu, 1x 10ug M175-0100		
	Lightning-Link® 175Lu, 1x 100ug M175-0100		
	Lightning-Link 175 Lu kit - 1 x 100ug M176-0010		
	Lightning-Link 176Yb - 1 x 10 µg M176-0100		
	Lightning-Link 176Yb - 1 x 100 µg		
P901-0005	LifeXtend HRP Conjugate Stabilizer. 50ml S228-0005	InnovaCoat® GOLD 3 Reaction 10nm Mini Kit S230-0005	InnovaCoat® GOLD 3
S311-0010	LL Rapid Rhodamine (3 reactions each up to 200ug)		
S311-0030	LL Rapid Rhodamine (3 reactions each up to 20ug) S320-		
0005	LL Rapid DyLight 350 (1 reaction up to 200ug)		
S321-0005	LL Rapid DyLight 405 (1 reaction up to 200ug)		
S321-0015	Lightning-Link Rapid DyLight 405 (1-2mg)		
S321-0030	LL Rapid DyLight 405 (3 reactions each up to 20ug)		
S322-0005	LL Rapid Dylight 488 (1 reaction up to 200ug)		
S322-0010	LL Rapid Dylight 488 (3 reactions each up to 200ug)		
S322-0015	Lightning-Link® Rapid DyLight® 488 Labeling Kit S322-		
0030	LL Rapid Dylight 488 (3 reactions each up to 20ug) S323-0010	LL Rapid Dylight 550 (3 reactions up to 200ug) S323-0030	LL Rapid Dylight 550
S324-0010	LL Rapid Dylight 594 (3 reactions each up to 200ug)		
S325-0005	LL Rapid Dylight 633 (1 reaction up to 200ug)		
S325-0030	LL Rapid Dylight 633 (3 reactions each up to 20ug) S326-		
0010	LL Rapid Dylight 650 (3 reactions each up to 200ug)		
S326-0015	Lightning-Link® Rapid DyLight® 650 Labeling Kit - 1 x up to 2mg Ab		
S326-0030	LL Rapid DyLight 650 (3 reactions each up to 20ug)		
S327-0030	LL Rapid DyLight 680 (3 reactions each up to 20ug)		
S340-0010	LL Rapid Cy3 (3 reactions each up to 200ug)		
S342-0010	LL Rapid Cy5 (3 reactions each up to 200ug)		
S342-0015	LL Rapid Cy5 (1 reaction up to 2mg scale)		
S342-0030	LightningLink® Rapid Cy5 Labeling Kit 3 up 20µg Ab		
S349-0005	LL Rapid Atto 390 Labeling Kit (1 x up to 200µg Ab S349-		
0010	LL Rapid Atto 390 (1 reaction up to 200ug)		
S349-1000	LL Rapid Atto 390 Labeling Kit 10 x up to 200µg Ab		
S350-0005	LL Rapid Atto488 (1x100ug)		
S350-1000	LL Rapid Atto 488 Labeling Kit 10 x up to 200µg Ab		
S351-0005	LL Rapid Atto565 (1 reaction up to 200ug) S351-		
0010	LL Rapid Atto 565 (1 reaction up to 200ug)		
S352-0005	LL Rapid Atto 594 Labeling Kit (1 x up to 200µg Ab S353-		
0005	LL Rapid Atto 633 Labeling Kit (1 x up to 200µg) S353-1000	LL Rapid Atto 633 Labeling Kit 10 x up to 200µg Ab S354-0005	LL Rapid Atto 700 La
	Biotin Type B Labeling Kit 3 up 200µg Ab S371-0015	LL Rapid Biotin	
	Type B Labeling Kit 1 up to 2mg Ab S371-0030	LL Rapid Biotin Type B 3	
	vials up to 20ug Ab vial		

S371-1000	Lightning-link Rapid Biotin Type B (x10)	
S701-0000	Lightning-Link HRP (3x100ug)	
S701-0002	Lightning-Link HRP (1x1mg) S701-	
0003	Lightning-Link HRP (5x1mg) S701-0004	
	Lightning-Link HRP (1x5mg) S701-0010	
	Lightning-Link HRP (1x100ug) S701-0030	
	Lightning-Link HRP (3x10ug)	
S701-1000	LightningLink® HRP Labeling Kit 10 up to 400µg Ab	
S702-0005	Lightning-Link AP (1x100ug)	
S702-0010	Lightning-Link AP (3x100ug)	
S702-0015	Lightning-Link AP (1x1mg) S702-	
0030	Lightning-Link AP (3x10ug)	
S702-1000	LL Alkaline Phosphatase Labeling Kit 10 x 100µg Ab	
S703-0004	Lightning-Link R-PE (1x5mg) S703-	
0005	Lightning-Link R-PE (1x100ug) S703-0010	
	Lightning-Link R-PE (3x100ug) S703-0015	
	Lightning-Link R-PE (1x1mg) S703-0030	
	Lightning-Link R-PE (3x10ug)	
S703-0500	Lightning-Link R-PE Conjugation Kit 5mg	
S704-0005	Lightning-Link Biotin (Type A - 1x100ug)	
S704-0010	LightningLink Biotin Type A 3 reaction up to 200ug	
S704-0015	Lightning-Link Biotin Type A 1 reaction up to 2mg	
S704-0030	LightningLink Biotin Type A 3 reactions up to 20ug	
S705-0005	Lightning-Link APC (1x100ug)	
S705-0010	Lightning-Link APC (3x100ug)	
S705-0015	Lightning-Link APC (1x1mg) S705-	
0030	Lightning-Link APC (3x10ug)	
S705-1000	Lightning-Link® APC Labeling Kit (10 x 100µg Ab)	
S706-0010	Lightning-Link GOx (3x100ug)	
S706-0015	Lightning-Link GOx (1x1mg)	
S707-0005	LightningLink Fluoresce 1 REACTI 100200ug Ab scale	
S707-0010	LightningLink Fluoresce 3 REACTI 100200ug Ab scale	
S707-0015	LightningLink Fluorescein 1 reaction 12mg Ab scale S707-	
0030	LightningLink Fluorescein 3 REACTI each up to 20ug S708-0005	Lightning-Link Streptavidin (1x100ug)
S708-0010	Lightning-Link Streptavidin (3x100ug)	
S708-0015	Lightning-Link Streptavidin (1x1mg) S708-	
0030	Lightning-Link Streptavidin (3x10ug)	
S710-0030	LightningLink Rhodamine 3 REACTI each up 20ug DISC	
S714-0010	LightningLink Texas Red 3 REACTI each 200ug DISC S714-	
0030	LightningLink Texas Red 3 REACTI each up 20ug DISC S715-0010	LightningLink Biotin Type B 3 reaction up to 200ug S715-0015
S718-0010	Lightning-Link PerCP (3x100ug)	
S718-0015	Lightning-Link PerCP (1x1mg) S718-	
0030	Lightning-Link PerCP (3x10ug)	
S749-0005	LightningLink® Atto 655 Labeling Kit 1 up 200µg Ab	
S750-0005	LightningLink® Atto 680 Labeling Kit 1 up 200µg Ab	
S760-0005	Lightning-Link PE/Cy5 (1x100ug)	
S760-0010	Lightning-Link PE/Cy5 (3x100ug) S760-	
0015	Lightning-Link PE/Cy5 (1x1mg) S760-0030	
	Lightning-Link PE/Cy5 (3x10ug) S761-0005	
	Lightning-Link PE/Cy5.5 (1x100ug) S761-0010	Lightning-Link PE/Cy5.5 (3x100ug) S761-0015
	Lightning-Link PE/Cy5.5 (1x1mg)	
S761-0030	Lightning-Link® R-PE/Cy5.5 Labeling Kit - 3 x 10µg Ab	

S762-0005	Lightning-Link PE/Cy7 (1x100ug)	
S762-0010	Lightning-Link PE/Cy7 (3x100ug)	
S762-0015	Lightning-Link PE/Cy7 (1x1mg)	
S762-0030	Lightning-Link PE/Cy7 AB	
(3x10ug)		
S763-0005	Lightning-Link PerCP/Cy5.5	
(1x100ug) S763-0010	Lightning-Link PerCP/Cy5.5	
(3x100ug) S763-0015	Lightning-Link PerCP/Cy5.5	
(1x1mg) S763-0030	Lightning-Link PerCP/Cy5.5 (3x10ug)	
S764-0005	Lightning-Link APC/Cy5.5 (1x100ug)	
S764-0010	Lightning-Link APC/Cy5.5 (3x100ug)	
S764-0015	Lightning-Link APC/Cy5.5 (1x1mg)	
S765-0005	Lightning Link APC/Cy7 (1x100ug)	
S765-0010	Lightning-Link APC/Cy7 (3x100ug)	
S765-0015	Lightning-Link APC/Cy7 (1x1mg)	
S765-0030	Lightning-Link APC/Cy7 (3x10ug)	
S767-0005	Lightning-Link PE/Texas Red	
(1x100ug) S767-0010	Lightning-Link PE/Texas Red	
(3x100ug) S767-0015	Lightning-Link PE/Texas Red	
(1x1mg) S767-0030	Lightning-Link PE/Texas Red (3x10ug)	
S768-0005	Lightning-Link PE/Atto594 (1x100ug)	
S780-0010	Lightning-Link Cy3 (3 reactions each up to 200ug)	
S780-0015	Lightning-Link Cy3 (1 reaction up to 2mg scale)	
S780-0030	Lightning-Link Cy3 3 reactions each to 20ug DISC	
S820-0100	AbSelect BSA Removal Kit - 1ml	
S832-0500	AbSelect Mouse TCS Purification System 3	
S860-0005	AbSelect Antibody Purification System 1 purificati	
S861-0010	AbSelect Antibody Concentration and Clean Kit 3	
630008	CaptSure DIY ELISA Buffer Pack	
6300006	CaptSure Assay plate - Bulk Pack (5x5 plates)	
6300008	CaptSure™ DIY ELISA Buffer Pack (5x96well)	
6300020	CaptSure ELISA LL Conjugation Pack	
6300020	CaptSure DIY ELISA	
6300021	CaptSure Assay Plate - Bulk pack (10x5 plates)	
6300022	CaptSure Assay plate- Bulk Pack (20x5 plates)	
6300026	CS CaptSure™ Antibody (5 mg/mL)	
6300027	CS CaptSure™ Antibody (5 mg/mL)	
6300028	CS CaptSure™ Antibody (5 mg/mL)	
4010-0030	CaptSure Tag Check & Go!	
ELK001	ELISA-ONE™ for phospho AKT 1/2/3 (pS473) ELK002	
	ELISA-ONE™ for total AKT 1/2/3	
ELK003	ELISA-ONE™ for phospho & total AKT 1/2/3	
ELK003	ELISA-ONE™ for AKT 1/2/3	
ELK004	ELISA-ONE™ for phospho ERK 1/2 (pT202/pY204) ELK005	ELISA-ONE™ for total ERK 1/2
ELK006	ELISA-ONE™ for phospho & total ERK 1/2	
ELK007	ELISA-ONE™ for phospho NF-κB p65 (pS536) ELK008	
	ELISA-ONE for total NF-κB p65	
ELK009	ELISA-ONE™ for phospho & total NF-κB p65	
ELK010	ELISA-ONE™ for phospho SMAD1 (pS463/pS465) ELK011	ELISA-ONE™ for total SMAD1
ELK012	ELISA-ONE™ for phospho & total SMAD1	
ELK013	ELISA-ONE for phospho STAT3 (pY705) ELK014	ELISA-ONE™ for total STAT3
ELK015	ELISA-ONE™ for phospho & total STAT3	
ELK016	ELISA-ONE™ for phospho STAT5 (pY694/pY699) ELK017	ELISA-ONE™ for total STAT5
ELK018	ELISA-ONE™ for phospho & total STAT5	

Catalog Number	Description	Size
ALSU-AB-100ml	Activation Buffer A - Ultra	100mL Buffer
ALSU-AB-10ml	Activation Buffer A - Ultra	10mL Buffer
ALSU-ABB-100ml	Activation Buffer B - Ultra	100mL Buffer
ALSU-ABB-10ml	Activation Buffer B - Ultra	10mL Buffer
ALSU-ABC-100ml	Activation Buffer C - Ultra	100mL Buffer
ALSU-ABC-10ml	Activation Buffer C - Ultra	10mL Buffer
ALSU-ACAB-0.06mL	AlphaLISA CaptSure Acceptor Beads - Ultra	0.06ml Beads
ALSU-ACAB-1.2mL	AlphaLISA CaptSure Acceptor Beads - Ultra	1.2ml Beads
ALSU-ACAB-6mL	AlphaLISA CaptSure Acceptor Beads - Ultra	6ml Beads
ALSU-ASDB-0.06mL	AlphaScreen Streptavidin Donor Beads - Ultra	0.06ml Beads
ALSU-ASDB-1.2mL	AlphaScreen Streptavidin Donor Beads - Ultra	1.2ml Beads
ALSU-ASDB-6mL	AlphaScreen Streptavidin Donor Beads - Ultra	6ml Beads
ALSUCUS90984	ELISAONE - p-Insulin Receptor (Tyr1150/1151)	100 points
ALSU-CUSTOM		500 points
ALSU-DB-100ml	Dilution Buffer - Ultra	100mL Buffer
ALSU-DB-10ml	Dilution Buffer - Ultra	10mL Buffer
ALSU-LB-100mL	Lysis Buffer - Ultra	100mL Buffer
ALSU-LB-10mL	Lysis Buffer - Ultra	10mL Buffer
ALSU-LB-1L	CETSA Cell Lysis Buffer 2 Bulk - Ultra	1L Buffer
ALSU-LB-5L	CETSA Cell Lysis Buffer 2 Bulk - Ultra	5L Buffer
ALSU-LB-10L	CETSA Cell Lysis Buffer 2 Bulk - Ultra	10L Buffer
ALSU-OLDPEGFR-A10K	EGF Receptor p-(Tyr1068) - Ultra_OLD	10,000 points
ALSU-OLDPEGFR-A500	EGF Receptor p-(Tyr1068) - Ultra_OLD	500 points
ALSU-OLDPEGFR-A50K	EGF Receptor p-(Tyr1068) - Ultra_OLD	50,000 points
ALSU-OLDPEGFR-A-HV	EGF Receptor p-(Tyr1068) - Ultra_OLD	100 points
ALSU-OLDPEIF2-A10K	eIF2a p-(Ser51) - Ultra_OLD	10,000 points
ALSU-OLDPEIF2-A500	eIF2a p-(Ser51) - Ultra_OLD	500 points
ALSU-OLDPEIF2-A50K	eIF2a p-(Ser51) - Ultra_OLD	50,000 points
ALSU-OLDPEIF2-A-HV	eIF2a p-(Ser51) - Ultra_OLD	100 points
ALSU-OLDPIGFR-A10K	IGF-1 Receptor b p-(Tyr1135/1136) - Ultra_OLD	10,000 points
ALSU-OLDPIGFR-A500	IGF-1 Receptor b p-(Tyr1135/1136) - Ultra_OLD	500 points
ALSU-OLDPIGFR-A50K	IGF-1 Receptor b p-(Tyr1135/1136) - Ultra_OLD	50,000 points
ALSU-OLDPIGFR-A-HV	IGF-1 Receptor b p-(Tyr1135/1136) - Ultra_OLD	100 points
ALSU-OLDPIGFR-A-L	IGF-1 Receptor b p-(Tyr1135/1136) -Ultra Lysate_OLD	Lysates
ALSU-PINR-A10K	Insulin Receptor b p-(Tyr1150/1151) - Ultra_OLD	10,000 points
ALSU-PINR-A500	Insulin Receptor b p-(Tyr1150/1151) - Ultra_OLD	500 points
ALSU-PINR-A50K	Insulin Receptor b p-(Tyr1150/1151) - Ultra_OLD	50,000 points
ALSU-PINR-A-HV	Insulin Receptor b p-(Tyr1150/1151) - Ultra_OLD	100 points
ALSU-PINR-A-L	Insulin Receptor b p-(Tyr1150/1151) -Ultra Lysate	Lysates
ALSU-OLDPP38-A10K	p38 MAPK p-(Thr180/Tyr182) -OLD- Ultra	10,000 points
ALSU-OLDPP38-A500	p38 MAPK p-(Thr180/Tyr182) -OLD- Ultra	500 points
ALSU-OLDPP38-A50K	p38 MAPK p-(Thr180/Tyr182) -OLD- Ultra	50,000 points
ALSU-OLDPP38-A-HV	p38 MAPK p-(Thr180/Tyr182) -OLD- Ultra	100 points
ALSU-OLDPP38-A-L	p38 MAPK p-(Thr180/Tyr182) -OLD Ultra Lysate	Lysates
ALSU-OLDPST5-A10K	STAT5 p-(Tyr694/699) - OLD - Ultra	10,000 points
ALSU-OLDPST5-A500	STAT5 p-(Tyr694/699) - OLD - Ultra	500 points
ALSU-OLDPST5-A50K	STAT5 p-(Tyr694/699) - OLD - Ultra	50,000 points
ALSU-OLDPST5-A-HV	STAT5 p-(Tyr694/699) - OLD - Ultra	100 points
ALSU-OLDPST5-A-L	STAT5 p-(Tyr694/699) -OLD - Ultra Lysate	Lysates

ALSU-OLDTP38-A10K	p38 MAPKa Total - OLD- Ultra	10,000 points
ALSU-OLDTP38-A500	p38 MAPKa Total - OLD- Ultra	500 points
ALSU-OLDTP38-A50K	p38 MAPKa Total - OLD- Ultra	50,000 points
ALSU-OLDTP38-A-HV	p38 MAPKa Total - OLD- Ultra	100 points
ALSU-OLDTP38-A-L	p38 MAPKa Total - OLD-Ultra Lysate	Lysates
ALSU-AASYN-A10K	α -Synuclein Aggregate Specific - Ultra	10,000 points
ALSU-AASYN-A500	α -Synuclein Aggregate Specific - Ultra	500 points
ALSU-AASYN-A50K	α -Synuclein Aggregate Specific - Ultra	50,000 points
ALSU-AASYN-A-HV	α -Synuclein Aggregate Specific - Ultra	100 points
ALSU-AASYN-A-L	α -Synuclein Aggregate Specific - Ultra Lysate	Lysates
ALSU-ACP53-A10K	Acetylated p53 (Lys382) - Ultra	10,000 points
ALSU-ACP53-A500	Acetylated p53 (Lys382) - Ultra	500 points
ALSU-ACP53-A50K	Acetylated p53 (Lys382) - Ultra	50,000 points
ALSU-ACP53-A-HV	Acetylated p53 (Lys382) - Ultra	100 points
ALSU-ACP53-A-L	Acetylated p53 (Lys382) - Ultra Lysate	Lysates
ALSU-P4EBP-A10K	4E-BP1 p-(Thr37/46) - Ultra	10,000 points
ALSU-P4EBP-A500	4E-BP1 p-(Thr37/46) - Ultra	500 points
ALSU-P4EBP-A50K	4E-BP1 p-(Thr37/46) - Ultra	50,000 points
ALSU-P4EBP-A-HV	4E-BP1 p-(Thr37/46) - Ultra	100 points
ALSU-P4EBP-A-L	4E-BP1 p-(Thr37/46) -Ultra Lysate	Lysates
ALSU-PACC-A10K	ACC p-(Ser79) - Ultra	10,000 points
ALSU-PACC-A500	ACC p-(Ser79) - Ultra	500 points
ALSU-PACC-A50K	ACC p-(Ser79) - Ultra	50,000 points
ALSU-PACC-A-HV	ACC p-(Ser79) - Ultra	100 points
ALSU-PACC-A-L	ACC p-(Ser79) - Ultra Lysate	Lysates
ALSU-PAKT-A10K	AKT1/2/3 p-(Thr308) - Ultra	10,000 points
ALSU-PAKT-A500	AKT1/2/3 p-(Thr308) - Ultra	500 points
ALSU-PAKT-A50K	AKT1/2/3 p-(Thr308) - Ultra	50,000 points
ALSU-PAKT-A-HV	AKT1/2/3 p-(Thr308) - Ultra	100 points
ALSU-PAKT-A-L	AKT1/2/3 p-(Thr308) -Ultra Lysate	Lysates
ALSU-PAKT-B10K	AKT1/2/3 p-(Ser473) - Ultra	10,000 points
ALSU-PAKT-B500	AKT1/2/3 p-(Ser473) - Ultra	500 points
ALSU-PAKT-B50K	AKT1/2/3 p-(Ser473) - Ultra	50,000 points
ALSU-PAKT-B-HV	AKT1/2/3 p-(Ser473) - Ultra	100 points
ALSU-PAKT-B-L	AKT1/2/3 p-(Ser473) -Ultra Lysate	Lysates
ALSU-PAKT1-C10K	AKT1 p-(Ser473) - Ultra	10,000 points
ALSU-PAKT1-C500	AKT1 p-(Ser473) - Ultra	500 points
ALSU-PAKT1-C50K	AKT1 p-(Ser473) - Ultra	50,000 points
ALSU-PAKT1-C-HV	AKT1 p-(Ser473) - Ultra	100 points
ALSU-PAKT1-C-L	AKT1 p-(Ser473) - Ultra Lysate	Lysates
ALSU-PALK-A10K	ALK p-(Tyr1586) - Ultra	10,000 points
ALSU-PALK-A500	ALK p-(Tyr1586) - Ultra	500 points
ALSU-PALK-A50K	ALK p-(Tyr1586) - Ultra	50,000 points
ALSU-PALK-A-HV	ALK p-(Tyr1586) - Ultra	100 points
ALSU-PALK-A-L	ALK p-(Tyr1586) - Ultra Lysate	Lysates
ALSU-PALK-B10K	ALK p-(Tyr1604) - Ultra	10,000 points
ALSU-PALK-B500	ALK p-(Tyr1604) - Ultra	500 points
ALSU-PALK-B50K	ALK p-(Tyr1604) - Ultra	50,000 points
ALSU-PALK-B-HV	ALK p-(Tyr1604) - Ultra	100 points
ALSU-PALK-B-L	ALK p-(Tyr1604) - Ultra Lysate	Lysates

ALSU-PAMPK-A10K	AMPK α 1/2 p-(Thr172) - Ultra	10,000 points
ALSU-PAMPK-A500	AMPK α 1/2 p-(Thr172) - Ultra	500 points
ALSU-PAMPK-A50K	AMPK α 1/2 p-(Thr172) - Ultra	50,000 points
ALSU-PAMPK-A-HV	AMPK α 1/2 p-(Thr172) - Ultra	100 points
ALSU-PAMPK-A-L	AMPK α 1/2 p-(Thr172) - Ultra Lysate	Lysates
ALSU-PASYN-A10K	α -Synuclein p-(Ser129) - Ultra	10,000 points
ALSU-PASYN-A500	α -Synuclein p-(Ser129) - Ultra	500 points
ALSU-PASYN-A50K	α -Synuclein p-(Ser129) - Ultra	50,000 points
ALSU-PASYN-A-HV	α -Synuclein p-(Ser129) - Ultra	100 points
ALSU-PASYN-A-L	α -Synuclein p-(Ser129) - Ultra Lysate	Lysates
ALSU-PBTK-A10K	p-Btk p-(Tyr223) - Ultra	10,000 points
ALSU-PBTK-A500	p-Btk p-(Tyr223) - Ultra	500 points
ALSU-PBTK-A50K	p-Btk p-(Tyr223) - Ultra	50,000 points
ALSU-PBTK-A-HV	p-Btk p-(Tyr223) - Ultra	100 points
ALSU-PBTK-A-L	p-Btk p-(Tyr223) - Ultra Lysate	Lysates
ALSU-PBTK-B10K	p-Btk p-(Tyr551) - Ultra	10,000 points
ALSU-PBTK-B500	p-Btk p-(Tyr551) - Ultra	500 points
ALSU-PBTK-B50K	p-Btk p-(Tyr551) - Ultra	50,000 points
ALSU-PBTK-B-HV	p-Btk p-(Tyr551) - Ultra	100 points
ALSU-PBTK-B-L	p-Btk p-(Tyr551) - Ultra Lysate	Lysates
ALSU-PCHK1-A10K	CHK1 p-(Ser345) - Ultra	10,000 points
ALSU-PCHK1-A500	CHK1 p-(Ser345) - Ultra	500 points
ALSU-PCHK1-A50K	CHK1 p-(Ser345) - Ultra	50,000 points
ALSU-PCHK1-A-HV	CHK1 p-(Ser345) - Ultra	100 points
ALSU-PCHK1-A-L	CHK1 p-(Ser345) - Ultra Lysate	Lysates
ALSU-PCMET-A10K	cMet p-(Tyr1234/1235) - Ultra	10,000 points
ALSU-PCMET-A500	cMet p-(Tyr1234/1235) - Ultra	500 points
ALSU-PCMET-A50K	cMet p-(Tyr1234/1235) - Ultra	50,000 points
ALSU-PCMET-A-HV	cMet p-(Tyr1234/1235) - Ultra	100 points
ALSU-PCMET-A-L	cMet p-(Tyr1234/1235) - Ultra Lysate	Lysates
ALSU-PCOF-A10K	Cofilin p-(Ser3) - Ultra	10,000 points
ALSU-PCOF-A500	Cofilin p-(Ser3) - Ultra	500 points
ALSU-PCOF-A50K	Cofilin p-(Ser3) - Ultra	50,000 points
ALSU-PCOF-A-HV	Cofilin p-(Ser3) - Ultra	100 points
ALSU-PCOF-A-L	Cofilin p-(Ser3) - Ultra Lysate	Lysates
ALSU-PCREB-A10K	CREB p-(Ser133) - Ultra	10,000 points
ALSU-PCREB-A500	CREB p-(Ser133) - Ultra	500 points
ALSU-PCREB-A50K	CREB p-(Ser133) - Ultra	50,000 points
ALSU-PCREB-A-HV	CREB p-(Ser133) - Ultra	100 points
ALSU-PCREB-A-L	CREB p-(Ser133) -Ultra Lysate	Lysates
ALSU-PEB2-A10K	ErbB2 p-(Tyr1221/1222) - Ultra	10,000 points
ALSU-PEB2-A500	ErbB2 p-(Tyr1221/1222) - Ultra	500 points
ALSU-PEB2-A50K	ErbB2 p-(Tyr1221/1222) - Ultra	50,000 points
ALSU-PEB2-A-HV	ErbB2 p-(Tyr1221/1222) - Ultra	100 points
ALSU-PEB2-A-L	ErbB2 p-(Tyr1221/1222) - Ultra Lysate	Lysates
ALSU-PEGFR-A10K	EGF Receptor p-(Tyr1068) - Ultra_OLD	10,000 points
ALSU-PEGFR-A500	EGF Receptor p-(Tyr1068) - Ultra_OLD	500 points
ALSU-PEGFR-A50K	EGF Receptor p-(Tyr1068) - Ultra_OLD	50,000 points
ALSU-PEGFR-A-HV	EGF Receptor p-(Tyr1068) - Ultra_OLD	100 points
ALSU-PEGFR-A-L	EGF Receptor p-(Tyr1068) -Ultra Lysate	Lysates

ALSU-PEGFR-B10K	EGF Receptor p-(Tyr1068) - Ultra	10,000 points
ALSU-PEGFR-B500	EGF Receptor p-(Tyr1068) - Ultra	500 points
ALSU-PEGFR-B50K	EGF Receptor p-(Tyr1068) - Ultra	50,000 points
ALSU-PEGFR-B-HV	EGF Receptor p-(Tyr1068) - Ultra	100 points
ALSU-PEGFR-B-L	EGF Receptor p-(Tyr1068) -Ultra Lysate	Lysates
ALSU-PEIF2-A-L	eIF2a p-(Ser51) - Ultra Lysate	Lysates
ALSU-PEIF2-B10K	eIF2a p-(Ser51) - Ultra	10,000 points
ALSU-PEIF2-B500	eIF2a p-(Ser51) - Ultra	500 points
ALSU-PEIF2-B50K	eIF2a p-(Ser51) - Ultra	50,000 points
ALSU-PEIF2-B-HV	eIF2a p-(Ser51) - Ultra	100 points
ALSU-PEIF2-B-L	eIF2a p-(Ser51) -Ultra Lysate	Lysates
ALSU-PEIF4-A10K	eIF4E p-(Ser209) - Ultra	10,000 points
ALSU-PEIF4-A500	eIF4E p-(Ser209) - Ultra	500 points
ALSU-PEIF4-A50K	eIF4E p-(Ser209) - Ultra	50,000 points
ALSU-PEIF4-A-HV	eIF4E p-(Ser209) - Ultra	100 points
ALSU-PEIF4-A-L	eIF4E p-(Ser209) -Ultra Lysate	Lysates
ALSU-PERK-A10K	ERK1/2 p-(Thr202/Tyr204) - Ultra	10,000 points
ALSU-PERK-A500	ERK1/2 p-(Thr202/Tyr204) - Ultra	500 points
ALSU-PERK-A50K	ERK1/2 p-(Thr202/Tyr204) - Ultra	50,000 points
ALSU-PERK-A-HV	ERK1/2 p-(Thr202/Tyr204) - Ultra	100 points
ALSU-PERK-A-L	ERK1/2 p-(Thr202/Tyr204) -Ultra Lysate	Lysates
ALSU-PGS3B-A10K	GSK3b p-(Ser9) - Ultra	10,000 points
ALSU-PGS3B-A500	GSK3b p-(Ser9) - Ultra	500 points
ALSU-PGS3B-A50K	GSK3b p-(Ser9) - Ultra	50,000 points
ALSU-PGS3B-A-HV	GSK3b p-(Ser9) - Ultra	100 points
ALSU-PGS3B-A-L	GSK3 b p-(Ser9) -Ultra Lysate	Lysates
ALSU-PIGFR-B10K	IGF-1 Receptor b p-(Tyr1135/1136) - Ultra	10,000 points
ALSU-PIGFR-B500	IGF-1 Receptor b p-(Tyr1135/1136) - Ultra	500 points
ALSU-PIGFR-B50K	IGF-1 Receptor b p-(Tyr1135/1136) - Ultra	50,000 points
ALSU-PIGFR-B-HV	IGF-1 Receptor b p-(Tyr1135/1136) - Ultra	100 points
ALSU-PIGFR-B-L	IGF-1 Receptor b p-(Tyr1135/1136) -Ultra Lysate	Lysates
ALSU-PIKKA-A10K	IKKa p-(Ser176/180) - Ultra	10,000 points
ALSU-PIKKA-A500	IKKa p-(Ser176/180) - Ultra	500 points
ALSU-PIKKA-A50K	IKKa p-(Ser176/180) - Ultra	50,000 points
ALSU-PIKKA-A-HV	IKKa p-(Ser176/180) - Ultra	100 points
ALSU-PIKKA-A-L	IKKa p-(Ser176/180) -Ultra Lysate	Lysates
ALSU-PINR-B10K	Insulin Receptor b p-(Tyr1150/1151) - Ultra	10,000 points
ALSU-PINR-B500	Insulin Receptor b p-(Tyr1150/1151) - Ultra	500 points
ALSU-PINR-B50K	Insulin Receptor b p-(Tyr1150/1151) - Ultra	50,000 points
ALSU-PINR-B-HV	Insulin Receptor b p-(Tyr1150/1151) - Ultra	100 points
ALSU-PINR-B-L	Insulin Receptor b p-(Tyr1150/1151) -Ultra Lysate	Lysates
ALSU-PJNK-A10K	JNK1/2/3 p-(Thr183/Tyr185) -Ultra	10,000 points
ALSU-PJNK-A500	JNK1/2/3 p-(Thr183/Tyr185) -Ultra	500 points
ALSU-PJNK-A50K	JNK1/2/3 p-(Thr183/Tyr185) -Ultra	50,000 points
ALSU-PJNK-A-HV	JNK1/2/3 p-(Thr183/Tyr185) -Ultra	100 points
ALSU-PJNK-A-L	JNK1/2/3 p-(Thr183/Tyr185) -Ultra, Lysate	Lysates
ALSU-PLCK-A10K	Lck p-(Tyr505) - Ultra	10,000 points
ALSU-PLCK-A500	Lck p-(Tyr505) - Ultra	500 points
ALSU-PLCK-A50K	Lck p-(Tyr505) - Ultra	50,000 points
ALSU-PLCK-A-HV	Lck p-(Tyr505) - Ultra	100 points

ALSU-PLCK-A-L	Lck p-(Tyr505) - Ultra, Lysate	Lysates
ALSU-PLRRK2-A10K	LRRK2 p-(Ser935) - Ultra	10,000 points
ALSU-PLRRK2-A500	LRRK2 p-(Ser935) - Ultra	500 points
ALSU-PLRRK2-A50K	LRRK2 p-(Ser935) - Ultra	50,000 points
ALSU-PLRRK2-A-HV	LRRK2 p-(Ser935) - Ultra	100 points
ALSU-PLRRK2-A-L	LRRK2 p-(Ser935) - Ultra, Lysate	Lysates
ALSU-PMEK1-A10K	MEK1 p-(Ser218/222) - Ultra	10,000 points
ALSU-PMEK1-A500	MEK1 p-(Ser218/222) - Ultra	500 points
ALSU-PMEK1-A50K	MEK1 p-(Ser218/222) - Ultra	50,000 points
ALSU-PMEK1-A-HV	MEK1 p-(Ser218/222) - Ultra	100 points
ALSU-PMEK1-A-L	MEK1 p-(Ser218/222) -Ultra Lysate	Lysates
ALSU-PMKK4-A10K	MKK4 p-(Ser257) - Ultra	10,000 points
ALSU-PMKK4-A500	MKK4 p-(Ser257) - Ultra	500 points
ALSU-PMKK4-A50K	MKK4 p-(Ser257) - Ultra	50,000 points
ALSU-PMKK4-A-HV	MKK4 p-(Ser257) - Ultra	100 points
ALSU-PMKK4-A-L	MKK4 p-(Ser257) - Ultra Lysate	Lysates
ALSU-PMTOR-A10K	mTOR p-(Ser2448) - Ultra_OLD	10,000 points
ALSU-PMTOR-A500	mTOR p-(Ser2448) - Ultra_OLD	500 points
ALSU-PMTOR-A50K	mTOR p-(Ser2448) - Ultra_OLD	50,000 points
ALSU-PMTOR-A-HV	mTOR p-(Ser2448) - Ultra_OLD	100 points
ALSU-PMTOR-A-L	mTOR p-(Ser2448) -Ultra Lysate_OLD	Lysates
ALSU-PMTOR-B10K	mTOR p-(Ser2481) - Ultra	10,000 points
ALSU-PMTOR-B500	mTOR p-(Ser2481) - Ultra	500 points
ALSU-PMTOR-B50K	mTOR p-(Ser2481) - Ultra	50,000 points
ALSU-PMTOR-B-HV	mTOR p-(Ser2481) - Ultra	100 points
ALSU-PMTOR-B-L	mTOR p-(Ser2481) - Ultra Lysate	Lysates
ALSU-PMTOR-C10K	mTOR p-(Ser2448) - Ultra	10,000 points
ALSU-PMTOR-C500	mTOR p-(Ser2448) - Ultra	500 points
ALSU-PMTOR-C50K	mTOR p-(Ser2448) - Ultra	50,000 points
ALSU-PMTOR-C-HV	mTOR p-(Ser2448) - Ultra	100 points
ALSU-PMTOR-C-L	mTOR p-(Ser2448) -Ultra Lysate	Lysates
ALSU-PNFKB-A10K	NF-kB p65 p-(Ser536) - Ultra	10,000 points
ALSU-PNFKB-A500	NF-kB p65 p-(Ser536) - Ultra	500 points
ALSU-PNFKB-A50K	NF-kB p65 p-(Ser536) - Ultra	50,000 points
ALSU-PNFKB-A-HV	NF-kB p65 p-(Ser536) - Ultra	100 points
ALSU-PNFKB-A-L	NF-kB p65 p-(Ser536) -Ultra Lysate	Lysates
ALSU-PP38-B10K	p38 MAPK p-(Thr180/Tyr182) - Ultra	10,000 points
ALSU-PP38-B500	p38 MAPK p-(Thr180/Tyr182) - Ultra	500 points
ALSU-PP38-B50K	p38 MAPK p-(Thr180/Tyr182) - Ultra	50,000 points
ALSU-PP38-B-HV	p38 MAPK p-(Thr180/Tyr182) - Ultra	100 points
ALSU-PP38-B-L	p38 MAPK p-(Thr180/Tyr182) -Ultra Lysate	Lysates
ALSU-PP53-A10K	p53 p-(Ser15) - Ultra	10,000 points
ALSU-PP53-A500	p53 p-(Ser15) - Ultra	500 points
ALSU-PP53-A50K	p53 p-(Ser15) - Ultra	50,000 points
ALSU-PP53-A-HV	p53 p-(Ser15) - Ultra	100 points
ALSU-PP53-A-L	p53 p-(Ser15) - Ultra Lysate	Lysates
ALSU-PP70-A10K	p70S6K p-(Thr389) - Ultra	10,000 points
ALSU-PP70-A500	p70S6K p-(Thr389) - Ultra	500 points
ALSU-PP70-A50K	p70S6K p-(Thr389) - Ultra	50,000 points
ALSU-PP70-A-HV	p70S6K p-(Thr389) - Ultra	100 points

ALSU-PP70-A-L	p70S6K p-(Thr389) - Ultra Lysate	Lysates
ALSU-PPD1-A10K	p-PD-1 (pan Tyr) - Ultra	10,000 points
ALSU-PPD1-A500	p-PD-1 (pan Tyr) - Ultra	500 points
ALSU-PPD1-A50K	p-PD-1 (pan Tyr) - Ultra	50,000 points
ALSU-PPD1-A-HV	p-PD-1 (pan Tyr) - Ultra	100 points
	p-PD-1 (pan Tyr) - Ultra Lysate	Lysates
ALSU-PPDGF-A10K	PDGF Receptor β (Tyr751) - Ultra	10,000 points
ALSU-PPDGF-A500	PDGF Receptor β (Tyr751) - Ultra	500 points
ALSU-PPDGF-A50K	PDGF Receptor β (Tyr751) - Ultra	50,000 points
ALSU-PPDGF-A-HV	PDGF Receptor β (Tyr751) - Ultra	100 points
ALSU-PPDGF-A1-L	PDGF Receptor β (Tyr751) - Ultra Lysate	Lysates
ALSU-PPKC-A10K	PKC theta p-(Thr538) - Ultra	10,000 points
ALSU-PPKC-A500	PKC theta p-(Thr538) - Ultra	500 points
ALSU-PPKC-A50K	PKC theta p-(Thr538) - Ultra	50,000 points
ALSU-PPKC-A-HV	PKC theta p-(Thr538) - Ultra	100 points
ALSU-PPKC-A-L	PKC theta p-(Thr538) - Ultra Lysate	Lysates
ALSU-PRB-A10K	Rb p-(Ser807/811) - Ultra	10,000 points
ALSU-PRB-A500	Rb p-(Ser807/811) - Ultra	500 points
ALSU-PRB-A50K	Rb p-(Ser807/811) - Ultra	50,000 points
ALSU-PRB-A-HV	Rb p-(Ser807/811) - Ultra	100 points
ALSU-PRB-A-L	Rb p-(Ser807/811) - Ultra Lysate	Lysates
ALSU-PRB-B10K	Rb p-(Thr821/826) - Ultra	10,000 points
ALSU-PRB-B500	Rb p-(Thr821/826) - Ultra	500 points
ALSU-PRB-B50K	Rb p-(Thr821/826) - Ultra	50,000 points
ALSU-PRB-B-HV	Rb p-(Thr821/826) - Ultra	100 points
ALSU-PRB-B-L	Rb p-(Thr821/826) - Ultra Lysate	Lysates
ALSU-PS6R-A10K	RP S6 p-(Ser240/244) - Ultra	10,000 points
ALSU-PS6R-A500	RP S6 p-(Ser240/244) - Ultra	500 points
ALSU-PS6R-A50K	RP S6 p-(Ser240/244) - Ultra	50,000 points
ALSU-PS6R-A-HV	RP S6 p-(Ser240/244) - Ultra	100 points
ALSU-PS6R-A-L	RP S6 p-(Ser240/244) - Ultra Lysate	Lysates
ALSU-PSHP1-A10K	SHP-1 p-(Tyr536) - Ultra	10,000 points
ALSU-PSHP1-A500	SHP-1 p-(Tyr536) - Ultra	500 points
ALSU-PSHP1-A50K	SHP-1 p-(Tyr536) - Ultra	50,000 points
ALSU-PSHP1-A-HV	SHP-1 p-(Tyr536) - Ultra	100 points
ALSU-PSHP1-A-L	SHP-1 p-(Tyr536) - Ultra Lysate	Lysates
ALSU-PSHP1-B10K	SHP-1 p-(Tyr564) - Ultra	10,000 points
ALSU-PSHP1-B500	SHP-1 p-(Tyr564) - Ultra	500 points
ALSU-PSHP1-B50K	SHP-1 p-(Tyr564) - Ultra	50,000 points
ALSU-PSHP1-B-HV	SHP-1 p-(Tyr564) - Ultra	100 points
ALSU-PSHP1-B-L	SHP-1 p-(Tyr564) - Ultra Lysate	Lysates
ALSU-PSHP2-A10K	SHP-2 p-(Tyr542) - Ultra	10,000 points
ALSU-PSHP2-A500	SHP-2 p-(Tyr542) - Ultra	500 points
ALSU-PSHP2-A50K	SHP-2 p-(Tyr542) - Ultra	50,000 points
ALSU-PSHP2-A-HV	SHP-2 p-(Tyr542) - Ultra	100 points
ALSU-PSHP2-A-L	SHP-2 p-(Tyr542) - Ultra Lysate	Lysates
ALSU-PSHP2-B10K	SHP-2 p-(Tyr580) - Ultra	10,000 points
ALSU-PSHP2-B500	SHP-2 p-(Tyr580) - Ultra	500 points
ALSU-PSHP2-B50K	SHP-2 p-(Tyr580) - Ultra	50,000 points
ALSU-PSHP2-B-HV	SHP-2 p-(Tyr580) - Ultra	100 points

ALSU-PSHP2-B-L	SHP-2 p-(Tyr580) - Ultra Lyate	Lysates
ALSU-PSLP-A10K	SLP-76 p-(Ser376) - Ultra	10,000 points
ALSU-PSLP-A500	SLP-76 p-(Ser376) - Ultra	500 points
ALSU-PSLP-A50K	SLP-76 p-(Ser376) - Ultra	50,000 points
ALSU-PSLP-A-HV	SLP-76 p-(Ser376) - Ultra	100 points
ALSU-PSLP-A-L	SLP-76 p-(Ser376) -Ultra Lysate	Lysates
ALSU-PSM1-A10K	SMAD1 p-(Ser463/465) - Ultra	10,000 points
ALSU-PSM1-A500	SMAD1 p-(Ser463/465) - Ultra	500 points
ALSU-PSM1-A50K	SMAD1 p-(Ser463/465) - Ultra	50,000 points
ALSU-PSM1-A-HV	SMAD1 p-(Ser463/465) - Ultra	100 points
ALSU-PSM1-A-L	SMAD1 p-(Ser463/465) -Ultra Lysate	Lysates
ALSU-PSM2-A10K	SMAD2 p-(Ser465/467) - Ultra	10,000 points
ALSU-PSM2-A500	SMAD2 p-(Ser465/467) - Ultra	500 points
ALSU-PSM2-A50K	SMAD2 p-(Ser465/467) - Ultra	50,000 points
ALSU-PSM2-A-HV	SMAD2 p-(Ser465/467) - Ultra	100 points
ALSU-PSM2-A-L	SMAD2 p-(Ser465/467) - Ultra Lysate	Lysates
ALSU-PSM3-A10K	SMAD3 p-(Ser423/425) - Ultra	10,000 points
ALSU-PSM3-A500	SMAD3 p-(Ser423/425) - Ultra	500 points
ALSU-PSM3-A50K	SMAD3 p-(Ser423/425) - Ultra	50,000 points
ALSU-PSM3-A-HV	SMAD3 p-(Ser423/425) - Ultra	100 points
ALSU-PSM3-A-L	SMAD3 p-(Ser423/425) -Ultra Lysate	Lysates
ALSU-PSRC-A10K	Src p-(Tyr419) - Ultra	10,000 points
ALSU-PSRC-A500	Src p-(Tyr419) - Ultra	500 points
ALSU-PSRC-A50K	Src p-(Tyr419) - Ultra	50,000 points
ALSU-PSRC-A-HV	Src p-(Tyr419) - Ultra	100 points
ALSU-PSRC-A-L	Src p-(Tyr419) - Ultra Lysate	Lysates
ALSU-PST1-A10K	STAT1 p-(Tyr701) - Ultra	10,000 points
ALSU-PST1-A500	STAT1 p-(Tyr701) - Ultra	500 points
ALSU-PST1-A50K	STAT1 p-(Tyr701) - Ultra	50,000 points
ALSU-PST1-A-HV	STAT1 p-(Tyr701) - Ultra	100 points
ALSU-PST1-A-L	STAT1 p-(Tyr701) -Ultra Lysate	Lysates
ALSU-PST1-B10K	STAT1 p-(Ser727) - Ultra	10,000 points
ALSU-PST1-B500	STAT1 p-(Ser727) - Ultra	500 points
ALSU-PST1-B50K	STAT1 p-(Ser727) - Ultra	50,000 points
ALSU-PST1-B-HV	STAT1 p-(Ser727) - Ultra	100 points
ALSU-PST1-B-L	STAT1 p-(Ser727) -Ultra Lysate	Lysates
ALSU-PST3-A10K	STAT3 p-(Tyr705) - Ultra	10,000 points
ALSU-PST3-A500	STAT3 p-(Tyr705) - Ultra	500 points
ALSU-PST3-A50K	STAT3 p-(Tyr705) - Ultra	50,000 points
ALSU-PST3-A-HV	STAT3 p-(Tyr705) - Ultra	100 points
ALSU-PST3-A-L	STAT3 p-(Tyr705) -Ultra Lysate	Lysates
ALSU-PST4-A10K	STAT4 p-(Tyr693) - Ultra	10,000 points
ALSU-PST4-A500	STAT4 p-(Tyr693) - Ultra	500 points
ALSU-PST4-A50K	STAT4 p-(Tyr693) - Ultra	50,000 points
ALSU-PST4-A-HV	STAT4 p-(Tyr693) - Ultra	100 points
ALSU-PST4-A-L	STAT4 p-(Tyr693) -Ultra Lysate	Lysates
ALSU-PST5-B10K	STAT5 p-(Tyr694/699) - Ultra	10,000 points
ALSU-PST5-B500	STAT5 p-(Tyr694/699) - Ultra	500 points
ALSU-PST5-B50K	STAT5 p-(Tyr694/699) - Ultra	50,000 points
ALSU-PST5-B-HV	STAT5 p-(Tyr694/699) - Ultra	100 points

ALSU-PST5-B-L	STAT5 p-(Tyr694/699) -Ultra Lysate	Lysates
ALSU-PST6-A10K	STAT6 p-(Tyr641) - Ultra	10,000 points
ALSU-PST6-A500	STAT6 p-(Tyr641) - Ultra	500 points
ALSU-PST6-A50K	STAT6 p-(Tyr641) - Ultra	50,000 points
ALSU-PST6-A-HV	STAT6 p-(Tyr641) - Ultra	100 points
ALSU-PST6-A-L	STAT6 p-(Tyr641) -Ultra Lysate	Lysates
ALSU-PSYK-A10K	SYK p-(Tyr525/526) - Ultra	10,000 points
ALSU-PSYK-A500	SYK p-(Tyr525/526) - Ultra	500 points
ALSU-PSYK-A50K	SYK p-(Tyr525/526) - Ultra	50,000 points
ALSU-PSYK-A-HV	SYK p-(Tyr525/526) - Ultra	100 points
ALSU-PSYK-A-L	SYK p-(Tyr525/526) -Ultra Lysate	Lysates
ALSU-PSYK-B10K	SYK p-(Tyr352) - Ultra	10,000 points
ALSU-PSYK-B500	SYK p-(Tyr352) - Ultra	500 points
ALSU-PSYK-B50K	SYK p-(Tyr352) - Ultra	50,000 points
ALSU-PSYK-B-HV	SYK p-(Tyr352) - Ultra	100 points
ALSU-PSYK-B-L	SYK p-(Tyr352) - Ultra Lysate	Lysates
ALSU-PTRKAB-A10K	TrkA p-(Tyr674/675) - TrkB (Tyr706/707) - Ultra	10,000 points
ALSU-PTRKAB-A500	TrkA p-(Tyr674/675) - TrkB (Tyr706/707) - Ultra	500 points
ALSU-PTRKAB-A50K	TrkA p-(Tyr674/675) - TrkB (Tyr706/707) - Ultra	50,000 points
ALSU-PTRKAB-A-HV	TrkA p-(Tyr674/675) - TrkB (Tyr706/707) - Ultra	100 points
ALSU-PVGFR-A10K	VEGF Receptor2 p-(Tyr1175) - Ultra	10,000 points
ALSU-PVGFR-A500	VEGF Receptor2 p-(Tyr1175) - Ultra	500 points
ALSU-PVGFR-A50K	VEGF Receptor2 p-(Tyr1175) - Ultra	50,000 points
ALSU-PVGFR-A-HV	VEGF Receptor2 p-(Tyr1175) - Ultra	100 points
ALSU-PVGFR-A-L	VEGF Receptor2 p-(Tyr1175) -Ultra Lysate	Lysates
ALSU-PVGFR-B10K	VEGF Receptor2 p-(Tyr951) - Ultra	10,000 points
ALSU-PVGFR-B500	VEGF Receptor2 p-(Tyr951) - Ultra	500 points
ALSU-PVGFR-B50K	VEGF Receptor2 p-(Tyr951) - Ultra	50,000 points
ALSU-PVGFR-B-HV	VEGF Receptor2 p-(Tyr951) - Ultra	100 points
ALSU-PVGFR-B-L	VEGF Receptor2 p-(Tyr951) - Ultra Lysate	Lysates
ALSU-PVGFR-C10K	VEGF Receptor2 p-(Tyr1214) - Ultra	10,000 points
ALSU-PVGFR-C500	VEGF Receptor2 p-(Tyr1214) - Ultra	500 points
ALSU-PVGFR-C50K	VEGF Receptor2 p-(Tyr1214) - Ultra	50,000 points
ALSU-PVGFR-C-HV	VEGF Receptor2 p-(Tyr1214) - Ultra	100 points
ALSU-PVGFR-C-L	VEGF Receptor2 p-(Tyr1214) - Ultra Lysate	Lysates
ALSU-PZAP-A10K	ZAP-70 p-(Tyr319) - Ultra	10,000 points
ALSU-PZAP-A500	ZAP-70 p-(Tyr319) - Ultra	500 points
ALSU-PZAP-A50K	ZAP-70 p-(Tyr319) - Ultra	50,000 points
ALSU-PZAP-A-HV	ZAP-70 p-(Tyr319) - Ultra	100 points
ALSU-PZAP-A-L	ZAP-70 p-(Tyr319) - Ultra Lysate	Lysates
ALSU-RBUF-A10K		10,000 points
ALSU-TAKT1-A10K	AKT 1 Total - Ultra	10,000 points
ALSU-TAKT1-A500	AKT 1 Total - Ultra	500 points
ALSU-TAKT1-A50K	AKT 1 Total - Ultra	50,000 points
ALSU-TAKT1-A-HV	AKT 1 Total - Ultra	100 points
ALSU-TAKT1-A-L	AKT 1 Total -Ultra Lysate	Lysates
ALSU-TAKT-B10K	AKT 1/2/3 Total - Ultra	10,000 points
ALSU-TAKT-B500	AKT 1/2/3 Total - Ultra	500 points
ALSU-TAKT-B50K	AKT 1/2/3 Total - Ultra	50,000 points
ALSU-TAKT-B-HV	AKT 1/2/3 Total - Ultra	100 points

ALSU-TAKT-B-L	AKT 1/2/3 Total - Ultra Lysate	Lysates
ALSU-TALK-A-10K	ALK Total - Ultra	10,000 points
ALSU-TALK-A-500	ALK Total - Ultra	500 points
ALSU-TALK-A-50K	ALK Total - Ultra	50,000 points
ALSU-TALK-A-HV	ALK Total - Ultra	100 points
ALSU-TALK-A-L	ALK Total - Ultra Lysate	Lysates
ALSU-TAMPK-A10K	AMPK α 1/2 Total - Ultra	10,000 points
ALSU-TAMPK-A500	AMPK α 1/2 Total - Ultra	500 points
ALSU-TAMPK-A50K	AMPK α 1/2 Total - Ultra	50,000 points
ALSU-TAMPK-A-HV	AMPK α 1/2 Total - Ultra	100 points
ALSU-TAMPK-A-L	AMPK α 1/2 Total - Ultra Lysate	Lysates
ALSU-TASYN-A10K	α -Synuclein Total - Ultra	10,000 points
ALSU-TASYN-A500	α -Synuclein Total - Ultra	500 points
ALSU-TASYN-A50K	α -Synuclein Total - Ultra	50,000 points
ALSU-TASYN-A-HV	α -Synuclein Total - Ultra	100 points
ALSU-TASYN-A-L	α -Synuclein Total - Ultra Lysate	Lysates
ALSU-TBTK-A10K	Btk Total - Ultra	10,000 points
ALSU-TBTK-A500	Btk Total - Ultra	500 points
ALSU-TBTK-A50K	Btk Total - Ultra	50,000 points
ALSU-TBTK-A-HV	Btk Total - Ultra	100 points
ALSU-TBTK-A-L	Btk Total - Ultra Lysate	Lysates
ALSU-TCHK1-A10K	CHK1 Total - Ultra	10,000 points
ALSU-TCHK1-A500	CHK1 Total - Ultra	500 points
ALSU-TCHK1-A50K	CHK1 Total - Ultra	50,000 points
ALSU-TCHK1-A-HV	CHK1 Total - Ultra	100 points
ALSU-TCHK1-A-L	CHK1 Total - Ultra Lysate	Lysates
ALSU-TCOF-A10K	Cofilin Total - Ultra	10,000 points
ALSU-TCOF-A500	Cofilin Total - Ultra	500 points
ALSU-TCOF-A50K	Cofilin Total - Ultra	50,000 points
ALSU-TCOF-A-HV	Cofilin Total - Ultra	100 points
ALSU-TCOF-A-L	Cofilin Total - Ultra Lysate	Lysates
ALSU-TCREB-A10K	CREB Total - Ultra	10,000 points
ALSU-TCREB-A500	CREB Total - Ultra	500 points
ALSU-TCREB-A50K	CREB Total - Ultra	50,000 points
ALSU-TCREB-A-HV	CREB Total - Ultra	100 points
ALSU-TCREB-A-L	CREB Total - Ultra, Lysate	Lysates
ALSU-TEGFR-A10K	EGF Receptor Total - Ultra	10,000 points
ALSU-TEGFR-A500	EGF Receptor Total - Ultra	500 points
ALSU-TEGFR-A50K	EGF Receptor Total - Ultra	50,000 points
ALSU-TEGFR-A-HV	EGF Receptor Total - Ultra	100 points
ALSU-TEGFR-A-L	EGF Receptor Total - Ultra Lysate	Lysates
ALSU-TEIF2-A10K	eIF2a Total - Ultra	10,000 points
ALSU-TEIF2-A500	eIF2a Total - Ultra	500 points
ALSU-TEIF2-A50K	eIF2a Total - Ultra	50,000 points
ALSU-TEIF2-A-HV	eIF2a Total - Ultra	100 points
ALSU-TEIF2-A-L	eIF2a Total -Ultra Lysate	Lysates
ALSU-TEB2-A10K	ErbB2 Total - Ultra	10,000 points
ALSU-TEB2-A500	ErbB2 Total - Ultra	500 points
ALSU-TEB2-A50K	ErbB2 Total - Ultra	50,000 points
ALSU-TEB2-A-HV	ErbB2 Total - Ultra	100 points

ALSU-TEB2-A-L	ErbB2 Total - Ultra, Lysate	Lysates
ALSU-TERK-A10K	ERK 1/2 Total - Ultra	10,000 points
ALSU-TERK-A500	ERK 1/2 Total - Ultra	500 points
ALSU-TERK-A50K	ERK 1/2 Total - Ultra	50,000 points
ALSU-TERK-A-HV	ERK 1/2 Total - Ultra	100 points
ALSU-TERK-A-L	ERK 1/2 Total -Ultra Lysate	Lysates
ALSU-TGAPD-A10K	GAPDH Total - Ultra	10,000 points
ALSU-TGAPD-A500	GAPDH Total - Ultra	500 points
ALSU-TGAPD-A50K	GAPDH Total - Ultra	50,000 points
ALSU-TGAPD-A-HV	GAPDH Total - Ultra	100 points
ALSU-TGAPD-A-L	GAPDH Total -Ultra Lysate	Lysates
ALSU-TGAPD-B10K	GAPDH Total Mouse/Human reactive - Ultra	10,000 points
ALSU-TGAPD-B500	GAPDH Total Mouse/Human reactive - Ultra	500 points
ALSU-TGAPD-B50K	GAPDH Total Mouse/Human reactive - Ultra	50,000 points
ALSU-TGAPD-B-HV	GAPDH Total Mouse/Human reactive - Ultra	100 points
ALSU-TGAPD-B-L	GAPDH Total Mouse/Human reactive -Ultra Lysate	Lysates
ALSU-TIGFR-A10K	IGF-1 Receptor β Total - Ultra	10,000 points
ALSU-TIGFR-A500	IGF-1 Receptor β Total - Ultra	500 points
ALSU-TIGFR-A50K	IGF-1 Receptor β Total - Ultra	50,000 points
ALSU-TIGFR-A-HV	IGF-1 Receptor β Total - Ultra	100 points
ALSU-TIGFR-A-L	IGF-1 Receptor β Total - Ultra Lysate	Lysates
ALSU-TINR-A10K	Insulin Receptor β Total - Ultra	10,000 points
ALSU-TINR-A500	Insulin Receptor β Total - Ultra	500 points
ALSU-TINR-A50K	Insulin Receptor β Total - Ultra	50,000 points
ALSU-TINR-A-HV	Insulin Receptor β Total - Ultra	100 points
ALSU-TINR-A-L	Insulin Receptor β Total - Ultra Lysate	Lysates
ALSU-TLCK-A10K	Lck Total - Ultra	10,000 points
ALSU-TLCK-A500	Lck Total - Ultra	500 points
ALSU-TLCK-A50K	Lck Total - Ultra	50,000 points
ALSU-TLCK-A-HV	Lck Total - Ultra	100 points
ALSU-TLCK-A-L	Lck Total - Ultra, Lysate	Lysates
ALSU-TMEK1-A10K	MEK1 Total - Ultra	10,000 points
ALSU-TMEK1-A500	MEK1 Total - Ultra	500 points
ALSU-TMEK1-A50K	MEK1 Total - Ultra	50,000 points
ALSU-TMEK1-A-HV	MEK1 Total - Ultra	100 points
ALSU-TMEK1-A-L	MEK1 Total -Ultra Lysate	Lysates
ALSU-TMKK4-A10K	MKK4 Total - Ultra	10,000 points
ALSU-TMKK4-A500	MKK4 Total - Ultra	500 points
ALSU-TMKK4-A50K	MKK4 Total - Ultra	50,000 points
ALSU-TMKK4-A-HV	MKK4 Total - Ultra	100 points
ALSU-TMKK4-A-L	MKK4 Total - Ultra Lysate	Lysates
ALSU-TMTOR-A10K	mTOR Total - Ultra_OLD	10,000 points
ALSU-TMTOR-A500	mTOR Total - Ultra_OLD	500 points
ALSU-TMTOR-A50K	mTOR Total - Ultra_OLD	50,000 points
ALSU-TMTOR-A-HV	mTOR Total - Ultra_OLD	100 points
ALSU-TMTOR-A-L	mTOR Total -Ultra Lysate_OLD	Lysates
ALSU-TMTOR-B10K	mTOR Total - Ultra	10,000 points
ALSU-TMTOR-B500	mTOR Total - Ultra	500 points
ALSU-TMTOR-B50K	mTOR Total - Ultra	50,000 points
ALSU-TMTOR-B-HV	mTOR Total - Ultra	100 points

ALSU-TMTOR-B-L	mTOR Total -Ultra Lysate	Lysates
ALSU-TNFKB-A10K	NFkB Total - Ultra	10,000 points
ALSU-TNFKB-A500	NFkB Total - Ultra	500 points
ALSU-TNFKB-A50K	NFkB Total - Ultra	50,000 points
ALSU-TNFKB-A-HV	NFkB Total - Ultra	100 points
ALSU-TNFKB-A-L	NFkB Total - Ultra Lysate	Lysates
ALSU-TP38-B10K	p38 MAPKa Total - Ultra	10,000 points
ALSU-TP38-B500	p38 MAPKa Total - Ultra	500 points
ALSU-TP38-B50K	p38 MAPKa Total - Ultra	50,000 points
ALSU-TP38-B-HV	p38 MAPKa Total - Ultra	100 points
ALSU-TP38-B-L	p38 MAPKa Total -Ultra Lysate	Lysates
ALSU-TP53-A10K	p53 Total - Ultra	10,000 points
ALSU-TP53-A500	p53 Total - Ultra	500 points
ALSU-TP53-A50K	p53 Total - Ultra	50,000 points
ALSU-TP53-A-HV	p53 Total - Ultra	100 points
ALSU-TP53-A-L	p53 Total - Ultra Lysate	Lysates
ALSU-TP70-A10K	p70S6K Total - Ultra	10,000 points
ALSU-TP70-A500	p70S6K Total - Ultra	500 points
ALSU-TP70-A50K	p70S6K Total - Ultra	50,000 points
ALSU-TP70-A-HV	p70S6K Total - Ultra	100 points
ALSU-TP70-A-L	p70S6K Total -Ultra Lysate	Lysates
ALSU-TPD1-A10K	PD-1 Total - Ultra	10,000 points
ALSU-TPD1-A500	PD-1 Total - Ultra	500 points
ALSU-TPD1-A50K	PD-1 Total - Ultra	50,000 points
ALSU-TPD1-A-HV	PD-1 Total - Ultra	100 points
ALSU-TPD1-A-L	PD-1 Total - Ultra, Lysate	Lysates
ALSU-TPDGF-A10K	PDGF Receptor β Total - Ultra	10,000 points
ALSU-TPDGF-A500	PDGF Receptor β Total - Ultra	500 points
ALSU-TPDGF-A50K	PDGF Receptor β Total - Ultra	50,000 points
ALSU-TPDGF-A-HV	PDGF Receptor β Total - Ultra	100 points
ALSU-TPDGF-A-L	PDGF Receptor β Total - Ultra Lysate	Lysates
ALSU-TRAF-A10K	Raf-1 Total - Ultra	10,000 points
ALSU-TRAF-A500	Raf-1 Total - Ultra	500 points
ALSU-TRAF-A50K	Raf-1 Total - Ultra	50,000 points
ALSU-TRAF-A1-HV	Raf-1 Total - Ultra	100 points
ALSU-TRAF-A-L	Raf-1 Total - Ultra Lysate	Lysates
ALSU-TRAS-A10K	Ras Total - Ultra	10,000 points
ALSU-TRAS-A500	Ras Total - Ultra	500 points
ALSU-TRAS-A50K	Ras Total - Ultra	50,000 points
ALSU-TRAS-A-HV	Ras Total - Ultra	100 points
ALSU-TRAS-A-L	Ras Total - Ultra Lysate	Lysates
ALSU-TRB-A10K	Rb Total - Ultra	10,000 points
ALSU-TRB-A500	Rb Total - Ultra	500 points
ALSU-TRB-A50K	Rb Total - Ultra	50,000 points
ALSU-TRB-A-HV	Rb Total - Ultra	100 points
ALSU-TRB-A-L	Rb Total - Ultra Lysate	Lysates
ALSU-TSHP1-A10K	SHP-1 Total - Ultra	10,000 points
ALSU-TSHP1-A500	SHP-1 Total - Ultra	500 points
ALSU-TSHP1-A50K	SHP-1 Total - Ultra	50,000 points
ALSU-TSHP1-A-HV	SHP-1 Total - Ultra	100 points

ALSU-TSHP1-A-L	SHP-1 Total - Ultra Lysate	Lysates
ALSU-TSHP2-A10K	SHP-2 Total - Ultra	10,000 points
ALSU-TSHP2-A500	SHP-2 Total - Ultra	500 points
ALSU-TSHP2-A50K	SHP-2 Total - Ultra	50,000 points
ALSU-TSHP2-A-HV	SHP-2 Total - Ultra	100 points
ALSU-TSHP2-A-L	SHP-2 Total - Ultra Lysate	Lysates
ALSU-TSLP-A10K	SLP-76 Total - Ultra	10,000 points
ALSU-TSLP-A500	SLP-76 Total - Ultra	500 points
ALSU-TSLP-A50K	SLP-76 Total - Ultra	50,000 points
ALSU-TSLP-A-HV	SLP-76 Total - Ultra	100 points
ALSU-TSLP-A-L	SLP-76 Total - Ultra Lysate	Lysates
ALSU-TSM1-A10K	SMAD1 Total - Ultra	10,000 points
ALSU-TSM1-A500	SMAD1 Total - Ultra	500 points
ALSU-TSM1-A50K	SMAD1 Total - Ultra	50,000 points
ALSU-TSM1-A-HV	SMAD1 Total - Ultra	100 points
ALSU-TSM1-A-L	SMAD1 Total - Ultra Lysate	Lysates
ALSU-TSM2-A10K	SMAD2 Total - Ultra	10,000 points
ALSU-TSM2-A500	SMAD2 Total - Ultra	500 points
ALSU-TSM2-A50K	SMAD2 Total - Ultra	50,000 points
ALSU-TSM2-A-HV	SMAD2 Total - Ultra	100 points
ALSU-TSM2-A-L	SMAD2 Total - Ultra Lysate	Lysates
ALSU-TSM3-A10K	SMAD3 Total - Ultra	10,000 points
ALSU-TSM3-A500	SMAD3 Total - Ultra	500 points
ALSU-TSM3-A50K	SMAD3 Total - Ultra	50,000 points
ALSU-TSM3-A-HV	SMAD3 Total - Ultra	100 points
ALSU-TSM3-A-L	SMAD3 Total - Ultra Lysate	Lysates
ALSU-TST3-A10K	STAT3 Total - Ultra	10,000 points
ALSU-TST3-A500	STAT3 Total - Ultra	500 points
ALSU-TST3-A50K	STAT3 Total - Ultra	50,000 points
ALSU-TST3-A-HV	STAT3 Total - Ultra	100 points
ALSU-TST3-A-L	STAT3 Total -Ultra Lysate	Lysates
ALSU-TST4-A10K	STAT4 Total - Ultra	10,000 points
ALSU-TST4-A500	STAT4 Total - Ultra	500 points
ALSU-TST4-A50K	STAT4 Total - Ultra	50,000 points
ALSU-TST4-A-HV	STAT4 Total - Ultra	100 points
ALSU-TST4-A-L	STAT4 Total - Ultra Lysate	Lysates
ALSU-TST5-A10K	STAT5 Total - Ultra	10,000 points
ALSU-TST5-A500	STAT5 Total - Ultra	500 points
ALSU-TST5-A50K	STAT5 Total - Ultra	50,000 points
ALSU-TST5-A-HV	STAT5 Total - Ultra	100 points
ALSU-TST5-A-L	STAT5 Total -Ultra Lysate	Lysates
ALSU-TST6-A10K	STAT6 Total - Ultra	10,000 points
ALSU-TST6-A500	STAT6 Total - Ultra	500 points
ALSU-TST6-A50K	STAT6 Total - Ultra	50,000 points
ALSU-TST6-A-HV	STAT6 Total - Ultra	100 points
ALSU-TST6-A-L	STAT6 Total - Ultra Lysate	Lysates
ALSU-TSYK-A10K	SYK Total - Ultra	10,000 points
ALSU-TSYK-A500	SYK Total - Ultra	500 points
ALSU-TSYK-A50K	SYK Total - Ultra	50,000 points
ALSU-TSYK-A-HV	SYK Total - Ultra	100 points

ALSU-TSYK-A-L	SYK Total -Ultra Lysate	Lysates
ALSU-TVGFR-A10K	VEGF Receptor2 Total - Ultra	10,000 points
ALSU-TVGFR-A500	VEGF Receptor2 Total - Ultra	500 points
ALSU-TVGFR-A50K	VEGF Receptor2 Total - Ultra	50,000 points
ALSU-TVGFR-A-HV	VEGF Receptor2 Total - Ultra	100 points
ALSU-TSYK-A-L	VEGF Receptor2 Total - Ultra Lysate	Lysates
ALSU-TZAP-A10K	ZAP-70 Total - Ultra	10,000 points
ALSU-TZAP-A500	ZAP-70 Total - Ultra	500 points
ALSU-TZAP-A50K	ZAP-70 Total - Ultra	50,000 points
ALSU-TZAP-A-HV	ZAP-70 Total - Ultra	100 points
ALSU-TZAP-A-L	ZAP-70 Total - Ultra Lysate	Lysates
CETSA-AKT1-A500	AKT1 CETSA	500 points
CETSA-AKT1-A5K1	AKT1 CETSA	5000 points
CETSA-AKT1-A5K2	AKT1 CETSA	5000 points
CETSA-AKT1-A5K3	AKT1 CETSA	5000 points
CETSA-AKT1-A5K4	AKT1 CETSA	5000 points
CETSA-AKT1-A5K5	AKT1 CETSA	5000 points
CETSA-p38-A500	p38 CETSA	500 points
CETSA-p38-A5K1	p38 CETSA	5000 points
CETSA-p38-A5K2	p38 CETSA	5000 points
CETSA-p38-A5K3	p38 CETSA	5000 points
CETSA-p38-A5K4	p38 CETSA	5000 points
CETSA-p38-A5K5	p38 CETSA	5000 points
CETSA-MEK1-A500	MEK1 CETSA	500 points
CETSA-MEK1-A5K1	MEK1 CETSA	5000 points
CETSA-MEK1-A5K2	MEK1 CETSA	5000 points
CETSA-MEK1-A5K3	MEK1 CETSA	5000 points
CETSA-MEK1-A5K4	MEK1 CETSA	5000 points
CETSA-MEK1-A5K5	MEK1 CETSA	5000 points
CETSA-BUF2-100mL	CETSA Cell Lysis Buffer2	100mL
MPSU-CUSTOM		
MPSU-ACAT-0.06mL	Alpha 545 Terbium CaptSure Acceptor Beads - Multiple}	0.06ml Beads
MPSU-ACAT-1.2mL	Alpha 545 Terbium CaptSure Acceptor Beads - Multiple}	1.2ml Beads
MPSU-ACAT-6.0mL	Alpha 545 Terbium CaptSure Acceptor Beads - Multiple}	6ml Beads
MPSU-PTAMPK-K10K	AMPK α 1/2 p-(Thr172) 615 (Eu)+ Total AMPK α 1/2 545 (Tb) - Multiplex	10,000 points
MPSU-PTAMPK-K500	AMPK α 1/2 p-(Thr172) 615 (Eu)+ Total AMPK α 1/2 545 (Tb) - Multiplex	500 points
MPSU-PTAMPK-K50K	AMPK α 1/2 p-(Thr172) 615 (Eu)+ Total AMPK α 1/2 545 (Tb) - Multiplex	50,000 points
MPSU-PTAMPK-K-HV	AMPK α 1/2 p-(Thr172) 615 (Eu)+ Total AMPK α 1/2 545 (Tb) - Multiplex	100 points
MPSU-PTAMPK-K-L	Multiplex AMPK α 1/2, Lysate	Lysates
MPSU-ATP53-K10K	Acetylated p53 (Lys382) 615 (Eu)+ Total p53 545 (Tb) - Multiplex	10,000 points
MPSU-ATP53-K500	Acetylated p53 (Lys382) 615 (Eu)+ Total p53 545 (Tb) - Multiplex	500 points
MPSU-ATP53-K50K	Acetylated p53 (Lys382) 615 (Eu)+ Total p53 545 (Tb) - Multiplex	50,000 points

MPSU-ATP53-K-HV	Acetylated p53 (Lys382) 615 (Eu)+ Total p53 545 (Tb) - Multiplex	100 points
MPSU-ATP53-K-L	Multiplex Acetylated p53, Lysate	Lysates
MPSU-PTAKT-K10K	Akt1/2/3 p-(Ser473) 615 (Eu)+ Total AKT 545 (Tb) - Multiplex	10,000 points
MPSU-PTAKT-K500	Akt1/2/3 p-(Ser473) 615 (Eu)+ Total AKT 545 (Tb) - Multiplex	500 points
MPSU-PTAKT-K50K	Akt1/2/3 p-(Ser473) 615 (Eu)+ Total AKT 545 (Tb) - Multiplex	50,000 points
MPSU-PTAKT-K-HV	Akt1/2/3 p-(Ser473) 615 (Eu)+ Total AKT 545 (Tb) - Multiplex	100 points
MPSU-PTAKT-K-L	Multiplex AKT, Lysate	Lysates
MPSU-PTBTK-K10K	Btk p-(Tyr223) 615 (Eu) + Total Btk 545 (Tb) -	10,000 points
MPSU-PTBTK-K500	Btk p-(Tyr223) 615 (Eu) + Total Btk 545 (Tb) -	500 points
MPSU-PTBTK-K50K	Btk p-(Tyr223) 615 (Eu) + Total Btk 545 (Tb) -	50,000 points
MPSU-PTBTK-K-HV	Btk p-(Tyr223) 615 (Eu) + Total Btk 545 (Tb) -	100 points
MPSU-PTBTK-K-L	Multiplex Btk, Lysate	Lysates
MPSU-PTERK-K10K	ERK1/2 p-(Thr202/Tyr204) 615 (Eu) + Total ERK 545 (Tb) - Multiplex	10,000 points
MPSU-PTERK-K500	ERK1/2 p-(Thr202/Tyr204) 615 (Eu) + Total ERK 545 (Tb) - Multiplex	500 points
MPSU-PTERK-K50K	ERK1/2 p-(Thr202/Tyr204) 615 (Eu) + Total ERK 545 (Tb) - Multiplex	50,000 points
MPSU-PTERK-K-HV	ERK1/2 p-(Thr202/Tyr204) 615 (Eu) + Total ERK 545 (Tb) - Multiplex	100 points
MPSU-PTERK-K-L	Multiplex ERK, Lysate	Lysates
MPSU-PTEGFR-K10K	EGF Receptor p-(Tyr1068) 615 (Eu) + Total EGF Receptor 545 (Tb) - Multiplex	10,000 points
MPSU-PTEGFR-K500	EGF Receptor p-(Tyr1068) 615 (Eu) + Total EGF Receptor 545 (Tb) - Multiplex	500 points
MPSU-PTEGFR-K50K	EGF Receptor p-(Tyr1068) 615 (Eu) + Total EGF Receptor 545 (Tb) - Multiplex	50,000 points
MPSU-PTEGFR-K-HV	EGF Receptor p-(Tyr1068) 615 (Eu) + Total EGF Receptor 545 (Tb) - Multiplex	100 points
MPSU-PTEGFR-K-L	Multiplex EGF Receptor, Lysate	Lysates
MPSU-PTEIF2-K10K	eIF2 α p-(Ser51) 615 (Eu) + Total eIF2 α 545 (Tb) - Multiplex	10,000 points
MPSU-PTEIF2-K500	eIF2 α p-(Ser51) 615 (Eu) + Total eIF2 α 545 (Tb) - Multiplex	500 points
MPSU-PTEIF2-K50K	eIF2 α p-(Ser51) 615 (Eu) + Total eIF2 α 545 (Tb) - Multiplex	50,000 points
MPSU-PTEIF2-K-HV	eIF2 α p-(Ser51) 615 (Eu) + Total eIF2 α 545 (Tb) - Multiplex	100 points
MPSU-PTEIF2-K-L	Multiplex EIF2 α , Lysate	Lysates
MPSU-PTEB2-K10K	ErbB2 p-(Tyr1221/1222) 615 (Eu) + Total ErbB2 545 (Tb) - Multiplex	10,000 points
MPSU-PTEB2-K500	ErbB2 p-(Tyr1221/1222) 615 (Eu) + Total ErbB2 545 (Tb) - Multiplex	500 points
MPSU-PTEB2-K50K	ErbB2 p-(Tyr1221/1222) 615 (Eu) + Total ErbB2 545 (Tb) - Multiplex	50,000 points

MPSU-PTEB2-K-HV	ErbB2 p-(Tyr1221/1222) 615 (Eu) + Total ErbB2 545 (Tb) - Multiplex	100 points
MPSU-PTEB2-K-L	Multiplex ErbB2, Lysate	Lysates
MPSU-PTIGFR-K10K	IGF-1 Receptor β (Tyr1135/1136) + Total IGF-1 Receptor β - Multiplex	10,000 points
MPSU-PTIGFR-K500	IGF-1 Receptor β (Tyr1135/1136) + Total IGF-1 Receptor β - Multiplex	500 points
MPSU-PTIGFR-K50K	IGF-1 Receptor β (Tyr1135/1136) + Total IGF-1 Receptor β - Multiplex	50,000 points
MPSU-PTIGFR-K-HV	IGF-1 Receptor β (Tyr1135/1136) + Total IGF-1 Receptor β - Multiplex	100 points
MPSU-PTIGFR-K-L	Multiplex IGF-1 Receptor β , Lysate	Lysates
MPSU-PTINR-K10K	Insulin Receptor β (Tyr1150/1151) + Total Insulin Receptor β - Multiplex	10,000 points
MPSU-PTINR-K500	Insulin Receptor β (Tyr1150/1151) + Total Insulin Receptor β - Multiplex	500 points
MPSU-PTINR-K50K	Insulin Receptor β (Tyr1150/1151) + Total Insulin Receptor β - Multiplex	50,000 points
MPSU-PTINR-K-HV	Insulin Receptor β (Tyr1150/1151) + Total Insulin Receptor β - Multiplex	100 points
MPSU-PTINR-K-L	Multiplex Insulin Receptor β , Lysate	Lysates
MPSU-PTMEK1-K10K	MEK1 p-(Ser218/222) 615 (Eu) + Total MEK1 545 (Tb) - Multiplex	10,000 points
MPSU-PTMEK1-K500	MEK1 p-(Ser218/222) 615 (Eu) + Total MEK1 545 (Tb) - Multiplex	500 points
MPSU-PTMEK1-K50K	MEK1 p-(Ser218/222) 615 (Eu) + Total MEK1 545 (Tb) - Multiplex	50,000 points
MPSU-PTMEK1-K-HV	MEK1 p-(Ser218/222) 615 (Eu) + Total MEK1 545 (Tb) - Multiplex	100 points
MPSU-PTMEK1-K-L	Multiplex MEK1, Lysate	Lysates
MPSU-PTNFkB-K10K	NF κ B p65 p-(Ser536) 615 (Eu) + Total NF κ B p65 545 (Tb) - Multiplex	10,000 points
MPSU-PTNFkB-K500	NF κ B p65 p-(Ser536) 615 (Eu) + Total NF κ B p65 545 (Tb) - Multiplex	500 points
MPSU-PTNFkB-K50K	NF κ B p65 p-(Ser536) 615 (Eu) + Total NF κ B p65 545 (Tb) - Multiplex	50,000 points
MPSU-PTNFkB-K-HV	NF κ B p65 p-(Ser536) 615 (Eu) + Total NF κ B p65 545 (Tb) - Multiplex	100 points
MPSU-PTNFkB-K-L	Multiplex NF κ B p65, Lysate	Lysates
MPSU-PTP53-K10K	p53 p-(Ser15) 615 (Eu) + Total p53 545 (Tb) - Multiplex	10,000 points
MPSU-PTP53-K500	p53 p-(Ser15) 615 (Eu) + Total p53 545 (Tb) - Multiplex	500 points
MPSU-PTP53-K150K	p53 p-(Ser15) 615 (Eu) + Total p53 545 (Tb) - Multiplex	50,000 points
MPSU-PTP53-K-HV	p53 p-(Ser15) 615 (Eu) + Total p53 545 (Tb) - Multiplex	100 points
MPSU-PTP53-K-L	Multiplex p53, Lysate	Lysates
MPSU-PTP70-K10K	p70 S6K p-(Thr389) 615 (Eu) + Total P70 S6K 545 (Tb) - Multiplex	10,000 points
MPSU-PTP70-K500	p70 S6K p-(Thr389) 615 (Eu) + Total P70 S6K 545 (Tb) - Multiplex	500 points
MPSU-PTP70-K50K	p70 S6K p-(Thr389) 615 (Eu) + Total P70 S6K 545 (Tb) - Multiplex	50,000 points

MPSU-PTP70-K-HV	p70 S6K p-(Thr389) 615 (Eu) + Total P70 S6K 545 (Tb) - Multiplex	100 points
MPSU-PTP70-K-L	Multiplex p70 S6K, Lysate	Lysates
MPSU-PTST3-K10K	STAT3 p-(Tyr705) 615 (Eu) + Total STAT3 545 (Tb) - Multiplex	10,000 points
MPSU-PTST3-K500	STAT3 p-(Tyr705) 615 (Eu) + Total STAT3 545 (Tb) - Multiplex	500 points
MPSU-PTST3-K50K	STAT3 p-(Tyr705) 615 (Eu) + Total STAT3 545 (Tb) - Multiplex	50,000 points
MPSU-PTST3-K-HV	STAT3 p-(Tyr705) 615 (Eu) + Total STAT3 545 (Tb) - Multiplex	100 points
MPSU-PTST3-K-L	Multiplex STAT3, Lysate	Lysates
MPSU-PTST5-K10K	STAT5 p-(Tyr694/695) 615 (Eu) + Total STAT5 545 (Tb) - Multiplex	10,000 points
MPSU-PTST5-K500	STAT5 p-(Tyr694/695) 615 (Eu) + Total STAT5 545 (Tb) - Multiplex	500 points
MPSU-PTST5-K50K	STAT5 p-(Tyr694/695) 615 (Eu) + Total STAT5 545 (Tb) - Multiplex	50,000 points
MPSU-PTST5-K-HV	STAT5 p-(Tyr694/695) 615 (Eu) + Total STAT5 545 (Tb) - Multiplex	100 points
MPSU-PTST5-K-L	Multiplex STAT5, Lysate	Lysates
MPSU-PTSYK-K10K	SYK p-(Tyr525/526) 615 (Eu) + Total SYK 545 (Tb) - Multiplex	10,000 points
MPSU-PTSYK-K500	SYK p-(Tyr525/526) 615 (Eu) + Total SYK 545 (Tb) - Multiplex	500 points
MPSU-PTSYK-K50K	SYK p-(Tyr525/526) 615 (Eu) + Total SYK 545 (Tb) - Multiplex	50,000 points
MPSU-PTSYK-K-HV	SYK p-(Tyr525/526) 615 (Eu) + Total SYK 545 (Tb) - Multiplex	100 points
MPSU-PTSYK-K-L	Multiplex SYK, Lysate	Lysates
TBSU-P4EBP-A10K	4E-BP1 p-(Thr37/46) - TBSU	10,000 points
TBSU-P4EBP-A500	4E-BP1 p-(Thr37/46) - TBSU	500 points
TBSU-P4EBP-A50K	4E-BP1 p-(Thr37/46) - TBSU	50,000 points
TBSU-P4EBP-A-HV	4E-BP1 p-(Thr37/46) - TBSU	100 points
TBSU-PAKT-A10K	AKT1/2/3 p-(Thr308) protein - TBSU	10,000 points
TBSU-PAKT-A500	AKT1/2/3 p-(Thr308) protein - TBSU	500 points
TBSU-PAKT-A50K	AKT1/2/3 p-(Thr308) protein - TBSU	50,000 points
TBSU-PAKT-A-HV	AKT1/2/3 p-(Thr308) protein - TBSU	100 points
TBSU-PAKT-B10K	AKT1/2/3 p-(Ser473) - TBSU	10,000 points
TBSU-PAKT-B500	AKT1/2/3 p-(Ser473) - TBSU	500 points
TBSU-PAKT-B50K	AKT1/2/3 p-(Ser473) - TBSU	50,000 points
TBSU-PAKT-B-HV	AKT1/2/3 p-(Ser473) - TBSU	100 points
TBSU-PCREB-A10K	CREB p-(Ser133) -TBSU	10,000 points
TBSU-PCREB-A500	CREB p-(Ser133) -TBSU	500 points
TBSU-PCREB-A50K	CREB p-(Ser133) -TBSU	50,000 points
TBSU-PCREB-A-HV	CREB p-(Ser133) -TBSU	100 points
TBSU-PEGFR-A10K	EGF Receptor p-(Tyr1068) - TBSU	10,000 points
TBSU-PEGFR-A500	EGF Receptor p-(Tyr1068) - TBSU	500 points
TBSU-PEGFR-A50K	EGF Receptor p-(Tyr1068) - TBSU	50,000 points
TBSU-PEGFR-A-HV	EGF Receptor p-(Tyr1068) - TBSU	100 points

TBSU-PEIF2-B10K	eIF2a p-(Ser51) - TBSU	10,000 points
TBSU-PEIF2-B500	eIF2a p-(Ser51) - TBSU	500 points
TBSU-PEIF2-B50K	eIF2a p-(Ser51) - TBSU	50,000 points
TBSU-PEIF2-B-HV	eIF2a p-(Ser51) - TBSU	100 points
TBSU-PEIF4-A10K	eIF4E p-(Ser209) - TBSU	10,000 points
TBSU-PEIF4-A500	eIF4E p-(Ser209) - TBSU	500 points
TBSU-PEIF4-A50K	eIF4E p-(Ser209) - TBSU	50,000 points
TBSU-PEIF4-A-HV	eIF4E p-(Ser209) - TBSU	100 points
TBSU-PERK-A10K	ERK1/2 p-(Thr202/Tyr204) - TBSU	10,000 points
TBSU-PERK-A500	ERK1/2 p-(Thr202/Tyr204) - TBSU	500 points
TBSU-PERK-A50K	ERK1/2 p-(Thr202/Tyr204) - TBSU	50,000 points
TBSU-PERK-A-HV	ERK1/2 p-(Thr202/Tyr204) - TBSU	100 points
TBSU-PGS3B-A10K	GSK3b p-(Ser9) - TBSU	10,000 points
TBSU-PGS3B-A500	GSK3b p-(Ser9) - TBSU	500 points
TBSU-PGS3B-A50K	GSK3b p-(Ser9) - TBSU	50,000 points
TBSU-PGS3B-A-HV	GSK3b p-(Ser9) - TBSU	100 points
TBSU-PIGFR-B10K	IGF-1 Receptor b p-(Tyr1135/1136) - TBSU	10,000 points
TBSU-PIGFR-B500	IGF-1 Receptor b p-(Tyr1135/1136) - TBSU	500 points
TBSU-PIGFR-B50K	IGF-1 Receptor b p-(Tyr1135/1136) - TBSU	50,000 points
TBSU-PIGFR-B-HV	IGF-1 Receptor b p-(Tyr1135/1136) - TBSU	100 points
TBSU-PIKKA-A10K	IKKa p-(Ser176/180) - TBSU	10,000 points
TBSU-PIKKA-A500	IKKa p-(Ser176/180) - TBSU	500 points
TBSU-PIKKA-A50K	IKKa p-(Ser176/180) - TBSU	50,000 points
TBSU-PIKKA-A-HV	IKKa p-(Ser176/180) - TBSU	100 points
TBSU-PINR-A10K	Insulin Receptor b p-(Tyr1150/1151) - TBSU	10,000 points
TBSU-PINR-A500	Insulin Receptor b p-(Tyr1150/1151) - TBSU	500 points
TBSU-PINR-A50K	Insulin Receptor b p-(Tyr1150/1151) - TBSU	50,000 points
TBSU-PINR-A-HV	Insulin Receptor b p-(Tyr1150/1151) - TBSU	100 points
TBSU-PJNK-A10K	JNK1/2/3 p-(Thr183/Tyr185) - TBSU	10,000 points
TBSU-PJNK-A500	JNK1/2/3 p-(Thr183/Tyr185) - TBSU	500 points
TBSU-PJNK-A50K	JNK1/2/3 p-(Thr183/Tyr185) - TBSU	50,000 points
TBSU-PJNK-A-HV	JNK1/2/3 p-(Thr183/Tyr185) - TBSU	100 points
TBSU-PMEK1-A10K	MEK1 p-(Ser218/222) - TBSU	10,000 points
TBSU-PMEK1-A500	MEK1 p-(Ser218/222) - TBSU	500 points
TBSU-PMEK1-A50K	MEK1 p-(Ser218/222) - TBSU	50,000 points
TBSU-PMEK1-A-HV	MEK1 p-(Ser218/222) - TBSU	100 points
TBSU-PMTOR-A10K	mTOR p-(Ser2448) - TBSU	10,000 points
TBSU-PMTOR-A500	mTOR p-(Ser2448) - TBSU	500 points
TBSU-PMTOR-A50K	mTOR p-(Ser2448) - TBSU	50,000 points
TBSU-PMTOR-A-HV	mTOR p-(Ser2448) - TBSU	100 points
TBSU-PNFKB-A10K	NF-kB p65 p-(Ser536) - TBSU	10,000 points
TBSU-PNFKB-A500	NF-kB p65 p-(Ser536) - TBSU	500 points
TBSU-PNFKB-A50K	NF-kB p65 p-(Ser536) - TBSU	50,000 points
TBSU-PNFKB-A-HV	NF-kB p65 p-(Ser536) - TBSU	100 points
TBSU-PP38-B10K	p38MAPK p-(Thr180/Tyr182) - TBSU	10,000 points
TBSU-PP38-B500	p38MAPK p-(Thr180/Tyr182) - TBSU	500 points
TBSU-PP38-B50K	p38MAPK p-(Thr180/Tyr182) - TBSU	50,000 points
TBSU-PP38-B-HV	p38MAPK p-(Thr180/Tyr182) - TBSU	100 points
TBSU-PP70-A10K	p70S6K p-(Thr389) - TBSU	10,000 points
TBSU-PP70-A500	p70S6K p-(Thr389) - TBSU	500 points

TBSU-PP70-A50K	p70S6K p-(Thr389) - TBSU	50,000 points
TBSU-PP70-A-HV	p70S6K p-(Thr389) - TBSU	100 points
TBSU-PS6R-A10K	RP S6 p-(Ser240/244) - TBSU	10,000 points
TBSU-PS6R-A500	RP S6 p-(Ser240/244) - TBSU	500 points
TBSU-PS6R-A50K	RP S6 p-(Ser240/244) - TBSU	50,000 points
TBSU-PS6R-A-HV	RP S6 p-(Ser240/244) - TBSU	100 points
TBSU-PSLP-A10K	SLP-76 p-(Ser376) - TBSU	10,000 points
TBSU-PSLP-A500	SLP-76 p-(Ser376) - TBSU	500 points
TBSU-PSLP-A50K	SLP-76 p-(Ser376) - TBSU	50,000 points
TBSU-PSLP-A-HV	SLP-76 p-(Ser376) - TBSU	100 points
TBSU-PSM1-A10K	SMAD1 p-(Ser463/465) - TBSU	10,000 points
TBSU-PSM1-A500	SMAD1 p-(Ser463/465) - TBSU	500 points
TBSU-PSM1-A50K	SMAD1 p-(Ser463/465) - TBSU	50,000 points
TBSU-PSM1-A-HV	SMAD1 p-(Ser463/465) - TBSU	100 points
TBSU-PSM3-A10K	SMAD3 p-(Ser423/425) - TBSU	10,000 points
TBSU-PSM3-A500	SMAD3 p-(Ser423/425) - TBSU	500 points
TBSU-PSM3-A50K	SMAD3 p-(Ser423/425) - TBSU	50,000 points
TBSU-PSM3-A-HV	SMAD3 p-(Ser423/425) - TBSU	100 points
TBSU-PST1-A10K	STAT1 p-(Tyr701) - TBSU	10,000 points
TBSU-PST1-A500	STAT1 p-(Tyr701) - TBSU	500 points
TBSU-PST1-A50K	STAT1 p-(Tyr701) - TBSU	50,000 points
TBSU-PST1-A-HV	STAT1 p-(Tyr701) - TBSU	100 points
TBSU-PST1-B10K	STAT1 p-(Ser727) - TBSU	10,000 points
TBSU-PST1-B500	STAT1 p-(Ser727) - TBSU	500 points
TBSU-PST1-B50K	STAT1 p-(Ser727) - TBSU	50,000 points
TBSU-PST1-B-HV	STAT1 p-(Ser727) - TBSU	100 points
TBSU-PST3-A10K	STAT3 p-(Tyr705) - TBSU	10,000 points
TBSU-PST3-A500	STAT3 p-(Tyr705) - TBSU	500 points
TBSU-PST3-A50K	STAT3 p-(Tyr705) - TBSU	50,000 points
TBSU-PST3-A-HV	STAT3 p-(Tyr705) - TBSU	100 points
TBSU-PST4-A10K	STAT4 p-(Tyr693) - TBSU	10,000 points
TBSU-PST4-A500	STAT4 p-(Tyr693) - TBSU	500 points
TBSU-PST4-A50K	STAT4 p-(Tyr693) - TBSU	50,000 points
TBSU-PST4-A-HV	STAT4 p-(Tyr693) - TBSU	100 points
TBSU-PST5-B10K	STAT5 p-(Tyr694/699) - TBSU	10,000 points
TBSU-PST5-B500	STAT5 p-(Tyr694/699) - TBSU	500 points
TBSU-PST5-B50K	STAT5 p-(Tyr694/699) - TBSU	50,000 points
TBSU-PST5-B-HV	STAT5 p-(Tyr694/699) - TBSU	100 points
TBSU-PST6-A10K	STAT6 p-(Tyr641) - TBSU	10,000 points
TBSU-PST6-A500	STAT6 p-(Tyr641) - TBSU	500 points
TBSU-PST6-A50K	STAT6 p-(Tyr641) - TBSU	50,000 points
TBSU-PST6-A-HV	STAT6 p-(Tyr641) - TBSU	100 points
TBSU-PSYK-A10K	SYK p-(Tyr525/526) - TBSU	10,000 points
TBSU-PSYK-A500	SYK p-(Tyr525/526) - TBSU	500 points
TBSU-PSYK-A50K	SYK p-(Tyr525/526) - TBSU	50,000 points
TBSU-PSYK-A-HV	SYK p-(Tyr525/526) - TBSU	100 points
TBSU-PVGFR-A10K	VEGF Receptor2 p-(Tyr1175) - TBSU	10,000 points
TBSU-PVGFR-A500	VEGF Receptor2 p-(Tyr1175) - TBSU	500 points
TBSU-PVGFR-A50K	VEGF Receptor2 p-(Tyr1175) - TBSU	50,000 points
TBSU-PVGFR-A-HV	VEGF Receptor2 p-(Tyr1175) - TBSU	100 points

TBSU-TCOF-A10K	Cofilin (Total) - TBSU	10,000 points
TBSU-TCOF-A500	Cofilin (Total) - TBSU	500 points
TBSU-TCOF-A50K	Cofilin (Total) - TBSU	50,000 points
TBSU-TCOF-A-HV	Cofilin (Total) - TBSU	100 points
TGR38S10K	p38 MAPK p-(Thr180/Tyr182) - SureFire	10,000 points
TGR38S500	p38 MAPK p-(Thr180/Tyr182) - SureFire	500 points
TGR38S50K	p38 MAPK p-(Thr180/Tyr182) - SureFire	50,000 points
TGR38S-L	p38 MAPK p-(Thr180/Tyr182) - Lysate	Lysates
TGR4E2S10K	4E-BP1 p-(Thr70) - SureFire	10,000 points
TGR4E2S500	4E-BP1 p-(Thr70) - SureFire	500 points
TGR4E2S50K	4E-BP1 p-(Thr70) - SureFire	50,000 points
TGR4E2S-L	4E-BP1 p-(Thr70) - Lysates	Lysates
TGR4ES10K	4E-BP1 p-(Thr37/46) - SureFire	10,000 points
TGR4ES500	4E-BP1 p-(Thr37/46) - SureFire	500 points
TGR4ES50K	4E-BP1 p-(Thr37/46) - SureFire	50,000 points
TGR4ES-L	4E-BP1 p-(Thr37/46) - Lysates	Lysates
TGR702S10K	P70 S6 Kinase p-(Thr421/Ser424) - SureFire	10,000 points
TGR702S500	P70 S6 Kinase p-(Thr421/Ser424) - SureFire	500 points
TGR702S50K	P70 S6 Kinase p-(Thr421/Ser424) - SureFire	50,000 points
TGR702S-L	P70 S6 Kinase p-(Thr421/Ser424) - Lysate	Lysates
TGR703S10K	P70 S6 Kinase p-(Thr229) - SureFire	10,000 points
TGR703S500	P70 S6 Kinase p-(Thr229) - SureFire	500 points
TGR703S50K	P70 S6 Kinase p-(Thr229) - SureFire	50,000 points
TGR703S-L	P70 S6K p-(Thr229) - Lysate	Lysates
TGR70S10K	P70 S6 Kinase p-(Thr389) - SureFire	10,000 points
TGR70S500	P70 S6 Kinase p-(Thr389) - SureFire	500 points
TGR70S50K	P70 S6 Kinase p-(Thr389) - SureFire	50,000 points
TGR70S-L	P70 S6K p-(Thr389) - Lysate	Lysates
TGRA2S10K	AKT1 p-(Thr308) - SureFire	10,000 points
TGRA2S500	AKT1 p-(Thr308) - SureFire	500 points
TGRA2S50K	AKT1 p-(Thr308) - SureFire	50,000 points
TGRA2S-L	AKT1 p-(Thr308) - Lysate	Lysates
TGRA3S10K	AKT1/2/3 p-(Thr308) - SureFire	10,000 points
TGRA3S500	AKT1/2/3 p-(Thr308) - SureFire	500 points
TGRA3S50K	AKT1/2/3 p-(Thr308) - SureFire	50,000 points
TGRA3S-L	AKT1/2/3 p-(Thr308) - Lysate	Lysates
TGRA4S10K	AKT1/2/3 p-(Ser473) - SureFire	10,000 points
TGRA4S500	AKT1/2/3 p-(Ser473) - SureFire	500 points
TGRA4S50K	AKT1/2/3 p-(Ser473) - SureFire	50,000 points
TGRA4S-L	AKT1/2/3 p-(Ser473) - Lysate	Lysates
TGRA5S10K	AKT1 p-(Ser473) - SureFire	10,000 points
TGRA5S500	AKT1 p-(Ser473) - SureFire	500 points
TGRA5S50K	AKT1 p-(Ser473) - SureFire	50,000 points
TGRA5S-L	AKT1 p-(Ser473) - Lysate	Lysates
TGRAB100ML	Activation Buffer - SureFire	100mL Buffer
TGRAB10ML	Activation Buffer - SureFire	10mL Buffer
TGRABB100ML	Activation Buffer B - SureFire	100mL Buffer
TGRABB10ML	Activation Buffer B - SureFire	10mL Buffer
TGRABC100ML	Activation Buffer C - SureFire	100mL Buffer
TGRABC10ML	Activation Buffer C - SureFire	10mL Buffer

TGRAF1S10K	ATF-1 p-(Ser63) - SureFire	10,000 points
TGRAF1S500	ATF-1 p-(Ser63) - SureFire	500 points
TGRAF1S50K	ATF-1 p-(Ser63) - SureFire	50,000 points
TGRAF1S-L	ATF-1 p-(Ser63) - Lysate	Lysates
TGRAF2S10K	ATF2 p-(Thr71) - SureFire	10,000 points
TGRAF2S500	ATF2 p-(Thr71) - SureFire	500 points
TGRAF2S50K	ATF2 p-(Thr71) - SureFire	50,000 points
TGRAF2S-L	ATF2 p-(Thr71) - Lysate	Lysates
TGRAL2S10K	ALK p-(Tyr1604) - SureFire	10,000 points
TGRAL2S500	ALK p-(Tyr1604) - SureFire	500 points
TGRAL2S50K	ALK p-(Tyr1604) - SureFire	50,000 points
TGRAL2S-L	ALK p-(Tyr1604) - Lysate	Lysates
TGRALS10K	ALK p-(Thr1586) - SureFire	10,000 points
TGRALS500	ALK p-(Thr1586) - SureFire	500 points
TGRALS50K	ALK p-(Thr1586) - SureFire	50,000 points
TGRALS-L	ALK p-(Thr1586) - Lysate	Lysates
TGRAS10K	AKT p-(Ser473) - SureFire	10,000 points
TGRAS500	AKT p-(Ser473) - SureFire	500 points
TGRAS50K	AKT p-(Ser473) - SureFire	50,000 points
TGRAS-L	AKT p-(Ser473) - Lysate	Lysates
TGRB2S10K	Bad p-(Ser136) - SureFire	10,000 points
TGRB2S500	Bad p-(Ser136) - SureFire	500 points
TGRB2S50K	Bad p-(Ser136) - SureFire	50,000 points
TGRB2S-L	Bad p-(Ser136) - Lysate	Lysates
TGRBCS10K	β -Catenin p-(Ser45) - SureFire	10,000 points
TGRBCS500	β -Catenin p-(Ser45) - SureFire	500 points
TGRBCS50K	β -Catenin p-(Ser45) - SureFire	50,000 points
TGRBCS-L	β -Catenin p-(Ser45) - Lysate	Lysates
TGRBS10K	Bad p-(Ser112) - SureFire	10,000 points
TGRBS500	Bad p-(Ser112) - SureFire	500 points
TGRBS50K	Bad p-(Ser112) - SureFire	50,000 points
TGRBS-L	Bad p-(Ser112) - Lysate	Lysates
TGRC9S10K	Caspase-9 p-(Ser196) - SureFire	10,000 points
TGRC9S500	Caspase-9 p-(Ser196) - SureFire	500 points
TGRC9S50K	Caspase-9 p-(Ser196) - SureFire	50,000 points
TGRC9S-L	Caspase-9 p-(Ser196) - Lysate	Lysates
TGRCBS10K	CREB p-(Ser133) - SureFire	10,000 points
TGRCBS500	CREB p-(Ser133) - SureFire	500 points
TGRCBS50K	CREB p-(Ser133) - SureFire	50,000 points
TGRCBS-L	CREB p-(Ser133) - Lysate	Lysates
TGRCHK1S10K	Chk-1 p-(Ser345) - SureFire	10,000 points
TGRCHK1S500	Chk-1 p-(Ser345) - SureFire	500 points
TGRCHK1S50K	Chk-1 p-(Ser345) - SureFire	50,000 points
TGRCHK1S-L	Chk-1 p-(Ser345) - Lysate	Lysates
TGRCHK2S10K	Chk-2 p-(Thr68) - SureFire	10,000 points
TGRCHK2S500	Chk-2 p-(Thr68) - SureFire	500 points
TGRCHK2S50K	Chk-2 p-(Thr68) - SureFire	50,000 points
TGRCHK2S-L	Chk-2 p-(Thr68) - Lysate	Lysates
TGRCJ2S10K	c-Jun p-(Ser73) - SureFire	10,000 points
TGRCJ2S500	c-Jun p-(Ser73) - SureFire	500 points

TGRCJ2S50K	c-Jun p-(Ser73) - SureFire	50,000 points
TGRCJ2S-L	c-Jun p-(Ser73) - Lysate	Lysates
TGRCJS10K	c-Jun p-(Ser63) - SureFire	10,000 points
TGRCJS500	c-Jun p-(Ser63) - SureFire	500 points
TGRCJS50K	c-Jun p-(Ser63) - SureFire	50,000 points
TGRCJS-L	c-Jun p-(Ser63) - Lysate	Lysates
TGRCMS10K	c-Met p-(Tyr1234/1235) - SureFire	10,000 points
TGRCMS500	c-Met p-(Tyr1234/1235) - SureFire	500 points
TGRCMS50K	c-Met p-(Tyr1234/1235) - SureFire	50,000 points
TGRCMS-L	c-Met p-(Tyr1234/1235) - Lysate	Lysates
TGRCOFS10K	Cofilin p-(Ser3) - SureFire	10,000 points
TGRCOFS500	Cofilin p-(Ser3) - SureFire	500 points
TGRCOFS50K	Cofilin p-(Ser3) - SureFire	50,000 points
TGRCOFS-L	Cofilin p-(Ser3) - Lysate	Lysates
TGRCUS	Antibodies	
TGRCustom		
TGRDB100ML	Dilution Buffer - SureFire	100mL Buffer
TGRDB10ML	Dilution Buffer - SureFire	10mL Buffer
TGREB2S10K	ErbB2 p-(Tyr1221/1222) - SureFire	10,000 points
TGREB2S500	ErbB2 p-(Tyr1221/1222) - SureFire	500 points
TGREB2S50K	ErbB2 p-(Tyr1221/1222) - SureFire	50,000 points
TGREB2S-L	ErbB2 p-(Tyr1221/1222) - SureFire	Lysates
TGREIF4S10K	eIF4E p-(Ser209) - SureFire	10,000 points
TGREIF4S500	eIF4E p-(Ser209) - SureFire	500 points
TGREIF4S50K	eIF4E p-(Ser209) - SureFire	50,000 points
TGREIF4S-L	eIF4E p-(Ser209) - Lysate	Lysates
TGRELKS10K	Elk-1 p-(Ser383) - SureFire	10,000 points
TGRELKS500	Elk-1 p-(Ser383) - SureFire	500 points
TGRELKS50K	Elk-1 p-(Ser383) - SureFire	50,000 points
TGRELKS-L	Elk-1 p-(Ser383) - Lysate	Lysates
TGRERS10K	EGF Receptor p-(Tyr1068) - SureFire	10,000 points
TGRERS500	EGF Receptor p-(Tyr1068) - SureFire	500 points
TGRERS50K	EGF Receptor p-(Tyr1068) - SureFire	50,000 points
TGRERS-L	EGF Receptor p-(Tyr1068) - Lysate	Lysates
TGRESB10K	ERK1/2 p-(Thr202/Tyr204) - SureFire	10,000 points
TGRESB500	ERK1/2 p-(Thr202/Tyr204) - SureFire	500 points
TGRESB50K	ERK1/2 p-(Thr202/Tyr204) - SureFire	50,000 points
TGRESB-L	ERK1/2 p-(Thr202/Tyr204) - Lysate	Lysates
TGRGAS10K	GSK3 α p-(Ser21) - SureFire	10,000 points
TGRGAS500	GSK3 α p-(Ser21) - SureFire	500 points
TGRGAS50K	GSK3 α p-(Ser21) - SureFire	50,000 points
TGRGAS-L	GSK3 α p-(Ser21) - Lysate	Lysates
TGRGBS10K	GSK3 β p-(Ser9) - SureFire	10,000 points
TGRGBS500	GSK3 β p-(Ser9) - SureFire	500 points
TGRGBS50K	GSK3 β p-(Ser9) - SureFire	50,000 points
TGRGBS-L	GSK3 β p-(Ser9) - Lysate	Lysates
TGRGDS10K	GAPDH Total - SureFire	10,000 points
TGRGDS500	GAPDH Total - SureFire	500 points
TGRGDS50K	GAPDH Total - SureFire	50,000 points
TGRGDS-L	GAPDH Total - Lysate	Lysates

TGRH3S10K	Histone H3 p-(Ser10) - SureFire	10,000 points
TGRH3S500	Histone H3 p-(Ser10) - SureFire	500 points
TGRH3S50K	Histone H3 p-(Ser10) - SureFire	50,000 points
TGRH3S-L	Histone H3 p-(Ser10) - Lysate	Lysates
TGRHS27S10K	HSP27 p-(Ser82) - SureFire	10,000 points
TGRHS27S500	HSP27 p-(Ser82) - SureFire	500 points
TGRHS27S50K	HSP27 p-(Ser82) - SureFire	50,000 points
TGRHS27S-L	HSP27 p-(Ser82) - Lysate	Lysates
TGRIKS10K	IκBa p-(Ser32/36) - SureFire	10,000 points
TGRIKS500	IκBa p-(Ser32/36) - SureFire	500 points
TGRIKS50K	IκBa p-(Ser32/36) - SureFire	50,000 points
TGRIKS-L	IκBa p-(Ser32/36) - Lysate	Lysates
TGRIRS10K	Insulin Receptor p-(Tyr1150/1151) - SureFire	10,000 points
TGRIRS500	Insulin Receptor p-(Tyr1150/1151) - SureFire	500 points
TGRIRS50K	Insulin Receptor p-(Tyr1150/1151) - SureFire	50,000 points
TGRIRS-L	Insulin Receptor p-(Tyr1150/1151) - Lysate	Lysates
TGRJPS10K	JNK1/2/3 p-(Thr183/Tyr185) - SureFire	10,000 points
TGRJPS500	JNK1/2/3 p-(Thr183/Tyr185) - SureFire	500 points
TGRJPS50K	JNK1/2/3 p-(Thr183/Tyr185) - SureFire	50,000 points
TGRJPS-L	JNK1/2/3 p-(Thr183/Tyr185) - Lysate	Lysates
TGRJS10K	JNK 1/3 p-(Thr183/Tyr185) - SureFire	10,000 points
TGRJS500	JNK 1/3 p-(Thr183/Tyr185) - SureFire	500 points
TGRJS50K	JNK 1/3 p-(Thr183/Tyr185) - SureFire	50,000 points
TGRJS-L	JNK 1/3 p-(Thr183/Tyr185) - Lysate	Lysates
TGRKAS10K	IKKα p-(Ser176/180) - SureFire	10,000 points
TGRKAS500	IKKα p-(Ser176/180) - SureFire	500 points
TGRKAS50K	IKKα p-(Ser176/180) - SureFire	50,000 points
TGRKAS-L	IKKα p-(Ser176/180) - Lysate	Lysates
TGRKBS10K	IKKβ p-(Ser177/181) - SureFire	10,000 points
TGRKBS500	IKKβ p-(Ser177/181) - SureFire	500 points
TGRKBS50K	IKKβ p-(Ser177/181) - SureFire	50,000 points
TGRKBS-L	IKKβ p-(Ser177/181) - Lysate	Lysates
TGRLB100ML	Lysis Buffer (5x) - SureFire	100mL Buffer
TGRLB10ML	Lysis Buffer (5x) - SureFire	10mL Buffer
TGRMK3S10K	MKK3/6 p-(Ser189/207) - SureFire	10,000 points
TGRMK3S500	MKK3/6 p-(Ser189/207) - SureFire	500 points
TGRMK3S50K	MKK3/6 p-(Ser189/207) - SureFire	50,000 points
TGRMK3S-L	MKK3/6 p-(Ser189/207) - Lysate	Lysates
TGRMK4S10K	MKK4 p-(Ser257/T261) - SureFire	10,000 points
TGRMK4S500	MKK4 p-(Ser257/T261) - SureFire	500 points
TGRMK4S50K	MKK4 p-(Ser257/T261) - SureFire	50,000 points
TGRMK4S-L	MKK4 p-(Ser257/T261) - Lysate	Lysates
TGRMS10K	MEK-1 p-(Ser218/222) - SureFire	10,000 points
TGRMS500	MEK-1 p-(Ser218/222) - SureFire	500 points
TGRMS50K	MEK-1 p-(Ser218/222) - SureFire	50,000 points
TGRMS-L	MEK-1 p-(Ser218/222) - Lysate	Lysates
TGRNFS10K	NFκB p65 p-(Ser536) - SureFire	10,000 points
TGRNFS500	NFκB p65 p-(Ser536) - SureFire	500 points
TGRNFS50K	NFκB p65 p-(Ser536) - SureFire	50,000 points
TGRNFS-L	NFκB p65 p-(Ser536) - Lysate	Lysates

TGROLDES10K	ERK1/2 p-(Thr202/Tyr204) _ OLD - SureFire	10,000 points
TGROLDES500	ERK1/2 p-(Thr202/Tyr204) _ OLD - SureFire	500 points
TGROLDES50K	ERK1/2 p-(Thr202/Tyr204) _ OLD - SureFire	50,000 points
TGROLDES-L	ERK1/2 p-(Thr202/Tyr204) - OLD-Lysate SureFire	Lysates
TGRP532S10K	p53 p-(Ser392) - SureFire	10,000 points
TGRP532S500	p53 p-(Ser392) - SureFire	500 points
TGRP532S50K	p53 p-(Ser392) - SureFire	50,000 points
TGRP532S-L	p53 p-(Ser392) - Lysate	Lysates
TGRP53S10K	p53 p-(Ser15) - SureFire	10,000 points
TGRP53S500	p53 p-(Ser15) - SureFire	500 points
TGRP53S50K	p53 p-(Ser15) - SureFire	50,000 points
TGRP53S-L	p53 p-(Ser15) - Lysate	Lysates
TGRPS10K	PDK-1 p-(Ser241) - SureFire	10,000 points
TGRPS500	PDK-1 p-(Ser241) - SureFire	500 points
TGRPS50K	PDK-1 p-(Ser241) - SureFire	50,000 points
TGRPS-L	PDK-1 p-(Ser241) - Lysate	Lysates
TGRS1S10K	STAT-1 p-(Tyr701) - SureFire	10,000 points
TGRS1S500	STAT-1 p-(Tyr701) - SureFire	500 points
TGRS1S50K	STAT-1 p-(Tyr701) - SureFire	50,000 points
TGRS1S-L	STAT-1 p-(Tyr701) - Lysate	Lysates
TGRS3S10K	STAT3 p-(Tyr705) - SureFire	10,000 points
TGRS3S500	STAT3 p-(Tyr705) - SureFire	500 points
TGRS3S50K	STAT3 p-(Tyr705) - SureFire	50,000 points
TGRS3S-L	STAT3 p-(Tyr705) - Lysate	Lysates
TGRS5S10K	STAT5 p-(Tyr694/699) - SureFire	10,000 points
TGRS5S500	STAT5 p-(Tyr694/699) - SureFire	500 points
TGRS5S50K	STAT5 p-(Tyr694/699) - SureFire	50,000 points
TGRS5S-L	STAT5 p-(Tyr694/699) - Lysate	Lysates
TGRS6P2S10K	Ribosomal S6 p-(Ser240/244) - SureFire	10,000 points
TGRS6P2S500	Ribosomal S6 p-(Ser240/244) - SureFire	500 points
TGRS6P2S50K	Ribosomal S6 p-(Ser240/244) - SureFire	50,000 points
TGRS6P2S-L	Ribosomal S6 p-(Ser240/244) - Lysate	Lysates
TGRS6PS10K	Ribosomal S6 p-(Ser235/236) - SureFire	10,000 points
TGRS6PS500	Ribosomal S6 p-(Ser235/236) - SureFire	500 points
TGRS6PS50K	Ribosomal S6 p-(Ser235/236) - SureFire	50,000 points
TGRS6PS-L	Ribosomal S6 p-(Ser235/236) - Lysate	Lysates
TGRSM1S10K	SMAD1 p-(Ser463/465) - SureFire	10,000 points
TGRSM1S500	SMAD1 p-(Ser463/465) - SureFire	500 points
TGRSM1S50K	SMAD1 p-(Ser463/465) - SureFire	50,000 points
TGRSM1S-L	SMAD1 p-(Ser463/465) - Lysate	Lysates
TGRSM2S10K	SMAD2 p-(Ser465/467) - SureFire	10,000 points
TGRSM2S500	SMAD2 p-(Ser465/467) - SureFire	500 points
TGRSM2S50K	SMAD2 p-(Ser465/467) - SureFire	50,000 points
TGRSM2S-L	SMAD2 p-(Ser465/467) - Lysate	Lysates
TGRSM3S10K	SMAD3 p-(Ser423/425) - SureFire	10,000 points
TGRSM3S500	SMAD3 p-(Ser423/425) - SureFire	500 points
TGRSM3S50K	SMAD3 p-(Ser423/425) - SureFire	50,000 points
TGRSM3S-L	SMAD3 p-(Ser423/425) - Lysate	Lysates
TGRT2A2S10K	Topoisomerase IIα p-(Ser1106) - SureFire	10,000 points
TGRT2A2S500	Topoisomerase IIα p-(Ser1106) - SureFire	500 points

TGRT2A2S50K	Topoisomerase IIα p-(Ser1106) - SureFire	50,000 points
TGRT2A2S-L	Topoisomerase IIα p-(Ser1106) - Lysate	Lysates
TGRT2AS10K	Topoisomerase IIα p-(Thr1343) - SureFire	10,000 points
TGRT2AS500	Topoisomerase IIα p-(Thr1343) - SureFire	500 points
TGRT2AS50K	Topoisomerase IIα p-(Thr1343) - SureFire	50,000 points
TGRT2AS-L	Topoisomerase IIα p-(Thr1343) - Lysate	Lysates
TGRT38S10K	p38 MAPKα Total - SureFire	10,000 points
TGRT38S500	p38 MAPKα Total - SureFire	500 points
TGRT38S50K	p38 MAPKα Total - SureFire	50,000 points
TGRT38S-L	p38 MAPKα Total - Lysate	Lysates
TGRT53S10K	p53 Total - SureFire	10,000 points
TGRT53S500	p53 Total - SureFire	500 points
TGRT53S50K	p53 Total - SureFire	50,000 points
TGRT53S-L	p53 Total - Lysate	Lysates
TGRT70S10K	p70 S6 Kinase Total - SureFire	10,000 points
TGRT70S500	p70 S6 Kinase Total - SureFire	500 points
TGRT70S50K	p70 S6 Kinase Total - SureFire	50,000 points
TGRT70S-L	p70 S6K Total - Lysate	Lysates
TGRTA1S10K	Akt1 Total - SureFire	10,000 points
TGRTA1S500	Akt1 Total - SureFire	500 points
TGRTA1S50K	Akt1 Total - SureFire	50,000 points
TGRTA1S-L	Akt1 Total - Lysate	Lysates
TGRTALS10K	ALK Total - SureFire	10,000 points
TGRTALS500	ALK Total - SureFire	500 points
TGRTALS50K	ALK Total - SureFire	50,000 points
TGRTALS-L	ALK Total - Lysate	Lysates
TGRTAPS10K	Akt1/2/3 Total - SureFire	10,000 points
TGRTAPS500	Akt1/2/3 Total - SureFire	500 points
TGRTAPS50K	Akt1/2/3 Total - SureFire	50,000 points
TGRTAPS-L	Akt1/2/3 Total - Lysate	Lysates
TGRTES10K	ERK Total - OLD-SureFire	10,000 points
TGRTES500	ERK Total - OLD-SureFire	500 points
TGRTES50K	ERK Total - OLD-SureFire	50,000 points
TGRTESB10K	ERK Total - SureFire	10,000 points
TGRTESB500	ERK Total - SureFire	500 points
TGRTESB50K	ERK Total - SureFire	50,000 points
TGRTESBS-L	ERK Total - Lysate	Lysates
TGRTES-L	ERK1/2 p-(Thr202/Tyr204) _ OLD - Lysate	Lysates
TGRTIKS10K	IκBα Total - SureFire	10,000 points
TGRTIKS500	IκBα Total - SureFire	500 points
TGRTIKS50K	IκBα Total - SureFire	50,000 points
TGRTIKS-L	IκBα Total - Lysate	Lysates
TGRTJS10K	JNK1/2/3 Total - SureFire	10,000 points
TGRTJS500	JNK1/2/3 Total - SureFire	500 points
TGRTJS50K	JNK1/2/3 Total - SureFire	50,000 points
TGRTJS-L	JNK1/2/3 Total - Lysate	Lysates
TGRTNFS10K	NFκB p65 Total - SureFire	10,000 points
TGRTNFS500	NFκB p65 Total - SureFire	500 points
TGRTNFS50K	NFκB p65 Total - SureFire	50,000 points
TGRTNFS-L	NFκB p65 Total - Lysate	Lysates

TGRTT2AS10K	Topoisomerase II α Total - SureFire	10,000 points
TGRTT2AS500	Topoisomerase II α Total - SureFire	500 points
TGRTT2AS50K	Topoisomerase II α Total - SureFire	50,000 points
TGRTT2AS-L	Topoisomerase II α Total - Lysate	Lysates
TGRVRS10K	VEGF Receptor2 p-(Tyr1175) - SureFire	10,000 points
TGRVRS500	VEGF Receptor2 p-(Tyr1175) - SureFire	500 points
TGRVRS50K	VEGF Receptor2 p-(Tyr1175) - SureFire	50,000 points
TGRVRS-L	VEGF Receptor2 p-(Tyr1175) - Lysate	Lysates

ELISA Kits

Invitrogen InstantOne branded

<i>Cat No</i>	<i>InstantOne Kit Names</i>
85-86011-11	Total ERK 1/2
85-86012-11	phospho-ERK 1/2 (T202/Y204)
85-86013-11	ERK 1/2 Total/Phospho
85-86014-11	AKT/ERK Activation
85-86018-11	Erk/Akt/p70 S6K Activation
85-86022-11	phospho-p38 MAPK (T180/Y182)
85-86042-11	phospho-AKT 1/2/3 (S473)
85-86046-11	Akt Total/Phospho
85-86047-11	Total AKT1
85-86051-11	Total p70S6K
85-86052-11	phospho-p70S6K (T389)
85-86053-11	p70 S6K Total/Phospho
85-86081-11	Total NF-kB p65
85-86082-11	phospho-NF-kB p65 (S536)
85-86083-11	NFk β p65 Total/Phospho
85-86101-11	Total STAT3
85-86102-11	phospho-STAT3 (Y705)
85-86103-11	STAT3 Total/Phospho
85-86111-11	Total STAT5 A/B
85-86112-11	phospho-STAT5 A/B (Y694/699)
85-86113-11	STAT5 Total/Phospho
85-86181-11	Total Smad1
85-86182-11	phospho-Smad 1 (S463/465)
85-86183-11	Smad 1 Total/Phospho
85-86192-11	phospho-Smad 3 (S423/425)
85-86195-11	MAPK Family Activation
85-86196-11	Total JNK 1/2
85-86197-11	phospho-JNK 1/2 (T183/Y185)
85-86198-11	JNK 1/2 Total/Phospho
IOCLB1	Lysis Buffer (5X), 100mL
IOES1	Enhancer Solution, 100mL
IOWB1	Wash Buffer (10X), 500mL

Abcam SimpleStep branded

<i>Cat #</i>	<i>SimpleStep Name:</i>
SEKT001	AKT 1/2/3 (pS473) proteins
SEKT003	AKT 1/2/3 Total proteins
SEKT006	ERK1/2 (pT202/Y204) proteins
SEKT007	ERK1/2 Total proteins
SEKT011	JNK1/2 (pT183/Y185) proteins

SEKT012	JNK1/2 Total proteins
SEKT013	NFκB p65 (pS536) proteins
SEKT014	NFκB p65 Total proteins
SEKT015	p38 MAPKα (pT180/Y182) proteins
SEKT017	p70S6K (pT389) proteins
SEKT018	p70S6K Total proteins
SEKT020	STAT3 (pY705) proteins
SEKT021	STAT3 Total proteins
SEKT022	STAT5 A/B (pY694/699) proteins
SEKT023	SMAD1 p-S463/465 proteins
SEKT024	SMAD1 Total Proteins
SEKT025	SMAD3 p-S423/425 proteins
SEKT035	STAT5 A/B Total proteins
SETP001	AKT1/2/3 (pS473) + total AKT 1/2/3 proteins
SETP004	ERK1/2 (pT202/Y204) + total ERK proteins
SETP006	JNK1/2 (pT183/Y185) + total JNK proteins
SETP007	NFκB p65 (pS536) + total NFκB p65 proteins
SETP009	p70S6K (pT389) + total p70S6K proteins
SETP010	STAT3 (pY705) + total STAT3 proteins
SETP011	SMAD1 p-S463/465 + SMAD1 Total
SETP016	STAT5 A/B (p-Y694/699) + total STAT5 A/Bproteins
SEL001	AKT, Control Lysate
SEL005	ERK, Control Lysate
SEL009	JNK, Control Lysate
SEL010	NFKBp65, Control Lysate
SEL013	p70 S6 K, Control Lysate
SEL015	SMAD1, Control Lysate
SEL016	SMAD3, Control Lysate
SEL018	STAT3, Control Lysate
SEL019	STAT5, Control Lysate

Expedeon ELISA-One branded

<i>Cat No</i>	<i>ELISA-ONE Expedeon Names</i>
ELK001	phospho-AKT 1/2/3 (Ser473)
ELK002	Total AKT1/2/3
ELK003	phospho-AKT 1/2/3 (Ser473) + Total AKT1/2/3
ELK004	phospho-ERK 1/2 (Thr202/Tyr204)
ELK005	Total ERK 1/2
ELK006	phospho-ERK 1/2 (Thr202/Tyr204) + Total ERK 1/2
ELK007	phospho-NF-κB p65 (Ser536)
ELK008	Total NF-κB p65
ELK009	phospho-NF-κB p65 (Ser536) + Total NF-κB p65
ELK010	phospho-SMAD 1 (Ser463/465)
ELK011	Total SMAD 1
ELK012	phospho-SMAD 1 (Ser463/465) + Total SMAD 1
ELK013	phospho-STAT3 (Tyr705)
ELK014	Total STAT3
ELK015	phospho-STAT3 (Tyr705) + Total STAT3
ELK016	phospho-STAT5 (Tyr694/699)
ELK017	Total STAT5

ELK018	phospho-STAT5 (Tyr694/699) + Total STAT5
ELK020	phospho-p38 MAPK α (Thr180/Tyr182)
ELK029	phospho-SMAD 3 (Ser423/425)
ELK037	phospho-JNK 1/2 (Thr183/Tyr185)
ELK038	Total JNK 1/2
ELK039	phospho-JNK 1/2 (Thr183/Tyr185) + Total JNK 1/2
ELK043	phospho-p70S6K (Thr389)
ELK044	Total p70S6K
ELK045	phospho-p70S6K (Thr389) + Total p70 S6K
EBB001	500 mL 10X Wash Buffer
EBB002	100 mL Enhancer Solution
EBB003	100 mL 5X Lysis Buffer

Products currently seeking PerkinElmer approval for discontinuation - no sales in last two years.

AKT 1 Total (TGRTA1S)
 ALK pY1586 (TGRALS)
 ALK Total (TGRTALS)
 ATF1 pS63 (TGRAF1S)
 Caspase-9 pS196 (TGRC9S)
 c-Jun pS63 (TGRCJS)
 Elk1 pS383 (TGRELKS)
 ERK 1/2 Total - OLD (TGRTES)
 MEK1 pS218/222 (TGRMS)
 p70 S6K pT421/S424 (TGR702S)
 SMAD2 pS465/467 (TGRSM2S)
 Topoisomerase II α pS1106 (TGRT2A2S)
 Topoisomerase II α pT1343 (TGRT2AS)

SCHEDULE 15 US EQUIPMENT

FA No.	FA Description	FA SubClass Code	FA Posting Type	Amount
FA145134	PDI - Gelfree Lid Mold	INJCTMOLD	Acquisition Cost	13,000.00
FA145135	PDI - Gelfree Enclosure Mold	INJCTMOLD	Acquisition Cost	17,000.00
FA145140	PDI - Gelfree Cartridge 3.0 Gasket Mold	INJCTMOLD	Acquisition Cost	7,000.00
FA145157	PDI - Molds Gelfree Cartridge	INJCTMOLD	Acquisition Cost	25,540.00
FA145201	Cap Ver. 12 Mold	INJCTMOLD	Acquisition Cost	3,766.96
FA145222	Reservoir ver, 12 no-rib	INJCTMOLD	Acquisition Cost	1,725.95
FA145281	Reservoir 52-Rib Mold	INJCTMOLD	Acquisition Cost	5,378.94
FA145601	Mold, Reservoir 2D Gel	INJCTMOLD	Acquisition Cost	1,350.78
FA145611	Mold, Horizontal Gel	INJCTMOLD	Acquisition Cost	296.31
FA145701	Mold, Cassette 1+1	INJCTMOLD	Acquisition Cost	13,899.75
FA145702	Mold, Cassette 1+1 Rev B/C	INJCTMOLD	Acquisition Cost	4,623.15
FA145703	Press, Pneumatic Cassette Assy	INJCTMOLD	Acquisition Cost	1,293.00
FA145704	Mold, Cassette 1+1 Rev D	INJCTMOLD	Acquisition Cost	6,572.75
FA145710	Comb Cassette 17-well 4-up	INJCTMOLD	Acquisition Cost	8,889.38
FA145720	Mold Comb Narrow Finger	INJCTMOLD	Acquisition Cost	303.18
FA145730	Mold Cassette 8x10 cm	INJCTMOLD	Acquisition Cost	32,523.75
FA145731	Modification of 8x10 Cassette Mold	INJCTMOLD	Acquisition Cost	5,078.63
FA145740	Cavity Block 12 well comb insert with hole	INJCTMOLD	Acquisition Cost	5,469.84
FA145741	Add 17 Well Modified Comb to 12 Well Insert	INJCTMOLD	Acquisition Cost	3,633.44
FA145750	10x10 Cassette Retainer Hot Half Insert	INJCTMOLD	Acquisition Cost	5,653.80
FA145751	New 10x10 Cassette Retainer Ejector Half Insert	INJCTMOLD	Acquisition Cost	4,667.60
FA145752	New 10x10 4 Cavity Mold	INJCTMOLD	Acquisition Cost	950.00
FA145752A	New 10x10 4 Cavity Mold	INJCTMOLD	Acquisition Cost	880.00
FA145752B	New 10x10 4-Cavity Mold	INJCTMOLD	Acquisition Cost	49,310.94
FA145753	New 8x10 4 Cavity Mold	INJCTMOLD	Acquisition Cost	840.00
FA145753A	New 8x10 4 Cavity Mold	INJCTMOLD	Acquisition Cost	40,746.60
FA145754	New 9x10R Cavity and Core Block	INJCTMOLD	Acquisition Cost	6,062.68
FA145755	Add Notch for Combs to 10x10 No Relief	INJCTMOLD	Acquisition Cost	725.00

FA Posting Date	Document No.	FA No.	FA Description	FA SubClass Code	FA Posting Type	Amount
12/31/14	OB FA 2018	FA143365	Cassette Press Automation Machine	LABEQUIP	Acquisition Cost	25,081.97
09/30/15	OB FA 2018	FA143366	Cassette Press Automation Machine-2015 costs	LABEQUIP	Acquisition Cost	4,287.69
01/06/16	OB FA 2018	FA143366A	Cassette Press Automation Machine	LABEQUIP	Acquisition Cost	1,134.89
10/20/15	OB FA 2018	FA143367	Cassette Press Bonding Automation Project	LABEQUIP	Acquisition Cost	7,129.77
01/27/16	OB FA 2018	FA143368	Cassette Press Bonding Automation Machine	LABEQUIP	Acquisition Cost	1,190.00
02/15/16	OB FA 2018	FA143368A	Cassette Press Bonding Machine	LABEQUIP	Acquisition Cost	1,680.00
09/01/16	OB FA 2018	FA143369	Bonding Apparatus for Press & Print Machine	LABEQUIP	Acquisition Cost	10,857.01
12/07/10	OB FA 2018	FA143435	Go-Packer Mago-Packer Machine 2002-558	LABEQUIP	Acquisition Cost	5,981.25
12/22/10	OB FA 2018	FA143436	Go-Packer Mago-Packer Machine 2002-558	LABEQUIP	Acquisition Cost	1,163.77

SCHEDULE 16
DEFINITIONS AND INTERPRETATION

1. In this Agreement each of the following words and expressions shall have the following meanings:

"10X Contract" means the 10X Feature Barcoding Compatible Product Agreement a draft of which has been disclosed to the Purchaser (Data Room: 20.12);

"2006 Act" means the Companies Act 2006;

"Accounts" means the audited statement of financial position, statement of comprehensive income, statement of changes in equity, statement of cash flows and the notes thereto of each Group Company for the 12 month period ended on the Accounts Date;

"Accounts Date" means 31 December 2018;

"AcquisitionCo Accounts" means the consolidated income statement and the consolidated balance sheet of the Company and the US Assets for the 9 month period ended on 30 September 2019;

"Acquisitions" the acquisitions of shares or assets provided for in the Acquisition Agreements;

"Acquisition Agreements" means the Innova SPA, the TGR SPA, the Protein Discovery SPA and any other agreement for the acquisition of shares (or business purchase agreement) entered into by, or assigned to, any Group Company in the five (5) year period prior to the date of this Agreement;

"Actions" claims, actions, proceedings, damages, demands, judgments, sums payable, liabilities and losses (which includes any diminution in the value of the Shares, or the shares in the Subsidiaries directly or indirectly held by the Company or the assets of the Company or the Subsidiaries) (in each case, whether or not successful, compromised, settled, withdrawn or which shall become unenforceable by the lapse of time or otherwise);

"Affiliate" in relation to any person, any other person directly or indirectly Controlled by, or Controlling of, or under common Control with, that person and, in the case of a trust, any trustee or beneficiary (actual or potential) of that trust;

"Applicable Laws" all laws, regulations, directives, statutes, subordinate legislation, common law and civil codes of any jurisdiction, all judgments, orders, notices, instructions, decisions and awards of any court or competent authority or tribunal exercising statutory or delegated powers and all codes of practice having force of law, statutory guidance and policy notes, in each case to the extent applicable to the Parties or any of them, any Group Company, or as the context requires;

"Boost" means Boost & Co (acting through IL2 (2018) S.A.R.L for the purposes of the Boost Facility Contracts;

"Boost Facility Contracts" means each of:

- (a) the loan agreement dated 28 August 2018 between the Company and Boost; and
- (b) the subscription deed dated 28 August 2019 between the Seller and Boost;

"Business Day" a day (other than a Saturday or Sunday) on which banks are open for general business in London;

"Business Warranties" the warranties given in Part 2 of Schedule 7;

"Change of Control Consents" means the written consents to the Transaction from the counterparties of the Change of Control Contracts;

"Change of Control Contracts" means

- (a) the agreement between Expedeon Holdings Limited and a redacted counterparty dated 1 July 2018 (as amended) (Data Room: 20.04.41-42);
- (b) the agreement between Innova Biosciences Limited and a redacted counterparty, dated 21 February 2008 (Data Room: 20.09.10);
- (c) the agreement between Innova Biosciences Limited and a redacted counterparty, dated 10 October 2007 (Data Room: 20.03.03);
- (d) the agreement between Innova Biosciences Limited and a redacted counterparty, dated 10 February 2017 (Data Room: 20.03.05);
- (e) the undated agreement between Innova Biosciences Limited and a redacted counterparty, (as amended) (Data Room: 20.06.01-04); and
- (f) the agreement between TGR Biosciences Pty Ltd and a redacted counterparty, dated 20 February 2015 (as amended) (Data Room: 20.11.21-24);

"Claim" means all and any of a General Claim, a Title and Capacity Claim, a Tax Claim or an Indemnity Claim;

"Claim Retention Release Date" means the date which is 10 Business Days after the admission, settlement or determination or a judgment in respect of which the appeal period has lapsed, of any Claim being the subject of a retention under paragraph 2.2.1 of Schedule 4.

"Company" means Expedeon Holdings Limited, a company incorporated in England and Wales with registered number 06785444 further details of which are set out in Part 1 of Schedule 2;

"Company Cyber Incident" has the meaning given in paragraph 8.3 of Schedule 7;

"Competition Authority" means any national, supra-national or regional, state, municipal, government or governmental, quasi-governmental, statutory, regulatory or investigative body, administrative agency, court or tribunal, in any jurisdiction, responsible for the investigation, prosecution or determination of any matters relating to antitrust, competition, mergers, unfair competition, consumer protection, anti-competitive agreements, practices or behaviour or any similar matter;

"Completion" means completion of the sale and purchase of the Shares and US Assets in accordance with Clause 7;

"Completion Consideration Amount" means €105,600,000.00;

"Completion Date" means 1 January 2020 or at such other time as the Seller and Purchaser shall agree in writing;

"Condition" has the meaning given to it in Clause 5.1;

"Confidential Information" has the meaning given to that term in Clause 17.4;

"Consultancy Agreement" means the consultancy agreement in the agreed form to be entered into by the Seller and the Purchaser at Completion;

"Contingent Consideration" means any outstanding contingent consideration payable by the "Buyer" (as defined in the TGR SPA) to the "Sellers" (as defined in the TGR SPA) pursuant to the TGR SPA;

"Contingent Consideration Indemnity Claim" means a claim against the Seller under the Contingent Consideration indemnity;

"Contingent Consideration Indemnity" means the indemnity provided by the Seller in Clause 9.1.2;

"Contingent Consideration Retention Release Date" the date which is ten (10) Business Days after the payment by the Seller of any Contingent Consideration which remained outstanding as at the Escrow Release Date;

"Control" the power of a person to secure, directly or indirectly, (whether by the holding of shares, possession of voting rights or by virtue of any other power conferred by the articles of association, constitution, partnership deed or other documents regulating another person or otherwise) that the affairs of such other person are conducted in accordance with his or its wishes and **"Controlled"** and **"Controlling"** shall be construed accordingly;

"Corruption Law(s)" all Applicable Laws in connection with bribery and corruption, including:

- (a) the principles described in the Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed in Paris on 17 December, 1997, which entered into force on 15 February, 1999, and the Convention's Commentaries; and
- (b) the United States Foreign Corrupt Practices Act ("**FCPA**"); and
- (c) the United Kingdom Bribery Act 2010 and, in relation to conduct prior to the Bribery Act 2010 being brought into force, the United Kingdom Public Bodies Corrupt Practices Act 1889 and the Prevention of Corruption Act 1906 (together with the United Kingdom Bribery Act 2010, the "**UK Corruption Laws**"),

and for these purposes the offences created by the FCPA and the UK Corruption Laws are deemed to apply to the Company, any Group Company, and any director, Employee or agent of the Company or any Group Company irrespective of the jurisdictional scope of FCPA and the UK Corruption Laws;

"Costs" all costs, charges and expenses (including those suffered or incurred in establishing or enforcing a right to be indemnified under this Agreement and any irrevocable VAT);

"CTA 2010" the Corporation Tax Act 2010;

"CTO Waiver Deed" means the deed of waiver to be entered into between Expedeon Limited and Nicholas Gee, in the agreed form;

"Cyber Incident" has the meaning given in paragraph 8.1.1 of Schedule 7;

"Data Protection Authority" each body responsible for the enforcement of the Data Protection Legislation;

"Data Protection Legislation" means (i) the GDPR; (ii) any legislation in force from time to time which implements or is related to the European Community's Directive 2002/58/EC concerning the processing of personal data and the protection of privacy in the electronic communications sector; and (iii) any applicable legislation in force from time to time in any relevant jurisdiction relating to privacy or the processing of Personal Data;

"Data Room" means the contents of the Ansarada online data room made available by the Seller hosted at https://dataroom.ansarada.com/_mvc/ProjectAlpha-DR%7C54666/3079496/spa/documents as at 00.01am GMT on the date of this Agreement, a copy of which is included in the USB stick to be delivered to the Purchaser within three (3) Business Days of this Agreement, save that, where the term "Data Room" is used in Part 2 of Schedule 7, the term shall exclude those documents excluded from the scope of general disclosure pursuant to paragraph 3.8 of the Signing Disclosure Letter;

"Deed of Assignment" means a deed of assignment in the agreed form, pursuant to which the Identified Contracts will be assigned to the Company;

"Disclosed Schemes" means the:

- (a) People's Pension: Expedeon Limited Pension Scheme;
- (b) Scottish Widows: Innova Biosciences Ltd Group Personal Pension Scheme;
- (c) Prudential: Prudential Stakeholder Pension Novexin Limited;
- (d) The Canada Life Group Life Master Trust on behalf of Expedeon Limited;
- (e) Hargreaves Lansdown HL SIPP Single Contribution;

"Disclosure Letters" means the Signing Disclosure Letter and the Supplemental Disclosure Letter (if any);

"Distribution Agreements" means the Qualiphi Distribution Agreement and the TruePrime Distribution Agreement;

"Effective Time" means 00.01 GMT on 1 January 2020 (or such other time as the Parties agree in writing);

"Employee" any individual who has entered into or works under a contract of employment or any other contract whereby the individual undertakes to do or perform personally any work or services (save where such services are performed for a client or customer of a profession or business undertaking carried on by the individual);

"Employment Claims" means any claim for medical, dental, life insurance, health accident, disability or any other form of benefits brought by or in respect of the US Employees or the spouses, dependents or beneficiaries thereof, or any other current or former employees, officers, directors, independent contractors or consultants of the US Seller, or the spouses, dependents or beneficiaries thereof;

"Encumbrance" any claim, option, charge (fixed or floating), mortgage, lien, pledge, equity, encumbrance, right to acquire, right of pre-emption, right of first refusal, title retention or any other third party right, or other security interest or any other agreement or arrangement having a similar effect or any agreement to create any of the foregoing;

"Environment" air (including air within buildings and air within other natural or man-made structures above or below ground), water (including groundwater and water within any natural or man-made structure and territorial, coastal and inland waters), land (including land under water, surface land and sub-surface land) and any organisms or ecosystems supported by the air, water or land;

"Environmental Agreement" an agreement, covenant, guarantee or indemnity entered into or agreed before Completion under which any Group Company has a duty, obligation or liability (actual, contingent or otherwise) to remediate pollution or contamination of the Environment or otherwise to restore, pay, compensate or reimburse in respect of remediation or harm caused by pollution or contamination of the Environment;

"Environmental Condition":

- (a) the presence of a Hazardous Substance at, in, on, under or about any relevant property on or before Completion including migration or release (whether occurring, in either case, before or after Completion) from any relevant property;
- (b) noise, vibration, radiation, dust, odour or nuisance present at or arising from any relevant property on or before Completion; or
- (c) a breach of Environmental Law by any Group Company or in relation to any relevant property before Completion requiring corrective action;

"Environmental Law" each Applicable Law which relates to pollution or protection of the Environment, or human health and safety, or the generation, transportation, storage, treatment, disposal or presence of any Hazardous Substance;

"Environmental Permit" any consent, permission, licence, accreditation, approval or other authorisation issued, registration made or exemption granted, pursuant to Environmental Law;

"Escrow Account" has the meaning given to it in the Escrow Agreement;

"Escrow Agents" means the Seller's Solicitors and the Purchaser's Solicitors (or any such other escrow agent as is agreed in writing by the parties);

"Escrow Agreement" means the escrow agreement between the Seller, the Purchaser and the Escrow Agents to be entered into prior to Completion;

"Escrow Amount" means €14,400,000;

"Escrow Release Date" means two (2) years after Completion;

"Estimated Net Debt" has the meaning given to it in Schedule 3;

"Estimated Net Debt Statement" means the statement of Estimated Net Debt to be delivered in accordance with Clause 3.4 based on the form of the Net Debt Statement;

"Excluded US Business" means the electrophoretic instrument business conducted by the US Seller as at the date of this Agreement;

"Financial Conduct Authority" the Financial Conduct Authority;

"Financial Information" means:

- (d) the documents contained in folder 1.25.03>Innova sale from AG to Holdings in the Data Room;
- (e) the documents contained in folder 2.06>Quarterly financial statements in the Data Room;
- (f) document 2.44>Top 8 Customers Quarterly details in the Data Room;
- (g) document 2.45> Revenue Tier 2 Companies List in the Data Room;
- (h) document 2.46>Tier Three Product Revenue in the Data Room;
- (i) the documents contained in folder 2.47>Cash balances in the Data Room;
- (j) document 3.03>Exp Holdings Grp Tax Summary in the Data Room;
- (k) the documents contained in folder 3.04>Tax Returns in the Data Room;
- (l) document 3.08>Related Party transactions Exp Inc in the Data Room;
- (m) the documents contained in folder 3.35>Tax Computations in the Data Room;
- (n) the documents contained in folder 3.42>Australian R&D Tax Incentive in the Data Room;
- (o) the documents contained in folder 23.03>Additional Financial Information in the Data Room (including documents 23.03.03>RE_Final diligence list and 23.03.09>Transfer pricing);
- (p) the quarterly product and customer sales analysis to Q3 2019 (and the reconciliation between this analysis and the consolidated PLs) provided by the Seller to the Purchaser via: (i) an email dated 11 October 2019 (timed 17.51 UK time) from a representative of the Seller to a representative of the Purchaser; and (ii) an email dated 24 October 2019 (timed 15.57 UK time) from a representative of the Seller to a representative of the Purchaser;
- (q) the reconciliations between the 31 December 18 consolidation and the statutory accounts for: (i) Innova Biosciences Limited (as provided by the Seller to the Purchaser via an email from a representative of the Seller to a representative of the Purchaser dated 15 October 2019 (timed 18.22 UK time)); and (ii) TGR Biosciences Pty Ltd (as provided by the Seller to the Purchaser via an email from a representative of the Seller to the Purchaser's advisers dated 18 October 2019 (timed 00.19 UK time));
- (r) the draft statutory accounts as at 31 December 18 for Innova Biosciences Limited provided by the Seller to the Purchaser via an email from a representative of the Seller to a representative of the Purchaser dated 15 October 2019 (timed 18.22 UK time));
- (s) the final statutory accounts for TGR Biosciences Pty Ltd (as provided by the Seller to the Purchaser via an email from a representative of the Seller to a representative of the Purchaser dated 18 October 2019 (timed 09.47 UK time));

"Freehold Transfer" has the meaning given to it in 8.18.1;

"FRS 101" Financial Reporting Standard 101 "Reduced Disclosure Framework" as issued by the Financial Reporting Council;

"Full Title Guarantee" with the benefit of the implied covenants set out in Part 1 of the Law of Property (Miscellaneous Provisions) Act 1994 when a disposition is expressed to be made with full title guarantee;

"Fundamental IP Warranties" means the Seller Warranties provided at paragraphs 6.1.1 to 6.1.3 (inclusive) and 6.3 of Part 2 of Schedule 7;

"Fundamental Warranties" means the Title and Capacity Warranties and the Fundamental IP Warranties;

"GDPR" means the General Data Protection Regulation (EU) 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data;

"General Claim" means a claim for breach of any of the Business Warranties and a claim against the Seller pursuant to Clause 8.9 (other than in respect of a Title and Capacity Claim);

"General Indemnity Claim" means a claim under any of the Contingent Consideration Indemnity, the US Inc Indemnity, the Norman Way Indemnity and the Shareholder Claim Indemnity;

"Group" means the Company and the Subsidiaries;

"Group Company" means any one of the Company and the Subsidiaries;

"Group Relief" has the meaning given to that term in the Tax Deed;

"Hazardous Substances" means any natural or artificial substance or thing (whether in solid, liquid or gaseous form) which is (alone or in combination) capable of causing harm to human health or to the Environment;

"Hedging Agreement" means the forward contract confirmation dated 24 April 2019 and associated terms and conditions entered into between TGR Biosciences Pty Ltd and Western Union Business Solutions (Australia) Pty Limited;

"Heuking" means Heuking Kuhn Luer Wotjek;

"Indemnified Person" an entity which is, or a person who is, on or at any time after the date of this Agreement, a member of the Purchaser Group or a director, Employee or agent of a member of the Purchaser Group or the trustees of the Disclosed Schemes;

"Indemnity Claim" a claim against the Seller pursuant to any of the provisions of Clause 9.1;

"Identified Contracts" means:

- (a) the license and supply agreement between Innova Biosciences Limited and a redacted party dated 14 March 2017; as amended (and assigned by Innova Biosciences Limited to the Seller) by an amendment agreement dated 28 May 2018 (Data Room 20.07.01, 25-26); and
- (b) the supply agreement between Innova Biosciences Limited and a redacted party dated 15 November 2011; as amended (and assigned by Innova Biosciences Limited to the Seller) by an amendment agreement dated 17 November 2018 (Data Room 20.07.01, 27 – 28);
- (c) the Innova SPA;

"IFRS" means means International Financial Reporting Standards (including International Accounting Standards (IAS)) issued by the International Accounting Standards Board

"Information Technology" means the computer systems, communications systems (other than public communications networks), Software, hardware, devices and websites which are owned or used by a Group Company;

"Information Technology Agreements" all subsisting agreements (including all side letters, oral agreements or arrangements) relating to the Information Technology, including all insurance policies, licence, lease, development, maintenance, support, escrow, security,

disaster recovery, website hosting, outsourcing, facilities management, utilisation, bureau, on-line services and service agreements;

"Innova SPA" means the sale and purchase agreement relating to the issued share capital of Innova Biosciences Limited dated 8 May 2017 between the Seller, Nicholas Gee, Steven Howell, Timothy Barnard and others;

"Intellectual Property" all inventions (whether patentable or not), patents, utility models, petty patents, registered designs, design rights, database rights, copyright and related rights, moral rights, semiconductor topography rights, plant variety rights, trade marks, service marks, logos, get up, trade names, business names, domain names, (in each case whether registered or unregistered) and including any applications for registration and any renewals or extensions of any of the foregoing, and, in each case, the goodwill attaching to any of the foregoing, rights to sue for passing off or for unfair competition, all Know How, confidential information and trade secrets and any rights or forms of protection of a similar nature or having equivalent or similar effect to any of them which subsist anywhere in the world;

"Irrevocable Undertakings" means the irrevocable commitments to be provided by certain shareholders of the Seller to the Purchaser to vote in favour of the Shareholder Resolution;

"ITEPA" means the Income Tax (Earnings and Pensions) Act 2003;

"Know How" all know how, trade secrets and confidential information, in any form (including paper, electronically stored data, magnetic media, film and microfilm) including financial and technical information, drawings, formulae, test results or reports, project reports and testing procedures, information relating to the working of any product, process, invention, improvement or development, instruction and training manuals, tables of operating conditions, information concerning intellectual property portfolio and strategy, market forecasts, lists or particulars of customers and suppliers, sales targets, sales statistics, prices, discounts, margins, future business strategy, tenders, price sensitive information, market research reports, information relating to research and development and business development and planning reports and any information derived from any of them;

"Lion Assets" means the Caco-2 cell lines and any derivative or other cell lines sold as at the date of this Agreement (including all Intellectual Property in the same), including all rights acquired as a result of the acquisition of Lion Biosciences;

"Material Contract" means any of the Tier 1 Contracts and any contract entered into by any member of the Group relating to annual income or expenditure in excess of €100,000;

"Management Services Termination Deed" means the termination deed terminating all management service agreements between the Seller and the group in the agreed form;

"Managers" means Heikki Lanckriet and David Roth;

"Norman Way" means the property at Unit 25 Norman Way, Over, Cambridge, CB24 5QE;

"Norman Way Freehold" means Unit 25 Norman Way, Over, Cambridge, CB24 5QE (registered freehold under title number CB101090);

"Norman Way Indemnity" means the indemnity provided by the Seller in Clause 9.1.4;

"Norman Way Lease" means the lease in relation to Norman Way to be entered into between the Seller (or an Affiliate of the Seller, excluding a Group Company) and the Company at Completion;

"Norman Way Lease Term Sheet" means the term sheet in the agreed form in relation to the proposed terms of the Norman Way Lease;

"Norman Way Transfer Consideration" means the consideration payable by the Seller or its nominated Affiliate to the Buyer for the transfer of Norman Way, being the net book value of the Norman Way property and the improvements made to Norman Way as at 31 December 2019;

"Option" means any option, warrant, convertible security or similar right to acquire shares in the Company or the Seller;

"Optionholder" means any holder of an Option as at the Completion Date;

"Option Lapse Notice" means the notice to be provided by the Seller to Optionholders in relation to the lapse of their Options at Completion in the agreed form;

"Overdue Accounts" means the audited accounts for the Company and Expedeon Limited for the year ended 31 December 2018;

"Party" or **"Parties"** a party or the parties to this Agreement;

"Permitted Logo" shall mean the logo set out in Schedule 9;

"Personal Data" any information relating to an identifiable person who can be directly or indirectly identified in particular by reference to an identifier;

"Post Completion Payment Date" means the date being 10 Business Days after the date on which Net Debt is agreed between the Seller and the Purchaser, or otherwise determined, in accordance with Schedule 3;

"Pre-Completion Reorganisation" means the transfer of the US Seller to the Seller or an Affiliate of the Seller in accordance with Clause 6 prior to Completion;

"Prepayment Facilities" means each of:

- (d) the Boost Facility Contracts;
- (e) the Santander Facilities; and
- (f) the Santander Overdraft.

"Prepayment Notice" means a written notice of prepayment to be delivered to Santander or Boost under and in accordance with the terms of the applicable Prepayment Facility;

"Product Materials" means all laboratory, pre-clinical, clinical and other scientific, technical and regulatory data and information relating to the Products, including any biological assets, such as antibodies, nucleic acids or gene sequences, which relate to the research, development, testing and evaluation, approval, manufacture and/or sale of the Products;

"Products" means any and all products currently manufactured, distributed or sold by any Group Company as at the date of this Agreement (excluding any products manufactured by Expedeon Biotech S.L.U.);

"Protein Discovery SPA" means the sale and purchase agreement between the Company and Protein Discovery Inc dated 18 November 2011;

"Public Official" means any person (whether appointed or elected) holding a legislative, administrative, or judicial office, including any person employed by or acting on behalf of a public agency, a public enterprise (including any officer or Employee of a state-owned or state-operated entity) or a public international organisation;

"Purchase Price" means €120,000,000;

"Purchaser Group" the Purchaser and its group undertakings from time to time including, after Completion, the Company and the Subsidiaries;

"Purchaser's Nominated Account" has the meaning given to it in the Escrow Agreement;

"Qualiphi Distribution Agreement" means the distribution agreement to be entered into between Expedeon Biotech SLU and the Purchaser in relation to the supply of the QUALIPHI DNA polymerase enzyme and use of the Qualiphi IP in the agreed form;

"Qualiphi IP" means all Intellectual Property held by or licenced to Expedeon Biotech S.L.U. or any other Seller Group Company which relates to the QUALIPHI DNA polymerase enzyme.

"Real Properties" the leasehold and freehold properties listed in Schedule 11;

"Repeated Warranties" means the warranties to be given by the Seller at Completion pursuant to Clause 8.2;

"Reporting Packs" means the quarterly reporting packs covering the four quarters ending on the Accounts Date and the three quarters ending on 30 September 2019 and included in the Data Room at section 2.06.04;

"Sanctioned Person" a person that is listed on, or owned or controlled by, or acting on behalf of, a person listed on any Sanctions List;

"Sanctions" any laws or regulations relating to economic or financial sanctions or trade embargoes or related restrictive measures imposed, administered or enforced from time to time by a Sanctions Authority;

"Sanctions Authority" (i) the United Nations Security Council; (ii) the United States government; (iii) the European Union; (iv) the United Kingdom government; (v) the respective governmental institutions and agencies of any of the foregoing, including without limitation, the Office of Foreign Assets Control of the US Department of Treasury ("**OFAC**"), the United States Department of State and Department of Commerce, and Her Majesty's Treasury; and (vi) any other governmental institution or agency with responsibility for imposing, administering or enforcing Sanctions with jurisdiction over any Group Company (together, "**Sanctions Authorities**");

"Sanctions List" the Specially Designated Nationals and Blocked Persons list maintained by OFAC, the Denied Persons List maintained by the US Department of Commerce, the Consolidated List of Financial Sanctions Targets maintained by Her Majesty's Treasury, or any other list issued or maintained by any Sanctions Authorities of persons subject to Sanctions (including investment or related restrictions), each as amended, supplemented or substituted from time to time;

"Santander" means Santander UK plc;

"Santander Facilities" means each of:

- (a) the £120,000 facility letter dated 7 May 2019 between Expedeon Limited and Santander;
- (b) the £467,735 facility letter dated 3 March 2017 (as amended on 13 March 2017) between Expedeon Limited and Santander; and
- (c) the £112,500 facility letter dated 3 March 2017 (as amended on 13 March 2017) between Expedeon Limited and Santander;

"Santander Overdraft" means the offer letter in relation to a £30,000 cross-currency overdraft facility from Santander dated 23 April 2015;

"Security" means the legal charge dated 10 April 2017 between Expedeon Limited and Santander;

"Seller Group Company" the Seller and the group undertakings of the Seller (excluding any Group Company);

"Seller Group IP" means any Intellectual Property owned by or licensed to the Sellers after Completion which has been used for, or in connection with, the operation of the other US Assets or the business of any Group Company in the three (3) years prior to the date of the Agreement;

"Seller's Share Plan" means the Sygnis AG Enterprise Management Incentive Plan adopted by the Supervisory and Management Boards of the Seller in 2017;

"Seller Warranties" the Title and Capacity Warranties, the Business Warranties and the Tax Warranties;

"Seller's Nominated Account" has the meaning given to it in the Escrow Agreement;

"Seller's Solicitors" means DWF Law LLP of 20 Fenchurch Street, London;

"Seller US IP" means any Intellectual Property owned or licensed by the Seller Group which is required for the operation of the US Assets;

"Senior Employees" means Employees earning annual remuneration in excess of £60,000 per annum;

"Settlement Agreement" means the agreement in the agreed form to be executed by Expedeon Limited on the one part and each of Heikki Lanckriet and David Roth on the other;

"Shareholder Approval" means the approval of shareholders of the Seller that requires a majority of not less than 75 per cent of the share capital of the Seller represented at the passing of the Shareholder Resolution;

"Shareholder Approval Documentation" means the Shareholder Circular and any public notice regarding the convening of the Shareholder Meeting required under applicable German law, including the German Stock Corporation Act and the German Securities Trading Act;

"Shareholder Claim" means any claim filed by a shareholder of the Seller against the Shareholder Approval, including contestation claims (*Anfechtungsklagen*) and claims for annulment (*Nichtigkeitssklagen*).

"Shareholder Claim Indemnity" means the indemnity provided by the Seller in Clause 9.1.3;

"Shareholder Circular" means the shareholder circular (*Einberufung*) in the agreed form to be issued and published by the Seller in connection with the Shareholder Meeting and Shareholder Approval, including all documentation that needs to be attached to the shareholder circular to properly inform the shareholders of the Seller about the Transaction;

"Shareholder Meeting" means an extraordinary meeting of the shareholders of the Seller to approve the Transaction;

"Shareholder Resolution" means a shareholder resolution of the Seller's shareholders approving this Agreement and the sale and transfer of the Shares and the sale of the US Assets pursuant to this Agreement;

"Shares" the 18,328,724 issued ordinary shares of £0.01 each and 2,500,000 issued B ordinary shares of \$0.50 each in the capital of the Company;

"Shrinkwrap Software" third party software sold in a standard configuration and readily available to the public on standard terms and conditions;

"Signing Disclosure Letter" the letter dated the same date as this Agreement from the Seller to the Purchaser in relation to the Seller Warranties given at signing;

"Supplemental Disclosure Letter" the letter to be provided at Completion from the Seller to the Purchaser in relation to the Repeated Warranties only;

"Software" all software used in connection with the business of a Group Company as is currently conducted or contemplated to be conducted, including Shrinkwrap Software and firmware that relates to or is comprised in hardware, together with all supporting documentation and materials necessary to enable a user to make full use of the functionality of, or to administer effectively, such software and firmware;

"Subsidiaries" the undertakings further details of which are set out in Part 2 of Schedule 2;

"Tax Authority" has the meaning given to that term in the Tax Deed;

"Tax Claim" any claim under the Tax Deed or for breach of any of the Tax Warranties;

"Tax Deed" the deed in relation to Tax entered into pursuant to this Agreement in the agreed form;

"Tax Records" means all returns, information, statements, accounts, registrations, computations, disclosures, notices, claims, disclaimers, elections, surrenders and applications relating to Tax;

"Tax Relief" has the meaning given to that term in the Tax Deed;

"Tax Statute" any directive, statute, enactment, law or regulation wherever enacted or issued, coming into force or entered into providing for or imposing any Tax, or providing for the reporting, collection, assessment or administration of any Tax liability, and shall include orders, regulations, instruments, bye-laws or other subordinate legislation made under the relevant statute or statutory provision and any directive, statute, enactment, law, order, regulation or provision that amends, extends, consolidates or replaces the same or that has been amended, extended, consolidated or replaced by the same;

"Tax Warranties" the warranties given in Part 3 of Schedule 7;

"Tax Warranty Claim" means any claim for breach of any of the Tax Warranties;

"Taxation" or **"Tax"** have the meaning given to those terms in the Tax Deed;

"Termination Deed" means the termination deeds in the agreed form to be entered into by the Managers at Completion;

"TGR Consideration Payment Date" means the date for payment of the final Contingent Consideration under the TGR SPA;

"TGR SPA" the agreement for the acquisition of shares in TGR Biosciences PTY LTD dated 15 March 2018 between the Seller, the Company, Michael Crouch (as trustee for the Michael Crouch Family Trust), Anthony James Sheehan (as trustee for the A Sheehan Family Trust), Andrew Sneddon (as trustee for the Sneddon Family Superannuation Fund), Judith Sneddon (as trustee for the Sneddon Family Superannuation Fund), Anne Hinton and Robin Holmes;

"Third Party" has the meaning given to that term in Clause 17.11;

"Third Party Claim" has the meaning given to that term in Clause 10.15;

"Tier 1 Contract" means a contract entered into by a Group Company with one of the customers listed in document 2.44 in the Data Room;

"Title and Capacity Claim" a claim for breach of any of the Title and Capacity Warranties;

"Title and Capacity Warranties" the warranties given in Part 1 of Schedule 7;

"Transaction" means the sale and purchase of the Shares and the US Assets in accordance with the terms of this Agreement;

"Transaction Documents" means this Agreement, the Disclosure Letters, the Tax Deed and the documents in the agreed form;

"TruePrime Distribution Agreement" means the distribution agreement to be entered into between Expedeon Biotech SLU and the Purchaser in relation to the supply of 'TruePrime' and 'Sunscript' products in the agreed form;

"US Transitional Services Agreement" the agreement to be entered into at Completion pursuant to which the US Seller will procure the provision of certain transitional services to the Group;

"US Assets" means each of:

- (a) the US Customer Lists and Database;
- (b) the US IP;
- (c) the US Inventory;
- (d) the US Equipment;
- (e) the Lion Assets;
- (f) any licence agreements granted by NaviCyte Scientific (or any other Seller Group Company) relating to the Caco-2 cell lines; and
- (g) the exclusive distribution agreements between NaviCyte Scientific and each of MKSCC and Yale in respect of the Caco-2 cell lines (including the C2BBel 9a clone of Caco-2) and any other agreements that grant NaviCyte Scientific (or any

other Seller Group Company) the benefit of any rights needed to commercialise cell lines that comprise the Lion Assets ;

"US Contract" means the non-exclusive distribution agreement between the US Seller and VWR International LLC dated 24 June 2018;

"US Customer Lists and Database" means all of the customer lists and databases (including any data relating to the US Seller's customers) of the US Seller (excluding any customer lists and databases / data which solely relate to the Excluded US Business);

"US Effective Time" means 00.01am EST on 1 January 2020;

"US Employees" means Haewon Chong and Sarah Scott;

"US Equipment" means the equipment set out in Schedule 15;

"US Inc Indemnity" means the indemnity provided by the Seller in Clause 9.1.1;

"US Inc Indemnity Claim" means a claim against the Seller under the US Inc Indemnity;

"US Inc Transfer Agreement" means the agreement in the agreed form pursuant to which the US Seller shall be transferred by the Company to the Seller;

"US Inc Transfer Date" means the date of completion of the transfer of the entire issued share capital of the US Seller to the Seller;

"US Inventory" means all inventory held by the US Seller excluding any inventory relating solely to the Excluded US Business;

"US IP" means any Intellectual Property owned by the US Seller which has been used exclusively for, or in connection with, the operation of the US Assets in the twelve (12) months before the date of this Agreement; and

"VAT" has the meaning given to that term in the Tax Deed.

2. In this Agreement, words and expressions defined in the Companies Acts shall bear the same meaning as in those Acts unless expressly stated otherwise.
3. In this Agreement, except where the context otherwise requires:
 - 3.1 any reference to this Agreement includes the Schedules and Appendices to it each of which forms part of this Agreement for all purposes;
 - 3.2 a reference to an enactment, EU instrument or statutory provision shall include a reference to any subordinate legislation made under the relevant enactment, EU instrument or statutory provision and is a reference to that enactment, EU instrument, statutory provision or subordinate legislation as from time to time amended, modified, incorporated or reproduced and to any enactment, EU instrument, statutory provision or subordinate legislation that from time to time (with or without modifications) re-enacts, replaces, consolidates, incorporates or reproduces it;
 - 3.3 words in the singular shall include the plural and vice versa;
 - 3.4 references to one gender include other genders;
 - 3.5 a reference to a person shall include a reference to a firm, a body corporate, an unincorporated association, a partnership or to an individual's executors or administrators;
 - 3.6 a reference to a Clause, paragraph, Schedule (other than to a schedule to a statutory provision) or Appendix shall be a reference to a Clause, paragraph, Schedule or Appendix (as the case may be) of or to this Agreement;
 - 3.7 if a period of time is specified as from a given day, or from the day of an act or event, it shall be calculated exclusive of that day;
 - 3.8 references to any English legal term for any action, remedy, method of judicial proceeding, legal document, legal status, court, official or any legal concept or thing shall in respect of any jurisdiction other than England be deemed to include what most nearly approximates the English legal term in that jurisdiction and references to any English statute or

enactment shall be deemed to include any equivalent or analogous laws or rules in any other jurisdiction;

- 3.9 a person shall be deemed to be connected with another if that person is connected with another within the meaning of section 1122 of the CTA 2010;
- 3.10 references to writing shall include any modes of reproducing words in any legible form and shall include email except where expressly stated otherwise;
- 3.11 a reference to a balance sheet or profit and loss account shall include a reference to any note forming part of it;
- 3.12 a reference to "includes" or "including" shall mean "includes without limitation" or "including without limitation";
- 3.13 references to documents "in the agreed form" or any similar expression shall be to documents agreed between the Parties, annexed to this Agreement and initialled for identification by, or on behalf of, the Seller and the Purchaser;
- 3.14 the contents page and headings in this Agreement are for convenience only and shall not affect its interpretation; and
- 3.15 references to this Agreement include this Agreement as amended or supplemented in accordance with its terms.

Executed as a Deed by **EXPEDEON AG**
acting by _____ in the
presence of:

(Signature of director)

(Name of witness)

(Address of witness)

(Signature of witness)

Executed as a Deed by **EXPEDEON INC**
acting by _____ in the
presence of:

(Signature of director)

(Name of witness)

(Address of witness)

(Signature of witness)

Executed as a Deed by **ABCAM PLC** acting
by in the presence of:

.....
(Signature of director)

.....
(Name of witness)

.....
(Address of witness)

.....
(Signature of witness)

Executed as a Deed by **ABCAM INC** acting
by in the presence of:

.....
(Signature of director)

.....
(Name of witness)

.....
(Address of witness)

.....
(Signature of witness)